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Background: Several reports have identified different patterns of Parkinson’s disease 
progression in individuals carrying missense variants in GBA or LRRK2 genes. The overall 
contribution of genetic factors to the severity and progression of Parkinson’s disease, 
however, has not been well studied. 
Objectives: To test the association between genetic variants and the clinical features of 
Parkinson’s disease on a genome-wide scale.
Methods: We accumulated individual data from 12 longitudinal cohorts in a total of 4,093 
patients with 22,307 observations over a median of 3.81 years. Genome-wide associations 
were evaluated for 25 cross-sectional and longitudinal phenotypes. Specific variants of 
interest, including 90 recently-identified disease risk variants, were also investigated post-hoc 
for candidate associations with these phenotypes.
Results: Two variants were genome-wide significant. Rs382940(T>A), within the intron of 
SLC44A1, was associated with reaching Hoehn and Yahr stage 3 or higher faster (HR 2.04 
[1.58, 2.62], P-value = 3.46E-8). Rs61863020(G>A), an intergenic variant and eQTL for 
ADRA2A, was associated with a lower prevalence of insomnia at baseline (OR 0.63 [0,52, 
0.75], P-value = 4.74E-8). In the targeted analysis, we found nine associations between 
known Parkinson’s risk variants and more severe motor/cognitive symptoms. Also, we 
replicated previous reports of GBA coding variants (rs2230288: p.E365K, rs75548401: 
p.T408M) being associated with greater motor and cognitive decline over time, and APOE E4 
tagging variant (rs429358) being associated with greater cognitive deficits in patients. 
Conclusions: We identified novel genetic factors associated with heterogeneity of 
Parkinson’s disease. The results can be used for validation or hypothesis tests regarding 
Parkinson’s disease. 
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Parkinson’s disease (PD) is clinically defined by its motor features of rigidity, bradykinesia, 
gait disturbance, and tremor. Although these prominent features are important for diagnosis, 
patients with PD also suffer from many non-motor features such as constipation, urinary 
incontinence, orthostatic hypotension, REM sleep behavior disorder (RBD), apathy, 
hyposmia, and cognitive impairment.1 Moreover, patients develop motor complications, 
including wearing off and dyskinesia, as side effects of medication. The onset, intensity and 
progression of these different PD clinical features vary among individuals, and the 
mechanisms underlying this heterogeneity are not well understood.
Recent genome-wide studies have identified 90 common variants associated with the risk of 
PD, with an overall heritability estimated to be between 22-27%.2,3 While previous studies 
have indicated the importance of genetic contributions to disease risk, the contribution of 
genetic factors to PD progression and heterogeneity has not been well studied. Investigating 
genetic factors associated with disease progression and heterogeneity in disease presentation 
is an important step in elucidating the underlying molecular mechanisms and identifying 
better patient stratification in clinical trials.4
Longitudinal patient cohorts are powerful resources that can be used to explore the impact of 
genetics on the trajectory of PD-related phenotypes; the inherent precision of repeated 
measurements over time provides more power to detect these associations. However, the 
available number of participants in each study is usually not enough to conduct a genome-
wide association study (GWAS). In this study, we accumulated 22,307 follow-up visits from 
4,093 patients across 12 cohorts (Table 1) and performed meta-analyses of longitudinal 
GWAS on the progression markers of Parkinson’s disease. Using the results from this meta-
analysis, we evaluated how known risk variants, including the 90 recently identified variants 
for PD,3 GBA protein coding mutations, and APOE tagging variants were associated with the 
progression of phenotypes. To maximize the utility of this work to other researchers, we have 
made all results from this study publicly searchable and available for download. 
(https://pdgenetics.shinyapps.io/pdprogmetagwasbrowser/)
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Twelve longitudinal cohorts of PD patients recruited across North America, Europe and 
Australia were included in our study. The following observational studies were included: the 
Drug Interaction with Genes in Parkinson's Disease (DIGPD), the Harvard Biomarkers Study 
(HBS), the Oslo Parkinson's Disease study (partly including retrospective data), the 
Norwegian ParkWest study (PARKWEST), the Parkinson’s Disease Biomarker Program 
(PDBP), the Parkinsonism Incidence and Cognitive and Non-motor heterogeneity In 
Cambridgeshire (PICNICS), the Parkinson’s Progression Markers Initiative (PPMI), and the 
Profiling Parkinson’s disease study (PROPARK). The four cohorts included were 
randomized clinical trials: the Deprenyl and Tocopherol Antioxidative Therapy of 
Parkinsonism (DATATOP), the NIH Exploratory Trials in Parkinson's Disease Large Simple 
Study 1 (NET-PD_LS1), the ParkFit study (PARKFIT), and the Parkinson Research 
Examination of CEP-1347 Trial study with its subsequent prospective study 
(PreCEPT/PostCEPT). More details of these cohorts are described in Appendix. Participants’ 
information and genetic samples were obtained under appropriate written consent and with 
local institutional and ethical approvals.
Phenotyping
Each cohort had a different set of recorded biomarkers and phenotypes associated with 
Parkinson’s disease. We selected the following continuous and binomial biomarkers based on 
their clinical importance and availability. For continuous outcomes, we collected the scores 
of Hoehn and Yahr staging scale (HY),5 total and sub-scores of the Unified Parkinson’s 
Disease Rating Scale (UPDRS) or the Movement Disorder Society revised UPDRS version 
(MDS-UPDRS),6 Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment 
(MoCA)7 and the modified Schwab and England Activities of Daily Living Scale (SEADL). 
With the exception of the subscores of UPDRS/MDS-UPDRS part 4, total scores and the 
subscores of UPDRS and MDS-UPDRS were normalized to the population-baseline mean 
and standard deviation and converted to Z values. The subscores of UPDRS/MDS-UPDRS 
part 4, measuring complication of treatment, were normalized to the mean and standard 
deviation of all observations because the score was 0 at the baseline for the de-novo PD 
Page 9 of 106































































cohorts. We also determined whether subjects were recorded as presenting the following 
binomial outcomes during participant visits: constipation, cognitive impairment, depression, 
daytime sleepiness, Hoehn and Yahr stage of 3 or worse (HY3), hyposmia, insomnia, motor 
fluctuation, REM sleep behavior disorder (RBD), restless legs syndrome (RLS), and an 
SEADL of 70 or less (SEADL70). Because study-specific criteria for these binomial 
outcomes were not consistent amongst the studies, we tried to use the common criteria for 
these binomial outcomes if we had access to the raw data from the studies. The details of the 
definitions of binomial outcomes are provided in the Supplemental Table 1.
Genetics data
The genotyping was conducted with NeuroX, a targeted chip for neurodegenerative disease,8 
for NET-PD_LS1, a part of DIGPD (DIGPD_neuroX), HBS, PDBP, and PRECEPT. The rest 
of DIGPD (DIGPD_chip) were genotyped using Illumina Multi-Ethnic Genotyping Array. 
Participants in DATATOP, OSLO, PARKFIT, PARKWEST, PICNICS, and PROPARK 
were genotyped using Illumina Infinium OmniExpress array. Whole genome sequencing data 
was used for PPMI, with the detailed methods for genome sequencing provided on the PPMI 
website (https://www.ppmi-info.org/).
Variant inclusion criteria consisted of call rate > 0.95, MAF > 0.01, and Hardy-Weinberg 
equilibrium test statistic > 1E-4. Participants were excluded due to the following criteria: 
high-missingness (> 5% for genotyped variants), sex discordance, extreme heterozygosity (F 
statistics > 0.15), Non-European ancestry confirmed by joint analysis with HapMap 3 data 
using principal component (Outside of mean +/- 6 SD in PC1 or PC2 for European reference 
samples) (International HapMap 3 Consortium et al., 2010), and excessive relatedness 
(pairwise kinships > 0.125). We used PLINK version 1.9 for the above filtering.9 
For all samples and variants passing quality control, imputation was conducted for 
chromosome 1 to 22 using Minimac3 using the Haplotype Reference Consortium panel 
(HRC r1.1) and Eagle v2.3 for phasing at the Michigan Imputation Server10, with the 
exception of the whole genome sequenced PPMI dataset. SNPs with an imputation quality of 
R2 less than 0.3 and MAF < 1% were excluded. After quality control, the number of variants 
were approximately 2.6 - 2.9 million in NET-PD_LS1, DIGPD_neuroX, HBS, PDBP, and 
PRECEPT; 7.7 - 7.8 million in PICNICS, PROPARK, PARKWEST, DATATOP, PARKFIT, 
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DIGPD, and OSLO; and 8.6 million in PPMI. Note that the cohorts genotyped by NeuroX 
had relatively less genome coverage than others. 
Cohort-level analyses
We conducted a separate GWAS for each cohort per phenotype of interest. In addition, 
DIGPD cohorts were analyzed separately according to the genotyping array used 
(DIGPD_neuroX cohort and DIGPD_chip cohort). Each outcome was analyzed by an 
additive model with covariates. For the binomial outcomes at baseline visit, when the 
outcomes were positive for more than 5% of participants and >20 counts, logistic regression 
analyses were conducted. Those without the binomial outcome at baseline were followed-up 
until either censored or the development of the outcome. If more than 20 events were 
observed during follow-ups, the outcome was analyzed using cox proportional hazard models 
with time-varying covariates. For the analysis of continuous traits, linear mixed models were 
used to evaluate the variants’ association for the outcome. Age at diagnosis, year from 
diagnosis to the observation, and sex were adjusted for in all analyses. In addition, the 
following covariates were associated with the outcome of interest in a backwards stepwise 
manner: quadratic age, quadratic years from diagnosis, years of education, medication status 
(levodopa usage, dopamine agonist usage, using either dopamine agonist or levodopa), and a 
Hoehn and Yahr score of 2 or more at the first observation (except for the models regressing 
for Hoehn and Yahr score itself or UPDRS motor score). These covariates were selected per 
study using Akaike’s Information Criteria (AIC) for logistic models and Cox survival 
models, and conditional AIC (cAIC) for linear mixed effect models. The cohort level 
analyses were conducted with R (version 3.5.0 https://www.r-project.org/) and rvtests.11 R 
package ‘cAIC4’ was used to calculate cAIC.12
Meta-Analyses
The results from cohort-level analyses were combined using an inverse variance weighted 
fixed effect model. If the study-specific genomic inflation factor was more than 1.2, the study 
was excluded from the meta-analysis. Five of the 204 GWAS were excluded based on these 
criteria. For other cohorts, the overall alpha error was corrected using the genomic inflation 
factor before the meta-analysis. Meta-analyses were carried out with METAL.13 From the 
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meta-analysis results, we only evaluated variants with MAF > 0.05 due to statistical power 
constraints. We also excluded variants with minor allele frequency variability greater than 
15% across cohorts. Further exclusions at the meta-analysis level include variants with 
Cochran's Q-test for heterogeneity < 0.05 and a total participant N < 1000. The null 
hypothesis was tested with a significance level of 5E-8 on a two-sided test. For genome-wide 
signals, additional visualization and functional analyses were conducted using LocusZoom,14 
FUMA (http://fuma.ctglab.nl/snp2gene/, version 1.3.3d).15 FUMA is a web-based annotation 
tool using MAGMA to conduct gene-based tests, a gene-set analysis and a tissue expression 
analysis. We applied a default setting. Also, we explored in eQTLGen database 
(http://www.eqtlgen.org/)16 and meta-analyzed expression data in the brain accessible from 
the study by Qi et al.17 
Associations with the variants of interest, including the recently identified 90 risk variants for 
PD, known LRRK2 and GBA variants, and APOE, were extracted from the meta-analysis 
results. We exploratory evaluated the associations of these variants and clinical features 
based on the significance level of 0.05, applying the Bonferroni adjustment of a maximum of 
25 tests per variant (raw P-value < 0.002). 
The summary of analytical processes is shown in figure 1.
Data availability
The summary statistics of the meta-analysis results, including the ones which were not 
evaluated in this manuscript, are publicly available for convenient browsing and 
downloading. (https://pdgenetics.shinyapps.io/pdprogmetagwasbrowser/)
Results
Novel GWAS associations with PD progression markers
The cohort characteristics are provided in Table 1. Overall, we analyzed 4,093 participants 
with 22,307 longitudinal data points over a median of 3.81 years. These cohorts varied in the 
years between enrollment and diagnosis, as well as follow-up durations. DATATOP, 
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ParkWest, PPMI, and PreCEPT/PostCEPT enrolled untreated PD patients while others 
enrolled both treated and untreated patients. Considering the difference in design and 
recruitment strategies in the cohorts (Appendix), it is important to adjust for baseline 
characteristics as well as the follow-up lengths per cohort-level. All cohort-specific models 
for analysis are listed in Supplemental Table 2. 
In total, 204 GWAS were conducted and combined into 33 meta-analyses. Eight meta-
analyses were not evaluated because of the small number of total participants in the analyses 
(N total <1000). Those excluded were baseline analyses for RBD, RLS and SEADL70; and 
longitudinal analyses for constipation, daytime sleepiness, hyposmia, RBD, and RLS. 
Therefore, we investigated 9 binomial traits at baseline, 7 binomial traits for survival, and 9 
continuous traits over the follow-ups. The genomic inflation factor was the mean value of 
0.993, SD of 0.023, and the range was [0.951, 1.031] across meta-analyses. The study 
specific genomic inflation factors were provided in Supplemental Table 3. 
One association with the progression of PD was of genome-wide significance (P-value < 
5.00E-08). The minor allele of rs382940 (chr9:108058562T>A), an intronic variant of 
SLC44A1, was associated with a higher hazard ratio (HR) of reaching Hoehn and Yahr stage 
3.0 or greater (HR 2.04 [1.58, 2.62], P-value = 3.46E-8 (Estimates in a random effect model, 
1.97 [1.38, 2.81], P-value = 1.96E-4)). When considering the baseline observations, the 
minor allele of rs61863020 (chr10:112956055G>A), an intergenic variant, was significantly 
associated with the lower baseline OR of having insomnia (OR 0.63 [0,52, 0.75], P-value = 
4.74E-8 (The same estimates and P-value in a random effect model)). Locus plots and forest 
plots for these two associations are shown in Figure 2. Cochran’s Q statistics, I-square and 
forest plots all showed no evidence of heterogeneity for these associations. (Figure 2)
To evaluate the potential molecular mechanism for the two genome-wide signals, we 
explored eQTL datasets in blood and brain,16,17 and functional annotation of the GWAS 
summary statistics using FUMA. Although it is in a regulatory region of SLC44A1, rs382940 
itself was not reported to be an eQTL in blood or brain. Gene-based tests using the GWAS 
summary statistics for reaching HY3 showed that SLC44A1 was significant gene-wise(P-
value = 5.8E-07 < Bonferroni correction threshold = 2.7E-6, supplemental figure 1). 
Rs61863020 was a significant eQTL for ADRA2A (α-2A adrenergic receptor) (P-value = 
7.2E-4, the Bonferroni corrected P-value = 6.5E-3, up-regulation for A allele) in the brain. 
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In the meta-analysis results from the other clinical outcomes, rs382940 was associated with 
higher scores in the UPDRS part 2 and part 3 (UPDRS2_scaled: 0.36 [0.15, 0.57], P-value = 
8.21E-04; UPDRS3_scaled: 0.29 [0.14, 0.45], P-value = 2.18E-04). These findings are 
consistent with the primary association of rs382940 and reaching HY3, which is a significant 
motor milestone (bilateral signs on clinical examination and the emergence of postural 
instability). Except for the association with having insomnia at baseline, rs61863020 was not 
significantly associated with other clinical variables in this analysis after adjusting for 25 
tests. Of note, the variant was not associated with the development of insomnia in the 
survival analysis. This could be due to low power of the analysis (N=1,112) or the variant 
may be important for the development of insomnia in an earlier phase of the disease.
Targeted assessment for the PD risk variants
Of the 90 risk variants from the recently published PD GWAS, rs34637584 (LRRK2 
p.G2019S) and rs76763715 (GBA p.N370S) were not available in the meta-analyses because 
of their minor allele frequency (MAF) < 0.01. The remaining 88 PD GWAS risk SNPs were 
assessed in our 25 GWAS summary sets, resulting in evaluations of 2022 candidate 
associations. 112 associations between known genetic risk variants and clinical markers had 
raw p-values less than 0.05. After Bonferroni correction for all evaluated candidate 
associations, nine surpassed the threshold of the analyses-wide significance for the maximum 
of 25 analyses per variant (raw P-value < 0.002). The directions of these associations 
generally indicated that having the higher risk allele was associated with more severe deficits 
in both the cognitive and motor domains of PD, but not for sleeping problems. Having the 
risk allele (A) of rs1293298 (intron variant of CTSB) was associated with a lower risk of 
developing insomnia (HR 0.79 [0.69, 0.91], P-value = 1.2E-3), and the risk allele (A) of 
rs6500328 (intron variant of NOD2) and (A) of rs76116224 (intergenic variant close to 3’ 
end of KCNS3) were associated with a lower prevalence of daytime sleepiness at baseline 
(OR 0.76 [0.64, 0.90], P-value = 1.4E-3; OR 0.47 [0.32, 0.68], P-value = 8.4E-5; 
respectively). Among the nine associations with analysis-wide significance, three were 
significant after adjusting for 88 variants (raw P-value < 5.68E-4), and one among them had 
test-wide significance (raw P-value < 2.47E-5). Figure 3 shows the strength of the 
associations for the selected variants with associations of analyses-wide significance in at 
least one analysis. This figure suggests that some risk variants were associated with specific 
clinical features. For example, rs35749011 was associated with both the HR of cognitive 
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impairment at test-wide significance (HR 2.45 [1.64, 3.65] for the minor allele, P-value = 
1.1E-5) and lower MoCA score over time at analyses-wide significance (-1.16 [-1.89, -0.43], 
P-value = 0.0018). Although it is an intergenic variant whose closest gene is KRTCAP2, the 
variant is in high LD (r2 = 0.78) with rs2230288 (GBA p.E365K),18,19 and has a similar 
spectrum of phenotype associations as rs2230288. Other notable variants with variant-wide 
significance were rs76904798, the intergenic variant close to the 5’ end of LRRK2, for 
reaching HY3 (HR 1.32 [1.14, 1.54] with the minor allele of T, P-value = 3.0E-4), and 
rs76116224 and the baseline OR of having daytime sleepiness mentioned above. The detailed 
information for all of the test results is provided as supplemental material. (Supplemental 
Table 4 and Supplemental Figure 2) 
GBA protein coding variants and APOE tagging variants
In the focused analyses for GBA coding variants, rs75548401, GBA p.T408M, was associated 
with the faster development of HY3 (HR 2.35 [1.58, 3.49], P-value = 2.5E-5). rs2230288, 
GBA p.E365K, was associated with the higher odds of having cognitive impairment at 
baseline (OR 2.05 [1.33, 3.18], P-value = 1.3E-3), faster development of cognitive 
impairment (HR 2.58 [1.71, 3.89] P-value = 5.5E-6), and lower MoCA score at the analysis-
wide significance (Beta -1.23 [-1.97, -0.50], P-value = 1.0E-3). We previously reported these 
associations20 and we were able to confirm them in our updated analysis with more stringent 
multiple testing correction (FDR vs Bonferroni).  
The C allele of rs429358, the tagging variant for the APOE E4 allele, was associated with 
lower MMSE (Beta-0.20 [-0.33, -0.07], P-value = 2.8E-3) and lower MoCA (Beta -0.52 [-
0.86, -0.17], P-value = 3.4E-3) as expected. Moreover, it was associated with higher UPDRS 
part 1 scores (Beta 0.12 [0.04, 0.20] in Z score, P-value = 4.5E-3). We did not have enough 
evidence to conclude that the APOE E4 allele was associated with the prevalence of cognitive 
impairment at baseline (P-value = 0.4) or its development during follow-ups (P-value = 
0.034). The T allele of rs7412 showed no association with these measurements, also 
predicted as this variant tagging APOE E2.
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We conducted GWAS using longitudinal data from multiple PD cohorts to investigate 
markers of PD progression and heterogeneity. Of the 25 meta-analyses that we evaluated, we 
identified two variant-phenotype associations with genome-wide significance. 
We also evaluated the summary statistics to assess clinical value of the variants of interest. 
One of our genome-wide hits, rs382940, in the intron of SLC44A1, was associated with a 
faster rate of progression to reach HY3. SLC44A1, soluble carrier 44A1, is also referred to as 
choline transporter-like protein 1 (CTL1). The gene is ubiquitously expressed in the brain, 
colon, thyroid and other organs and is involved in choline transport. No associations with PD 
and this variant or the gene itself have been reported so far although it has been studied in 
several vitro and vivo studies.21–24 Further investigation is warranted. The search of the Brain 
eQTL database suggested that another GWAS-signal, rs61863020, was associated with 
ADRA2A expression, a gene reported to be associated with arousal/sleep state.25 ADRA2A is 
consistently expressed in locus coeruleus as well as nigral dopamine neurons and pyramidal 
neurons of the human brain (http://www.humanbraincode.org/).26 The ADRA2A-encoded 
alpha2 adrenoreceptor modulates norepinephrine levels. In addition, norepinephrine27 and its 
receptors28,29 have been linked to PD in multiple model systems.
Interestingly, neither of the variants were reported to be associated with the incidence of 
Parkinson’s disease in the recent case-control analysis of PD.3 A case-control study cannot 
address some mechanisms which contribute to the heterogeneity of PD such as genetic effects 
only relevant to cases or interactions with PD treatments. The discrepancy between the case-
control GWAS and our study may reflect this point.
In the targeted assessments, we confirmed the previous results of the associations between 
GBA risk variants and motor and cognitive aspects of PD.30–34 In contrast with GBA variants, 
association studies of APOE and cognitive function in PD have yielded mixed results 
previously.35–39 Our data supported the association of APOE and cognitive function on two 
measurements; MMSE and MoCA. 
The strength of the current study is the hypothesis-free approach of GWAS, which can be 
powerful in identifying new associations and expanding our biological knowledge-base. 
While the associations here should be replicated and further investigated with vivo/vitro 
experiments, these findings suggest the prioritization of the two variants and loci for future 
validations. We have reported all of the summary results on our publicly accessible site to 
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benefit researchers so that they may conduct/replicate the analysis of variants of interest in 
their own research. 
The major limitation of this study is the heterogeneity of the cohorts, which is apparent in 
several ways: baseline characteristics, definitions of binomial outcomes, patterns for clinical 
care over the course of follow-up, the platforms for genotyping/sequencing, and sample 
acquisition/enrollment practices. By meta-analyzing at the dataset-level and exercising 
careful quality control throughout, we tried to extract the most generalizable and reliable 
results across cohorts. 
Another limitation is the power of the study. Although we have aggregated the largest 
collection of longitudinal data in PD genetics so far, more data would be needed to identify 
relatively small differences expected within PD patients compared to the case-vs-control 
setting. From the meta-analysis results, we estimated that if we had 30% more participants in 
the same setting, we would have had at least one variant of the genome-wide significance 
(5E-8) in 21 out of 25 phenotypes (Supplemental Table 5). Additionally, our study results can 
be a valuable resource for validation and hypothesis testing as we have shown in our targeted 
analysis. The study website aims to provide other researchers with a tool to explore variants 
of their interest easily for all included phenotypes. 
(https://pdgenetics.shinyapps.io/pdprogmetagwasbrowser/)
In our survival analysis, we did not explicitly check the proportional hazard assumption. If a 
variant effect changed over time, the result would be interpreted as the average HR over time. 
Also, the result would be biased when one of the covariates violated the proportional hazard 
assumption in our model and it was also associated with the variant dosage. Replication is 
important in this regard as well.
Finally, the study participants were restricted to individuals with European ancestry. We are 
now striving to collect more data, including from populations that are under-represented in 
this study, to improve our understanding of this topic in future studies.
Conclusion
With 4,093 participants and 22,307 longitudinal data points over a median of 3.81 years, we 
performed 25 GWAS meta-analyses. We found two genome-wide significant signals: the rate 
to reach HY3 during the disease course and rs382940; and the prevalence of insomnia at 
baseline and rs61863020. We also conducted targeted assessments of previously published 
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variants of interest using the GWAS results. These results provide valuable insights into how 
genetic factors contribute to the heterogeneity of PD and disease progression. 
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Appendix: The description of study cohorts (A). IPDGC collaborators (B)
Supplemental table 1: Cohort specific definitions of binomial outcomes
Supplemental table 2: Analytical models per datasets
Supplemental table 3: The study-specific genomic inflation factors
Supplemental table 4: The meta-analysis results of the association between risk variants and 
the clinical features and progression of Parkinson’s disease
Supplemental table 5: The estimated study size to detect at least one variant with genome-
wide significance
Supplemental figure 1: Gene-based test for reaching Hoehn and Yahr stage 3 or higher
Supplemental figure 2: Heatmap for the meta-analysis results of the association between risk 
variants and the clinical features and progression of Parkinson’s disease
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Figure legends
Figure 1:  Graphical overview of the analysis strategy.
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* DIGPD cohort was analyzed separately depending on the genotyping system.
Rsq, R square; MAF, Minor allele frequency; HWE, Hardy–Weinberg equilibrium test; OR, 
Odds ratio; HR, Hazard ratio; PC, Principal components; AAD, Age at diagnosis; YfD, Years 
from diagnosis to observation; HY score, the score on the Hoehn and Yahr scale; 
Figure 2: Locuszoom plots and forest plots of the two genome-wide significant hits. A: The 
locus plot for rs382940 which is associated with HY3. B: The locus plot for rs61863020 
which is associated with insomnia. C: The forest plot for rs382940. D: The forest plot for 
rs61863020.
Figure 3: Heatmap of the Parkinson’s disease GWAS loci associated with progression 
markers
Cream, P-value > 0.05; light green, P-value < 0.05; green: P-value < 0.002; blue, P-value < 
5.68E-4; dark blue, P-value < 2.47E-5). 
CONST, constipation; COGi, cognitive impairment; DEPR, depression; HY3, Hoehn and 
Yahr score; INS, insomnia; MMSE, Mini-Mental State Examination; MOCA, Montreal 
Cognitive Assessment; SEADL70, the modified Schwab and England Activities of Daily 
Living Scale; SLEEP, daytime sleepiness; UPDRS, Unified Parkinson’s Disease Rating Scale 
(UPDRS) or the Movement Disorder Society revised UPDRS, scaled at the baseline 
(UPDRS1-3) or during the course. 
Suffix of ‘base’ indicates the logistic regression model at baseline, ‘surv’ for the survival 
analysis over the course, and ‘cont’ for the linear mixed effect model for continuous outcome 
analyzed by linear mixed model. 
Figure 4: Heatmap of the GBA and APOE variants associated with progression markers
Cream, P-value > 0.05; light green, P-value < 0.05; green: Bonferroni corrected P-value < 
0.05; 
CONST, constipation; COGi, cognitive impairment; DEPR, depression; HY3, Hoehn and 
Yahr score; INS, insomnia; MMSE, Mini-Mental State Examination; MOCA, Montreal 
Cognitive Assessment; SEADL, the modified Schwab and England Activities of Daily Living 
Scale; SLEEP, daytime sleepiness; UPDRS, Unified Parkinson’s Disease Rating Scale 
(UPDRS) or the Movement Disorder Society revised UPDRS, scaled at the baseline 
(UPDRS1-3) or during the course. 
Suffix of ‘base’ indicates the logistic regression model at baseline, ‘surv’ for the survival 
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analysis over the course, and ‘cont’ for the linear mixed effect model for continuous outcome　
analyzed by linear mixed model.
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Background: Several reports have identified different patterns of Parkinson’s disease 
progression in individuals carrying missense variants in GBA or LRRK2 genes. The overall 
contribution of genetic factors to the severity and progression of Parkinson’s disease, 
however, has not been well studied. 
Objectives: To test the association between genetic variants and the clinical features and 
progression of Parkinson’s disease on a genome-wide scale.
Methods: We accumulated individual data from 12 longitudinal cohorts in a total of 4,093 
patients with 22,307 observations over a median of 3.81 years. Genome-wide associations 
were evaluated for 25 cross-sectional and longitudinal phenotypes. Specific variants of 
interest, including 90 recently-identified disease risk variants, were also investigated post-hoc 
for candidate associations with these phenotypes.
Results: Two variants were genome-wide significant. Rs382940(T>A), within the intron of 
SLC44A1, was associated with reaching Hoehn and Yahr stage 3 or higher faster (HR 2.04 
[1.58, 2.62], P-value = 3.46E-8). Rs61863020(G>A), an intergenic variant and eQTL for 
ADRA2A, was associated with a lower prevalence of insomnia at baseline (OR 0.63 [0,52, 
0.75], P-value = 4.74E-8). In the targeted analysis, we found nine associations between 
known Parkinson’s risk variants and more severe motor/cognitive symptoms. Also, we 
replicated previous reports of GBA coding variants (rs2230288: p.E365K, rs75548401: 
p.T408M) being associated with greater motor and cognitive decline over time, and APOE E4 
tagging variant (rs429358) being associated with greater cognitive deficits in patients. 
Conclusions: We identified novel genetic factors associated with heterogeneity of 
Parkinson’s disease. The results can be used for validation or hypothesis tests 
regardingprovide new insights into the pathogenesis of  Parkinson’s disease. 
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Parkinson’s disease (PD) is clinically defined by its motor features of rigidity, bradykinesia, 
gait disturbance, and tremor. Although these prominent features are important for diagnosis, 
patients with PD also suffer from many non-motor features such as constipation, urinary 
incontinence, orthostatic hypotension, REM sleep behavior disorder (RBD), apathy, 
hyposmia, and cognitive impairment.1 Moreover, patients develop motor complications, 
including wearing off and dyskinesia, as side effects of medication. The onset, intensity and 
progression of these different PD clinical features vary among individuals, and the 
mechanisms underlying this heterogeneity are not well understood.
Recent genome-wide studies have identified 90 common variants associated with the risk of 
PD, with an overall heritability estimated to be between 22-27%.2,3 While previous studies 
have indicated the importance of genetic contributions to disease risk, the contribution of 
genetic factors to PD progression and heterogeneity has not been well studied. Investigating 
genetic factors associated with disease progression and heterogeneity in disease presentation 
is an important step in elucidating the underlying molecular mechanisms and identifying 
better patient stratification in clinical trials.4
Longitudinal patient cohorts are powerful resources that can be used to explore the impact of 
genetics on the trajectory of PD-related phenotypes; the inherent precision of repeated 
measurements over time provides more power to detect these associations. However, the 
available number of participants in each study is usually not enough to conduct a genome-
wide association study (GWAS). In this study, we accumulated 22,307 follow-up visits from 
4,093 patients across 12 cohorts (Table 1) and performed meta-analyses of longitudinal 
GWAS on the progression markers of Parkinson’s disease. Using the results from this meta-
analysis, we evaluated how known risk variants, including the 90 recently identified variants 
for PD,3 GBA protein coding mutations, and APOE tagging variants were associated with the 
progression of phenotypes. To maximize the utility of this work to other researchers, we have 
made all results from this study publicly searchable and available for download. 
(https://pdgenetics.shinyapps.io/pdprogmetagwasbrowser/)
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Twelve longitudinal cohorts of PD patients recruited across North America, Europe and 
Australia were included in our study. The following observational studies were included: the 
Drug Interaction with Genes in Parkinson's Disease (DIGPD), the Harvard Biomarkers Study 
(HBS), the Oslo Parkinson's Disease study (partly including retrospective data), the 
Norwegian ParkWest study (PARKWEST), the Parkinson’s Disease Biomarker Program 
(PDBP), the Parkinsonism Incidence and Cognitive and Non-motor heterogeneity In 
Cambridgeshire (PICNICS), the Parkinson’s Progression Markers Initiative (PPMI), and the 
Profiling Parkinson’s disease study (PROPARK). The four cohorts included were 
randomized clinical trials: the Deprenyl and Tocopherol Antioxidative Therapy of 
Parkinsonism (DATATOP), the NIH Exploratory Trials in Parkinson's Disease Large Simple 
Study 1 (NET-PD_LS1), the ParkFit study (PARKFIT), and the Parkinson Research 
Examination of CEP-1347 Trial study with its subsequent prospective study 
(PreCEPT/PostCEPT). More details of these cohorts are described in Appendix. Participants’ 
information and genetic samples were obtained under appropriate written consent and with 
local institutional and ethical approvals.
Phenotyping
Each cohort had a different set of recorded biomarkers and phenotypes associated with 
Parkinson’s disease. We selected the following continuous and binomial biomarkers based on 
their clinical importance and availability. For continuous outcomes, we collected the scores 
of Hoehn and Yahr staging scale (HY),5 total and sub-scores of the Unified Parkinson’s 
Disease Rating Scale (UPDRS) or the Movement Disorder Society revised UPDRS version 
(MDS-UPDRS),6 Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment 
(MoCA)7 and the modified Schwab and England Activities of Daily Living Scale (SEADL). 
With the exception of the subscores of UPDRS/MDS-UPDRS part 4, total scores and the 
subscores of UPDRS and MDS-UPDRS were normalized to the population-baseline mean 
and standard deviation and converted to Z values. The subscores of UPDRS/MDS-UPDRS 
part 4, measuring complication of treatment, were normalized to the mean and standard 
deviation of all observations because the score was 0 at the baseline for the de-novo PD 
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cohorts. We also determined whether subjects were recorded as presenting the following 
binomial outcomes during participant visits: constipation, cognitive impairment, depression, 
daytime sleepiness, Hoehn and Yahr stage of 3 or worse (HY3), hyposmia, insomnia, motor 
fluctuation, REM sleep behavior disorder (RBD), restless legs syndrome (RLS), and an 
SEADL of 70 or less (SEADL70). Because study-specific criteria for these binomial 
outcomes were not consistent amongst the studies, we tried to use the common criteria for 
these binomial outcomes if we had access to the raw data from the studies. The details of the 
definitions of binomial outcomes are provided in the Supplemental Table 1.
Genetics data
The genotyping was conducted with NeuroX, a targeted chip for neurodegenerative disease,8 
for NET-PD_LS1, a part of DIGPD (DIGPD_neuroX), HBS, PDBP, and PRECEPT. The rest 
of DIGPD (DIGPD_chip) were genotyped using Illumina Multi-Ethnic Genotyping Array. 
Participants in DATATOP, OSLO, PARKFIT, PARKWEST, PICNICS, and PROPARK 
were genotyped using Illumina Infinium OmniExpress array. Whole genome sequencing data 
was used for PPMI, with the detailed methods for genome sequencing provided on the PPMI 
website (https://www.ppmi-info.org/).
Variant inclusion criteria consisted of call rate > 0.95, MAF > 0.01, and Hardy-Weinberg 
equilibrium test statistic > 1E-4. Participants were excluded due to the following criteria: 
high-missingness (> 5% for genotyped variants), sex discordance, extreme heterozygosity (F 
statistics > 0.15), Non-European ancestry confirmed by joint analysis with HapMap 3 data 
using principal component (Outside of mean +/- 6 SD in PC1 or PC2 for European reference 
samples) (International HapMap 3 Consortium et al., 2010), and excessive relatedness 
(pairwise kinships > 0.125). We used PLINK version 1.9 for the above filtering.9 
For all samples and variants passing quality control, imputation was conducted for 
chromosome 1 to 22 using Minimac3 using the Haplotype Reference Consortium panel 
(HRC r1.1) and Eagle v2.3 for phasing at the Michigan Imputation Server10, with the 
exception of the whole genome sequenced PPMI dataset. SNPs with an imputation quality of 
R2 less than 0.3 and MAF < 1% were excluded. After quality control, the number of variants 
were approximately 2.6 - 2.9 million in NET-PD_LS1, DIGPD_neuroX, HBS, PDBP, and 
PRECEPT; 7.7 - 7.8 million in PICNICS, PROPARK, PARKWEST, DATATOP, PARKFIT, 
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DIGPD, and OSLO; and 8.6 million in PPMI. Note that the cohorts genotyped by NeuroX 
had relatively less genome coverage than others. 
Cohort-level analyses
We conducted a separate GWAS for each cohort per phenotype of interest. In addition, 
DIGPD cohorts were analyzed separately according to the genotyping array used 
(DIGPD_neuroX cohort and DIGPD_chip cohort). Each outcome was analyzed by an 
additive model with covariates. For the binomial outcomes at baseline visit, when the 
outcomes were positive for more than 5% of participants and >20 counts, logistic regression 
analyses were conducted. Those without the binomial outcome at baseline were followed-up 
until either censored or the development of the outcome. If more than 20 events were 
observed during follow-ups, the outcome was analyzed using cox proportional hazard models 
with time-varying covariates. For the analysis of continuous traits, linear mixed models were 
used to evaluate the variants’ association for the outcome. Age at diagnosis, year from 
diagnosis to the observation, and sex were adjusted for in all analyses. In addition, the 
following covariates were associated with the outcome of interest in a backwards stepwise 
manner: quadratic age, quadratic years from diagnosis, years of education, medication status 
(levodopa usage, dopamine agonist usage, using either dopamine agonist or levodopa), and a 
Hoehn and Yahr score of 2 or more at the first observation (except for the models regressing 
for Hoehn and Yahr score itself or UPDRS motor score). These covariates were selected per 
study using Akaike’s Information Criteria (AIC) for logistic models and Cox survival 
models, and conditional AIC (cAIC) for linear mixed effect models. The cohort level 
analyses were conducted with R (version 3.5.0 https://www.r-project.org/) and rvtests.11 R 
package ‘cAIC4’ was used to calculate cAIC.12
Meta-Analyses
The results from cohort-level analyses were combined using an inverse variance weighted 
fixed effect model. If the study-specific genomic inflation factor was more than 1.2, the study 
was excluded from the meta-analysis. Five of the 204 GWAS were excluded based on these 
criteria. For other cohorts, the overall alpha error was corrected using the genomic inflation 
factor before the meta-analysis. Meta-analyses were carried out with METAL.13 From the 
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meta-analysis results, we only evaluated variants with MAF > 0.05 due to statistical power 
constraints. We also excluded variants with minor allele frequency variability greater than 
15% across cohorts. Further exclusions at the meta-analysis level include variants with 
Cochran's Q-test for heterogeneity < 0.05 and a total participant N < 1000. The null 
hypothesis was tested with a significance level of 5E-8 on a two-sided test. For genome-wide 
signals, additional visualization and functional analyses were conducted using LocusZoom,14 
FUMA (http://fuma.ctglab.nl/snp2gene/, version 1.3.3d).15 FUMA is a web-based annotation 
tool using MAGMA to conduct gene-based tests, a gene-set analysis and a tissue expression 
analysis. We applied a default setting. Also, we explored in eQTLGen database 
(http://www.eqtlgen.org/)16 and meta-analyzed expression data in the brain accessible from 
the study by Qi et al.17 
Associations with the variants of interest, including the recently identified 90 risk variants for 
PD, known LRRK2 and GBA variants, and APOE, were extracted from the meta-analysis 
results. We exploratory evaluated the associations of these variants and clinical features 
based on the significance level of 0.05, applying the Bonferroni adjustment of a maximum of 
25 tests per variant (raw P-value < 0.002). 
The summary of analytical processes is shown in figure 1.
Data availability
The summary statistics of the meta-analysis results, including the ones which were not 
evaluated in this manuscript, are publicly available for convenient browsing and 
downloading. (https://pdgenetics.shinyapps.io/pdprogmetagwasbrowser/)
Results
Novel GWAS associations with PD progression markers
The cohort characteristics are provided in Table 1. Overall, we analyzed 4,093 participants 
with 22,307 longitudinal data points over a median of 3.81 years. These cohorts varied in the 
years between enrollment and diagnosis, as well as follow-up durations. DATATOP, 
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ParkWest, PPMI, and PreCEPT/PostCEPT enrolled untreated PD patients while others 
enrolled both treated and untreated patients. Considering the difference in design and 
recruitment strategies in the cohorts (Appendix), it is important to adjust for baseline 
characteristics as well as the follow-up lengths per cohort-level. All cohort-specific models 
for analysis are listed in Supplemental Table 2. 
In total, 204 GWAS were conducted and combined into 33 meta-analyses. Eight meta-
analyses were not evaluated because of the small number of total participants in the analyses 
(N total <1000). Those excluded were baseline analyses for RBD, RLS and SEADL70; and 
longitudinal analyses for constipation, daytime sleepiness, hyposmia, RBD, and RLS. 
Therefore, we investigated 9 binomial traits at baseline, 7 binomial traits for survival, and 9 
continuous traits over the follow-ups. The genomic inflation factor was the mean value of 
0.993, SD of 0.023, and the range was [0.951, 1.031] across meta-analyses. The study 
specific genomic inflation factors were provided in Supplemental Table 3. 
One association with the progression of PD was of genome-wide significance (P-value < 
5.00E-08). The minor allele of rs382940 (chr9:108058562T>A), an intronic variant of 
SLC44A1, was associated with a higher hazard ratio (HR) of reaching Hoehn and Yahr stage 
3.0 or greater (HR 2.04 [1.58, 2.62], P-value = 3.46E-8 (Estimates in a random effect model, 
1.97 [1.38, 2.81], P-value = 1.96E-4)). When considering the baseline observations, the 
minor allele of rs61863020 (chr10:112956055G>A), an intergenic variant, was significantly 
associated with the lower baseline OR of having insomnia (OR 0.63 [0,52, 0.75], P-value = 
4.74E-8 (The same estimates and P-value in a random effect model)). Locus plots and forest 
plots for these two associations are shown in Figure 2. Cochran’s Q statistics, I-square and 
forest plots all showed no evidence of heterogeneity for these associations. (Figure 2)
To evaluate the potential molecular mechanism for the two genome-wide signals, we 
explored eQTL datasets in blood and brain,16,17 and functional annotation of the GWAS 
summary statistics using FUMA. Although it is in a regulatory region of SLC44A1, rs382940 
itself was not reported to be an eQTL in blood or brain. Gene-based tests using the GWAS 
summary statistics for reaching HY3 showed that SLC44A1 was significant gene-wise(P-
value = 5.8E-07 < Bonferroni correction threshold = 2.7E-6, supplemental figure 1). 
Rs61863020 was a significant eQTL for ADRA2A (α-2A adrenergic receptor) (P-value = 
7.2E-4, the Bonferroni corrected P-value = 6.5E-3, up-regulation for A allele) in the brain. 
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In the meta-analysis results from the other clinical outcomes, rs382940 was associated with 
higher scores in the UPDRS part 2 and part 3 (UPDRS2_scaled: 0.36 [0.15, 0.57], P-value = 
8.21E-04; UPDRS3_scaled: 0.29 [0.14, 0.45], P-value = 2.18E-04). These findings are 
consistent with the primary association of rs382940 and reaching HY3, which is a significant 
motor milestone (bilateral signs on clinical examination and the emergence of postural 
instability). Except for the association with having insomnia at baseline, rs61863020 was not 
significantly associated with other clinical variables in this analysis after adjusting for 25 
tests. Of note, the variant was not associated with the development of insomnia in the 
survival analysis. This could be due to low power of the analysis (N=1,112) or the variant 
may be important for the development of insomnia in an earlier phase of the disease.
Targeted assessment for the PD risk variants
Of the 90 risk variants from the recently published PD GWAS, rs34637584 (LRRK2 
p.G2019S) and rs76763715 (GBA p.N370S) were not available in the meta-analyses because 
of their minor allele frequency (MAF) < 0.01. The remaining 88 PD GWAS risk SNPs were 
assessed in our 25 GWAS summary sets, resulting in evaluations of 2022 candidate 
associations. 112 associations between known genetic risk variants and clinical markers had 
raw p-values less than 0.05. After Bonferroni correction for all evaluated candidate 
associations, nine surpassed the threshold of the analyses-wide significance for the maximum 
of 25 analyses per variant (raw P-value < 0.002). The directions of these associations 
generally indicated that having the higher risk allele was associated with more severe deficits 
in both the cognitive and motor domains of PD, but not for sleeping problems. Having the 
risk allele (A) of rs1293298 (intron variant of CTSB) was associated with a lower risk of 
developing insomnia (HR 0.79 [0.69, 0.91], P-value = 1.2E-3), and the risk allele (A) of 
rs6500328 (intron variant of NOD2) and (A) of rs76116224 (intergenic variant close to 3’ 
end of KCNS3) were associated with a lower prevalence of daytime sleepiness at baseline 
(OR 0.76 [0.64, 0.90], P-value = 1.4E-3; OR 0.47 [0.32, 0.68], P-value = 8.4E-5; 
respectively). Among the nine associations with analysis-wide significance, three were 
significant after adjusting for 88 variants (raw P-value < 5.68E-4), and one among them had 
test-wide significance (raw P-value < 2.47E-5). Figure 3 shows the strength of the 
associations for the selected variants with associations of analyses-wide significance in at 
least one analysis. This figure suggests that some risk variants were associated with specific 
clinical features. For example, rs35749011 was associated with both the HR of cognitive 
Page 39 of 106































































impairment at test-wide significance (HR 2.45 [1.64, 3.65] for the minor allele, P-value = 
1.1E-5) and lower MoCA score over time at analyses-wide significance (-1.16 [-1.89, -0.43], 
P-value = 0.0018). Although it is an intergenic variant whose closest gene is KRTCAP2, the 
variant is in high LD (r2 = 0.78) with rs2230288 (GBA p.E365K),18,19 and has a similar 
spectrum of phenotype associations as rs2230288. Other notable variants with variant-wide 
significance were rs76904798, the intergenic variant close to the 5’ end of LRRK2, for 
reaching HY3 (HR 1.32 [1.14, 1.54] with the minor allele of T, P-value = 3.0E-4), and 
rs76116224 and the baseline OR of having daytime sleepiness mentioned above. The detailed 
information for all of the test results is provided as supplemental material. (Supplemental 
Table 4 and Supplemental Figure 2) 
GBA protein coding variants and APOE tagging variants
In the focused analyses for GBA coding variants, rs75548401, GBA p.T408M, was associated 
with the faster development of HY3 (HR 2.35 [1.58, 3.49], P-value = 2.5E-5). rs2230288, 
GBA p.E365K, was associated with the higher odds of having cognitive impairment at 
baseline (OR 2.05 [1.33, 3.18], P-value = 1.3E-3), faster development of cognitive 
impairment (HR 2.58 [1.71, 3.89] P-value = 5.5E-6), and lower MoCA score at the analysis-
wide significance (Beta -1.23 [-1.97, -0.50], P-value = 1.0E-3). We previously reported these 
associations20 (in press at Neurology Genetics) and we were able to confirm them in our 
updated analysis with more stringent multiple testing correction (FDR vs Bonferroni).  
The C allele of rs429358, the tagging variant for the APOE E4 allele, was associated with 
lower MMSE (Beta-0.20 [-0.33, -0.07], P-value = 2.8E-3) and lower MoCA (Beta -0.52 [-
0.86, -0.17], P-value = 3.4E-3) as expected. Moreover, it was associated with higher UPDRS 
part 1 scores (Beta 0.12 [0.04, 0.20] in Z score, P-value = 4.5E-3). We did not have enough 
evidence to conclude that the APOE E4 allele was associated with the prevalence of cognitive 
impairment at baseline (P-value = 0.4) or its development during follow-ups (P-value = 
0.034). The T allele of rs7412 showed no association with these measurements, also 
predicted as this variant tagging APOE E2.
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We conducted GWAS using longitudinal data from multiple PD cohorts to investigate 
markers of PD progression and heterogeneity. Of the 25 meta-analyses that we evaluated, we 
identified two variant-phenotype associations with genome-wide significance. 
We also evaluated the summary statistics to assess clinical value of the variants of interest. 
One of our genome-wide hits, rs382940, in the intron of SLC44A1, was associated with a 
faster rate of progression to reach HY3. SLC44A1, soluble carrier 44A1, is also referred to as 
choline transporter-like protein 1 (CTL1). The gene is ubiquitously expressed in the brain, 
colon, thyroid and other organs and is involved in choline transport. No associations with PD 
and this variant or the gene itself have been reported so far although it has been studied in 
several vitro and vivo studies.21–24 Further investigation is warranted. The search of the Brain 
eQTL database suggested that another GWAS-signal, rs61863020, was associated with 
ADRA2A expression, a gene reported to be associated with arousal/sleep state.25 ADRA2A is 
consistently expressed in locus coeruleus as well as nigral dopamine neurons and pyramidal 
neurons of the human brain (http://www.humanbraincode.org/).26 The ADRA2A-encoded 
alpha2 adrenoreceptor modulates norepinephrine levels. In addition, norepinephrine27 and its 
receptors28,29 have been linked to PD in multiple model systems.
Interestingly, neither of the variants were reported to be associated with the incidence of 
Parkinson’s disease in the recent case-control analysis of PD.3 A case-control study cannot 
address some mechanisms which contribute to the heterogeneity of PD such as genetic effects 
only relevant to cases or interactions with PD treatments. The discrepancy between the case-
control GWAS and our study may reflect this point.
In the targeted assessments, we confirmed the previous results of the associations between 
GBA risk variants and motor and cognitive aspects of PD.30–34 In contrast with GBA variants, 
association studies of APOE and cognitive function in PD have yielded mixed results 
previously.35–39 Our data supported the association of APOE and cognitive function on two 
measurements; MMSE and MoCA. 
The strength of the current study is the hypothesis-free approach of GWAS, which can be 
powerful in identifying new associations and expanding our biological knowledge-base. 
While the associations here should be replicated and further investigated with vivo/vitro 
experiments, these findings suggest the prioritization of the two variants and loci for future 
validations. We have reported all of the summary results on our publicly accessible site to 
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benefit researchers so that they may conduct/replicate the analysis of variants of interest in 
their own research. 
The major limitation of this study is the heterogeneity of the cohorts, which is apparent in 
several ways: baseline characteristics, definitions of binomial outcomes, patterns for clinical 
care over the course of follow-up, the platforms for genotyping/sequencing, and sample 
acquisition/enrollment practices. By meta-analyzing at the dataset-level and exercising 
careful quality control throudghout, we tried to extract the most generalizable and reliable 
results across cohorts. 
Another limitation is the power of the study. Although we have aggregated the largest 
collection of longitudinal data in PD genetics so far, more data would be needed to identify 
relatively small differences expected within PD patients compared to the case-vs-control 
setting. From the meta-analysis results, we estimated that if we had 30% more participants in 
the same setting, we would have had at least one variant of the genome-wide significance 
(5E-810) in 21 out of 25 phenotypes (Supplemental Table 5). Additionally, our study results 
can be a valuable resource for validation and hypothesis testing as we have shown in our 
targeted analysis. The study website aims to provide other researchers with a tool to explore 
variants of their interest easily for all included phenotypes. 
(https://pdgenetics.shinyapps.io/pdprogmetagwasbrowser/)
In our survival analysis, we did not explicitly check the proportional hazard assumption. If a 
variant effect changed over time, the result would be interpreted as the average HR over time. 
Also, the result would be biased when one of the covariates violated the proportional hazard 
assumption in our model and it was also associated with the variant dosage. Replication is 
important in this regard as well.
Finally, the study participants were restricted to individuals with European ancestry. We are 
now striving to collect more data, including from populations that are under-represented in 
this study, to improve our understanding of this topic in future studies.
Conclusion
With 4,093 participants and 22,307 longitudinal data points over a median of 3.81 years, we 
performed 25 GWAS meta-analyses. We found two genome-wide significant signals: the rate 
to reach HY3 during the disease course and rs382940; and the prevalence of insomnia at 
baseline and rs61863020. We also conducted targeted assessments of previously published 
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variants of interest using the GWAS results. These results provide valuable insights into how 
genetic factors contribute to the heterogeneity of PD and disease progression. 
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Appendix: The description of study cohorts (A). IPDGC collaborators (B)
Supplemental table 1: Cohort specific definitions of binomial outcomes
Supplemental table 2: Analytical models per datasets
Supplemental table 3: The study-specific genomic inflation factors
Supplemental table 4: The meta-analysis results of the association between risk variants and 
the clinical features and progression of Parkinson’s disease
Supplemental table 5: The estimated study size to detect at least one variant with genome-
wide significance
Supplemental figure 1: Gene-based test for reaching Hoehn and Yahr stage 3 or higher
Supplemental figure 2: Heatmap for the meta-analysis results of the association between risk 
variants and the clinical features and progression of Parkinson’s disease
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Figure legends
Figure 1:  Graphical overview of the analysis strategy.
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* DIGPD cohort was analyzed separately depending on the genotyping system.
Rsq, R square; MAF, Minor allele frequency; HWE, Hardy–Weinberg equilibrium test; OR, 
Odds ratio; HR, Hazard ratio; PC, Principal components; AAD, Age at diagnosis; YfD, Years 
from diagnosis to observation; HY score, the score on the Hoehn and Yahr scale; 
Figure 2: Locuszoom plots and forest plots of the two genome-wide significant hits. A: The 
locus plot for rs382940 which is associated with HY3. B: The locus plot for rs61863020 
which is associated with insomnia. C: The forest plot for rs382940. D: The forest plot for 
rs61863020.
Figure 3: Heatmap of the Parkinson’s disease GWAS loci associated with progression 
markers
Cream, P-value > 0.05; light green, P-value < 0.05; green: P-value < 0.002; blue, P-value < 
5.68E-4; dark blue, P-value < 2.47E-5). 
CONST, constipation; COGi, cognitive impairment; DEPR, depression; HY3, Hoehn and 
Yahr score; INS, insomnia; MMSE, Mini-Mental State Examination; MOCA, Montreal 
Cognitive Assessment; SEADL70, the modified Schwab and England Activities of Daily 
Living Scale; SLEEP, daytime sleepiness; UPDRS, Unified Parkinson’s Disease Rating Scale 
(UPDRS) or the Movement Disorder Society revised UPDRS, scaled at the baseline 
(UPDRS1-3) or during the course. 
Suffix of ‘base’ indicates the logistic regression model at baseline, ‘surv’ for the survival 
analysis over the course, and ‘cont’ for the linear mixed effect model for continuous outcome 
analyzed by linear mixed model. 
Figure 4: Heatmap of the GBA and APOE variants associated with progression markers
Cream, P-value > 0.05; light green, P-value < 0.05; green: Bonferroni corrected P-value < 
0.05; 
CONST, constipation; COGi, cognitive impairment; DEPR, depression; HY3, Hoehn and 
Yahr score; INS, insomnia; MMSE, Mini-Mental State Examination; MOCA, Montreal 
Cognitive Assessment; SEADL, the modified Schwab and England Activities of Daily Living 
Scale; SLEEP, daytime sleepiness; UPDRS, Unified Parkinson’s Disease Rating Scale 
(UPDRS) or the Movement Disorder Society revised UPDRS, scaled at the baseline 
(UPDRS1-3) or during the course. 
Suffix of ‘base’ indicates the logistic regression model at baseline, ‘surv’ for the survival 
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analysis over the course, and ‘cont’ for the linear mixed effect model for continuous outcome　
analyzed by linear mixed model.
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n 428 108 235 503 340 318 332 147 515 117 441 318 291
Total number of visits 3,303 268 811 1,206 2,209 2,086 664 294 2,360 358 2,436 4,983 1,599
Number of visits per 
participants 









































































































  142 
(33.2)    44 (40.7)    91 (38.7) 
  174 
(34.6)   122 (35.9) 
  106 
( 33.3) 
  109 
(32.8)    55 (37.4) 
  202 
(39.2) 
   43 
(36.8) 
  159 
(36.1) 
  105 
(33.0) 
  105 
(36.1) 
Having HY2 or larger at 
baseline (%)
  197 
(46.0)    68 (65.4) 
  151 
(64.3) 
  420 
(84.5) -
   22 
(100.0) 
  314 
(94.6)    85 (57.8) 
  426 
(83.0) 
   62 
(53.0) 
  242 
(54.9) 
  198 
(62.5) 
  271 
(96.1) 























Use of levodopa (%)     0 ( 0.0)    64 (59.8) 
  161 
(68.5) 
  353 
(70.2)   171 (50.6) - -     0 ( 0.0) 
  409 
(83.1) 
   35 
(29.9)     3 ( 0.9)     0 ( 0.0) 
  199 
(68.4) 
Use of agonist (%)     0 ( 0.0)    88 (81.5) 
  163 
(69.4) 
  198 
(39.4)   231 (68.3) - -     0 ( 0.0) 
  277 
(56.3) 
   22 
(18.8)     0 ( 0.0)     1 ( 0.3) 
  218 
(74.9) 
Hyposmia (%)     0 ( 0.0)    33 (30.8)    66 (28.4) - - - -    53 (36.1) 
  295 
(63.6) -
  185 
(44.6) -
  170 
(63.7) 
Cognitive impairment (%)
   24 
( 5.6)     1 ( 0.9)     2 ( 0.9)    59 (11.9)    27 ( 7.9) -
   55 
(16.6)    27 (18.4) 
  119 
(23.2) 
   11 
( 9.4) 
   35 
( 7.9)     3 ( 0.9)    76 (27.1) 
Motor fluctuations (%) -    14 (13.1)    32 (13.6) 
  198 
(39.9)    87 (25.7) - -     4 ( 2.7) 
  176 
(37.3)     0 ( 0.0)     0 ( 0.0) -    92 (32.3) 
Dyskinesias (%)     3 ( 0.7)     4 ( 3.7)    13 ( 5.5) 
  168 
(33.8)     5 ( 1.5) - -     2 ( 1.4) 
  118 
(25.0)     0 ( 0.0)     0 ( 0.0) -    80 (27.8) 
Depression (%)
   11 
( 2.6)    29 (27.1)    77 (33.3)    28 (10.3)    31 ( 9.2) - -    20 (13.6)    59 (12.5) 
   26 
(22.2) 
  141 
(33.8)
   72 
(22.6)    48 (16.6) 
Restless legs syndrome (%) -    16 (15.7)    34 (14.5)    30 (10.4) - - - -
  107 
(24.4) -
   27 
(0.65) - -
Constipation (%)     9 ( 2.1)    17 (16.0)    48 (20.7) - - - -    17 (11.6) 
  255 
(54.0) 
   27 
(23.1) 
  149 
(33.8) -
  137 
(47.1) 
REM sleep behavior disorder 
(%) - - - - - - - -
  217 
(49.4) -
  104 
(24.9) - -
Daytime sleepiness (%)     3 ( 0.7)    51 (48.6) 
  104 
(44.3) - - - -    23 (15.6) 
  178 
(37.7) 
   24 
(20.5) 
   61 
(14.7) -
  125 
(43.0) 
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   11 
( 2.6)    31 (30.4)    86 (36.6) 
  170 
(33.9) - - -    45 (30.6) 
  332 
(70.3) 
   59 
(50.4) 
  109 
(24.7) -    83 (28.5) 
Hoehn Yahr scale 3 or greater 
(%)     0 ( 0.0)     2 ( 1.9)     3 ( 1.3)    59 (11.9)    10 ( 2.9)     0 (  0.0) 
   17 
( 5.1)    11 ( 7.5)    81 (15.8) 
   12 
(10.3)     2 ( 0.5)     0 ( 0.0) 
  115 
(40.8) 
SEADL 70 or less (%)     3 ( 0.7)    30 (30.0)    12 ( 5.1) -     2 ( 0.6) - -     5 ( 3.4)    75 (15.9) -     2 ( 0.5)     1 ( 0.3) -










































































































































Continous variables were summarized in Mean (SD). MMSE, Mini Mental State Exami-tion; Montreal Cognitive Assessment, SEADL, Schwab and England Activities of Daily 
Living Scale; UPDRS, Unified Parkinson Disease Rating Scale; MDS-UPDRS, Movment Disorder Society revised version of UPDRS.
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Supplementary Table 1. Cohort specific definitions of binomial outcomes
DATATOP DIGPD HBS NET-PD_LS1 Oslo ParkFit ParkWest PDBP PICNICS PPMI PreCEPT/  PostCEPT ProPark Udall
hyposmia - NMS question-ire, Q2 yes- - - - "Is your sense of smell normal?" YesUPSIT<21 - UPSIT<21 UPSIT<21 study question UPSIT<21
cognitive impariment MMSE<27 DSM IV criteria MMSE<27 SCOPA_COG<23- MMSE<27 MMSE<27 MoCA<24 MDS dementia criteriaMoCA<24 MMSE<27
SCOPA-COG value 
<23 Expert consensus review for Dementia
motor fluctuations - Neurologist diagnosisUPDRS4 Q32-Q35: >0 at any of themUPDRS4 off time>0- - UPDRS   Q35 0/1MDS-UPDRS4   off time>0MDS-UPDRS 4.3 >/= 1MDS-UPDRS 4.3 >/= 1-
SPES/SCOPA item 20 
>0 MDS-UPDRS4   off time>0
dyskinesia Report of dyskinesia as an adverse event during the studyNeurologist diagnosisUPDRS4 Q36-Q39: >0 at any of themUPDRS4 dyskinesia time>0- - UPDRS   Q32 >/= 1MDS-UPDRS4   dysk time>0MDS-UPDRS 4.1 >/= 1MDS-UPDRS 4.1 >/= 1-
SPES/SCOPA item 18 
>0 MDS-UPDRS4   dysk time>0
depression Report of depression as an adverse event during the studyNeurologist diagnosisGDS15 >5 BDI>14 - - UPDRS   3 >/= 2 HDRS>9 Beck depression inventory >9 or Geriatric Depression Scale (15 item)>5GDS15 5 UPDRS item 3 >0Beck DI score 14 GDS15 >4
restless legs syndrome - RLS criteria Past medical history- - - - MSQ3 yes - RBDSQ, RLS yes- - -
constipation Report of constipation as an adverse event during the studyNMS question-ire, Q5 yes- - - - - MDS-UPDRS1  Const>0MDS UPDRS item 1.11>/=1MDS-UPDRS1  Const>0MDS-UPDRS1  CNST>0
SCOPA-AUT item 5 
>0 -
RBD - - - - - - - MSQ1 yes - RBDSQ>5 - -- -
daytime sleepiess Report of drowsiness as an adverse event during the studyNeurologist diagnosis- - - - Epworth > 9 EPworth > 9 ESS>/=10 OR MDS-UPDRS 1.8>2EPworth > 9 MDS-UPDRS1  SLPD>0
SCOPA-SLEEP 
daytime sleepiness 
(section D) >4 -
insomnia Report of insomnia as an adverse event during the studyNeurologist diagnosisUPDRS4 Q41 - - - "Do you have problems sleeping?" YesUPDRS.Ins>0 MDS-UPDRS item 1.7 >/=1MDS-UPDRS  Ins>0MDS-UPDRS  SLP>0
SCOPA-SLEEP 
Nighttime (section B) 
>6 -
BDI, Beck;s Depression Inventory; GDS, Geriatric Depression Scale; HDRS, Hamilton Depression Rating Scale; MMSE, the Mini-Mental State Examination; MoCA Montreal Cognitive Assessment; MSQ, Mayo Sleep Questionnaire; NMS, Non-motor Symptoms Questionnaire; RBD, REM sleep Behavior Disorder; UPDRS Unified Parkinson's Disease Rating Scale (original); MDS-UPDRS, Movement disorder society revised UPDRS version; UPSIT, The University of Pennsylvania Smell Identification Test.
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Supplemental Table 2. Analytical models per datasets
DATASET ANALYSIS OUTCOME MODEL
DATATOP base COGi AAD+BLDfDIAG+FEMALE+YEARSEDUC
DATATOP cont HY AAD+FEMALE+YEARfDIAG
DATATOP cont MMSE AAD+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq
DATATOP cont SEADL AAD+FEMALE+YEARfDIAG+YEARfDIAGsq
DATATOP cont UPDRS_scaled AAD+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq
DATATOP surv COGi AAD+AADsq+BLDfDIAG+BLDfDIAGsq+FEMALE+YEARSEDUC
DATATOP surv HY3 AAD+BLDfDIAG+BLDfDIAGsq+FEMALE+firstHY2
DATATOP surv SEADL70 AAD+BLDfDIAG+FEMALE+YEARSEDUC+firstHY2
DIGPD_chip base DEPR AAD+BLDfDIAG+BLDfDIAGsq+LEVODOPA+FEMALE+YEARSEDUC
DIGPD_chip base HYPOSMIA AAD+BLDfDIAG+FEMALE+YEARSEDUC
DIGPD_chip base INS AAD+BLDfDIAG+FEMALE
DIGPD_chip base SEADL70 AAD+AADsq+BLDfDIAG+BLDfDIAGsq+FEMALE+YEARSEDUC
DIGPD_chip base SLEEP AAD+BLDfDIAG+DRT+FEMALE
DIGPD_chip cont HY AAD+FEMALE+YEARSEDUC+YEARfDIAG+firstHY2
DIGPD_chip cont MMSE AAD+FEMALE+YEARSEDUC+YEARfDIAG+firstHY2
DIGPD_chip cont SEADL AAD+AADsq+AGONIST+LEVODOPA+FEMALE+YEARSEDUC+YEARfDIAG
DIGPD_chip cont UPDRS_scaled AAD+AADsq+LEVODOPA+FEMALE+YEARSEDUC+YEARfDIAG+firstHY2
DIGPD_chip cont UPDRS1_scaled AAD+AADsq+FEMALE+YEARfDIAG
DIGPD_chip cont UPDRS2_scaled AAD+AADsq+LEVODOPA+FEMALE+YEARfDIAG+firstHY2
DIGPD_chip cont UPDRS3_scaled AAD+AADsq+LEVODOPA+FEMALE+YEARSEDUC+YEARfDIAG
DIGPD_chip cont UPDRS4_scaled AAD+FEMALE+YEARfDIAG
DIGPD_neuroX base CONST AAD+AGONIST+BLDfDIAG+BLDfDIAGsq+FEMALE
DIGPD_neuroX base DEPR AAD+BLDfDIAG+FEMALE
DIGPD_neuroX base HYPOSMIA AAD+BLDfDIAG+FEMALE+YEARSEDUC
DIGPD_neuroX base INS AAD+BLDfDIAG+FEMALE
DIGPD_neuroX base MOTORFLUX AAD+BLDfDIAG+BLDfDIAGsq+LEVODOPA+DRT+FEMALE
DIGPD_neuroX base RL AAD+BLDfDIAG+FEMALE
DIGPD_neuroX base SLEEP AAD+BLDfDIAG+BLDfDIAGsq+FEMALE+firstHY2
DIGPD_neuroX cont HY AAD+AGONIST+DRT+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq+firstHY2
DIGPD_neuroX cont MMSE AAD+AGONIST+LEVODOPA+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq+firstHY2
DIGPD_neuroX cont SEADL AAD+AGONIST+FEMALE+YEARfDIAG+YEARfDIAGsq
DIGPD_neuroX cont UPDRS_scaled AAD+AADsq+LEVODOPA+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq+firstHY2
DIGPD_neuroX cont UPDRS1_scaled AAD+FEMALE+YEARfDIAG+YEARfDIAGsq+firstHY2
DIGPD_neuroX cont UPDRS2_scaled AAD+AADsq+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq+firstHY2
DIGPD_neuroX cont UPDRS3_scaled AAD+AADsq+AGONIST+LEVODOPA+DRT+FEMALE+YEARfDIAG+YEARfDIAGsq
DIGPD_neuroX cont UPDRS4_scaled AAD+AADsq+FEMALE+YEARfDIAG+YEARfDIAGsq
DIGPD_neuroX surv CONST AAD+AADsq+BLDfDIAG+LEVODOPA+FEMALE+YEARSEDUC+firstHY2
DIGPD_neuroX surv DEPR AAD+BLDfDIAG+FEMALE
DIGPD_neuroX surv DYSKINESIAS AAD+BLDfDIAG+LEVODOPA+FEMALE
DIGPD_neuroX surv HYPOSMIA AAD+BLDfDIAG+LEVODOPA+FEMALE+firstHY2
DIGPD_neuroX surv INS AAD+AGONIST+BLDfDIAG+BLDfDIAGsq+FEMALE+YEARSEDUC
DIGPD_neuroX surv MOTORFLUX AAD+BLDfDIAG+LEVODOPA+FEMALE+firstHY2
DIGPD_neuroX surv RL AAD+AGONIST+BLDfDIAG+FEMALE
DIGPD_neuroX surv SLEEP AAD+AGONIST+BLDfDIAG+FEMALE+YEARSEDUC
HBS base COGi AAD+AGONIST+BLDfDIAG+LEVODOPA+FEMALE+YEARSEDUC
HBS base DEPR AAD+AGONIST+BLDfDIAG+LEVODOPA+FEMALE+firstHY2
HBS base DYSKINESIAS AAD+BLDfDIAG+LEVODOPA+FEMALE+YEARSEDUC+firstHY2
HBS base HY3 AAD+AGONIST+BLDfDIAG+LEVODOPA+FEMALE+YEARSEDUC+firstHY2
HBS base INS AAD+BLDfDIAG+LEVODOPA+FEMALE+firstHY2
HBS base MOTORFLUX AAD+BLDfDIAG+BLDfDIAGsq+LEVODOPA+FEMALE+firstHY2
HBS base RL AAD+AADsq+AGONIST+BLDfDIAG+FEMALE+YEARSEDUC+firstHY2
HBS cont HY AAD+LEVODOPA+FEMALE+YEARfDIAG+YEARfDIAGsq+firstHY2
HBS cont MMSE AAD+AADsq+AGONIST+FEMALE+YEARSEDUC+YEARfDIAG
HBS cont UPDRS_scaled AAD+AGONIST+LEVODOPA+FEMALE+YEARfDIAG+YEARfDIAGsq
HBS cont UPDRS1_scaled AAD+FEMALE+YEARfDIAG+firstHY2
HBS cont UPDRS2_scaled AAD+LEVODOPA+DRT+FEMALE+YEARfDIAG+YEARfDIAGsq+firstHY2
HBS cont UPDRS3_scaled AAD+AGONIST+LEVODOPA+FEMALE+YEARfDIAG+YEARfDIAGsq
HBS cont UPDRS4_scaled AAD+LEVODOPA+FEMALE+YEARfDIAG+YEARfDIAGsq+firstHY2
HBS surv COGi AAD+BLDfDIAG+FEMALE+YEARSEDUC
HBS surv DEPR AAD+BLDfDIAG+BLDfDIAGsq+LEVODOPA+FEMALE
HBS surv DYSKINESIAS AAD+BLDfDIAG+BLDfDIAGsq+LEVODOPA+FEMALE
HBS surv HY3 AAD+BLDfDIAG+DRT+FEMALE+firstHY2
HBS surv INS AAD+BLDfDIAG+FEMALE+firstHY2
HBS surv MOTORFLUX AAD+BLDfDIAG+DRT+FEMALE
NET-PD_LS1 base COGi AAD+BLDfDIAG+LEVODOPA+FEMALE+YEARSEDUC
NET-PD_LS1 base DEPR AAD+BLDfDIAG+FEMALE+YEARSEDUC
NET-PD_LS1 base MOTORFLUX AAD+BLDfDIAG+LEVODOPA+FEMALE
NET-PD_LS1 cont SEADL AAD+AADsq+LEVODOPA+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq
NET-PD_LS1 cont UPDRS_scaled AAD+AADsq+LEVODOPA+DRT+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq
NET-PD_LS1 cont UPDRS1_scaled AAD+AADsq+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq
NET-PD_LS1 cont UPDRS2_scaled AAD+AADsq+LEVODOPA+DRT+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq
NET-PD_LS1 cont UPDRS3_scaled AAD+AADsq+LEVODOPA+DRT+FEMALE+YEARSEDUC+YEARfDIAG
NET-PD_LS1 cont UPDRS4_scaled AAD+FEMALE+YEARfDIAG+YEARfDIAGsq
NET-PD_LS1 surv COGi AAD+BLDfDIAG+FEMALE
NET-PD_LS1 surv DEPR AAD+BLDfDIAG+BLDfDIAGsq+FEMALE+YEARSEDUC
NET-PD_LS1 surv DYSKINESIAS AAD+AADsq+BLDfDIAG+LEVODOPA+FEMALE
NET-PD_LS1 surv HY3 AAD+BLDfDIAG+FEMALE
NET-PD_LS1 surv MOTORFLUX AAD+BLDfDIAG+LEVODOPA+FEMALE
NET-PD_LS1 surv SEADL70 AAD+AADsq+BLDfDIAG+LEVODOPA+FEMALE
OSLO cont HY AAD+FEMALE+YEARfDIAG+YEARfDIAGsq
OSLO cont UPDRS3_scaled AAD+AADsq+FEMALE+YEARfDIAG+YEARfDIAGsq
OSLO surv HY3 AAD+AADsq+FEMALE
PARKFIT base COGi AAD+BLDfDIAG+FEMALE
PARKFIT cont HY AAD+AADsq+FEMALE+YEARfDIAG+YEARfDIAGsq+firstHY2
PARKFIT cont UPDRS_scaled AAD+AADsq+FEMALE+YEARfDIAG+YEARfDIAGsq+firstHY2
PARKFIT sngl MMSE AAD+FEMALE+YEARfDIAG
PARKWEST base COGi AAD+AADsq+BLDfDIAG+FEMALE+YEARSEDUC
PARKWEST base HYPOSMIA AAD+BLDfDIAG+FEMALE+firstHY2
PARKWEST base INS AAD+BLDfDIAG+FEMALE
PARKWEST base SLEEP AAD+BLDfDIAG+FEMALE
PARKWEST cont HY AAD+AADsq+AGONIST+LEVODOPA+FEMALE+YEARSEDUC+YEARfDIAG+firstHY2
PARKWEST cont MMSE AAD+AGONIST+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq
PARKWEST cont SEADL AAD+AADsq+LEVODOPA+FEMALE+YEARSEDUC+YEARfDIAG+firstHY2
PARKWEST cont UPDRS_scaled AAD+AGONIST+LEVODOPA+FEMALE+YEARSEDUC+YEARfDIAG+firstHY2
PARKWEST cont UPDRS1_scaled AAD+LEVODOPA+FEMALE+YEARSEDUC+YEARfDIAG+firstHY2
PARKWEST cont UPDRS2_scaled AAD+AADsq+LEVODOPA+FEMALE+YEARSEDUC+YEARfDIAG+firstHY2
PARKWEST cont UPDRS3_scaled AAD+AGONIST+LEVODOPA+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq
PARKWEST cont UPDRS4_scaled AAD+AGONIST+DRT+FEMALE+YEARfDIAG+firstHY2
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PARKWEST surv COGi AAD+BLDfDIAG+FEMALE+firstHY2
PDBP base CONST AAD+BLDfDIAG+BLDfDIAGsq+LEVODOPA+FEMALE+YEARSEDUC
PDBP base COGi AAD+BLDfDIAG+DRT+FEMALE+YEARSEDUC
PDBP base DEPR AAD+BLDfDIAG+FEMALE
PDBP base DYSKINESIAS AAD+AADsq+BLDfDIAG+BLDfDIAGsq+LEVODOPA+DRT+FEMALE+YEARSEDUC
PDBP base HY3 AAD+AADsq+BLDfDIAG+FEMALE+firstHY2
PDBP base HYPOSMIA AAD+BLDfDIAG+FEMALE
PDBP base INS AAD+AADsq+AGONIST+BLDfDIAG+LEVODOPA+FEMALE+YEARSEDUC
PDBP base MOTORFLUX AAD+BLDfDIAG+LEVODOPA+FEMALE+firstHY2
PDBP base RBD AAD+AADsq+BLDfDIAG+FEMALE+firstHY2+YEARSEDUC
PDBP base RL AAD+BLDfDIAG+LEVODOPA+FEMALE
PDBP base SEADL70 AAD+AADsq+BLDfDIAG+BLDfDIAGsq+LEVODOPA+DRT+FEMALE+firstHY2
PDBP base SLEEP AAD+AADsq+AGONIST+BLDfDIAG+BLDfDIAGsq+FEMALE
PDBP cont HY AAD+LEVODOPA+FEMALE+firstHY2+YEARfDIAG
PDBP cont MOCA AAD+FEMALE+YEARfDIAG+YEARSEDUC
PDBP cont SEADL AAD+AADsq+AGONIST+DRT+FEMALE+firstHY2+YEARfDIAG+YEARSEDUC
PDBP cont UPDRS_scaled AAD+AADsq+AGONIST+DRT+FEMALE+firstHY2+YEARfDIAG+YEARfDIAGsq+YEARSEDUC
PDBP cont UPDRS1_scaled AAD+AGONIST+FEMALE+firstHY2+YEARfDIAG+YEARfDIAGsq+YEARSEDUC
PDBP cont UPDRS2_scaled AAD+AADsq+LEVODOPA+FEMALE+firstHY2+YEARfDIAG+YEARfDIAGsq+YEARSEDUC
PDBP cont UPDRS3_scaled AAD+AGONIST+DRT+FEMALE+YEARfDIAG+YEARfDIAGsq+YEARSEDUC
PDBP cont UPDRS4_scaled AAD+AADsq+FEMALE+firstHY2+YEARfDIAG+YEARfDIAGsq
PDBP surv CONST AAD+AADsq+AGONIST+BLDfDIAG+LEVODOPA+FEMALE
PDBP surv COGi AAD+BLDfDIAG+FEMALE+YEARSEDUC
PDBP surv DEPR AAD+AADsq+BLDfDIAG+BLDfDIAGsq+FEMALE+YEARSEDUC
PDBP surv DYSKINESIAS AAD+AADsq+BLDfDIAG+DRT+FEMALE+firstHY2+YEARSEDUC
PDBP surv HY3 AAD+BLDfDIAG+FEMALE
PDBP surv HYPOSMIA AAD+BLDfDIAG+FEMALE+firstHY2
PDBP surv INS AAD+BLDfDIAG+FEMALE
PDBP surv MOTORFLUX AAD+BLDfDIAG+LEVODOPA+DRT+FEMALE+firstHY2
PDBP surv RBD AAD+BLDfDIAG+LEVODOPA+FEMALE
PDBP surv RL AAD+AGONIST+BLDfDIAG+LEVODOPA+FEMALE+YEARSEDUC
PDBP surv SEADL70 AAD+BLDfDIAG+FEMALE+firstHY2
PDBP surv SLEEP AAD+AGONIST+BLDfDIAG+DRT+FEMALE+YEARSEDUC
PICNICS base CONST AAD+BLDfDIAG+LEVODOPA+FEMALE
PICNICS base DEPR AAD+AGONIST+BLDfDIAG+FEMALE
PICNICS base INS AAD+BLDfDIAG+LEVODOPA+FEMALE+YEARSEDUC
PICNICS base SLEEP AAD+BLDfDIAG+LEVODOPA+DRT+FEMALE
PICNICS cont HY AAD+FEMALE+YEARfDIAG+YEARfDIAGsq+firstHY2
PICNICS cont MMSE AAD+AADsq+LEVODOPA+FEMALE+YEARSEDUC+YEARfDIAG+firstHY2
PICNICS cont MOCA AAD+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq+firstHY2
PICNICS cont UPDRS_scaled AAD+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq+firstHY2
PICNICS surv CONST AAD+BLDfDIAG+FEMALE
PICNICS surv COGi AAD+BLDfDIAG+BLDfDIAGsq+DRT+FEMALE
PICNICS surv DEPR AAD+AADsq+BLDfDIAG+LEVODOPA+FEMALE+YEARSEDUC
PICNICS surv HY3 AAD+BLDfDIAG+BLDfDIAGsq+DRT+FEMALE+firstHY2
PICNICS surv INS AAD+BLDfDIAG+FEMALE+YEARSEDUC
PICNICS surv MOTORFLUX AAD+AGONIST+BLDfDIAG+BLDfDIAGsq+FEMALE+firstHY2
PICNICS surv SLEEP AAD+AGONIST+BLDfDIAG+FEMALE
PPMI base CONST AAD+AADsq+BLDfDIAG+FEMALE
PPMI base COGi AAD+AADsq+BLDfDIAG+FEMALE+YEARSEDUC
PPMI base HYPOSMIA AAD+AADsq+BLDfDIAG+FEMALE
PPMI base INS AAD+BLDfDIAG+FEMALE
PPMI base RBD AAD+AADsq+BLDfDIAG+FEMALE
PPMI base SLEEP AAD+BLDfDIAG+FEMALE+YEARSEDUC
PPMI cont HY AAD+AADsq+FEMALE+MED+YEARfDIAG+YEARfDIAGsq
PPMI cont MOCA AAD+DRT+FEMALE+YEARSEDUC+YEARfDIAG
PPMI cont SEADL AAD+DRT+FEMALE+LEVODOPA+YEARSEDUC+YEARfDIAG+YEARfDIAGsq
PPMI cont UPDRS1 AAD+AGONIST+FEMALE+YEARfDIAG
PPMI cont UPDRS2 AAD+DRT+FEMALE+LEVODOPA+YEARfDIAG+YEARfDIAGsq
PPMI cont UPDRS3 AAD+FEMALE+MED+YEARfDIAG+YEARfDIAGsq
PPMI surv CONST AAD+BLDfDIAG+FEMALE
PPMI surv COGi AAD+BLDfDIAG+FEMALE+firstHY2
PPMI surv DYSKINESIAS AAD+BLDfDIAG+FEMALE+YEARSEDUC
PPMI surv HY3 AAD+BLDfDIAG+FEMALE+firstHY2
PPMI surv INS AAD+BLDfDIAG+FEMALE
PPMI surv MOTORFLUX AAD+AADsq+BLDfDIAG+FEMALE+YEARSEDUC
PPMI surv RBD AAD+BLDfDIAG+FEMALE+YEARSEDUC+firstHY2
PPMI surv SEADL70 AAD+AADsq+BLDfDIAG+BLDfDIAGsq+FEMALE
PPMI surv SLEEP AAD+BLDfDIAG+BLDfDIAGsq+FEMALE
PRECEPT base DEPR AAD+BLDfDIAG+FEMALE+firstHY2
PRECEPT cont HY AAD+AADsq+AGONIST+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq+firstHY2
PRECEPT cont MMSE AAD+AADsq+AGONIST+FEMALE+YEARSEDUC+YEARfDIAG
PRECEPT cont MOCA AAD+AADsq+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq+firstHY2
PRECEPT cont SEADL AAD+AADsq+AGONIST+LEVODOPA+DRT+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq+firstHY2
PRECEPT cont UPDRS_scaled AAD+AADsq+AGONIST+DRT+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq+firstHY2
PRECEPT cont UPDRS1_scaled AAD+AGONIST+DRT+FEMALE+YEARSEDUC+YEARfDIAG+firstHY2
PRECEPT cont UPDRS2_scaled AAD+AADsq+AGONIST+LEVODOPA+DRT+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq+firstHY2
PRECEPT cont UPDRS3_scaled AAD+AADsq+AGONIST+LEVODOPA+DRT+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq
PRECEPT surv CONST AAD+BLDfDIAG+FEMALE
PRECEPT surv COGi AAD+BLDfDIAG+FEMALE+YEARSEDUC
PRECEPT surv DEPR AAD+BLDfDIAG+FEMALE+YEARSEDUC
PRECEPT surv DYSKINESIAS AAD+AGONIST+BLDfDIAG+LEVODOPA+FEMALE+firstHY2
PRECEPT surv HY3 AAD+BLDfDIAG+FEMALE+firstHY2
PRECEPT surv HYPOSMIA AAD+AADsq+BLDfDIAG+LEVODOPA+FEMALE+firstHY2
PRECEPT surv INS AAD+BLDfDIAG+FEMALE
PRECEPT surv MOTORFLUX AAD+AADsq+AGONIST+BLDfDIAG+LEVODOPA+FEMALE
PRECEPT surv SEADL70 AAD+AADsq+BLDfDIAG+FEMALE+firstHY2
PRECEPT surv SLEEP AAD+BLDfDIAG+LEVODOPA+FEMALE+firstHY2
PROPARK base CONST AAD+AGONIST+BLDfDIAG+FEMALE
PROPARK base COGi AAD+BLDfDIAG+FEMALE+YEARSEDUC+firstHY2
PROPARK base DEPR AAD+BLDfDIAG+FEMALE
PROPARK base DYSKINESIAS AAD+AGONIST+BLDfDIAG+LEVODOPA+FEMALE+YEARSEDUC
PROPARK base HY3 AAD+BLDfDIAG+BLDfDIAGsq+FEMALE+firstHY2
PROPARK base HYPOSMIA AAD+BLDfDIAG+LEVODOPA+FEMALE
PROPARK base INS AAD+AGONIST+BLDfDIAG+LEVODOPA+FEMALE
PROPARK base MOTORFLUX AAD+AGONIST+BLDfDIAG+LEVODOPA+DRT+FEMALE+YEARSEDUC
PROPARK base SLEEP AAD+AGONIST+BLDfDIAG+LEVODOPA+FEMALE
PROPARK cont HY AAD+AGONIST+LEVODOPA+FEMALE+YEARSEDUC+YEARfDIAG
PROPARK cont MMSE AAD+AGONIST+FEMALE+YEARSEDUC+YEARfDIAG+YEARfDIAGsq
PROPARK surv CONST AAD+AADsq+BLDfDIAG+FEMALE+firstHY2
PROPARK surv COGi AAD+BLDfDIAG+BLDfDIAGsq+LEVODOPA+DRT+FEMALE+YEARSEDUC
PROPARK surv DEPR AAD+AADsq+BLDfDIAG+FEMALE
PROPARK surv DYSKINESIAS AAD+BLDfDIAG+BLDfDIAGsq+LEVODOPA+DRT+FEMALE
PROPARK surv HY3 AAD+AGONIST+BLDfDIAG+FEMALE
PROPARK surv INS AAD+AADsq+BLDfDIAG+BLDfDIAGsq+DRT+FEMALE
PROPARK surv MOTORFLUX AAD+BLDfDIAG+LEVODOPA+DRT+FEMALE
PROPARK surv SLEEP AAD+BLDfDIAG+FEMALE
base, logistic regression model at the baseline; surv, Cox survival model; cont, linear mixed effect model
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base, logistic regression model at the baseline; surv, Cox survival model; cont, linear mixed effect model
CONST, constipation; COGi, cognitive impairment; INS, insomnia; SLEEP, daytime sleepiness; MOTORFLUX, motor 
fluctuations; HY3, Hoehn Yahr scale 3 or greater; RBD, REM sleep behavior disorder; DEPR, depression; MMSE, Mini 
Mental State Exami-tion; Montreal Cognitive Assessment, SEADL, Schwab and England Activities of Daily Living Scale; 
UPDRS, Unified Parkinson Disease Rating Scale; MDS-UPDRS, Movment Disorder Society revised version of UPDRS.
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Supplemental Table 4  Risk associated variance and the results of meta-analysis
SNP dbSNP A1 A2 A1_Frq FrqSE Outcome Analysis N Beta SE 95% CI Isq Qtest p p<0.05 p<0.05/25 p<0.05/88 p<0.05/2022 NearGene
1:155135036 rs35749011 a g 0.0291 0.0119 COGi COGi_surv 2244 0.895 0.203 2.45 [1.64, 3.65] 0.00 0.794 1.06E-05 1 1 1 1 KRTCAP2
1:155135036 rs35749011 a g 0.0259 0.0067 MOCA MOCA_cont 1074 -1.164 0.373 -1.16 [-1.89, -0.43] 0.00 0.490 1.80E-03 1 1 1 0 KRTCAP2
1:155135036 rs35749011 a g 0.0310 0.0131 COGi COGi_base 2859 0.678 0.220 1.97 [1.28, 3.03] 0.00 0.848 2.02E-03 1 1 1 0 KRTCAP2
1:155135036 rs35749011 a g 0.0289 0.0113 HY HY_cont 3627 0.076 0.028 0.08 [0.02, 0.13] 0.00 0.531 7.10E-03 1 1 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0263 0.0080 SEADL SEADL_cont 2218 -1.641 0.748 -1.64 [-3.11, -0.18] 0.00 0.441 2.82E-02 1 1 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0223 0.0076 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.212 0.099 0.21 [0.02, 0.41] 0.00 0.879 3.32E-02 1 1 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0288 0.0156 DYSKINESIAS DYSKINESIAS_base 1232 0.643 0.307 1.90 [1.04, 3.47] 25.50 0.261 3.66E-02 1 1 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0265 0.0099 UPDRS_scaled UPDRS_scaled_cont 2994 0.153 0.076 0.15 [0.00, 0.30] 0.00 0.855 4.50E-02 1 1 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0274 0.0139 INS INS_base 2103 0.364 0.218 1.44 [0.94, 2.21] 0.00 0.493 9.48E-02 1 1 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0230 0.0075 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.157 0.099 0.16 [-0.04, 0.35] 0.00 0.704 1.15E-01 1 0 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0346 0.0161 HY3 HY3_base 1289 0.440 0.315 1.55 [0.84, 2.88] 0.00 0.469 1.63E-01 1 0 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0238 0.0119 MMSE MMSE_cont 2114 -0.211 0.155 -0.21 [-0.52, 0.09] 0.00 0.850 1.74E-01 1 0 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0244 0.0075 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.116 0.085 0.12 [-0.05, 0.28] 12.20 0.335 1.76E-01 1 0 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0332 0.0158 DEPR DEPR_surv 1314 0.301 0.229 1.35 [0.86, 2.12] 38.30 0.150 1.89E-01 1 0 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0267 0.0092 HY3 HY3_surv 2582 0.212 0.192 1.24 [0.85, 1.80] 4.00 0.402 2.70E-01 1 0 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0297 0.0140 SLEEP SLEEP_base 1724 0.245 0.237 1.28 [0.80, 2.03] 7.00 0.375 3.00E-01 1 0 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0298 0.0139 MOTORFLUX MOTORFLUX_base 1803 0.247 0.250 1.28 [0.78, 2.09] 0.00 0.619 3.25E-01 1 0 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0254 0.0088 DYSKINESIAS DYSKINESIAS_surv 1656 0.170 0.183 1.19 [0.83, 1.70] 0.00 0.956 3.51E-01 1 0 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0292 0.0137 HYPOSMIA HYPOSMIA_base 1588 0.198 0.245 1.22 [0.75, 1.97] 0.00 0.657 4.19E-01 1 0 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0243 0.0081 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.067 0.084 0.07 [-0.10, 0.23] 29.60 0.213 4.28E-01 1 0 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0235 0.0058 SEADL70 SEADL70_surv 1277 0.203 0.292 1.23 [0.69, 2.17] 0.00 0.567 4.86E-01 1 0 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0273 0.0082 MOTORFLUX MOTORFLUX_surv 1709 0.034 0.153 1.03 [0.77, 1.40] 0.00 0.813 8.24E-01 1 0 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0298 0.0145 CONST CONST_base 1472 0.040 0.238 1.04 [0.65, 1.66] 0.00 0.729 8.65E-01 1 0 0 0 KRTCAP2
1:155135036 rs35749011 a g 0.0268 0.0132 DEPR DEPR_base 1870 -0.003 0.302 1.00 [0.55, 1.80] 0.00 0.724 9.92E-01 1 0 0 0 KRTCAP2
2:18147848 rs76116224 a t 0.9045 0.0153 SLEEP SLEEP_base 1033 -0.765 0.195 0.47 [0.32, 0.68] 0.00 0.453 8.41E-05 1 0 0 0 KCNS3
2:18147848 rs76116224 a t 0.9038 0.0145 HY HY_cont 2574 -0.048 0.021 -0.05 [-0.09, -0.01] 0.00 0.513 2.11E-02 1 0 0 0 KCNS3
2:18147848 rs76116224 a t 0.9132 0.0094 SEADL70 SEADL70_surv 1100 -0.357 0.218 0.70 [0.46, 1.07] 0.00 0.702 1.01E-01 1 0 0 0 KCNS3
2:18147848 rs76116224 a t 0.9049 0.0148 INS INS_base 1529 -0.207 0.162 0.81 [0.59, 1.12] 45.70 0.101 2.01E-01 1 0 0 0 KCNS3
2:18147848 rs76116224 a t 0.8977 0.0094 UPDRS3_scaled UPDRS3_scaled_cont 1389 -0.089 0.073 -0.09 [-0.23, 0.05] 55.80 0.060 2.22E-01 1 0 0 0 KCNS3
2:18147848 rs76116224 a t 0.8983 0.0131 UPDRS4_scaled UPDRS4_scaled_cont 1091 0.091 0.081 0.09 [-0.07, 0.25] 0.00 0.425 2.59E-01 1 0 0 0 KCNS3
2:18147848 rs76116224 a t 0.9010 0.0112 COGi COGi_base 2369 -0.205 0.184 0.81 [0.57, 1.17] 0.00 0.708 2.63E-01 1 0 0 0 KCNS3
2:18147848 rs76116224 a t 0.9062 0.0130 HY3 HY3_surv 1991 -0.138 0.126 0.87 [0.68, 1.12] 49.40 0.065 2.74E-01 1 0 0 0 KCNS3
2:18147848 rs76116224 a t 0.8983 0.0135 UPDRS1_scaled UPDRS1_scaled_cont 1092 -0.107 0.102 -0.11 [-0.31, 0.09] 39.80 0.173 2.91E-01 1 0 0 0 KCNS3
2:18147848 rs76116224 a t 0.9053 0.0186 UPDRS_scaled UPDRS_scaled_cont 1941 -0.065 0.064 -0.06 [-0.19, 0.06] 36.20 0.152 3.14E-01 1 0 0 0 KCNS3
2:18147848 rs76116224 a t 0.9117 0.0128 COGi COGi_surv 1672 0.111 0.181 1.12 [0.78, 1.59] 0.00 0.590 5.38E-01 1 0 0 0 KCNS3
2:18147848 rs76116224 a t 0.9036 0.0090 DYSKINESIAS DYSKINESIAS_surv 1115 0.089 0.161 1.09 [0.80, 1.50] 0.00 0.475 5.79E-01 1 0 0 0 KCNS3
2:18147848 rs76116224 a t 0.9039 0.0126 DEPR DEPR_base 1119 -0.110 0.244 0.90 [0.56, 1.44] 0.00 0.713 6.53E-01 1 0 0 0 KCNS3
2:18147848 rs76116224 a t 0.9132 0.0180 SEADL SEADL_cont 1200 0.271 0.623 0.27 [-0.95, 1.49] 0.00 0.501 6.64E-01 1 0 0 0 KCNS3
2:18147848 rs76116224 a t 0.9205 0.0174 MMSE MMSE_cont 1565 0.046 0.109 0.05 [-0.17, 0.26] 0.00 0.984 6.70E-01 1 0 0 0 KCNS3
2:18147848 rs76116224 a t 0.8996 0.0128 UPDRS2_scaled UPDRS2_scaled_cont 1087 0.032 0.100 0.03 [-0.17, 0.23] 0.00 0.648 7.53E-01 1 0 0 0 KCNS3
2:18147848 rs76116224 a t 0.9019 0.0073 MOTORFLUX MOTORFLUX_base 1112 -0.045 0.218 0.96 [0.62, 1.46] 0.00 0.684 8.36E-01 1 0 0 0 KCNS3
12:40614434 rs76904798 t c 0.1552 0.0187 HY3 HY3_surv 2582 0.281 0.078 1.32 [1.14, 1.54] 17.90 0.283 3.01E-04 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1450 0.0114 DYSKINESIAS DYSKINESIAS_surv 1856 0.179 0.078 1.20 [1.03, 1.39] 0.00 0.456 2.12E-02 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1553 0.0172 MMSE MMSE_cont 2114 0.139 0.060 0.14 [0.02, 0.26] 0.00 0.936 2.12E-02 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1460 0.0158 HYPOSMIA HYPOSMIA_base 1588 0.207 0.115 1.23 [0.98, 1.54] 0.00 0.566 7.05E-02 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1522 0.0165 HY HY_cont 3627 0.020 0.012 0.02 [-0.00, 0.04] 14.40 0.303 1.02E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1458 0.0153 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.064 0.040 -0.06 [-0.14, 0.01] 0.00 0.657 1.05E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1472 0.0206 MOCA MOCA_cont 1074 0.268 0.166 0.27 [-0.06, 0.59] 33.90 0.209 1.07E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1540 0.0259 COGi COGi_surv 2244 -0.145 0.104 0.87 [0.71, 1.06] 0.00 0.792 1.64E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1508 0.0123 DEPR DEPR_surv 1314 -0.122 0.108 0.88 [0.72, 1.09] 0.00 0.485 2.59E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1521 0.0119 MOTORFLUX MOTORFLUX_base 1803 0.120 0.110 1.13 [0.91, 1.40] 18.80 0.295 2.76E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1479 0.0189 MOTORFLUX MOTORFLUX_surv 1709 0.060 0.066 1.06 [0.93, 1.21] 0.00 0.513 3.68E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1453 0.0158 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.032 0.040 -0.03 [-0.11, 0.05] 0.00 0.484 4.16E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1569 0.0225 INS INS_surv 1112 0.064 0.090 1.07 [0.89, 1.27] 0.00 0.464 4.75E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1555 0.0138 HY3 HY3_base 1289 -0.112 0.159 0.89 [0.66, 1.22] 9.20 0.333 4.81E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1490 0.0197 UPDRS_scaled UPDRS_scaled_cont 2994 0.022 0.032 0.02 [-0.04, 0.09] 0.00 0.457 4.86E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1463 0.0166 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.022 0.035 0.02 [-0.05, 0.09] 0.00 0.958 5.17E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1574 0.0197 DEPR DEPR_base 2138 0.077 0.121 1.08 [0.85, 1.37] 0.00 0.648 5.27E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1539 0.0210 INS INS_base 2220 -0.052 0.097 0.95 [0.79, 1.15] 14.60 0.316 5.95E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1531 0.0131 DYSKINESIAS DYSKINESIAS_base 1232 0.072 0.137 1.07 [0.82, 1.41] 5.90 0.346 5.98E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1536 0.0212 CONST CONST_base 1472 -0.059 0.117 0.94 [0.75, 1.19] 0.00 0.647 6.12E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1455 0.0117 SEADL SEADL_cont 2112 0.164 0.326 0.16 [-0.47, 0.80] 0.00 0.473 6.14E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1488 0.0132 COGi COGi_base 2859 -0.055 0.120 0.95 [0.75, 1.20] 0.00 0.429 6.44E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1522 0.0219 SLEEP SLEEP_base 1724 0.039 0.116 1.04 [0.83, 1.30] 0.00 0.640 7.40E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1464 0.0150 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.008 0.035 0.01 [-0.06, 0.08] 0.00 0.750 8.22E-01 1 0 0 0 LRRK2
12:40614434 rs76904798 t c 0.1431 0.0123 SEADL70 SEADL70_surv 1683 -0.002 0.127 1.00 [0.78, 1.28] 0.00 0.834 9.86E-01 1 0 0 0 LRRK2
4:77147969 rs4101061 a g 0.6937 0.0116 MMSE MMSE_cont 2114 0.153 0.046 0.15 [0.06, 0.24] 42.30 0.096 9.48E-04 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.7023 0.0107 MOTORFLUX MOTORFLUX_base 1803 -0.164 0.087 0.85 [0.72, 1.01] 43.60 0.131 5.98E-02 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6988 0.0192 HY3 HY3_surv 2582 -0.120 0.066 0.89 [0.78, 1.01] 0.00 0.443 6.59E-02 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6955 0.0108 HY3 HY3_base 1289 -0.142 0.121 0.87 [0.68, 1.10] 0.00 0.779 2.40E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6995 0.0095 COGi COGi_surv 2244 -0.082 0.078 0.92 [0.79, 1.07] 42.20 0.086 2.94E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.7004 0.0129 INS INS_base 2220 0.058 0.076 1.06 [0.91, 1.23] 35.00 0.149 4.47E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.7012 0.0097 COGi COGi_base 2859 -0.068 0.090 0.93 [0.78, 1.11] 0.00 0.958 4.51E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6968 0.0098 HY HY_cont 3627 -0.007 0.009 -0.01 [-0.02, 0.01] 33.70 0.121 4.70E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6979 0.0084 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.017 0.027 -0.02 [-0.07, 0.04] 0.00 0.637 5.33E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6996 0.0088 DYSKINESIAS DYSKINESIAS_base 1232 -0.065 0.109 0.94 [0.76, 1.16] 0.00 0.386 5.48E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6927 0.0107 MOCA MOCA_cont 1074 -0.071 0.128 -0.07 [-0.32, 0.18] 0.00 0.738 5.82E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.7051 0.0090 SEADL70 SEADL70_surv 1683 0.053 0.099 1.05 [0.87, 1.28] 0.00 0.891 5.94E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.7034 0.0136 MOTORFLUX MOTORFLUX_surv 1709 -0.026 0.052 0.97 [0.88, 1.08] 0.00 0.476 6.13E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.7024 0.0116 DYSKINESIAS DYSKINESIAS_surv 1856 -0.031 0.062 0.97 [0.86, 1.10] 0.00 0.908 6.22E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6997 0.0138 CONST CONST_base 1472 0.039 0.091 1.04 [0.87, 1.24] 0.00 0.898 6.65E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6998 0.0101 UPDRS_scaled UPDRS_scaled_cont 2994 0.011 0.025 0.01 [-0.04, 0.06] 0.00 0.793 6.78E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6972 0.0075 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.012 0.031 -0.01 [-0.07, 0.05] 15.00 0.316 6.94E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6969 0.0099 HYPOSMIA HYPOSMIA_base 1588 -0.032 0.086 0.97 [0.82, 1.14] 0.00 0.668 7.06E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.7003 0.0157 DEPR DEPR_base 2138 -0.034 0.097 0.97 [0.80, 1.17] 0.00 0.553 7.23E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6967 0.0079 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.006 0.031 -0.01 [-0.07, 0.05] 0.00 0.944 8.36E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6847 0.0218 INS INS_surv 1112 -0.010 0.067 0.99 [0.87, 1.13] 3.40 0.395 8.87E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6934 0.0087 SEADL SEADL_cont 2218 -0.033 0.246 -0.03 [-0.52, 0.45] 0.00 0.793 8.93E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6977 0.0145 SLEEP SLEEP_base 1724 0.004 0.089 1.00 [0.84, 1.19] 0.00 0.912 9.66E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6916 0.0116 DEPR DEPR_surv 1314 -0.003 0.079 1.00 [0.85, 1.16] 0.00 0.638 9.69E-01 1 0 0 0 FAM47E
4:77147969 rs4101061 a g 0.6962 0.0074 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.000 0.028 -0.00 [-0.05, 0.05] 0.00 0.513 9.94E-01 1 0 0 0 FAM47E
8:11712443 rs1293298 a c 0.7358 0.0103 INS INS_surv 1112 -0.230 0.071 0.79 [0.69, 0.91] 0.00 0.738 1.27E-03 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7483 0.0116 COGi COGi_base 2859 -0.178 0.096 0.84 [0.69, 1.01] 0.00 0.449 6.31E-02 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7453 0.0220 INS INS_base 2220 0.136 0.081 1.15 [0.98, 1.34] 0.00 0.784 9.23E-02 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7485 0.0195 UPDRS_scaled UPDRS_scaled_cont 2994 -0.041 0.027 -0.04 [-0.09, 0.01] 0.00 0.580 1.24E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7504 0.0158 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.049 0.033 -0.05 [-0.11, 0.02] 0.00 0.535 1.40E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7528 0.0177 MMSE MMSE_cont 2114 0.067 0.051 0.07 [-0.03, 0.17] 0.00 0.747 1.92E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7426 0.0190 CONST CONST_base 1472 -0.112 0.094 0.89 [0.74, 1.07] 0.00 0.572 2.34E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7442 0.0057 HY3 HY3_base 1289 0.161 0.137 1.17 [0.90, 1.54] 32.40 0.228 2.38E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7401 0.0120 MOCA MOCA_cont 1074 -0.131 0.133 -0.13 [-0.39, 0.13] 46.00 0.135 3.24E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7553 0.0202 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.028 0.030 -0.03 [-0.09, 0.03] 7.90 0.369 3.45E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7519 0.0149 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.031 0.033 0.03 [-0.03, 0.10] 0.00 0.756 3.46E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7478 0.0210 DEPR DEPR_base 2138 -0.091 0.101 0.91 [0.75, 1.11] 0.00 0.454 3.69E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7441 0.0136 DYSKINESIAS DYSKINESIAS_surv 1856 -0.051 0.065 0.95 [0.84, 1.08] 0.00 0.869 4.38E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7435 0.0132 SEADL70 SEADL70_surv 1683 -0.069 0.103 0.93 [0.76, 1.14] 9.70 0.351 5.04E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7504 0.0272 HY3 HY3_surv 2582 0.046 0.072 1.05 [0.91, 1.21] 16.40 0.297 5.21E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7444 0.0230 COGi COGi_surv 2244 0.049 0.087 1.05 [0.89, 1.24] 46.20 0.062 5.76E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7502 0.0144 DEPR DEPR_surv 1314 0.041 0.087 1.04 [0.88, 1.24] 0.00 0.447 6.40E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7515 0.0156 HYPOSMIA HYPOSMIA_base 1588 -0.033 0.089 0.97 [0.81, 1.15] 0.00 0.663 7.14E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7507 0.0164 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.008 0.029 -0.01 [-0.06, 0.05] 0.00 0.647 7.79E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7501 0.0197 SLEEP SLEEP_base 1724 -0.026 0.095 0.97 [0.81, 1.17] 21.00 0.269 7.82E-01 1 0 0 0 CTSB
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8:11712443 rs1293298 a c 0.7418 0.0069 DYSKINESIAS DYSKINESIAS_base 1232 0.032 0.117 1.03 [0.82, 1.30] 0.00 0.710 7.86E-01 1 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7461 0.0096 MOTORFLUX MOTORFLUX_base 1803 -0.010 0.094 0.99 [0.82, 1.19] 0.00 0.751 9.12E-01 0 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7511 0.0114 SEADL SEADL_cont 2218 -0.027 0.265 -0.03 [-0.55, 0.49] 6.20 0.382 9.19E-01 0 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7459 0.0100 MOTORFLUX MOTORFLUX_surv 1709 0.004 0.055 1.00 [0.90, 1.12] 0.00 0.683 9.46E-01 0 0 0 0 CTSB
8:11712443 rs1293298 a c 0.7519 0.0167 HY HY_cont 3627 0.001 0.010 0.00 [-0.02, 0.02] 0.00 0.654 9.51E-01 0 0 0 0 CTSB
16:50736656 rs6500328 a g 0.6003 0.0206 SLEEP SLEEP_base 1724 -0.272 0.085 0.76 [0.64, 0.90] 0.00 0.459 1.45E-03 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.6013 0.0151 MOCA MOCA_cont 1074 0.333 0.149 0.33 [0.04, 0.63] 37.50 0.187 2.56E-02 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.6035 0.0139 SEADL SEADL_cont 2218 -0.510 0.262 -0.51 [-1.02, 0.00] 28.00 0.205 5.19E-02 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.6086 0.0137 DEPR DEPR_base 2138 -0.143 0.090 0.87 [0.73, 1.03] 0.00 0.995 1.12E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.5790 0.0186 INS INS_surv 1112 -0.116 0.076 0.89 [0.77, 1.03] 16.80 0.305 1.24E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.6009 0.0197 INS INS_base 2220 -0.091 0.071 0.91 [0.80, 1.05] 0.00 0.724 1.98E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.6069 0.0100 MOTORFLUX MOTORFLUX_base 1803 -0.097 0.083 0.91 [0.77, 1.07] 57.10 0.053 2.42E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.6068 0.0147 DEPR DEPR_surv 1314 -0.104 0.096 0.90 [0.75, 1.09] 36.30 0.165 2.78E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.6091 0.0137 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.039 0.037 -0.04 [-0.11, 0.03] 0.00 0.658 2.91E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.6147 0.0187 UPDRS_scaled UPDRS_scaled_cont 2994 -0.024 0.028 -0.02 [-0.08, 0.03] 46.00 0.054 3.83E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.6093 0.0137 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.024 0.038 0.02 [-0.05, 0.10] 40.90 0.118 5.22E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.6057 0.0094 DYSKINESIAS DYSKINESIAS_base 1232 0.062 0.102 1.06 [0.87, 1.30] 0.00 0.654 5.45E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.5942 0.0185 DYSKINESIAS DYSKINESIAS_surv 1856 0.039 0.074 1.04 [0.90, 1.20] 46.50 0.082 5.97E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.5894 0.0260 HY3 HY3_surv 2582 0.035 0.071 1.04 [0.90, 1.19] 33.20 0.152 6.16E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.6016 0.0169 MMSE MMSE_cont 2114 -0.023 0.048 -0.02 [-0.12, 0.07] 32.60 0.168 6.34E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.5990 0.0289 MOTORFLUX MOTORFLUX_surv 1709 0.026 0.060 1.03 [0.91, 1.15] 0.00 0.972 6.61E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.6056 0.0182 COGi COGi_base 2859 -0.039 0.088 0.96 [0.81, 1.14] 0.00 0.607 6.61E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.5938 0.0216 CONST CONST_base 1472 -0.034 0.087 0.97 [0.81, 1.15] 52.40 0.078 7.00E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.6053 0.0142 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.012 0.032 -0.01 [-0.07, 0.05] 45.00 0.079 7.12E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.6073 0.0230 HY HY_cont 3627 -0.003 0.010 -0.00 [-0.02, 0.02] 26.70 0.182 7.39E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.6019 0.0122 HY3 HY3_base 1289 -0.035 0.119 0.97 [0.76, 1.22] 0.00 0.446 7.68E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.5948 0.0224 SEADL70 SEADL70_surv 1683 -0.021 0.105 0.98 [0.80, 1.20] 0.00 0.519 8.42E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.6081 0.0143 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.006 0.033 0.01 [-0.06, 0.07] 1.50 0.407 8.49E-01 0 0 0 0 NOD2
16:50736656 rs6500328 a g 0.5950 0.0213 HYPOSMIA HYPOSMIA_base 1588 -0.009 0.082 0.99 [0.84, 1.16] 0.00 0.506 9.09E-01 0 0 0 0 NOD2
12:133063768 rs11610045 a g 0.4962 0.0263 MMSE MMSE_cont 2114 0.137 0.044 0.14 [0.05, 0.22] 25.40 0.226 1.79E-03 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.4840 0.0236 DYSKINESIAS DYSKINESIAS_surv 1856 0.138 0.057 1.15 [1.03, 1.28] 0.00 0.513 1.50E-02 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.5042 0.0295 COGi COGi_base 2859 -0.185 0.085 0.83 [0.70, 0.98] 24.80 0.231 3.01E-02 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.4976 0.0303 HY3 HY3_base 1289 0.213 0.114 1.24 [0.99, 1.55] 61.90 0.073 6.09E-02 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.5054 0.0337 HY HY_cont 3627 -0.015 0.009 -0.02 [-0.03, 0.00] 11.70 0.330 7.90E-02 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.4949 0.0128 SEADL SEADL_cont 2218 0.372 0.232 0.37 [-0.08, 0.83] 29.20 0.195 1.09E-01 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.4881 0.0229 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.036 0.025 0.04 [-0.01, 0.08] 0.00 0.655 1.46E-01 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.4866 0.0219 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.039 0.029 -0.04 [-0.10, 0.02] 3.60 0.399 1.69E-01 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.4848 0.0230 INS INS_surv 1112 -0.086 0.062 0.92 [0.81, 1.04] 0.00 0.497 1.70E-01 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.5026 0.0265 DEPR DEPR_surv 1314 -0.096 0.075 0.91 [0.79, 1.05] 0.00 0.931 2.00E-01 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.5169 0.0384 HY3 HY3_surv 2582 -0.078 0.062 0.93 [0.82, 1.04] 31.10 0.170 2.11E-01 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.5000 0.0353 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.031 0.026 -0.03 [-0.08, 0.02] 5.80 0.386 2.26E-01 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.4815 0.0284 DYSKINESIAS DYSKINESIAS_base 1232 0.118 0.099 1.12 [0.93, 1.36] 0.00 0.795 2.33E-01 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.4862 0.0227 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.032 0.029 -0.03 [-0.09, 0.02] 38.00 0.139 2.57E-01 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.4874 0.0266 MOTORFLUX MOTORFLUX_base 1803 0.081 0.080 1.08 [0.93, 1.27] 0.00 0.811 3.13E-01 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.4949 0.0276 COGi COGi_surv 2244 -0.066 0.074 0.94 [0.81, 1.08] 25.80 0.214 3.73E-01 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.4943 0.0121 SEADL70 SEADL70_surv 1683 -0.080 0.092 0.92 [0.77, 1.11] 32.00 0.208 3.89E-01 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.5006 0.0308 UPDRS_scaled UPDRS_scaled_cont 2994 -0.019 0.023 -0.02 [-0.06, 0.03] 22.80 0.233 4.18E-01 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.4994 0.0238 HYPOSMIA HYPOSMIA_base 1588 0.040 0.079 1.04 [0.89, 1.21] 0.00 0.416 6.09E-01 0 0 0 0 FBRSL1
12:133063768 rs11610045 a g 0.4859 0.0228 MOTORFLUX MOTORFLUX_surv 1709 -0.014 0.048 0.99 [0.90, 1.08] 0.00 0.793 7.68E-01 0 0 0 0 FBRSL1
1:161469054 rs6658353 c g 0.5212 0.0110 HY3 HY3_base 1289 -0.365 0.117 0.69 [0.55, 0.87] 0.00 0.712 1.85E-03 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5130 0.0256 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.043 0.029 0.04 [-0.01, 0.10] 0.00 0.952 1.36E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5249 0.0186 HYPOSMIA HYPOSMIA_base 1588 0.111 0.080 1.12 [0.96, 1.31] 2.30 0.402 1.64E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5121 0.0208 DYSKINESIAS DYSKINESIAS_surv 1856 -0.077 0.058 0.93 [0.83, 1.04] 0.00 0.674 1.85E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5102 0.0303 MOCA MOCA_cont 1074 -0.156 0.119 -0.16 [-0.39, 0.08] 0.00 0.780 1.91E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5197 0.0123 COGi COGi_base 2859 0.103 0.086 1.11 [0.94, 1.31] 0.00 0.749 2.31E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5167 0.0267 UPDRS_scaled UPDRS_scaled_cont 2994 -0.028 0.023 -0.03 [-0.07, 0.02] 0.00 0.689 2.38E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5136 0.0240 DEPR DEPR_surv 1314 0.085 0.080 1.09 [0.93, 1.27] 18.10 0.296 2.88E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5296 0.0246 HY3 HY3_surv 2582 -0.059 0.061 0.94 [0.84, 1.06] 0.00 0.443 3.36E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5096 0.0290 MMSE MMSE_cont 2114 -0.034 0.044 -0.03 [-0.12, 0.05] 0.00 0.881 4.38E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5088 0.0244 MOTORFLUX MOTORFLUX_surv 1709 0.038 0.051 1.04 [0.94, 1.15] 0.00 0.907 4.55E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5229 0.0206 INS INS_base 2220 0.047 0.069 1.05 [0.91, 1.20] 0.00 0.940 5.00E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5198 0.0212 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.017 0.025 -0.02 [-0.07, 0.03] 0.00 0.682 5.01E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5011 0.0254 SEADL SEADL_cont 2218 -0.143 0.232 -0.14 [-0.60, 0.31] 0.00 0.510 5.39E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5145 0.0264 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.014 0.026 -0.01 [-0.06, 0.04] 21.80 0.256 5.99E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5278 0.0146 CONST CONST_base 1472 0.038 0.085 1.04 [0.88, 1.23] 8.20 0.360 6.54E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5058 0.0119 SEADL70 SEADL70_surv 1683 -0.038 0.093 0.96 [0.80, 1.16] 0.00 0.622 6.81E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5165 0.0228 COGi COGi_surv 2244 0.028 0.076 1.03 [0.89, 1.19] 42.40 0.085 7.17E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5284 0.0198 SLEEP SLEEP_base 1724 0.030 0.083 1.03 [0.88, 1.21] 31.70 0.186 7.19E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5104 0.0218 INS INS_surv 1112 0.021 0.069 1.02 [0.89, 1.17] 37.40 0.157 7.63E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5190 0.0274 DEPR DEPR_base 2138 -0.016 0.089 0.98 [0.83, 1.17] 0.00 0.503 8.59E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5154 0.0110 DYSKINESIAS DYSKINESIAS_base 1232 -0.015 0.101 0.99 [0.81, 1.20] 0.00 0.535 8.84E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5195 0.0135 MOTORFLUX MOTORFLUX_base 1803 -0.008 0.081 0.99 [0.85, 1.16] 0.00 0.571 9.21E-01 0 0 0 0 FCGR2A
1:161469054 rs6658353 c g 0.5111 0.0267 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.001 0.029 0.00 [-0.06, 0.06] 0.00 0.672 9.84E-01 0 0 0 0 FCGR2A
14:37989270 rs12147950 t c 0.4223 0.0257 SLEEP SLEEP_base 1724 0.253 0.084 1.29 [1.09, 1.52] 0.00 0.515 2.60E-03 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4159 0.0173 MMSE MMSE_cont 2114 -0.076 0.045 -0.08 [-0.16, 0.01] 0.00 0.670 9.52E-02 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4259 0.0243 INS INS_base 2220 -0.108 0.072 0.90 [0.78, 1.03] 21.70 0.257 1.33E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4160 0.0173 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.033 0.025 -0.03 [-0.08, 0.02] 12.50 0.335 1.91E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4245 0.0272 HYPOSMIA HYPOSMIA_base 1588 0.097 0.080 1.10 [0.94, 1.29] 0.00 0.788 2.25E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4202 0.0169 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.030 0.029 -0.03 [-0.09, 0.03] 0.00 0.665 3.07E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4155 0.0196 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.025 0.026 -0.03 [-0.08, 0.03] 0.00 0.796 3.30E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4309 0.0226 CONST CONST_base 1472 -0.078 0.085 0.93 [0.78, 1.09] 0.00 0.777 3.61E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4522 0.0219 MOCA MOCA_cont 1074 -0.097 0.118 -0.10 [-0.33, 0.13] 61.50 0.050 4.10E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4191 0.0180 DYSKINESIAS DYSKINESIAS_surv 1856 -0.042 0.059 0.96 [0.86, 1.08] 0.00 0.883 4.78E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4282 0.0318 SEADL SEADL_cont 2218 0.160 0.234 0.16 [-0.30, 0.62] 0.00 0.480 4.93E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4261 0.0234 UPDRS_scaled UPDRS_scaled_cont 2994 -0.016 0.024 -0.02 [-0.06, 0.03] 0.00 0.679 5.09E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4305 0.0260 COGi COGi_surv 2244 0.050 0.075 1.05 [0.91, 1.22] 0.00 0.973 5.09E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4207 0.0230 HY3 HY3_surv 2582 0.041 0.064 1.04 [0.92, 1.18] 0.00 0.552 5.21E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4236 0.0214 MOTORFLUX MOTORFLUX_base 1803 -0.041 0.082 0.96 [0.82, 1.13] 16.60 0.309 6.21E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4256 0.0214 HY3 HY3_base 1289 -0.053 0.118 0.95 [0.75, 1.20] 0.00 0.453 6.57E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4197 0.0204 DEPR DEPR_base 2138 0.030 0.092 1.03 [0.86, 1.23] 11.70 0.339 7.47E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4325 0.0248 HY HY_cont 3627 -0.003 0.009 -0.00 [-0.02, 0.01] 0.00 0.650 7.59E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4222 0.0249 MOTORFLUX MOTORFLUX_surv 1709 -0.014 0.050 0.99 [0.89, 1.09] 0.00 0.637 7.74E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4187 0.0166 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.006 0.029 -0.01 [-0.06, 0.05] 0.00 0.571 8.36E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4331 0.0205 INS INS_surv 1112 0.005 0.068 1.01 [0.88, 1.15] 0.00 0.425 9.40E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4326 0.0168 DYSKINESIAS DYSKINESIAS_base 1232 -0.002 0.104 1.00 [0.81, 1.22] 0.00 0.917 9.84E-01 0 0 0 0 MIPOL1
14:37989270 rs12147950 t c 0.4270 0.0201 SEADL70 SEADL70_surv 1683 0.001 0.092 1.00 [0.84, 1.20] 0.00 0.551 9.94E-01 0 0 0 0 MIPOL1
6:72487762 rs12528068 t c 0.2926 0.0073 INS INS_surv 1112 -0.222 0.075 0.80 [0.69, 0.93] 0.00 0.507 2.87E-03 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2840 0.0221 SEADL SEADL_cont 2218 0.707 0.257 0.71 [0.20, 1.21] 45.40 0.076 6.03E-03 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2860 0.0025 DYSKINESIAS DYSKINESIAS_base 1232 0.276 0.114 1.32 [1.05, 1.65] 17.10 0.299 1.56E-02 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2810 0.0163 DYSKINESIAS DYSKINESIAS_surv 1856 -0.102 0.066 0.90 [0.79, 1.03] 17.40 0.297 1.21E-01 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2809 0.0143 SEADL70 SEADL70_surv 1683 -0.150 0.108 0.86 [0.70, 1.06] 0.00 0.535 1.66E-01 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2875 0.0111 MOTORFLUX MOTORFLUX_surv 1709 -0.063 0.055 0.94 [0.84, 1.05] 40.70 0.119 2.54E-01 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2924 0.0197 COGi COGi_base 2859 0.087 0.096 1.09 [0.90, 1.32] 18.80 0.281 3.65E-01 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2840 0.0080 MOCA MOCA_cont 1074 -0.117 0.131 -0.12 [-0.37, 0.14] 16.90 0.307 3.73E-01 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.3008 0.0267 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.025 0.028 0.02 [-0.03, 0.08] 0.00 0.553 3.82E-01 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2859 0.0142 COGi COGi_surv 2244 -0.040 0.083 0.96 [0.82, 1.13] 0.00 0.911 6.28E-01 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2921 0.0256 UPDRS_scaled UPDRS_scaled_cont 2994 0.011 0.026 0.01 [-0.04, 0.06] 13.70 0.317 6.69E-01 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2840 0.0104 DEPR DEPR_surv 1314 0.028 0.086 1.03 [0.87, 1.22] 0.00 0.733 7.48E-01 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2937 0.0148 HYPOSMIA HYPOSMIA_base 1588 0.022 0.088 1.02 [0.86, 1.22] 0.00 0.673 8.02E-01 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2718 0.0265 MMSE MMSE_cont 2114 0.012 0.051 0.01 [-0.09, 0.11] 0.00 0.895 8.15E-01 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2940 0.0146 SLEEP SLEEP_base 1724 -0.011 0.094 0.99 [0.82, 1.19] 38.60 0.134 9.10E-01 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2878 0.0227 HY3 HY3_surv 2582 0.008 0.072 1.01 [0.88, 1.16] 37.80 0.117 9.14E-01 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2899 0.0114 CONST CONST_base 1472 0.010 0.096 1.01 [0.84, 1.22] 35.70 0.183 9.17E-01 0 0 0 0 RIMS1
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6:72487762 rs12528068 t c 0.2920 0.0195 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.003 0.028 0.00 [-0.05, 0.06] 54.30 0.053 9.21E-01 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2906 0.0097 MOTORFLUX MOTORFLUX_base 1803 -0.008 0.092 0.99 [0.83, 1.19] 0.00 0.591 9.33E-01 0 0 0 0 RIMS1
6:72487762 rs12528068 t c 0.2937 0.0136 INS INS_base 2220 -0.002 0.078 1.00 [0.86, 1.16] 22.60 0.250 9.80E-01 0 0 0 0 RIMS1
1:232664611 rs10797576 t c 0.1416 0.0080 MOTORFLUX MOTORFLUX_base 1803 0.337 0.114 1.40 [1.12, 1.75] 0.00 0.943 3.01E-03 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1371 0.0119 COGi COGi_base 2859 0.349 0.118 1.42 [1.12, 1.79] 4.40 0.396 3.16E-03 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1482 0.0136 DYSKINESIAS DYSKINESIAS_surv 1856 0.189 0.080 1.21 [1.03, 1.41] 0.00 0.640 1.75E-02 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1408 0.0148 MOCA MOCA_cont 1074 -0.383 0.175 -0.38 [-0.73, -0.04] 0.00 0.762 2.88E-02 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1390 0.0144 CONST CONST_base 1472 0.152 0.122 1.16 [0.92, 1.48] 0.00 0.566 2.14E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1381 0.0178 SLEEP SLEEP_base 1724 0.133 0.121 1.14 [0.90, 1.45] 0.00 0.546 2.70E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1479 0.0182 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.035 0.035 0.03 [-0.03, 0.10] 0.00 0.591 3.28E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1399 0.0034 DYSKINESIAS DYSKINESIAS_base 1232 -0.119 0.146 0.89 [0.67, 1.18] 0.00 0.996 4.14E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1379 0.0037 HY3 HY3_base 1289 -0.136 0.173 0.87 [0.62, 1.23] 34.00 0.220 4.31E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1360 0.0210 UPDRS_scaled UPDRS_scaled_cont 2994 0.023 0.034 0.02 [-0.04, 0.09] 0.00 0.944 5.00E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1361 0.0217 HY HY_cont 3627 0.008 0.013 0.01 [-0.02, 0.03] 3.10 0.414 5.25E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1440 0.0175 INS INS_surv 1112 0.057 0.095 1.06 [0.88, 1.27] 16.00 0.311 5.47E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1408 0.0187 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.021 0.037 0.02 [-0.05, 0.09] 0.00 0.951 5.75E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1415 0.0198 COGi COGi_surv 2244 0.057 0.111 1.06 [0.85, 1.32] 33.20 0.152 6.07E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1392 0.0168 HY3 HY3_surv 2582 0.048 0.094 1.05 [0.87, 1.26] 43.20 0.079 6.10E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1410 0.0162 HYPOSMIA HYPOSMIA_base 1588 0.049 0.116 1.05 [0.84, 1.32] 15.10 0.317 6.71E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1297 0.0192 MMSE MMSE_cont 2114 -0.027 0.066 -0.03 [-0.16, 0.10] 0.00 0.787 6.87E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1428 0.0201 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.013 0.042 -0.01 [-0.09, 0.07] 29.00 0.207 7.57E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1393 0.0173 INS INS_base 2220 -0.028 0.102 0.97 [0.80, 1.19] 0.00 0.498 7.86E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1446 0.0200 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.006 0.041 0.01 [-0.08, 0.09] 0.00 0.502 8.88E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1459 0.0118 SEADL70 SEADL70_surv 1683 -0.016 0.135 0.98 [0.76, 1.28] 13.60 0.327 9.05E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1379 0.0149 DEPR DEPR_surv 1314 0.009 0.118 1.01 [0.80, 1.27] 37.90 0.154 9.42E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1393 0.0129 MOTORFLUX MOTORFLUX_surv 1709 -0.005 0.072 0.99 [0.86, 1.15] 0.00 0.442 9.44E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1369 0.0172 DEPR DEPR_base 2138 0.007 0.133 1.01 [0.78, 1.31] 0.00 0.569 9.60E-01 0 0 0 0 SIPA1L2
1:232664611 rs10797576 t c 0.1351 0.0165 SEADL SEADL_cont 2218 -0.012 0.344 -0.01 [-0.69, 0.66] 0.00 0.473 9.73E-01 0 0 0 0 SIPA1L2
4:17968811 rs34025766 a t 0.1636 0.0118 DYSKINESIAS DYSKINESIAS_surv 1856 0.224 0.077 1.25 [1.08, 1.45] 32.30 0.182 3.50E-03 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1598 0.0093 SEADL SEADL_cont 2218 -0.758 0.312 -0.76 [-1.37, -0.15] 13.20 0.327 1.52E-02 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1645 0.0096 CONST CONST_base 1472 0.271 0.116 1.31 [1.05, 1.64] 48.60 0.100 1.90E-02 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1581 0.0127 MMSE MMSE_cont 2114 -0.129 0.060 -0.13 [-0.25, -0.01] 0.00 0.874 3.27E-02 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1617 0.0190 INS INS_surv 1112 0.173 0.084 1.19 [1.01, 1.40] 0.00 0.648 3.83E-02 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1604 0.0189 COGi COGi_surv 2244 0.201 0.098 1.22 [1.01, 1.48] 29.00 0.187 4.03E-02 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1601 0.0128 DEPR DEPR_surv 1314 0.200 0.099 1.22 [1.01, 1.48] 0.00 0.904 4.38E-02 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1536 0.0222 HY HY_cont 3627 0.022 0.012 0.02 [-0.00, 0.05] 33.60 0.122 6.29E-02 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1660 0.0106 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.062 0.037 0.06 [-0.01, 0.14] 0.00 0.541 9.60E-02 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1643 0.0078 SEADL70 SEADL70_surv 1683 0.129 0.118 1.14 [0.90, 1.43] 8.70 0.357 2.77E-01 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1574 0.0202 UPDRS_scaled UPDRS_scaled_cont 2994 0.031 0.032 0.03 [-0.03, 0.09] 14.10 0.313 3.34E-01 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1685 0.0079 DYSKINESIAS DYSKINESIAS_base 1232 0.124 0.131 1.13 [0.87, 1.46] 0.00 0.558 3.47E-01 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1634 0.0149 MOTORFLUX MOTORFLUX_surv 1709 -0.060 0.065 0.94 [0.83, 1.07] 0.00 0.718 3.53E-01 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1518 0.0221 HY3 HY3_surv 2582 0.068 0.087 1.07 [0.90, 1.27] 43.70 0.076 4.37E-01 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1659 0.0111 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.027 0.037 0.03 [-0.05, 0.10] 30.80 0.193 4.65E-01 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1638 0.0091 DEPR DEPR_base 2138 0.082 0.119 1.09 [0.86, 1.37] 0.00 0.681 4.91E-01 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1644 0.0108 SLEEP SLEEP_base 1724 0.040 0.116 1.04 [0.83, 1.30] 26.30 0.228 7.30E-01 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1643 0.0124 HYPOSMIA HYPOSMIA_base 1588 -0.035 0.108 0.97 [0.78, 1.19] 0.00 0.547 7.44E-01 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1571 0.0194 COGi COGi_base 2859 -0.033 0.121 0.97 [0.76, 1.23] 27.90 0.206 7.87E-01 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1675 0.0073 MOTORFLUX MOTORFLUX_base 1803 0.025 0.106 1.03 [0.83, 1.26] 0.00 0.906 8.14E-01 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1585 0.0239 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.007 0.034 -0.01 [-0.07, 0.06] 33.40 0.162 8.47E-01 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1675 0.0104 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.005 0.032 0.01 [-0.06, 0.07] 0.00 0.925 8.71E-01 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1632 0.0107 HY3 HY3_base 1289 -0.024 0.157 0.98 [0.72, 1.33] 0.00 0.960 8.77E-01 0 0 0 0 LCORL
4:17968811 rs34025766 a t 0.1657 0.0121 INS INS_base 2220 -0.015 0.095 0.99 [0.82, 1.19] 48.40 0.060 8.79E-01 0 0 0 0 LCORL
19:2341047 rs55818311 t c 0.6692 0.0133 DEPR DEPR_base 2138 0.287 0.101 1.33 [1.09, 1.62] 0.00 0.701 4.49E-03 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6744 0.0188 COGi COGi_base 2859 0.154 0.095 1.17 [0.97, 1.40] 1.00 0.421 1.04E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6784 0.0154 INS INS_surv 1112 -0.107 0.072 0.90 [0.78, 1.03] 0.00 0.550 1.36E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6614 0.0103 MMSE MMSE_cont 2114 -0.067 0.050 -0.07 [-0.16, 0.03] 0.00 0.628 1.80E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6673 0.0181 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.037 0.034 0.04 [-0.03, 0.10] 11.60 0.341 2.71E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6766 0.0149 CONST CONST_base 1472 0.078 0.091 1.08 [0.90, 1.29] 0.00 0.745 3.92E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6671 0.0199 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.023 0.029 -0.02 [-0.08, 0.03] 0.00 0.691 4.26E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6718 0.0208 UPDRS_scaled UPDRS_scaled_cont 2994 0.021 0.027 0.02 [-0.03, 0.07] 28.90 0.179 4.30E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6714 0.0140 SEADL SEADL_cont 2218 -0.205 0.268 -0.20 [-0.73, 0.32] 18.40 0.284 4.44E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6677 0.0191 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.025 0.034 0.03 [-0.04, 0.09] 2.10 0.409 4.51E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6786 0.0173 DYSKINESIAS DYSKINESIAS_surv 1856 -0.044 0.066 0.96 [0.84, 1.09] 0.00 0.974 5.06E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6613 0.0128 DEPR DEPR_surv 1314 0.057 0.087 1.06 [0.89, 1.25] 14.40 0.322 5.07E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6734 0.0165 HYPOSMIA HYPOSMIA_base 1588 0.045 0.086 1.05 [0.88, 1.24] 0.00 0.932 6.00E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6675 0.0166 INS INS_base 2220 0.030 0.075 1.03 [0.89, 1.19] 0.00 0.439 6.92E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6713 0.0182 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.008 0.030 0.01 [-0.05, 0.07] 21.40 0.259 7.98E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6683 0.0156 MOTORFLUX MOTORFLUX_base 1803 0.021 0.089 1.02 [0.86, 1.22] 0.00 0.623 8.11E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6722 0.0154 SLEEP SLEEP_base 1724 0.019 0.090 1.02 [0.85, 1.22] 0.00 0.748 8.32E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6832 0.0135 SEADL70 SEADL70_surv 1683 0.022 0.104 1.02 [0.83, 1.25] 0.00 0.783 8.32E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6753 0.0212 HY HY_cont 3627 0.002 0.010 0.00 [-0.02, 0.02] 0.00 0.701 8.49E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6798 0.0111 MOCA MOCA_cont 1074 -0.022 0.138 -0.02 [-0.29, 0.25] 0.00 0.551 8.73E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6635 0.0138 DYSKINESIAS DYSKINESIAS_base 1232 -0.009 0.110 0.99 [0.80, 1.23] 0.00 0.622 9.33E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6715 0.0192 COGi COGi_surv 2244 -0.006 0.085 0.99 [0.84, 1.17] 0.00 0.730 9.42E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6810 0.0138 MOTORFLUX MOTORFLUX_surv 1709 0.004 0.056 1.00 [0.90, 1.12] 3.40 0.400 9.42E-01 0 0 0 0 SPPL2B
19:2341047 rs55818311 t c 0.6654 0.0133 HY3 HY3_base 1289 -0.008 0.124 0.99 [0.78, 1.26] 0.00 0.416 9.47E-01 0 0 0 0 SPPL2B
17:59917366 rs61169879 t c 0.1669 0.0104 INS INS_base 2220 -0.270 0.098 0.76 [0.63, 0.93] 0.00 0.663 6.05E-03 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1627 0.0100 DYSKINESIAS DYSKINESIAS_surv 1523 -0.245 0.122 0.78 [0.62, 1.00] 0.00 0.435 4.54E-02 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1791 0.0208 HY HY_cont 3627 -0.022 0.014 -0.02 [-0.05, 0.00] 1.30 0.431 1.09E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1702 0.0071 MOCA MOCA_cont 1074 0.333 0.228 0.33 [-0.11, 0.78] 28.80 0.239 1.44E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1702 0.0094 MMSE MMSE_cont 2114 0.070 0.069 0.07 [-0.06, 0.20] 0.00 0.457 3.06E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1721 0.0067 DEPR DEPR_base 1800 -0.128 0.136 0.88 [0.67, 1.15] 9.40 0.357 3.47E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1681 0.0137 COGi COGi_surv 2075 -0.108 0.128 0.90 [0.70, 1.15] 0.00 0.549 4.00E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1637 0.0148 INS INS_surv 1112 -0.088 0.111 0.92 [0.74, 1.14] 0.00 0.713 4.28E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1714 0.0078 HY3 HY3_base 1289 -0.112 0.165 0.89 [0.65, 1.24] 28.40 0.247 5.00E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1671 0.0072 SEADL SEADL_cont 1878 0.258 0.420 0.26 [-0.56, 1.08] 32.80 0.178 5.39E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1594 0.0077 SEADL70 SEADL70_surv 1352 0.084 0.173 1.09 [0.77, 1.53] 0.00 0.613 6.29E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1614 0.0098 UPDRS2_scaled UPDRS2_scaled_cont 1763 -0.030 0.065 -0.03 [-0.16, 0.10] 0.00 0.851 6.46E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1765 0.0106 DEPR DEPR_surv 1125 0.074 0.161 1.08 [0.78, 1.48] 0.00 0.985 6.47E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1608 0.0103 UPDRS4_scaled UPDRS4_scaled_cont 1458 0.027 0.059 0.03 [-0.09, 0.14] 16.00 0.313 6.54E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1635 0.0118 HYPOSMIA HYPOSMIA_base 1588 0.045 0.111 1.05 [0.84, 1.30] 0.00 0.787 6.88E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1692 0.0065 MOTORFLUX MOTORFLUX_base 1466 -0.050 0.129 0.95 [0.74, 1.22] 0.00 0.594 6.96E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1747 0.0185 COGi COGi_base 2521 -0.047 0.120 0.95 [0.75, 1.21] 0.00 0.938 6.98E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1616 0.0093 UPDRS1_scaled UPDRS1_scaled_cont 1771 -0.021 0.066 -0.02 [-0.15, 0.11] 0.00 0.917 7.56E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1786 0.0218 UPDRS_scaled UPDRS_scaled_cont 2655 -0.010 0.041 -0.01 [-0.09, 0.07] 0.00 0.959 8.15E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1694 0.0066 DYSKINESIAS DYSKINESIAS_base 1232 0.033 0.146 1.03 [0.78, 1.38] 38.20 0.199 8.24E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1631 0.0099 MOTORFLUX MOTORFLUX_surv 1457 -0.021 0.097 0.98 [0.81, 1.18] 0.00 0.717 8.31E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1654 0.0099 UPDRS3_scaled UPDRS3_scaled_cont 2107 -0.011 0.051 -0.01 [-0.11, 0.09] 18.80 0.287 8.35E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1811 0.0218 HY3 HY3_surv 2254 -0.018 0.097 0.98 [0.81, 1.19] 0.00 0.908 8.51E-01 0 0 0 0 BRIP1
17:59917366 rs61169879 t c 0.1655 0.0111 CONST CONST_base 1472 -0.021 0.116 0.98 [0.78, 1.23] 0.00 0.597 8.55E-01 0 0 0 0 BRIP1
9:17727065 rs10756907 a g 0.7665 0.0147 COGi COGi_base 2859 0.287 0.106 1.33 [1.08, 1.64] 0.00 0.854 6.58E-03 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7668 0.0156 HY3 HY3_base 1289 0.281 0.146 1.32 [1.00, 1.76] 0.00 0.753 5.35E-02 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7550 0.0225 HY HY_cont 3627 0.018 0.010 0.02 [-0.00, 0.04] 0.00 0.766 6.97E-02 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7530 0.0141 DEPR DEPR_surv 1314 -0.145 0.090 0.87 [0.73, 1.03] 11.60 0.341 1.07E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7643 0.0229 MMSE MMSE_cont 2114 -0.068 0.052 -0.07 [-0.17, 0.03] 22.50 0.250 1.84E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7571 0.0154 CONST CONST_base 1472 0.128 0.098 1.14 [0.94, 1.38] 40.80 0.149 1.91E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7573 0.0258 INS INS_base 2220 0.104 0.082 1.11 [0.95, 1.30] 7.50 0.372 2.04E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7522 0.0180 HY3 HY3_surv 2582 -0.088 0.070 0.92 [0.80, 1.05] 0.00 0.527 2.14E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7650 0.0147 DYSKINESIAS DYSKINESIAS_surv 1856 0.086 0.069 1.09 [0.95, 1.25] 13.50 0.327 2.16E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7489 0.0212 SLEEP SLEEP_base 1724 0.099 0.096 1.10 [0.92, 1.33] 0.00 0.442 3.00E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7531 0.0230 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.031 0.033 0.03 [-0.03, 0.10] 7.50 0.371 3.50E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7616 0.0161 MOTORFLUX MOTORFLUX_surv 1709 -0.050 0.057 0.95 [0.85, 1.06] 0.00 0.620 3.82E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7636 0.0174 SEADL SEADL_cont 2218 -0.234 0.273 -0.23 [-0.77, 0.30] 0.00 0.943 3.92E-01 0 0 0 0 SH3GL2
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9:17727065 rs10756907 a g 0.7601 0.0166 MOCA MOCA_cont 1074 -0.116 0.140 -0.12 [-0.39, 0.16] 43.70 0.149 4.07E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7511 0.0212 HYPOSMIA HYPOSMIA_base 1588 0.057 0.092 1.06 [0.88, 1.27] 33.10 0.188 5.33E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7520 0.0226 DEPR DEPR_base 2138 0.064 0.106 1.07 [0.87, 1.31] 23.40 0.243 5.46E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7446 0.0262 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.017 0.030 0.02 [-0.04, 0.07] 0.00 0.617 5.74E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7621 0.0142 SEADL70 SEADL70_surv 1683 -0.029 0.105 0.97 [0.79, 1.19] 0.00 0.672 7.85E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7752 0.0154 DYSKINESIAS DYSKINESIAS_base 1232 -0.022 0.120 0.98 [0.77, 1.24] 0.00 0.781 8.53E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7565 0.0215 UPDRS_scaled UPDRS_scaled_cont 2994 0.005 0.027 0.00 [-0.05, 0.06] 9.50 0.355 8.55E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7606 0.0286 INS INS_surv 1112 -0.014 0.078 0.99 [0.85, 1.15] 47.10 0.093 8.55E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7507 0.0233 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.004 0.029 -0.00 [-0.06, 0.05] 0.00 0.791 9.01E-01 0 0 0 0 SH3GL2
9:17727065 rs10756907 a g 0.7679 0.0186 MOTORFLUX MOTORFLUX_base 1803 -0.007 0.095 0.99 [0.82, 1.20] 0.00 0.976 9.46E-01 0 0 0 0 SH3GL2
13:49927732 rs9568188 t c 0.7423 0.0204 DYSKINESIAS DYSKINESIAS_base 1232 -0.307 0.117 0.74 [0.58, 0.93] 12.70 0.318 8.91E-03 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7471 0.0080 SEADL70 SEADL70_surv 1683 -0.220 0.100 0.80 [0.66, 0.98] 0.00 0.585 2.82E-02 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7482 0.0249 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.062 0.034 -0.06 [-0.13, 0.00] 33.40 0.173 6.82E-02 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7434 0.0236 MMSE MMSE_cont 2114 0.092 0.051 0.09 [-0.01, 0.19] 0.00 0.826 7.36E-02 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7479 0.0241 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.035 0.029 -0.03 [-0.09, 0.02] 0.00 0.937 2.33E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7451 0.0290 DEPR DEPR_base 2138 -0.114 0.104 0.89 [0.73, 1.09] 0.00 0.574 2.74E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7470 0.0176 COGi COGi_surv 2244 -0.087 0.084 0.92 [0.78, 1.08] 0.00 0.758 2.99E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7489 0.0251 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.034 0.034 0.03 [-0.03, 0.10] 43.60 0.100 3.13E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7470 0.0247 DYSKINESIAS DYSKINESIAS_surv 1856 0.062 0.067 1.06 [0.93, 1.21] 6.50 0.378 3.56E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7409 0.0284 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.021 0.030 -0.02 [-0.08, 0.04] 0.00 0.866 4.78E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7556 0.0077 MOCA MOCA_cont 1074 -0.100 0.141 -0.10 [-0.38, 0.18] 0.00 0.802 4.79E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7410 0.0251 CONST CONST_base 1472 -0.062 0.097 0.94 [0.78, 1.14] 0.00 0.512 5.21E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7431 0.0210 MOTORFLUX MOTORFLUX_base 1803 0.058 0.096 1.06 [0.88, 1.28] 26.10 0.247 5.46E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7355 0.0278 HYPOSMIA HYPOSMIA_base 1588 -0.052 0.092 0.95 [0.79, 1.14] 0.00 0.651 5.70E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7298 0.0275 HY3 HY3_surv 2582 -0.038 0.072 0.96 [0.84, 1.11] 5.00 0.394 5.94E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7420 0.0174 MOTORFLUX MOTORFLUX_surv 1709 -0.028 0.055 0.97 [0.87, 1.08] 0.00 0.969 6.13E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7438 0.0237 UPDRS_scaled UPDRS_scaled_cont 2994 -0.012 0.027 -0.01 [-0.07, 0.04] 5.70 0.389 6.47E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7404 0.0276 HY HY_cont 3627 -0.003 0.010 -0.00 [-0.02, 0.02] 40.00 0.074 7.32E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7369 0.0294 SLEEP SLEEP_base 1724 0.025 0.095 1.03 [0.85, 1.23] 0.00 0.611 7.92E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7347 0.0206 COGi COGi_base 2859 -0.019 0.098 0.98 [0.81, 1.19] 0.00 0.816 8.48E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7313 0.0253 HY3 HY3_base 1289 0.019 0.132 1.02 [0.79, 1.32] 0.00 0.581 8.86E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7472 0.0222 INS INS_surv 1112 0.011 0.077 1.01 [0.87, 1.18] 0.00 0.426 8.91E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7496 0.0158 SEADL SEADL_cont 2218 0.014 0.273 0.01 [-0.52, 0.55] 0.00 0.855 9.60E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7475 0.0204 DEPR DEPR_surv 1314 -0.003 0.088 1.00 [0.84, 1.19] 0.00 0.759 9.76E-01 0 0 0 0 CAB39L
13:49927732 rs9568188 t c 0.7417 0.0255 INS INS_base 2220 -0.001 0.082 1.00 [0.85, 1.17] 36.60 0.137 9.93E-01 0 0 0 0 CAB39L
3:48748989 rs12497850 t g 0.6440 0.0143 INS INS_surv 1112 -0.175 0.067 0.84 [0.74, 0.96] 6.30 0.376 9.44E-03 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6408 0.0134 MOCA MOCA_cont 1074 0.237 0.123 0.24 [-0.01, 0.48] 0.00 0.447 5.51E-02 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6399 0.0174 HY3 HY3_base 1289 0.182 0.121 1.20 [0.95, 1.52] 2.60 0.358 1.32E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6598 0.0174 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.034 0.026 0.03 [-0.02, 0.09] 0.00 0.497 2.03E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6550 0.0195 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.034 0.030 0.03 [-0.02, 0.09] 27.20 0.221 2.58E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6495 0.0239 HYPOSMIA HYPOSMIA_base 1588 -0.088 0.084 0.92 [0.78, 1.08] 0.00 0.754 2.92E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6446 0.0235 COGi COGi_base 2859 -0.093 0.090 0.91 [0.76, 1.09] 0.00 0.667 2.99E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6423 0.0119 DYSKINESIAS DYSKINESIAS_surv 1856 0.048 0.059 1.05 [0.93, 1.18] 0.00 0.491 4.16E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6270 0.0271 HY3 HY3_surv 2582 -0.047 0.063 0.95 [0.84, 1.08] 0.00 0.914 4.58E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6444 0.0226 HY HY_cont 3627 0.006 0.009 0.01 [-0.01, 0.02] 12.80 0.320 5.08E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6488 0.0164 DYSKINESIAS DYSKINESIAS_base 1232 -0.069 0.105 0.93 [0.76, 1.15] 0.00 0.797 5.11E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6316 0.0147 DEPR DEPR_surv 1314 -0.048 0.078 0.95 [0.82, 1.11] 0.00 0.857 5.38E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6438 0.0212 SLEEP SLEEP_base 1724 0.047 0.086 1.05 [0.89, 1.24] 0.00 0.920 5.88E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6470 0.0239 UPDRS_scaled UPDRS_scaled_cont 2994 0.012 0.024 0.01 [-0.04, 0.06] 0.00 0.813 6.34E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6508 0.0191 SEADL SEADL_cont 2218 0.094 0.239 0.09 [-0.38, 0.56] 0.00 0.492 6.94E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6386 0.0153 DEPR DEPR_base 2138 -0.030 0.092 0.97 [0.81, 1.16] 0.00 0.523 7.48E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6453 0.0210 MMSE MMSE_cont 2114 0.010 0.045 0.01 [-0.08, 0.10] 19.70 0.274 8.22E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6563 0.0197 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.005 0.030 -0.01 [-0.06, 0.05] 6.10 0.381 8.64E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6414 0.0149 CONST CONST_base 1472 -0.015 0.088 0.99 [0.83, 1.17] 28.90 0.229 8.68E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6494 0.0147 MOTORFLUX MOTORFLUX_base 1803 -0.014 0.085 0.99 [0.84, 1.16] 0.00 0.715 8.69E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6416 0.0205 MOTORFLUX MOTORFLUX_surv 1709 0.003 0.050 1.00 [0.91, 1.11] 0.00 0.521 9.49E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6538 0.0188 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.001 0.027 0.00 [-0.05, 0.05] 0.00 0.928 9.75E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6511 0.0226 INS INS_base 2220 -0.002 0.073 1.00 [0.86, 1.15] 0.00 0.671 9.77E-01 0 0 0 0 IP6K2
3:48748989 rs12497850 t g 0.6506 0.0118 SEADL70 SEADL70_surv 1683 0.000 0.094 1.00 [0.83, 1.20] 0.00 0.632 9.97E-01 0 0 0 0 IP6K2
7:23300049 rs199351 a c 0.6076 0.0192 DEPR DEPR_base 2138 -0.242 0.093 0.79 [0.65, 0.94] 8.60 0.364 9.65E-03 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6086 0.0191 INS INS_base 2220 0.173 0.074 1.19 [1.03, 1.37] 0.00 0.441 1.87E-02 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.5927 0.0264 MMSE MMSE_cont 2114 0.071 0.045 0.07 [-0.02, 0.16] 0.00 0.488 1.12E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6005 0.0205 COGi COGi_surv 2244 -0.109 0.079 0.90 [0.77, 1.05] 3.70 0.404 1.67E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6175 0.0223 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.034 0.026 0.03 [-0.02, 0.09] 0.00 0.781 1.89E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6093 0.0200 MOTORFLUX MOTORFLUX_surv 1709 0.067 0.052 1.07 [0.97, 1.18] 33.30 0.174 2.00E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6081 0.0204 HYPOSMIA HYPOSMIA_base 1588 -0.103 0.084 0.90 [0.77, 1.06] 0.00 0.915 2.17E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6024 0.0188 HY3 HY3_surv 2582 0.070 0.066 1.07 [0.94, 1.22] 5.30 0.391 2.83E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6063 0.0138 COGi COGi_base 2859 -0.068 0.088 0.93 [0.79, 1.11] 5.30 0.389 4.44E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6037 0.0193 SEADL SEADL_cont 2218 0.168 0.238 0.17 [-0.30, 0.63] 0.00 0.579 4.82E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6004 0.0184 SEADL70 SEADL70_surv 1683 -0.059 0.094 0.94 [0.78, 1.13] 0.00 0.719 5.30E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6145 0.0247 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.017 0.030 -0.02 [-0.08, 0.04] 0.00 0.680 5.63E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6083 0.0212 SLEEP SLEEP_base 1724 0.036 0.087 1.04 [0.87, 1.23] 0.00 0.656 6.83E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6122 0.0089 MOTORFLUX MOTORFLUX_base 1803 -0.030 0.085 0.97 [0.82, 1.15] 0.00 0.859 7.27E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6104 0.0052 DYSKINESIAS DYSKINESIAS_base 1232 0.036 0.107 1.04 [0.84, 1.28] 0.00 0.483 7.34E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6180 0.0242 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.009 0.027 -0.01 [-0.06, 0.04] 6.50 0.380 7.42E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6246 0.0133 DEPR DEPR_surv 1314 0.026 0.083 1.03 [0.87, 1.21] 0.00 0.952 7.55E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6084 0.0066 HY3 HY3_base 1289 0.031 0.122 1.03 [0.81, 1.31] 26.10 0.259 8.02E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6139 0.0207 MOCA MOCA_cont 1074 0.029 0.124 0.03 [-0.21, 0.27] 0.00 0.788 8.15E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6145 0.0235 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.007 0.030 -0.01 [-0.07, 0.05] 12.80 0.332 8.21E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6078 0.0249 HY HY_cont 3627 0.001 0.009 0.00 [-0.02, 0.02] 0.00 0.747 8.76E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.5964 0.0205 INS INS_surv 1112 -0.008 0.069 0.99 [0.87, 1.13] 0.00 0.487 9.09E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6057 0.0175 CONST CONST_base 1472 0.006 0.089 1.01 [0.85, 1.20] 0.00 0.466 9.47E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6131 0.0189 DYSKINESIAS DYSKINESIAS_surv 1856 0.003 0.063 1.00 [0.89, 1.13] 0.00 0.840 9.65E-01 0 0 0 0 GPNMB
7:23300049 rs199351 a c 0.6088 0.0236 UPDRS_scaled UPDRS_scaled_cont 2994 0.000 0.024 -0.00 [-0.05, 0.05] 0.00 0.547 9.92E-01 0 0 0 0 GPNMB
4:951947 rs34311866 t c 0.7722 0.0213 DYSKINESIAS DYSKINESIAS_surv 1856 -0.170 0.066 0.84 [0.74, 0.96] 0.00 0.818 1.04E-02 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7714 0.0262 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.071 0.034 -0.07 [-0.14, -0.00] 0.00 0.828 3.73E-02 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7797 0.0276 HYPOSMIA HYPOSMIA_base 1588 -0.197 0.096 0.82 [0.68, 0.99] 42.00 0.125 3.98E-02 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7697 0.0179 HY3 HY3_surv 2582 -0.140 0.075 0.87 [0.75, 1.01] 0.00 0.715 6.14E-02 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7757 0.0200 SEADL70 SEADL70_surv 1683 -0.199 0.108 0.82 [0.66, 1.01] 0.00 0.475 6.70E-02 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7811 0.0218 DEPR DEPR_surv 1314 -0.159 0.092 0.85 [0.71, 1.02] 0.00 0.897 8.21E-02 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7873 0.0177 COGi COGi_base 2859 -0.148 0.101 0.86 [0.71, 1.05] 31.70 0.175 1.41E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7791 0.0286 SLEEP SLEEP_base 1724 -0.140 0.098 0.87 [0.72, 1.05] 0.00 0.922 1.53E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7772 0.0235 MMSE MMSE_cont 2114 0.065 0.054 0.06 [-0.04, 0.17] 0.00 0.590 2.33E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7708 0.0276 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.040 0.034 -0.04 [-0.11, 0.03] 0.00 0.995 2.40E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7731 0.0283 SEADL SEADL_cont 2218 0.328 0.284 0.33 [-0.23, 0.88] 0.00 0.526 2.48E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7795 0.0245 INS INS_base 2220 0.084 0.082 1.09 [0.93, 1.28] 0.00 0.810 3.08E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7745 0.0255 HY HY_cont 3627 -0.010 0.010 -0.01 [-0.03, 0.01] 23.20 0.215 3.56E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7768 0.0257 MOTORFLUX MOTORFLUX_base 1803 -0.076 0.095 0.93 [0.77, 1.12] 27.20 0.240 4.24E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7718 0.0199 INS INS_surv 1112 -0.054 0.076 0.95 [0.82, 1.10] 0.00 0.512 4.82E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7814 0.0140 COGi COGi_surv 2244 -0.052 0.092 0.95 [0.79, 1.14] 30.80 0.172 5.70E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7645 0.0256 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.015 0.029 -0.01 [-0.07, 0.04] 0.00 0.628 6.08E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7896 0.0125 DYSKINESIAS DYSKINESIAS_base 1232 0.054 0.119 1.06 [0.84, 1.33] 41.30 0.182 6.51E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7765 0.0249 UPDRS_scaled UPDRS_scaled_cont 2994 -0.013 0.028 -0.01 [-0.07, 0.04] 0.00 0.952 6.52E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7772 0.0203 MOTORFLUX MOTORFLUX_surv 1709 -0.022 0.057 0.98 [0.88, 1.09] 0.00 0.632 7.02E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7885 0.0140 HY3 HY3_base 1289 -0.051 0.134 0.95 [0.73, 1.24] 0.00 0.505 7.05E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7739 0.0255 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.009 0.031 0.01 [-0.05, 0.07] 0.00 0.478 7.77E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7710 0.0254 MOCA MOCA_cont 1074 -0.028 0.144 -0.03 [-0.31, 0.25] 0.00 0.628 8.45E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7787 0.0260 CONST CONST_base 1472 -0.019 0.101 0.98 [0.80, 1.20] 0.00 0.574 8.50E-01 0 0 0 0 TMEM175
4:951947 rs34311866 t c 0.7746 0.0296 DEPR DEPR_base 2138 0.001 0.107 1.00 [0.81, 1.23] 0.00 0.709 9.96E-01 0 0 0 0 TMEM175
17:44866805 rs11658976 a g 0.5958 0.0158 MOTORFLUX MOTORFLUX_base 1803 0.210 0.082 1.23 [1.05, 1.45] 0.00 0.609 1.05E-02 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5799 0.0184 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.062 0.028 0.06 [0.01, 0.12] 44.50 0.108 2.91E-02 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5980 0.0218 INS INS_surv 1112 0.129 0.073 1.14 [0.99, 1.31] 0.90 0.410 7.80E-02 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5968 0.0167 DYSKINESIAS DYSKINESIAS_base 1232 0.146 0.103 1.16 [0.95, 1.42] 0.00 0.739 1.58E-01 0 0 0 0 WNT3
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17:44866805 rs11658976 a g 0.5919 0.0241 INS INS_base 2220 0.090 0.070 1.09 [0.95, 1.26] 0.00 0.440 2.03E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5925 0.0279 HYPOSMIA HYPOSMIA_base 1588 -0.096 0.080 0.91 [0.78, 1.06] 29.20 0.216 2.27E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5801 0.0182 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.038 0.033 0.04 [-0.03, 0.10] 0.00 0.662 2.47E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5973 0.0168 DEPR DEPR_base 2138 0.092 0.089 1.10 [0.92, 1.31] 0.00 0.619 3.03E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.6053 0.0223 HY3 HY3_base 1289 -0.112 0.115 0.89 [0.71, 1.12] 63.50 0.064 3.29E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5946 0.0245 COGi COGi_base 2859 -0.071 0.085 0.93 [0.79, 1.10] 0.00 0.701 4.02E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5789 0.0186 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.027 0.033 0.03 [-0.04, 0.09] 0.00 0.833 4.17E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5917 0.0093 SEADL70 SEADL70_surv 1683 0.074 0.101 1.08 [0.88, 1.31] 0.00 0.612 4.63E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5905 0.0036 MOCA MOCA_cont 1074 -0.090 0.133 -0.09 [-0.35, 0.17] 0.00 0.968 4.96E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5769 0.0208 MMSE MMSE_cont 2114 0.030 0.048 0.03 [-0.06, 0.12] 0.00 0.718 5.33E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.6036 0.0322 HY3 HY3_surv 2582 0.041 0.069 1.04 [0.91, 1.19] 11.20 0.342 5.53E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5794 0.0185 SEADL SEADL_cont 2218 -0.146 0.256 -0.15 [-0.65, 0.35] 0.00 0.810 5.67E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5949 0.0258 SLEEP SLEEP_base 1724 -0.044 0.081 0.96 [0.82, 1.12] 0.00 0.777 5.86E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5923 0.0250 COGi COGi_surv 2244 -0.039 0.080 0.96 [0.82, 1.12] 0.00 0.604 6.28E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5820 0.0209 UPDRS_scaled UPDRS_scaled_cont 2994 0.012 0.026 0.01 [-0.04, 0.06] 0.00 0.905 6.48E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5970 0.0172 DYSKINESIAS DYSKINESIAS_surv 1856 0.030 0.067 1.03 [0.90, 1.17] 28.60 0.210 6.53E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5869 0.0217 HY HY_cont 3627 0.003 0.010 0.00 [-0.02, 0.02] 18.70 0.260 7.26E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5924 0.0152 MOTORFLUX MOTORFLUX_surv 1709 -0.017 0.055 0.98 [0.88, 1.09] 32.70 0.179 7.51E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.6017 0.0288 DEPR DEPR_surv 1314 0.013 0.089 1.01 [0.85, 1.21] 0.00 0.737 8.85E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5807 0.0171 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.001 0.029 -0.00 [-0.06, 0.06] 0.00 0.927 9.74E-01 0 0 0 0 WNT3
17:44866805 rs11658976 a g 0.5993 0.0192 CONST CONST_base 1472 0.002 0.084 1.00 [0.85, 1.18] 1.80 0.396 9.85E-01 0 0 0 0 WNT3
3:28705690 rs6808178 t c 0.3861 0.0201 MOCA MOCA_cont 1074 -0.310 0.122 -0.31 [-0.55, -0.07] 0.00 0.639 1.07E-02 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.4039 0.0193 MOTORFLUX MOTORFLUX_surv 1709 0.104 0.050 1.11 [1.01, 1.22] 0.00 0.841 3.94E-02 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.3909 0.0185 COGi COGi_base 2859 0.167 0.089 1.18 [0.99, 1.41] 16.30 0.302 6.12E-02 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.3965 0.0116 MOTORFLUX MOTORFLUX_base 1803 -0.123 0.085 0.88 [0.75, 1.04] 35.60 0.184 1.48E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.3961 0.0178 SLEEP SLEEP_base 1724 -0.125 0.087 0.88 [0.74, 1.05] 0.00 0.530 1.51E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.3929 0.0153 SEADL SEADL_cont 2218 -0.303 0.240 -0.30 [-0.77, 0.17] 0.00 0.849 2.06E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.4036 0.0116 MMSE MMSE_cont 2114 -0.052 0.046 -0.05 [-0.14, 0.04] 0.00 0.858 2.54E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.4169 0.0099 DEPR DEPR_surv 1314 -0.090 0.079 0.91 [0.78, 1.07] 0.00 0.731 2.55E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.3948 0.0122 DYSKINESIAS DYSKINESIAS_base 1232 0.119 0.106 1.13 [0.92, 1.38] 47.90 0.147 2.60E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.4008 0.0119 DEPR DEPR_base 2138 -0.093 0.093 0.91 [0.76, 1.09] 0.00 0.557 3.16E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.3929 0.0186 HYPOSMIA HYPOSMIA_base 1588 0.083 0.083 1.09 [0.92, 1.28] 1.60 0.406 3.20E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.3977 0.0209 COGi COGi_surv 2244 0.077 0.078 1.08 [0.93, 1.26] 31.90 0.163 3.21E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.3974 0.0194 HY HY_cont 3627 0.008 0.009 0.01 [-0.01, 0.03] 36.00 0.103 3.64E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.3899 0.0107 SEADL70 SEADL70_surv 1683 0.069 0.093 1.07 [0.89, 1.29] 7.30 0.365 4.61E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.4005 0.0163 HY3 HY3_base 1289 0.078 0.120 1.08 [0.85, 1.37] 32.90 0.225 5.19E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.4041 0.0113 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.017 0.030 -0.02 [-0.08, 0.04] 24.20 0.245 5.67E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.3946 0.0161 INS INS_base 2220 0.040 0.073 1.04 [0.90, 1.20] 35.40 0.146 5.85E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.4124 0.0237 HY3 HY3_surv 2582 -0.035 0.065 0.97 [0.85, 1.10] 0.00 0.773 5.87E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.3985 0.0173 UPDRS_scaled UPDRS_scaled_cont 2994 0.013 0.024 0.01 [-0.03, 0.06] 0.00 0.726 5.87E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.3924 0.0189 CONST CONST_base 1472 0.042 0.087 1.04 [0.88, 1.24] 0.00 0.412 6.31E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.4046 0.0113 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.009 0.030 0.01 [-0.05, 0.07] 0.00 0.518 7.75E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.4111 0.0211 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.006 0.027 0.01 [-0.05, 0.06] 36.30 0.139 8.35E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.3954 0.0199 INS INS_surv 1112 0.010 0.068 1.01 [0.88, 1.15] 41.00 0.132 8.88E-01 0 0 0 0 LINC00693
3:28705690 rs6808178 t c 0.4000 0.0163 DYSKINESIAS DYSKINESIAS_surv 1856 -0.006 0.061 0.99 [0.88, 1.12] 0.00 0.449 9.26E-01 0 0 0 0 LINC00693
5:102365794 rs26431 c g 0.7096 0.0138 DYSKINESIAS DYSKINESIAS_base 1232 0.287 0.113 1.33 [1.07, 1.66] 0.00 0.685 1.10E-02 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7120 0.0183 INS INS_base 2220 -0.138 0.075 0.87 [0.75, 1.01] 2.70 0.409 6.80E-02 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7123 0.0211 HYPOSMIA HYPOSMIA_base 1588 0.112 0.087 1.12 [0.94, 1.33] 15.60 0.314 1.99E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7112 0.0160 HY3 HY3_base 1289 -0.150 0.122 0.86 [0.68, 1.09] 0.00 0.894 2.20E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7154 0.0191 MOTORFLUX MOTORFLUX_base 1803 0.096 0.089 1.10 [0.93, 1.31] 0.00 0.599 2.80E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7088 0.0204 SLEEP SLEEP_base 1724 0.093 0.090 1.10 [0.92, 1.31] 41.80 0.112 3.01E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7244 0.0205 SEADL SEADL_cont 2218 0.254 0.263 0.25 [-0.26, 0.77] 0.00 0.467 3.34E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7131 0.0216 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.026 0.032 0.03 [-0.04, 0.09] 4.40 0.393 4.18E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7087 0.0182 DEPR DEPR_surv 1314 0.064 0.088 1.07 [0.90, 1.27] 1.50 0.407 4.65E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7130 0.0162 HY3 HY3_surv 2582 -0.047 0.067 0.95 [0.84, 1.09] 0.00 0.530 4.88E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7115 0.0186 DEPR DEPR_base 2138 0.068 0.099 1.07 [0.88, 1.30] 0.00 0.461 4.89E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7128 0.0210 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.017 0.028 -0.02 [-0.07, 0.04] 0.00 0.599 5.50E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7088 0.0155 CONST CONST_base 1472 0.052 0.091 1.05 [0.88, 1.26] 49.30 0.096 5.69E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7114 0.0219 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.018 0.032 0.02 [-0.04, 0.08] 7.40 0.372 5.79E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7096 0.0198 UPDRS_scaled UPDRS_scaled_cont 2994 -0.014 0.026 -0.01 [-0.06, 0.04] 0.00 0.842 5.81E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7130 0.0160 COGi COGi_surv 2244 0.039 0.083 1.04 [0.88, 1.22] 36.50 0.126 6.37E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7124 0.0244 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.012 0.027 0.01 [-0.04, 0.07] 9.20 0.358 6.55E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7132 0.0175 HY HY_cont 3627 -0.004 0.010 -0.00 [-0.02, 0.02] 0.00 0.578 6.94E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7062 0.0266 DYSKINESIAS DYSKINESIAS_surv 1856 0.022 0.063 1.02 [0.90, 1.16] 8.40 0.365 7.22E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7141 0.0248 MOTORFLUX MOTORFLUX_surv 1709 -0.012 0.054 0.99 [0.89, 1.10] 37.90 0.140 8.22E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7125 0.0230 SEADL70 SEADL70_surv 1683 0.019 0.103 1.02 [0.83, 1.25] 43.30 0.133 8.52E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7139 0.0192 INS INS_surv 1112 -0.012 0.071 0.99 [0.86, 1.14] 33.50 0.185 8.68E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7146 0.0103 MMSE MMSE_cont 2114 0.004 0.049 0.00 [-0.09, 0.10] 1.20 0.420 9.40E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7102 0.0206 COGi COGi_base 2859 -0.007 0.093 0.99 [0.83, 1.19] 0.00 0.868 9.44E-01 0 0 0 0 PAM
5:102365794 rs26431 c g 0.7097 0.0265 MOCA MOCA_cont 1074 0.004 0.131 0.00 [-0.25, 0.26] 8.90 0.349 9.74E-01 0 0 0 0 PAM
18:31304318 rs1941685 t g 0.5076 0.0221 SEADL SEADL_cont 2218 0.595 0.236 0.59 [0.13, 1.06] 34.30 0.154 1.18E-02 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5032 0.0204 CONST CONST_base 1472 -0.213 0.086 0.81 [0.68, 0.96] 0.00 0.913 1.31E-02 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5065 0.0254 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.074 0.030 -0.07 [-0.13, -0.02] 51.90 0.052 1.32E-02 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5075 0.0283 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.052 0.026 -0.05 [-0.10, -0.00] 0.00 0.628 4.64E-02 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5043 0.0274 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.046 0.030 -0.05 [-0.10, 0.01] 0.00 0.960 1.25E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5056 0.0246 UPDRS_scaled UPDRS_scaled_cont 2994 -0.037 0.024 -0.04 [-0.08, 0.01] 10.20 0.349 1.29E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5176 0.0265 MMSE MMSE_cont 2114 0.055 0.044 0.05 [-0.03, 0.14] 0.00 0.774 2.19E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5128 0.0135 COGi COGi_base 2859 0.074 0.087 1.08 [0.91, 1.28] 0.00 0.434 3.92E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5066 0.0157 HY3 HY3_surv 2582 -0.052 0.063 0.95 [0.84, 1.07] 0.90 0.427 4.12E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5045 0.0244 SLEEP SLEEP_base 1724 -0.066 0.084 0.94 [0.79, 1.10] 0.00 0.833 4.31E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5044 0.0231 HYPOSMIA HYPOSMIA_base 1588 -0.050 0.081 0.95 [0.81, 1.12] 0.00 0.686 5.40E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5080 0.0203 SEADL70 SEADL70_surv 1683 -0.056 0.093 0.95 [0.79, 1.13] 0.00 0.865 5.46E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5040 0.0209 INS INS_base 2220 0.040 0.070 1.04 [0.91, 1.19] 0.00 0.896 5.65E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5043 0.0170 DYSKINESIAS DYSKINESIAS_surv 1856 -0.023 0.058 0.98 [0.87, 1.09] 0.00 0.795 6.87E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5052 0.0194 MOTORFLUX MOTORFLUX_surv 1709 -0.018 0.049 0.98 [0.89, 1.08] 1.00 0.417 7.14E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5095 0.0203 COGi COGi_surv 2244 -0.023 0.076 0.98 [0.84, 1.13] 19.70 0.268 7.66E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5121 0.0183 MOTORFLUX MOTORFLUX_base 1803 -0.024 0.081 0.98 [0.83, 1.14] 0.00 0.687 7.67E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.4954 0.0154 MOCA MOCA_cont 1074 0.037 0.126 0.04 [-0.21, 0.28] 53.70 0.090 7.68E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5019 0.0249 HY HY_cont 3627 -0.002 0.009 -0.00 [-0.02, 0.02] 33.40 0.123 7.86E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5011 0.0221 DEPR DEPR_surv 1314 0.019 0.080 1.02 [0.87, 1.19] 3.10 0.397 8.12E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.4939 0.0145 INS INS_surv 1112 -0.011 0.066 0.99 [0.87, 1.13] 10.20 0.351 8.71E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5076 0.0252 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.003 0.027 0.00 [-0.05, 0.06] 0.00 0.723 9.03E-01 0 0 0 0 ASXL3
18:31304318 rs1941685 t g 0.5030 0.0248 DEPR DEPR_base 2138 -0.009 0.089 0.99 [0.83, 1.18] 0.00 0.918 9.18E-01 0 0 0 0 ASXL3
2:135464616 rs57891859 a g 0.7277 0.0177 INS INS_base 2220 0.205 0.082 1.23 [1.04, 1.44] 23.20 0.245 1.27E-02 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7271 0.0234 COGi COGi_surv 2244 -0.148 0.083 0.86 [0.73, 1.01] 29.80 0.180 7.32E-02 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7300 0.0232 HY HY_cont 3627 -0.016 0.010 -0.02 [-0.04, 0.00] 19.80 0.249 1.12E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7310 0.0163 DYSKINESIAS DYSKINESIAS_surv 1856 -0.097 0.065 0.91 [0.80, 1.03] 0.00 0.961 1.36E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7342 0.0185 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.044 0.033 0.04 [-0.02, 0.11] 23.20 0.252 1.78E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7164 0.0242 MMSE MMSE_cont 2114 0.067 0.050 0.07 [-0.03, 0.17] 47.20 0.066 1.80E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7282 0.0130 DEPR DEPR_surv 1314 0.110 0.088 1.12 [0.94, 1.32] 0.90 0.410 2.09E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7183 0.0204 SEADL SEADL_cont 2218 0.265 0.257 0.26 [-0.24, 0.77] 16.70 0.299 3.03E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7287 0.0140 MOTORFLUX MOTORFLUX_surv 1709 -0.054 0.055 0.95 [0.85, 1.06] 0.00 0.751 3.26E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7238 0.0128 DEPR DEPR_base 2138 0.091 0.102 1.10 [0.90, 1.34] 0.00 0.952 3.71E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7367 0.0183 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.019 0.033 0.02 [-0.05, 0.08] 35.80 0.155 5.73E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7311 0.0090 DYSKINESIAS DYSKINESIAS_base 1232 0.066 0.120 1.07 [0.84, 1.35] 0.00 0.418 5.86E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7225 0.0067 MOCA MOCA_cont 1074 0.064 0.133 0.06 [-0.20, 0.33] 0.00 0.490 6.28E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7333 0.0224 UPDRS_scaled UPDRS_scaled_cont 2994 0.012 0.027 0.01 [-0.04, 0.06] 24.60 0.217 6.46E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7277 0.0200 HYPOSMIA HYPOSMIA_base 1588 0.037 0.092 1.04 [0.87, 1.24] 0.00 0.945 6.85E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7159 0.0121 SEADL70 SEADL70_surv 1683 0.040 0.101 1.04 [0.85, 1.27] 0.00 0.571 6.90E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7371 0.0184 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.010 0.029 -0.01 [-0.07, 0.05] 31.50 0.199 7.19E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7317 0.0212 COGi COGi_base 2859 0.034 0.099 1.03 [0.85, 1.26] 18.90 0.280 7.31E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7247 0.0139 CONST CONST_base 1472 -0.032 0.097 0.97 [0.80, 1.17] 0.00 0.626 7.38E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7336 0.0216 HY3 HY3_surv 2582 -0.023 0.072 0.98 [0.85, 1.13] 0.00 0.650 7.49E-01 0 0 0 0 TMEM163
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2:135464616 rs57891859 a g 0.7270 0.0188 SLEEP SLEEP_base 1724 -0.023 0.096 0.98 [0.81, 1.18] 0.00 0.506 8.13E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7349 0.0119 HY3 HY3_base 1289 0.032 0.141 1.03 [0.78, 1.36] 62.70 0.068 8.19E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7207 0.0164 INS INS_surv 1112 0.015 0.071 1.02 [0.88, 1.17] 0.00 0.861 8.31E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7353 0.0175 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.004 0.030 -0.00 [-0.06, 0.05] 10.10 0.351 8.88E-01 0 0 0 0 TMEM163
2:135464616 rs57891859 a g 0.7279 0.0103 MOTORFLUX MOTORFLUX_base 1803 0.009 0.094 1.01 [0.84, 1.21] 0.00 0.454 9.22E-01 0 0 0 0 TMEM163
3:122196892 rs55961674 t c 0.1708 0.0163 SLEEP SLEEP_base 1724 0.267 0.107 1.31 [1.06, 1.61] 0.00 0.768 1.30E-02 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1662 0.0156 COGi COGi_base 2859 -0.185 0.118 0.83 [0.66, 1.05] 0.00 0.902 1.17E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1641 0.0184 HY3 HY3_surv 2582 0.129 0.087 1.14 [0.96, 1.35] 30.60 0.174 1.35E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1800 0.0101 MOCA MOCA_cont 1074 -0.183 0.160 -0.18 [-0.50, 0.13] 47.50 0.126 2.54E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1774 0.0170 INS INS_base 2220 0.082 0.091 1.09 [0.91, 1.30] 0.00 0.719 3.68E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1769 0.0173 DYSKINESIAS DYSKINESIAS_base 1232 -0.120 0.135 0.89 [0.68, 1.16] 0.00 0.848 3.76E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1738 0.0201 UPDRS_scaled UPDRS_scaled_cont 2994 -0.028 0.032 -0.03 [-0.09, 0.03] 0.00 0.536 3.81E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1814 0.0280 INS INS_surv 1112 0.067 0.088 1.07 [0.90, 1.27] 0.00 0.841 4.46E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1718 0.0096 SEADL70 SEADL70_surv 1683 0.085 0.122 1.09 [0.86, 1.38] 4.80 0.379 4.87E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1862 0.0233 DEPR DEPR_surv 1314 0.067 0.105 1.07 [0.87, 1.31] 0.00 0.784 5.23E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1778 0.0229 DYSKINESIAS DYSKINESIAS_surv 1856 -0.050 0.079 0.95 [0.81, 1.11] 0.00 0.833 5.29E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1794 0.0158 MMSE MMSE_cont 2114 0.036 0.058 0.04 [-0.08, 0.15] 0.00 0.860 5.36E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1706 0.0215 MOTORFLUX MOTORFLUX_surv 1709 -0.041 0.068 0.96 [0.84, 1.10] 0.00 0.575 5.42E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1742 0.0148 COGi COGi_surv 2244 0.059 0.098 1.06 [0.87, 1.29] 0.00 0.769 5.49E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1684 0.0161 HY3 HY3_base 1289 0.080 0.153 1.08 [0.80, 1.46] 0.00 0.560 6.04E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1711 0.0159 HYPOSMIA HYPOSMIA_base 1588 -0.049 0.103 0.95 [0.78, 1.16] 0.00 0.556 6.32E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1741 0.0214 HY HY_cont 3627 -0.005 0.012 -0.00 [-0.03, 0.02] 10.70 0.340 6.90E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1774 0.0116 SEADL SEADL_cont 2218 0.110 0.311 0.11 [-0.50, 0.72] 0.00 0.815 7.23E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1746 0.0194 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.011 0.035 -0.01 [-0.08, 0.06] 42.10 0.098 7.48E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1704 0.0141 CONST CONST_base 1472 -0.022 0.111 0.98 [0.79, 1.21] 0.00 0.976 8.40E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1789 0.0193 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.005 0.034 -0.00 [-0.07, 0.06] 0.00 0.842 8.91E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1802 0.0185 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.003 0.039 0.00 [-0.07, 0.08] 34.90 0.162 9.49E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1750 0.0171 MOTORFLUX MOTORFLUX_base 1803 0.006 0.108 1.01 [0.81, 1.24] 4.40 0.381 9.53E-01 0 0 0 0 KPNA1
3:122196892 rs55961674 t c 0.1813 0.0183 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.002 0.039 0.00 [-0.07, 0.08] 0.00 0.603 9.55E-01 0 0 0 0 KPNA1
10:121536327 rs117896735 a g 0.0219 0.0050 COGi COGi_base 2483 0.700 0.283 2.01 [1.16, 3.50] 0.00 0.435 1.32E-02 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0234 0.0035 MOTORFLUX MOTORFLUX_surv 1709 0.290 0.162 1.34 [0.97, 1.83] 48.40 0.071 7.39E-02 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0264 0.0056 MOCA MOCA_cont 1074 -0.500 0.415 -0.50 [-1.31, 0.31] 46.60 0.132 2.29E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0273 0.0087 UPDRS_scaled UPDRS_scaled_cont 2994 0.094 0.082 0.09 [-0.07, 0.25] 0.00 0.487 2.47E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0275 0.0103 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.108 0.104 0.11 [-0.10, 0.31] 0.00 0.915 3.00E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0182 0.0018 DYSKINESIAS DYSKINESIAS_base 1232 -0.346 0.356 0.71 [0.35, 1.42] 6.50 0.343 3.31E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0256 0.0070 DEPR DEPR_base 2138 -0.307 0.351 0.74 [0.37, 1.46] 0.00 0.911 3.82E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0232 0.0073 SLEEP SLEEP_base 1724 0.219 0.270 1.25 [0.73, 2.11] 0.00 0.860 4.17E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0209 0.0039 CONST CONST_base 1472 0.239 0.296 1.27 [0.71, 2.27] 25.00 0.255 4.19E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0239 0.0037 INS INS_surv 1112 -0.162 0.212 0.85 [0.56, 1.29] 0.00 0.662 4.44E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0276 0.0110 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.065 0.091 0.07 [-0.11, 0.24] 41.10 0.131 4.75E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0254 0.0036 SEADL SEADL_cont 2112 -0.512 0.798 -0.51 [-2.08, 1.05] 0.00 0.732 5.22E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0233 0.0031 DYSKINESIAS DYSKINESIAS_surv 1856 0.124 0.193 1.13 [0.77, 1.65] 0.00 0.601 5.23E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0292 0.0066 HY3 HY3_surv 2582 -0.118 0.196 0.89 [0.60, 1.31] 0.00 0.973 5.48E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0227 0.0068 HYPOSMIA HYPOSMIA_base 1588 0.156 0.261 1.17 [0.70, 1.95] 16.50 0.307 5.50E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0286 0.0098 HY HY_cont 3627 -0.017 0.029 -0.02 [-0.07, 0.04] 0.00 0.591 5.51E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0221 0.0066 INS INS_base 2220 -0.127 0.236 0.88 [0.55, 1.40] 0.00 0.582 5.91E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0220 0.0044 SEADL70 SEADL70_surv 1683 0.134 0.324 1.14 [0.61, 2.16] 0.00 0.804 6.78E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0233 0.0039 COGi COGi_surv 2075 0.113 0.273 1.12 [0.66, 1.91] 0.00 0.983 6.80E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0252 0.0044 DEPR DEPR_surv 1314 -0.066 0.277 0.94 [0.54, 1.61] 0.00 0.964 8.11E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0182 0.0023 MOTORFLUX MOTORFLUX_base 1803 -0.067 0.296 0.94 [0.52, 1.67] 0.00 0.884 8.21E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0277 0.0105 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.016 0.104 -0.02 [-0.22, 0.19] 0.00 0.698 8.78E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0297 0.0101 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.012 0.088 -0.01 [-0.18, 0.16] 0.00 0.713 8.97E-01 0 0 0 0 INPP5F
10:121536327 rs117896735 a g 0.0289 0.0078 MMSE MMSE_cont 2114 0.014 0.143 0.01 [-0.27, 0.29] 0.00 0.931 9.21E-01 0 0 0 0 INPP5F
13:97865021 rs4771268 t c 0.2272 0.0185 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.075 0.030 -0.07 [-0.13, -0.02] 0.00 0.486 1.34E-02 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2390 0.0098 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.051 0.029 -0.05 [-0.11, 0.00] 0.00 0.601 7.29E-02 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2336 0.0133 DYSKINESIAS DYSKINESIAS_surv 1856 -0.112 0.068 0.89 [0.78, 1.02] 0.00 0.831 1.02E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2284 0.0159 UPDRS_scaled UPDRS_scaled_cont 2994 -0.044 0.027 -0.04 [-0.10, 0.01] 0.00 0.443 1.10E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2198 0.0142 MMSE MMSE_cont 2114 0.079 0.051 0.08 [-0.02, 0.18] 0.00 0.912 1.25E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2258 0.0119 HY3 HY3_base 1289 -0.196 0.139 0.82 [0.63, 1.08] 29.30 0.243 1.60E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2305 0.0197 HY HY_cont 3627 -0.014 0.010 -0.01 [-0.03, 0.01] 0.00 0.453 1.75E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2283 0.0134 HYPOSMIA HYPOSMIA_base 1588 0.111 0.092 1.12 [0.93, 1.34] 0.00 0.691 2.26E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2331 0.0145 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.038 0.033 -0.04 [-0.10, 0.03] 9.60 0.355 2.52E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2329 0.0137 MOTORFLUX MOTORFLUX_surv 1709 -0.063 0.057 0.94 [0.84, 1.05] 28.70 0.209 2.68E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2292 0.0273 SEADL SEADL_cont 2112 0.298 0.271 0.30 [-0.23, 0.83] 5.20 0.387 2.71E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2291 0.0147 COGi COGi_base 2859 -0.103 0.103 0.90 [0.74, 1.10] 14.30 0.318 3.16E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2286 0.0211 DEPR DEPR_surv 1314 -0.079 0.093 0.92 [0.77, 1.11] 0.00 0.516 3.96E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2323 0.0143 INS INS_base 2220 -0.067 0.081 0.94 [0.80, 1.10] 0.00 0.444 4.12E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2214 0.0255 HY3 HY3_surv 2582 0.058 0.073 1.06 [0.92, 1.22] 0.00 0.849 4.24E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2334 0.0141 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.014 0.033 -0.01 [-0.08, 0.05] 20.70 0.272 6.80E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2255 0.0120 SLEEP SLEEP_base 1724 0.039 0.098 1.04 [0.86, 1.26] 49.40 0.065 6.89E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2271 0.0123 CONST CONST_base 1472 0.032 0.097 1.03 [0.85, 1.25] 0.00 0.829 7.41E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2317 0.0195 COGi COGi_surv 2244 -0.025 0.086 0.98 [0.82, 1.16] 24.40 0.227 7.76E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2352 0.0149 MOTORFLUX MOTORFLUX_base 1803 0.026 0.094 1.03 [0.85, 1.23] 0.00 0.596 7.83E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2261 0.0153 DEPR DEPR_base 2138 -0.019 0.103 0.98 [0.80, 1.20] 0.00 0.583 8.52E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2379 0.0328 MOCA MOCA_cont 1074 -0.023 0.142 -0.02 [-0.30, 0.26] 0.00 0.762 8.71E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2334 0.0177 SEADL70 SEADL70_surv 1683 -0.017 0.107 0.98 [0.80, 1.21] 0.00 0.431 8.75E-01 0 0 0 0 MBNL2
13:97865021 rs4771268 t c 0.2325 0.0143 DYSKINESIAS DYSKINESIAS_base 1232 0.005 0.119 1.00 [0.80, 1.27] 0.00 0.984 9.70E-01 0 0 0 0 MBNL2
16:19277493 rs6497339 a t 0.4787 0.0308 MOTORFLUX MOTORFLUX_surv 1709 0.119 0.048 1.13 [1.02, 1.24] 6.40 0.379 1.39E-02 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4743 0.0388 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.055 0.026 0.05 [0.00, 0.10] 0.00 0.724 3.13E-02 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4764 0.0147 CONST CONST_base 1472 -0.142 0.084 0.87 [0.74, 1.02] 0.00 0.967 8.86E-02 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4701 0.0336 SEADL70 SEADL70_surv 1683 0.143 0.091 1.15 [0.97, 1.38] 57.20 0.053 1.16E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4656 0.0392 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.045 0.029 0.04 [-0.01, 0.10] 32.40 0.181 1.19E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4729 0.0291 MOTORFLUX MOTORFLUX_base 1803 -0.119 0.081 0.89 [0.76, 1.04] 0.00 0.432 1.41E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4671 0.0245 COGi COGi_base 2859 0.124 0.085 1.13 [0.96, 1.34] 0.00 0.999 1.41E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4649 0.0350 UPDRS_scaled UPDRS_scaled_cont 2994 0.032 0.023 0.03 [-0.01, 0.08] 39.80 0.092 1.74E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4613 0.0106 HY3 HY3_base 1289 0.145 0.114 1.16 [0.92, 1.44] 8.00 0.337 2.04E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4622 0.0395 DYSKINESIAS DYSKINESIAS_surv 1856 0.072 0.057 1.07 [0.96, 1.20] 8.10 0.367 2.07E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4746 0.0249 INS INS_base 2220 0.076 0.069 1.08 [0.94, 1.24] 0.00 0.930 2.75E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4682 0.0303 DEPR DEPR_surv 1314 0.079 0.078 1.08 [0.93, 1.26] 0.00 0.646 3.10E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4823 0.0207 HYPOSMIA HYPOSMIA_base 1588 0.058 0.080 1.06 [0.91, 1.24] 0.00 0.875 4.67E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4783 0.0265 DEPR DEPR_base 2138 -0.047 0.089 0.95 [0.80, 1.14] 0.00 0.685 5.96E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4637 0.0289 COGi COGi_surv 2244 0.023 0.075 1.02 [0.88, 1.18] 18.40 0.279 7.60E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4697 0.0332 HY HY_cont 3627 0.002 0.009 0.00 [-0.01, 0.02] 19.80 0.249 7.91E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4753 0.0316 SEADL SEADL_cont 2218 -0.058 0.231 -0.06 [-0.51, 0.39] 0.00 0.636 8.01E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4750 0.0423 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.006 0.025 0.01 [-0.04, 0.05] 0.00 0.955 8.21E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4564 0.0277 INS INS_surv 1112 0.014 0.064 1.01 [0.89, 1.15] 0.00 0.934 8.24E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4818 0.0200 SLEEP SLEEP_base 1724 -0.018 0.084 0.98 [0.83, 1.16] 18.20 0.291 8.32E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4695 0.0397 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.006 0.029 0.01 [-0.05, 0.06] 0.00 0.975 8.45E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4729 0.0261 HY3 HY3_surv 2582 0.012 0.063 1.01 [0.90, 1.14] 0.00 0.536 8.46E-01 0 0 0 0 SYT17
16:19277493 rs6497339 a t 0.4571 0.0228 MOCA MOCA_cont 1074 -0.002 0.117 -0.00 [-0.23, 0.23] 24.40 0.265 9.85E-01 0 0 0 0 SYT17
4:90626111 rs356182 a g 0.5851 0.0112 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.071 0.029 0.07 [0.01, 0.13] 0.00 0.572 1.42E-02 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5815 0.0085 DEPR DEPR_surv 1314 0.182 0.080 1.20 [1.03, 1.40] 0.00 0.826 2.21E-02 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.6065 0.0160 DYSKINESIAS DYSKINESIAS_base 1232 -0.206 0.102 0.81 [0.67, 0.99] 0.00 0.492 4.44E-02 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5974 0.0168 COGi COGi_base 2859 0.146 0.089 1.16 [0.97, 1.38] 29.50 0.193 1.00E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5894 0.0132 MOTORFLUX MOTORFLUX_surv 1709 -0.080 0.049 0.92 [0.84, 1.02] 0.00 0.663 1.02E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5999 0.0164 HYPOSMIA HYPOSMIA_base 1588 -0.130 0.082 0.88 [0.75, 1.03] 0.00 0.928 1.12E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.6024 0.0151 MOTORFLUX MOTORFLUX_base 1803 -0.092 0.082 0.91 [0.78, 1.07] 29.70 0.224 2.61E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5697 0.0229 MOCA MOCA_cont 1074 -0.116 0.120 -0.12 [-0.35, 0.12] 7.60 0.355 3.34E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5920 0.0122 INS INS_surv 1112 -0.057 0.067 0.94 [0.83, 1.08] 31.70 0.198 3.95E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5876 0.0112 DYSKINESIAS DYSKINESIAS_surv 1856 -0.049 0.057 0.95 [0.85, 1.07] 0.00 0.922 3.96E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5840 0.0114 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.023 0.029 0.02 [-0.03, 0.08] 0.00 0.892 4.39E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5973 0.0183 DEPR DEPR_base 2138 0.067 0.091 1.07 [0.89, 1.28] 0.00 0.656 4.65E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5824 0.0121 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.019 0.026 -0.02 [-0.07, 0.03] 0.00 0.765 4.74E-01 0 0 0 0 SNCA
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4:90626111 rs356182 a g 0.5804 0.0238 COGi COGi_surv 2244 -0.051 0.075 0.95 [0.82, 1.10] 23.30 0.236 4.98E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5852 0.0172 UPDRS_scaled UPDRS_scaled_cont 2994 0.015 0.024 0.02 [-0.03, 0.06] 0.00 0.914 5.22E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5853 0.0121 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.016 0.025 -0.02 [-0.07, 0.03] 0.00 0.505 5.32E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5978 0.0155 CONST CONST_base 1472 0.040 0.086 1.04 [0.88, 1.23] 24.50 0.258 6.39E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5740 0.0222 SEADL SEADL_cont 2218 -0.086 0.235 -0.09 [-0.55, 0.37] 0.00 0.591 7.14E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.6000 0.0184 SLEEP SLEEP_base 1724 0.029 0.085 1.03 [0.87, 1.22] 0.00 0.596 7.32E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5778 0.0227 HY3 HY3_surv 2582 -0.019 0.064 0.98 [0.87, 1.11] 29.80 0.181 7.68E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5820 0.0176 HY HY_cont 3627 0.002 0.009 0.00 [-0.02, 0.02] 0.00 0.890 8.06E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5879 0.0160 SEADL70 SEADL70_surv 1683 -0.022 0.093 0.98 [0.82, 1.17] 45.60 0.119 8.15E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.5973 0.0195 HY3 HY3_base 1289 0.019 0.117 1.02 [0.81, 1.28] 0.00 0.840 8.69E-01 0 0 0 0 SNCA
4:90626111 rs356182 a g 0.6055 0.0167 INS INS_base 2220 -0.009 0.071 0.99 [0.86, 1.14] 0.00 0.604 8.95E-01 0 0 0 0 SNCA
4:15737348 rs4698412 a g 0.5809 0.0264 MOCA MOCA_cont 1074 -0.285 0.117 -0.28 [-0.51, -0.06] 0.00 0.527 1.45E-02 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5705 0.0164 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.040 0.029 -0.04 [-0.10, 0.02] 0.00 0.584 1.63E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5681 0.0263 COGi COGi_surv 2244 0.101 0.074 1.11 [0.96, 1.28] 0.00 0.930 1.74E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5697 0.0153 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.038 0.029 -0.04 [-0.09, 0.02] 0.00 0.761 1.81E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5643 0.0203 HY3 HY3_base 1289 -0.138 0.116 0.87 [0.69, 1.09] 10.50 0.327 2.33E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5601 0.0181 CONST CONST_base 1472 -0.102 0.086 0.90 [0.76, 1.07] 0.00 0.548 2.36E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5583 0.0154 MOTORFLUX MOTORFLUX_base 1803 -0.077 0.081 0.93 [0.79, 1.09] 12.50 0.334 3.46E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5817 0.0208 SEADL SEADL_cont 2112 0.215 0.229 0.22 [-0.23, 0.66] 0.00 0.861 3.48E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5698 0.0159 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.023 0.026 -0.02 [-0.07, 0.03] 0.00 0.809 3.68E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5571 0.0168 HYPOSMIA HYPOSMIA_base 1588 -0.069 0.081 0.93 [0.80, 1.09] 41.70 0.128 3.94E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5600 0.0146 INS INS_base 2220 0.055 0.071 1.06 [0.92, 1.21] 12.10 0.336 4.35E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5757 0.0150 HY3 HY3_surv 2582 -0.046 0.063 0.96 [0.84, 1.08] 0.00 0.471 4.71E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5600 0.0164 DYSKINESIAS DYSKINESIAS_base 1232 -0.069 0.102 0.93 [0.76, 1.14] 0.00 0.381 5.01E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5677 0.0222 INS INS_surv 1112 0.043 0.064 1.04 [0.92, 1.18] 0.00 0.732 5.02E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5798 0.0127 HY HY_cont 3627 0.006 0.009 0.01 [-0.01, 0.02] 0.00 0.612 5.12E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5625 0.0153 SEADL70 SEADL70_surv 1683 -0.050 0.092 0.95 [0.79, 1.14] 0.00 0.938 5.85E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5822 0.0086 MMSE MMSE_cont 2114 -0.020 0.044 -0.02 [-0.11, 0.07] 2.80 0.408 6.56E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5741 0.0193 DYSKINESIAS DYSKINESIAS_surv 1856 0.025 0.057 1.03 [0.92, 1.15] 0.00 0.808 6.56E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5734 0.0153 UPDRS_scaled UPDRS_scaled_cont 2994 -0.007 0.023 -0.01 [-0.05, 0.04] 27.20 0.194 7.78E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5588 0.0182 SLEEP SLEEP_base 1724 0.021 0.085 1.02 [0.86, 1.21] 0.00 0.623 8.09E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5767 0.0272 DEPR DEPR_surv 1314 -0.017 0.077 0.98 [0.84, 1.14] 44.10 0.111 8.24E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5648 0.0205 COGi COGi_base 2859 -0.019 0.087 0.98 [0.83, 1.16] 0.00 0.441 8.25E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5659 0.0156 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.002 0.025 -0.00 [-0.05, 0.05] 0.00 0.501 9.27E-01 0 0 0 0 BST1
4:15737348 rs4698412 a g 0.5663 0.0173 DEPR DEPR_base 2138 -0.003 0.091 1.00 [0.83, 1.19] 17.00 0.296 9.70E-01 0 0 0 0 BST1
17:42294337 rs2269906 a c 0.6706 0.0216 SLEEP SLEEP_base 1724 -0.217 0.089 0.80 [0.68, 0.96] 0.00 0.636 1.46E-02 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6617 0.0210 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.086 0.036 -0.09 [-0.16, -0.02] 38.40 0.136 1.56E-02 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6672 0.0172 CONST CONST_base 1472 -0.171 0.090 0.84 [0.71, 1.01] 0.00 0.473 5.74E-02 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6544 0.0228 SEADL SEADL_cont 2218 0.514 0.271 0.51 [-0.02, 1.05] 24.50 0.234 5.76E-02 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6608 0.0213 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.067 0.035 -0.07 [-0.14, 0.00] 0.00 0.779 6.03E-02 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6591 0.0200 INS INS_surv 1112 -0.138 0.074 0.87 [0.75, 1.01] 10.90 0.346 6.28E-02 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6687 0.0215 DEPR DEPR_base 2138 -0.172 0.095 0.84 [0.70, 1.01] 0.00 0.923 6.90E-02 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6720 0.0254 UPDRS_scaled UPDRS_scaled_cont 2994 -0.049 0.028 -0.05 [-0.10, 0.01] 0.00 0.961 8.08E-02 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6662 0.0212 HYPOSMIA HYPOSMIA_base 1588 0.129 0.085 1.14 [0.96, 1.35] 0.00 0.976 1.30E-01 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6562 0.0202 MOTORFLUX MOTORFLUX_base 1803 -0.117 0.086 0.89 [0.75, 1.05] 4.00 0.384 1.76E-01 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6728 0.0268 HY HY_cont 3627 -0.010 0.010 -0.01 [-0.03, 0.01] 0.00 0.963 3.27E-01 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6645 0.0223 MOTORFLUX MOTORFLUX_surv 1709 -0.050 0.057 0.95 [0.85, 1.06] 0.00 0.949 3.81E-01 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6654 0.0246 HY3 HY3_base 1289 -0.099 0.122 0.91 [0.71, 1.15] 2.70 0.358 4.17E-01 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6533 0.0230 DYSKINESIAS DYSKINESIAS_base 1232 -0.086 0.107 0.92 [0.74, 1.13] 36.30 0.208 4.22E-01 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6694 0.0191 MMSE MMSE_cont 2114 -0.035 0.050 -0.03 [-0.13, 0.06] 30.80 0.182 4.85E-01 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6482 0.0291 MOCA MOCA_cont 1074 -0.091 0.143 -0.09 [-0.37, 0.19] 0.00 0.590 5.25E-01 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6591 0.0244 INS INS_base 2220 0.038 0.074 1.04 [0.90, 1.20] 0.00 0.577 6.12E-01 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6682 0.0247 COGi COGi_base 2859 -0.047 0.093 0.95 [0.80, 1.15] 15.80 0.306 6.15E-01 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6731 0.0192 DEPR DEPR_surv 1314 -0.044 0.092 0.96 [0.80, 1.15] 44.10 0.111 6.34E-01 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6623 0.0125 SEADL70 SEADL70_surv 1683 -0.042 0.108 0.96 [0.78, 1.18] 4.50 0.381 6.94E-01 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6758 0.0219 HY3 HY3_surv 2582 -0.025 0.069 0.98 [0.85, 1.12] 0.00 0.827 7.14E-01 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6605 0.0213 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.011 0.031 -0.01 [-0.07, 0.05] 0.00 0.557 7.17E-01 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6628 0.0230 DYSKINESIAS DYSKINESIAS_surv 1856 0.022 0.070 1.02 [0.89, 1.17] 25.30 0.236 7.52E-01 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6643 0.0172 COGi COGi_surv 2244 -0.024 0.085 0.98 [0.83, 1.15] 0.00 0.464 7.75E-01 0 0 0 0 UBTF
17:42294337 rs2269906 a c 0.6645 0.0204 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.006 0.031 -0.01 [-0.07, 0.05] 0.00 0.878 8.52E-01 0 0 0 0 UBTF
3:182760073 rs10513789 t g 0.8232 0.0099 HY HY_cont 3627 -0.027 0.011 -0.03 [-0.05, -0.01] 0.00 0.644 1.48E-02 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8137 0.0188 CONST CONST_base 1472 0.210 0.110 1.23 [1.00, 1.53] 0.00 0.597 5.47E-02 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8110 0.0186 HY3 HY3_surv 2582 -0.139 0.082 0.87 [0.74, 1.02] 10.20 0.350 9.02E-02 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8254 0.0080 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.050 0.033 -0.05 [-0.12, 0.01] 0.00 0.806 1.30E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8276 0.0058 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.048 0.037 -0.05 [-0.12, 0.03] 0.00 0.874 1.99E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8139 0.0174 MOTORFLUX MOTORFLUX_surv 1709 0.075 0.064 1.08 [0.95, 1.22] 0.00 0.614 2.39E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8159 0.0165 DYSKINESIAS DYSKINESIAS_surv 1856 -0.087 0.074 0.92 [0.79, 1.06] 0.00 0.935 2.39E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8191 0.0137 SEADL70 SEADL70_surv 1683 -0.131 0.118 0.88 [0.70, 1.10] 39.60 0.158 2.65E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8271 0.0071 MOCA MOCA_cont 1074 0.167 0.153 0.17 [-0.13, 0.47] 0.00 0.424 2.75E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8178 0.0152 COGi COGi_surv 2244 -0.102 0.097 0.90 [0.75, 1.09] 0.00 0.817 2.91E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8144 0.0183 HY3 HY3_base 1289 -0.147 0.148 0.86 [0.65, 1.15] 0.00 0.379 3.20E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8187 0.0150 COGi COGi_base 2859 -0.106 0.112 0.90 [0.72, 1.12] 29.90 0.190 3.46E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8161 0.0153 INS INS_base 2220 -0.083 0.091 0.92 [0.77, 1.10] 0.00 0.708 3.64E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8275 0.0064 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.027 0.033 0.03 [-0.04, 0.09] 0.00 0.731 4.03E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8204 0.0137 MOTORFLUX MOTORFLUX_base 1803 -0.086 0.106 0.92 [0.75, 1.13] 0.00 0.828 4.15E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8140 0.0179 HYPOSMIA HYPOSMIA_base 1588 -0.050 0.104 0.95 [0.78, 1.17] 0.00 0.420 6.32E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8253 0.0069 UPDRS_scaled UPDRS_scaled_cont 2994 -0.012 0.030 -0.01 [-0.07, 0.05] 0.00 0.695 6.86E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8279 0.0058 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.015 0.037 -0.01 [-0.09, 0.06] 0.00 0.964 6.87E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8169 0.0180 SLEEP SLEEP_base 1724 0.036 0.107 1.04 [0.84, 1.28] 0.00 0.724 7.38E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8128 0.0251 INS INS_surv 1112 -0.026 0.085 0.97 [0.82, 1.15] 0.00 0.466 7.56E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8219 0.0148 DEPR DEPR_surv 1314 -0.030 0.099 0.97 [0.80, 1.18] 0.00 0.844 7.60E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8219 0.0140 DEPR DEPR_base 2138 -0.032 0.115 0.97 [0.77, 1.21] 0.00 0.988 7.83E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8195 0.0150 DYSKINESIAS DYSKINESIAS_base 1232 0.036 0.133 1.04 [0.80, 1.35] 0.00 0.711 7.90E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8268 0.0113 MMSE MMSE_cont 2114 -0.008 0.058 -0.01 [-0.12, 0.11] 0.00 0.914 8.97E-01 0 0 0 0 MCCC1
3:182760073 rs10513789 t g 0.8262 0.0055 SEADL SEADL_cont 2218 -0.037 0.299 -0.04 [-0.62, 0.55] 0.00 0.653 9.02E-01 0 0 0 0 MCCC1
6:112243291 rs997368 a g 0.8160 0.0265 DEPR DEPR_surv 1314 -0.232 0.096 0.79 [0.66, 0.96] 0.00 0.795 1.61E-02 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8127 0.0225 MOTORFLUX MOTORFLUX_surv 1709 -0.128 0.061 0.88 [0.78, 0.99] 0.00 0.773 3.61E-02 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8190 0.0171 HY3 HY3_surv 2582 -0.139 0.077 0.87 [0.75, 1.01] 3.20 0.408 7.07E-02 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8177 0.0230 COGi COGi_base 2859 -0.181 0.108 0.83 [0.68, 1.03] 4.30 0.397 9.20E-02 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8204 0.0203 COGi COGi_surv 2244 -0.141 0.092 0.87 [0.73, 1.04] 0.00 0.519 1.22E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8104 0.0299 INS INS_surv 1112 -0.114 0.082 0.89 [0.76, 1.05] 0.00 0.678 1.62E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8141 0.0205 DYSKINESIAS DYSKINESIAS_surv 1856 -0.097 0.072 0.91 [0.79, 1.05] 38.00 0.139 1.79E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8143 0.0048 SEADL70 SEADL70_surv 1683 -0.148 0.111 0.86 [0.69, 1.07] 0.00 0.698 1.81E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8028 0.0311 HY HY_cont 3627 -0.014 0.011 -0.01 [-0.04, 0.01] 0.00 0.995 2.07E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8000 0.0300 DEPR DEPR_base 2138 0.130 0.116 1.14 [0.91, 1.43] 23.90 0.239 2.64E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8002 0.0281 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.037 0.036 0.04 [-0.03, 0.11] 0.00 0.535 3.09E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8000 0.0303 INS INS_base 2220 0.086 0.089 1.09 [0.92, 1.30] 31.80 0.174 3.33E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8136 0.0265 CONST CONST_base 1472 -0.101 0.106 0.90 [0.74, 1.11] 48.00 0.103 3.42E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8174 0.0300 HY3 HY3_base 1289 0.130 0.149 1.14 [0.85, 1.53] 0.00 0.570 3.83E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8040 0.0109 MOCA MOCA_cont 1074 0.078 0.151 0.08 [-0.22, 0.37] 31.50 0.223 6.05E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8001 0.0287 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.014 0.031 -0.01 [-0.07, 0.05] 0.00 0.704 6.42E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8020 0.0279 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.017 0.036 -0.02 [-0.09, 0.05] 0.00 0.529 6.42E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8085 0.0335 SLEEP SLEEP_base 1724 -0.048 0.106 0.95 [0.77, 1.17] 0.00 0.775 6.47E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8139 0.0190 SEADL SEADL_cont 2218 0.131 0.298 0.13 [-0.45, 0.72] 0.00 0.603 6.61E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8030 0.0270 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.014 0.032 0.01 [-0.05, 0.08] 0.00 0.564 6.62E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8020 0.0275 DYSKINESIAS DYSKINESIAS_base 1232 -0.054 0.129 0.95 [0.74, 1.22] 0.00 0.737 6.77E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8038 0.0267 MOTORFLUX MOTORFLUX_base 1803 0.028 0.103 1.03 [0.84, 1.26] 19.30 0.292 7.89E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8123 0.0319 HYPOSMIA HYPOSMIA_base 1588 -0.010 0.102 0.99 [0.81, 1.21] 0.00 0.592 9.25E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8060 0.0277 UPDRS_scaled UPDRS_scaled_cont 2994 0.002 0.029 0.00 [-0.06, 0.06] 0.00 0.682 9.36E-01 0 0 0 0 FYN
6:112243291 rs997368 a g 0.8087 0.0323 MMSE MMSE_cont 2114 0.000 0.056 0.00 [-0.11, 0.11] 0.00 0.486 9.97E-01 0 0 0 0 FYN
17:76425480 rs666463 a t 0.8291 0.0103 INS INS_base 2220 -0.217 0.091 0.81 [0.67, 0.96] 0.00 0.569 1.67E-02 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8250 0.0169 MOTORFLUX MOTORFLUX_surv 1709 0.138 0.065 1.15 [1.01, 1.30] 34.50 0.165 3.22E-02 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8305 0.0093 DYSKINESIAS DYSKINESIAS_base 1232 0.271 0.138 1.31 [1.00, 1.72] 0.00 0.466 4.89E-02 0 0 0 0 DNAH17
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17:76425480 rs666463 a t 0.8331 0.0149 MMSE MMSE_cont 2114 -0.116 0.060 -0.12 [-0.23, 0.00] 41.50 0.102 5.46E-02 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8227 0.0124 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.051 0.033 0.05 [-0.01, 0.12] 0.00 0.513 1.20E-01 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8346 0.0159 DEPR DEPR_base 2138 -0.164 0.121 0.85 [0.67, 1.08] 40.90 0.106 1.75E-01 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8283 0.0088 MOTORFLUX MOTORFLUX_base 1803 0.134 0.108 1.14 [0.93, 1.41] 0.00 0.617 2.12E-01 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8365 0.0139 INS INS_surv 1112 0.098 0.087 1.10 [0.93, 1.31] 0.00 0.505 2.60E-01 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8272 0.0157 SEADL70 SEADL70_surv 1683 0.131 0.123 1.14 [0.90, 1.45] 43.00 0.135 2.86E-01 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8190 0.0210 HY3 HY3_surv 2582 -0.064 0.078 0.94 [0.81, 1.09] 0.00 0.665 4.14E-01 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8397 0.0278 DEPR DEPR_surv 1314 0.088 0.109 1.09 [0.88, 1.35] 0.00 0.965 4.19E-01 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8310 0.0204 MOCA MOCA_cont 1074 -0.114 0.164 -0.11 [-0.44, 0.21] 45.10 0.141 4.89E-01 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8258 0.0082 COGi COGi_base 2859 0.072 0.111 1.07 [0.86, 1.34] 0.00 0.745 5.16E-01 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8289 0.0196 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.025 0.039 -0.03 [-0.10, 0.05] 16.00 0.308 5.19E-01 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8247 0.0205 DYSKINESIAS DYSKINESIAS_surv 1856 0.046 0.075 1.05 [0.90, 1.21] 0.00 0.847 5.38E-01 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8267 0.0173 COGi COGi_surv 2244 0.050 0.097 1.05 [0.87, 1.27] 0.00 0.648 6.07E-01 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8272 0.0073 CONST CONST_base 1472 0.036 0.109 1.04 [0.84, 1.28] 37.50 0.171 7.42E-01 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8256 0.0088 SLEEP SLEEP_base 1724 -0.026 0.108 0.97 [0.79, 1.20] 0.00 0.864 8.07E-01 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8249 0.0090 HYPOSMIA HYPOSMIA_base 1588 -0.022 0.102 0.98 [0.80, 1.19] 0.00 0.481 8.32E-01 0 0 0 0 DNAH17
17:76425480 rs666463 a t 0.8269 0.0159 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.003 0.035 -0.00 [-0.07, 0.06] 17.80 0.290 9.30E-01 0 0 0 0 DNAH17
17:42434630 rs850738 a g 0.5920 0.0205 MMSE MMSE_cont 2114 0.109 0.045 0.11 [0.02, 0.20] 44.30 0.083 1.67E-02 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5854 0.0268 COGi COGi_base 2859 -0.207 0.087 0.81 [0.69, 0.96] 0.00 0.905 1.72E-02 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5964 0.0192 UPDRS_scaled UPDRS_scaled_cont 2994 -0.050 0.024 -0.05 [-0.10, -0.00] 0.00 0.597 3.57E-02 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5851 0.0279 DYSKINESIAS DYSKINESIAS_base 1232 -0.215 0.104 0.81 [0.66, 0.99] 0.00 0.595 3.80E-02 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5970 0.0148 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.059 0.029 -0.06 [-0.12, -0.00] 0.00 0.578 4.63E-02 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5976 0.0239 COGi COGi_surv 2244 -0.132 0.077 0.88 [0.75, 1.02] 0.00 0.697 8.54E-02 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5871 0.0255 MOTORFLUX MOTORFLUX_base 1803 -0.128 0.082 0.88 [0.75, 1.03] 30.80 0.216 1.18E-01 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5946 0.0170 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.041 0.026 -0.04 [-0.09, 0.01] 0.00 0.663 1.20E-01 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5908 0.0269 MOTORFLUX MOTORFLUX_surv 1709 -0.074 0.050 0.93 [0.84, 1.02] 0.00 0.907 1.35E-01 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5939 0.0261 DYSKINESIAS DYSKINESIAS_surv 1856 -0.087 0.060 0.92 [0.82, 1.03] 0.00 0.938 1.44E-01 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5866 0.0213 HY HY_cont 3627 -0.012 0.009 -0.01 [-0.03, 0.01] 0.00 0.591 1.96E-01 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5955 0.0144 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.032 0.026 -0.03 [-0.08, 0.02] 0.00 0.689 2.12E-01 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5965 0.0137 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.034 0.030 -0.03 [-0.09, 0.02] 0.00 0.554 2.42E-01 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5885 0.0290 HYPOSMIA HYPOSMIA_base 1588 -0.094 0.082 0.91 [0.78, 1.07] 13.70 0.327 2.48E-01 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5975 0.0130 SEADL SEADL_cont 2218 0.252 0.240 0.25 [-0.22, 0.72] 2.30 0.412 2.94E-01 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5869 0.0351 INS INS_surv 1112 -0.058 0.066 0.94 [0.83, 1.08] 0.20 0.415 3.86E-01 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5874 0.0321 CONST CONST_base 1472 0.068 0.086 1.07 [0.90, 1.27] 0.00 0.448 4.33E-01 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5697 0.0417 HY3 HY3_surv 2582 -0.045 0.066 0.96 [0.84, 1.09] 0.00 0.776 4.95E-01 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.6009 0.0225 MOCA MOCA_cont 1074 -0.075 0.123 -0.07 [-0.32, 0.17] 0.00 0.821 5.45E-01 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.6032 0.0158 SEADL70 SEADL70_surv 1683 -0.051 0.096 0.95 [0.79, 1.15] 0.00 0.506 5.96E-01 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5874 0.0381 DEPR DEPR_surv 1314 -0.032 0.081 0.97 [0.83, 1.13] 41.30 0.130 6.91E-01 0 0 0 0 FAM171A2
17:42434630 rs850738 a g 0.5904 0.0273 DEPR DEPR_base 2138 -0.001 0.091 1.00 [0.84, 1.19] 27.90 0.205 9.92E-01 0 0 0 0 FAM171A2
4:90636630 rs5019538 a g 0.6699 0.0086 MOTORFLUX MOTORFLUX_base 1803 -0.196 0.083 0.82 [0.70, 0.97] 46.30 0.114 1.80E-02 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6691 0.0131 MOTORFLUX MOTORFLUX_surv 1709 -0.114 0.051 0.89 [0.81, 0.98] 0.00 0.888 2.37E-02 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6709 0.0097 DYSKINESIAS DYSKINESIAS_base 1232 -0.229 0.103 0.80 [0.65, 0.97] 14.30 0.311 2.54E-02 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6593 0.0095 DEPR DEPR_surv 1314 0.169 0.082 1.18 [1.01, 1.39] 0.00 0.712 3.99E-02 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6574 0.0110 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.058 0.030 0.06 [-0.00, 0.12] 0.00 0.875 5.52E-02 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6674 0.0095 CONST CONST_base 1472 0.142 0.088 1.15 [0.97, 1.37] 0.00 0.578 1.07E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6694 0.0138 DEPR DEPR_base 2138 0.138 0.095 1.15 [0.95, 1.38] 0.00 0.954 1.45E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6659 0.0098 COGi COGi_base 2859 0.114 0.090 1.12 [0.94, 1.34] 0.00 0.495 2.05E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6672 0.0088 DYSKINESIAS DYSKINESIAS_surv 1856 -0.064 0.059 0.94 [0.84, 1.05] 0.00 0.854 2.82E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6587 0.0114 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.023 0.026 -0.02 [-0.07, 0.03] 0.00 0.507 3.72E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6518 0.0190 MMSE MMSE_cont 2114 -0.042 0.047 -0.04 [-0.13, 0.05] 0.00 0.544 3.73E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6564 0.0170 HY HY_cont 3627 0.007 0.009 0.01 [-0.01, 0.03] 3.10 0.414 4.37E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6698 0.0129 SLEEP SLEEP_base 1724 0.066 0.087 1.07 [0.90, 1.27] 0.00 0.636 4.53E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6570 0.0171 UPDRS_scaled UPDRS_scaled_cont 2994 0.017 0.025 0.02 [-0.03, 0.07] 0.00 0.478 4.78E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6661 0.0092 HY3 HY3_base 1289 -0.076 0.117 0.93 [0.74, 1.17] 4.20 0.352 5.14E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6569 0.0106 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.017 0.030 0.02 [-0.04, 0.08] 0.00 0.469 5.62E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6417 0.0167 MOCA MOCA_cont 1074 -0.066 0.124 -0.07 [-0.31, 0.18] 0.00 0.831 5.95E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6599 0.0135 SEADL70 SEADL70_surv 1683 0.044 0.097 1.04 [0.86, 1.26] 0.00 0.435 6.52E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6582 0.0175 COGi COGi_surv 2244 0.027 0.078 1.03 [0.88, 1.20] 0.00 0.472 7.28E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6690 0.0105 HYPOSMIA HYPOSMIA_base 1588 -0.027 0.084 0.97 [0.83, 1.15] 0.00 0.537 7.50E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6474 0.0196 SEADL SEADL_cont 2218 -0.060 0.243 -0.06 [-0.54, 0.42] 0.00 0.629 8.07E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6640 0.0082 INS INS_surv 1112 -0.016 0.067 0.98 [0.86, 1.12] 0.00 0.793 8.12E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6625 0.0156 HY3 HY3_surv 2582 -0.015 0.066 0.99 [0.87, 1.12] 46.50 0.060 8.22E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6574 0.0107 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.002 0.027 -0.00 [-0.05, 0.05] 0.00 0.431 9.56E-01 0 0 0 0 SNCA
4:90636630 rs5019538 a g 0.6736 0.0115 INS INS_base 2220 0.003 0.073 1.00 [0.87, 1.16] 0.00 0.754 9.66E-01 0 0 0 0 SNCA
11:83487277 rs12283611 a c 0.3978 0.0031 HY3 HY3_base 1289 -0.272 0.120 0.76 [0.60, 0.96] 47.80 0.147 2.31E-02 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4097 0.0154 DYSKINESIAS DYSKINESIAS_surv 1856 -0.091 0.057 0.91 [0.82, 1.02] 0.00 0.780 1.10E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4079 0.0196 HY HY_cont 3627 -0.014 0.009 -0.01 [-0.03, 0.00] 15.50 0.293 1.10E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4042 0.0266 HY3 HY3_surv 2582 -0.091 0.062 0.91 [0.81, 1.03] 0.00 0.595 1.45E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4087 0.0134 MMSE MMSE_cont 2114 0.062 0.044 0.06 [-0.02, 0.15] 0.00 0.716 1.58E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4221 0.0098 DEPR DEPR_surv 1314 0.099 0.077 1.10 [0.95, 1.28] 0.00 0.939 1.97E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4118 0.0186 SEADL70 SEADL70_surv 1683 -0.099 0.091 0.91 [0.76, 1.08] 0.00 0.909 2.77E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4122 0.0153 DEPR DEPR_base 2138 -0.095 0.089 0.91 [0.76, 1.08] 0.00 0.518 2.86E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.3985 0.0092 COGi COGi_base 2859 -0.067 0.086 0.94 [0.79, 1.11] 8.60 0.364 4.38E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4101 0.0142 MOTORFLUX MOTORFLUX_surv 1709 0.031 0.049 1.03 [0.94, 1.14] 0.00 0.923 5.35E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4005 0.0171 HYPOSMIA HYPOSMIA_base 1588 -0.048 0.079 0.95 [0.82, 1.11] 51.50 0.067 5.47E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4012 0.0073 MOTORFLUX MOTORFLUX_base 1803 -0.043 0.081 0.96 [0.82, 1.12] 0.00 0.837 5.93E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4126 0.0186 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.014 0.028 0.01 [-0.04, 0.07] 39.10 0.131 6.33E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4004 0.0098 CONST CONST_base 1472 0.032 0.084 1.03 [0.88, 1.22] 0.00 0.486 7.05E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4018 0.0155 INS INS_base 2220 -0.025 0.070 0.97 [0.85, 1.12] 0.00 0.619 7.14E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4031 0.0168 SLEEP SLEEP_base 1724 0.028 0.083 1.03 [0.87, 1.21] 33.10 0.175 7.34E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4046 0.0271 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.008 0.025 -0.01 [-0.06, 0.04] 37.10 0.133 7.48E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4086 0.0175 COGi COGi_surv 2244 -0.015 0.074 0.98 [0.85, 1.14] 0.00 0.869 8.36E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4114 0.0168 UPDRS_scaled UPDRS_scaled_cont 2994 0.004 0.023 0.00 [-0.04, 0.05] 32.20 0.150 8.79E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4088 0.0221 MOCA MOCA_cont 1074 0.013 0.118 0.01 [-0.22, 0.24] 0.00 0.808 9.16E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.3991 0.0026 DYSKINESIAS DYSKINESIAS_base 1232 0.008 0.102 1.01 [0.83, 1.23] 0.00 0.811 9.35E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4043 0.0197 SEADL SEADL_cont 2218 0.016 0.231 0.02 [-0.44, 0.47] 0.00 0.655 9.44E-01 0 0 0 0 DLG2
11:83487277 rs12283611 a c 0.4105 0.0189 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.001 0.025 -0.00 [-0.05, 0.05] 31.30 0.201 9.73E-01 0 0 0 0 DLG2
12:46419086 rs7134559 t c 0.4039 0.0173 SLEEP SLEEP_base 1724 -0.194 0.086 0.82 [0.70, 0.97] 16.20 0.306 2.37E-02 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.3891 0.0203 MMSE MMSE_cont 2114 0.077 0.045 0.08 [-0.01, 0.16] 23.50 0.242 8.62E-02 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.3954 0.0231 HY HY_cont 3627 -0.012 0.009 -0.01 [-0.03, 0.01] 7.40 0.373 1.68E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.4000 0.0251 COGi COGi_base 2859 -0.119 0.088 0.89 [0.75, 1.06] 0.00 0.481 1.78E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.4106 0.0103 MOCA MOCA_cont 1074 -0.155 0.120 -0.15 [-0.39, 0.08] 25.00 0.261 1.97E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.4085 0.0076 CONST CONST_base 1472 -0.107 0.086 0.90 [0.76, 1.06] 0.00 0.977 2.13E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.3992 0.0210 HY3 HY3_surv 2582 0.075 0.064 1.08 [0.95, 1.22] 26.90 0.205 2.38E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.4226 0.0084 DYSKINESIAS DYSKINESIAS_base 1232 0.120 0.103 1.13 [0.92, 1.38] 59.90 0.082 2.44E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.3978 0.0259 SEADL SEADL_cont 2218 0.215 0.233 0.21 [-0.24, 0.67] 0.00 0.690 3.58E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.4015 0.0204 HYPOSMIA HYPOSMIA_base 1588 -0.070 0.082 0.93 [0.79, 1.09] 49.30 0.079 3.94E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.4187 0.0264 INS INS_surv 1112 -0.052 0.066 0.95 [0.83, 1.08] 39.50 0.142 4.26E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.4045 0.0262 COGi COGi_surv 2244 -0.053 0.077 0.95 [0.82, 1.10] 26.90 0.205 4.91E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.4182 0.0080 HY3 HY3_base 1289 -0.072 0.121 0.93 [0.73, 1.18] 26.30 0.258 5.50E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.4079 0.0241 MOTORFLUX MOTORFLUX_surv 1709 -0.029 0.051 0.97 [0.88, 1.07] 25.50 0.235 5.65E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.4065 0.0145 DEPR DEPR_base 2138 -0.043 0.092 0.96 [0.80, 1.15] 5.10 0.391 6.41E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.3984 0.0238 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.011 0.025 0.01 [-0.04, 0.06] 41.60 0.128 6.47E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.3987 0.0244 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.011 0.026 -0.01 [-0.06, 0.04] 0.00 0.828 6.79E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.4112 0.0200 MOTORFLUX MOTORFLUX_base 1803 -0.031 0.082 0.97 [0.82, 1.14] 9.40 0.353 7.03E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.4084 0.0221 INS INS_base 2220 0.023 0.071 1.02 [0.89, 1.18] 0.00 0.784 7.44E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.4015 0.0230 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.006 0.029 0.01 [-0.05, 0.06] 0.00 0.850 8.26E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.4203 0.0220 DEPR DEPR_surv 1314 0.015 0.080 1.02 [0.87, 1.19] 0.00 0.607 8.49E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.3948 0.0243 UPDRS_scaled UPDRS_scaled_cont 2994 -0.003 0.024 -0.00 [-0.05, 0.04] 23.50 0.227 8.91E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.4040 0.0234 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.004 0.029 0.00 [-0.05, 0.06] 0.00 0.868 8.93E-01 0 0 0 0 SCAF11
12:46419086 rs7134559 t c 0.4020 0.0230 SEADL70 SEADL70_surv 1683 0.012 0.090 1.01 [0.85, 1.21] 0.00 0.477 8.99E-01 0 0 0 0 SCAF11
9:17579690 rs13294100 t g 0.3358 0.0130 HY HY_cont 3627 -0.021 0.009 -0.02 [-0.04, -0.00] 0.00 0.774 2.41E-02 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3360 0.0179 HY3 HY3_surv 2582 -0.123 0.066 0.88 [0.78, 1.01] 0.00 0.794 6.29E-02 0 0 0 0 SH3GL2
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9:17579690 rs13294100 t g 0.3311 0.0151 CONST CONST_base 1472 -0.152 0.089 0.86 [0.72, 1.02] 0.00 0.923 8.92E-02 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3424 0.0155 MOTORFLUX MOTORFLUX_base 1803 -0.127 0.086 0.88 [0.74, 1.04] 0.00 0.637 1.40E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3290 0.0218 DYSKINESIAS DYSKINESIAS_surv 1856 -0.088 0.061 0.92 [0.81, 1.03] 0.00 0.729 1.52E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3321 0.0199 HY3 HY3_base 1289 -0.172 0.123 0.84 [0.66, 1.07] 27.70 0.251 1.62E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3319 0.0201 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.033 0.026 -0.03 [-0.08, 0.02] 0.00 0.993 2.09E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3322 0.0191 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.031 0.030 0.03 [-0.03, 0.09] 0.00 0.993 2.97E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3349 0.0162 HYPOSMIA HYPOSMIA_base 1588 -0.084 0.084 0.92 [0.78, 1.08] 0.00 0.895 3.15E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3335 0.0102 MMSE MMSE_cont 2114 0.045 0.046 0.04 [-0.05, 0.14] 33.60 0.160 3.30E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3411 0.0150 SEADL SEADL_cont 2218 0.222 0.247 0.22 [-0.26, 0.71] 0.00 0.777 3.69E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3294 0.0172 COGi COGi_surv 2244 0.041 0.079 1.04 [0.89, 1.22] 0.00 0.611 6.08E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3249 0.0209 INS INS_surv 1112 -0.035 0.070 0.97 [0.84, 1.11] 9.30 0.356 6.23E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3393 0.0153 INS INS_base 2220 0.032 0.074 1.03 [0.89, 1.19] 36.90 0.134 6.62E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3254 0.0235 DEPR DEPR_surv 1314 -0.034 0.084 0.97 [0.82, 1.14] 0.00 0.945 6.86E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3357 0.0186 MOTORFLUX MOTORFLUX_surv 1709 -0.019 0.053 0.98 [0.88, 1.09] 0.00 0.591 7.20E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3339 0.0171 UPDRS_scaled UPDRS_scaled_cont 2994 0.009 0.024 0.01 [-0.04, 0.06] 0.00 0.838 7.20E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3407 0.0156 DEPR DEPR_base 2138 0.026 0.092 1.03 [0.86, 1.23] 0.00 0.710 7.74E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3348 0.0169 SLEEP SLEEP_base 1724 -0.025 0.087 0.98 [0.82, 1.16] 33.90 0.169 7.78E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3413 0.0161 DYSKINESIAS DYSKINESIAS_base 1232 0.025 0.106 1.03 [0.83, 1.26] 0.00 0.372 8.14E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3343 0.0188 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.005 0.030 -0.01 [-0.06, 0.05] 0.00 0.972 8.65E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3328 0.0232 SEADL70 SEADL70_surv 1683 -0.013 0.097 0.99 [0.82, 1.19] 0.00 0.552 8.94E-01 0 0 0 0 SH3GL2
9:17579690 rs13294100 t g 0.3327 0.0179 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.004 0.027 0.00 [-0.05, 0.06] 0.00 0.672 8.97E-01 0 0 0 0 SH3GL2
4:77198054 rs6854006 t c 0.3482 0.0132 HY3 HY3_base 1289 0.267 0.119 1.31 [1.03, 1.65] 25.70 0.261 2.55E-02 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3504 0.0110 DYSKINESIAS DYSKINESIAS_base 1232 0.191 0.105 1.21 [0.98, 1.49] 60.60 0.079 7.03E-02 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3481 0.0247 SLEEP SLEEP_base 1724 0.130 0.085 1.14 [0.96, 1.35] 0.00 0.831 1.27E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3550 0.0212 HYPOSMIA HYPOSMIA_base 1588 -0.106 0.082 0.90 [0.77, 1.06] 0.00 0.708 1.93E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3354 0.0216 HY HY_cont 3627 0.011 0.009 0.01 [-0.01, 0.03] 19.70 0.250 2.05E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3370 0.0192 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.035 0.030 0.03 [-0.02, 0.09] 0.00 0.864 2.46E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3370 0.0194 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.030 0.026 0.03 [-0.02, 0.08] 0.00 0.729 2.52E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3484 0.0188 COGi COGi_base 2859 0.096 0.087 1.10 [0.93, 1.30] 0.00 0.728 2.72E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3472 0.0141 MOTORFLUX MOTORFLUX_base 1803 -0.082 0.085 0.92 [0.78, 1.09] 0.00 0.694 3.34E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3388 0.0202 DEPR DEPR_base 2138 0.089 0.093 1.09 [0.91, 1.31] 0.00 0.716 3.39E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3281 0.0179 MMSE MMSE_cont 2114 -0.043 0.047 -0.04 [-0.13, 0.05] 0.00 0.588 3.60E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3363 0.0189 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.025 0.030 0.02 [-0.03, 0.08] 0.00 0.980 4.09E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3417 0.0211 INS INS_surv 1112 -0.047 0.066 0.95 [0.84, 1.09] 0.00 0.549 4.79E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3330 0.0050 DEPR DEPR_surv 1314 0.054 0.080 1.06 [0.90, 1.23] 17.10 0.303 4.98E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3398 0.0192 MOCA MOCA_cont 1074 -0.078 0.120 -0.08 [-0.31, 0.16] 0.00 0.930 5.18E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3319 0.0203 UPDRS_scaled UPDRS_scaled_cont 2994 0.016 0.024 0.02 [-0.03, 0.06] 11.60 0.336 5.18E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3484 0.0226 CONST CONST_base 1472 -0.049 0.086 0.95 [0.80, 1.13] 0.00 0.895 5.74E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3463 0.0130 MOTORFLUX MOTORFLUX_surv 1709 0.022 0.050 1.02 [0.93, 1.13] 47.00 0.079 6.68E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3376 0.0168 DYSKINESIAS DYSKINESIAS_surv 1856 -0.022 0.061 0.98 [0.87, 1.10] 48.30 0.071 7.24E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3418 0.0158 SEADL70 SEADL70_surv 1683 0.030 0.094 1.03 [0.86, 1.24] 0.00 0.488 7.54E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3422 0.0183 SEADL SEADL_cont 2218 -0.064 0.239 -0.06 [-0.53, 0.40] 0.00 0.628 7.88E-01 0 0 0 0 FAM47E-STBD1
4:77198054 rs6854006 t c 0.3344 0.0275 COGi COGi_surv 2244 -0.001 0.075 1.00 [0.86, 1.16] 0.00 0.831 9.89E-01 0 0 0 0 FAM47E-STBD1
2:96000943 rs2042477 a t 0.2330 0.0219 COGi COGi_surv 2244 0.208 0.094 1.23 [1.03, 1.48] 0.00 0.848 2.61E-02 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2217 0.0206 SLEEP SLEEP_base 1724 0.163 0.099 1.18 [0.97, 1.43] 0.00 0.834 9.80E-02 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2291 0.0172 INS INS_surv 1112 -0.142 0.087 0.87 [0.73, 1.03] 0.00 0.510 1.03E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2323 0.0234 DEPR DEPR_base 2138 0.163 0.105 1.18 [0.96, 1.45] 0.00 0.705 1.20E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2398 0.0121 SEADL70 SEADL70_surv 1683 -0.170 0.127 0.84 [0.66, 1.08] 14.50 0.322 1.81E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2340 0.0180 MOTORFLUX MOTORFLUX_base 1803 0.131 0.098 1.14 [0.94, 1.38] 0.00 0.635 1.82E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2308 0.0124 HY3 HY3_surv 2582 0.093 0.076 1.10 [0.95, 1.27] 0.00 0.982 2.22E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2385 0.0195 MOCA MOCA_cont 1074 0.179 0.161 0.18 [-0.14, 0.50] 0.00 0.879 2.67E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2259 0.0199 DEPR DEPR_surv 1314 -0.122 0.112 0.89 [0.71, 1.10] 0.00 0.810 2.76E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2400 0.0191 MMSE MMSE_cont 2114 -0.049 0.055 -0.05 [-0.16, 0.06] 0.00 0.899 3.76E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2208 0.0182 HYPOSMIA HYPOSMIA_base 1588 0.082 0.096 1.09 [0.90, 1.31] 0.00 0.994 3.94E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2413 0.0139 SEADL SEADL_cont 2218 0.228 0.299 0.23 [-0.36, 0.81] 18.40 0.285 4.45E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2250 0.0194 CONST CONST_base 1472 -0.078 0.103 0.93 [0.76, 1.13] 40.20 0.154 4.49E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2317 0.0208 MOTORFLUX MOTORFLUX_surv 1709 0.048 0.065 1.05 [0.92, 1.19] 0.00 0.506 4.60E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2364 0.0163 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.025 0.040 -0.02 [-0.10, 0.05] 0.00 0.853 5.41E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2325 0.0157 DYSKINESIAS DYSKINESIAS_base 1232 -0.052 0.124 0.95 [0.74, 1.21] 51.70 0.126 6.73E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2353 0.0143 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.011 0.034 0.01 [-0.06, 0.08] 0.00 0.448 7.56E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2258 0.0179 INS INS_base 2220 -0.023 0.084 0.98 [0.83, 1.15] 29.80 0.190 7.87E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2340 0.0145 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.008 0.035 -0.01 [-0.08, 0.06] 4.90 0.385 8.18E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2327 0.0165 COGi COGi_base 2859 0.019 0.102 1.02 [0.83, 1.24] 19.70 0.273 8.53E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2367 0.0175 DYSKINESIAS DYSKINESIAS_surv 1856 0.015 0.078 1.01 [0.87, 1.18] 33.90 0.169 8.53E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2362 0.0156 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.007 0.040 0.01 [-0.07, 0.09] 0.00 0.596 8.66E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2397 0.0155 UPDRS_scaled UPDRS_scaled_cont 2994 0.004 0.031 0.00 [-0.06, 0.06] 0.00 0.749 8.94E-01 0 0 0 0 KCNIP3
2:96000943 rs2042477 a t 0.2346 0.0173 HY HY_cont 3627 0.001 0.011 0.00 [-0.02, 0.02] 0.00 0.544 9.04E-01 0 0 0 0 KCNIP3
14:55348869 rs11158026 t c 0.3221 0.0201 COGi COGi_surv 2244 -0.186 0.084 0.83 [0.71, 0.98] 0.00 0.884 2.67E-02 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3184 0.0017 HY3 HY3_base 1289 -0.286 0.133 0.75 [0.58, 0.97] 0.00 0.891 3.14E-02 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3211 0.0128 MOTORFLUX MOTORFLUX_surv 1709 0.102 0.052 1.11 [1.00, 1.23] 0.00 0.940 5.10E-02 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3083 0.0218 UPDRS_scaled UPDRS_scaled_cont 2994 0.046 0.025 0.05 [-0.00, 0.10] 0.00 0.730 6.55E-02 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3108 0.0210 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.051 0.031 0.05 [-0.01, 0.11] 0.70 0.419 9.83E-02 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3044 0.0140 DEPR DEPR_surv 1314 0.138 0.085 1.15 [0.97, 1.35] 0.00 0.663 1.03E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3193 0.0150 SEADL SEADL_cont 2218 -0.373 0.246 -0.37 [-0.86, 0.11] 0.00 0.772 1.29E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3058 0.0240 HY HY_cont 3627 0.012 0.009 0.01 [-0.01, 0.03] 0.00 0.557 2.04E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3144 0.0197 MMSE MMSE_cont 2114 0.056 0.047 0.06 [-0.04, 0.15] 15.90 0.305 2.36E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3165 0.0172 COGi COGi_base 2859 0.106 0.094 1.11 [0.92, 1.34] 15.60 0.308 2.61E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3121 0.0194 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.021 0.027 0.02 [-0.03, 0.08] 0.00 0.437 4.38E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3162 0.0118 MOTORFLUX MOTORFLUX_base 1803 -0.065 0.090 0.94 [0.79, 1.12] 0.00 0.457 4.67E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3180 0.0224 HYPOSMIA HYPOSMIA_base 1588 -0.059 0.085 0.94 [0.80, 1.11] 0.00 0.561 4.88E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3197 0.0168 INS INS_surv 1112 -0.046 0.073 0.95 [0.83, 1.10] 0.00 0.919 5.28E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3191 0.0013 DYSKINESIAS DYSKINESIAS_base 1232 -0.072 0.115 0.93 [0.74, 1.16] 0.00 0.903 5.28E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3107 0.0193 DEPR DEPR_base 2138 0.054 0.096 1.06 [0.88, 1.27] 0.00 0.642 5.71E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3162 0.0139 DYSKINESIAS DYSKINESIAS_surv 1856 -0.027 0.062 0.97 [0.86, 1.10] 0.00 0.752 6.59E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3145 0.0223 SLEEP SLEEP_base 1724 -0.038 0.090 0.96 [0.81, 1.15] 0.00 0.964 6.76E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3245 0.0100 HY3 HY3_surv 2582 -0.018 0.069 0.98 [0.86, 1.12] 0.00 0.531 7.89E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3123 0.0201 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.008 0.031 0.01 [-0.05, 0.07] 0.00 0.683 7.94E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3097 0.0219 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.007 0.027 0.01 [-0.05, 0.06] 0.00 0.743 7.96E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3164 0.0189 CONST CONST_base 1472 -0.021 0.094 0.98 [0.81, 1.18] 44.80 0.124 8.25E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3177 0.0205 INS INS_base 2220 0.014 0.075 1.01 [0.88, 1.17] 0.00 0.801 8.49E-01 0 0 0 0 GCH1
14:55348869 rs11158026 t c 0.3207 0.0079 SEADL70 SEADL70_surv 1683 -0.010 0.097 0.99 [0.82, 1.20] 32.80 0.203 9.19E-01 0 0 0 0 GCH1
5:60137959 rs1867598 a g 0.8855 0.0165 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.091 0.041 0.09 [0.01, 0.17] 0.00 0.516 2.70E-02 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8811 0.0120 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.091 0.045 0.09 [0.00, 0.18] 49.90 0.062 4.33E-02 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8884 0.0166 UPDRS_scaled UPDRS_scaled_cont 2994 0.071 0.038 0.07 [-0.00, 0.14] 29.90 0.170 6.06E-02 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8947 0.0108 INS INS_base 2220 -0.139 0.109 0.87 [0.70, 1.08] 30.70 0.183 2.01E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8910 0.0193 HY HY_cont 3627 0.017 0.014 0.02 [-0.01, 0.04] 0.60 0.438 2.46E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8836 0.0192 SEADL SEADL_cont 2112 -0.413 0.378 -0.41 [-1.15, 0.33] 18.10 0.292 2.74E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8908 0.0139 SEADL70 SEADL70_surv 1683 -0.142 0.141 0.87 [0.66, 1.14] 22.10 0.274 3.12E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8882 0.0145 DYSKINESIAS DYSKINESIAS_surv 1856 0.090 0.092 1.09 [0.91, 1.31] 0.00 0.890 3.29E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8944 0.0119 HYPOSMIA HYPOSMIA_base 1588 0.114 0.129 1.12 [0.87, 1.44] 0.00 0.468 3.76E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8914 0.0150 MMSE MMSE_cont 2114 -0.061 0.072 -0.06 [-0.20, 0.08] 0.00 0.911 4.02E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8967 0.0030 MOTORFLUX MOTORFLUX_base 1803 0.105 0.130 1.11 [0.86, 1.43] 0.00 0.802 4.18E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8832 0.0171 MOCA MOCA_cont 1074 -0.149 0.198 -0.15 [-0.54, 0.24] 0.00 0.569 4.52E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8892 0.0032 DEPR DEPR_surv 1314 0.098 0.131 1.10 [0.85, 1.43] 36.50 0.164 4.58E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8975 0.0121 COGi COGi_base 2859 0.088 0.143 1.09 [0.83, 1.45] 0.00 0.708 5.36E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8956 0.0144 HY3 HY3_surv 2582 0.065 0.106 1.07 [0.87, 1.31] 19.30 0.272 5.41E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8914 0.0143 DEPR DEPR_base 2138 -0.077 0.144 0.93 [0.70, 1.23] 49.20 0.055 5.94E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8860 0.0107 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.019 0.039 0.02 [-0.06, 0.10] 16.60 0.306 6.20E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8858 0.0164 COGi COGi_surv 2244 0.051 0.123 1.05 [0.83, 1.34] 0.00 0.869 6.79E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8934 0.0103 INS INS_surv 1112 0.046 0.113 1.05 [0.84, 1.31] 0.00 0.953 6.82E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.9008 0.0045 CONST CONST_base 1472 -0.046 0.143 0.95 [0.72, 1.26] 53.70 0.071 7.46E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8956 0.0027 DYSKINESIAS DYSKINESIAS_base 1232 0.049 0.161 1.05 [0.77, 1.44] 43.50 0.171 7.61E-01 0 0 0 0 ELOVL7
5:60137959 rs1867598 a g 0.8829 0.0114 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.006 0.045 0.01 [-0.08, 0.09] 0.00 0.796 8.98E-01 0 0 0 0 ELOVL7
Page 72 of 106































































5:60137959 rs1867598 a g 0.8909 0.0123 MOTORFLUX MOTORFLUX_surv 1709 0.008 0.077 1.01 [0.87, 1.17] 31.50 0.188 9.20E-01 0 0 0 0 ELOVL7
1:226916078 rs4653767 t c 0.7302 0.0150 INS INS_surv 1112 0.168 0.076 1.18 [1.02, 1.37] 0.00 0.551 2.71E-02 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7288 0.0140 HY3 HY3_surv 2582 -0.100 0.071 0.90 [0.79, 1.04] 20.70 0.259 1.56E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7331 0.0150 COGi COGi_base 2859 -0.131 0.098 0.88 [0.72, 1.06] 0.00 0.748 1.79E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7232 0.0173 MOTORFLUX MOTORFLUX_base 1803 -0.102 0.091 0.90 [0.76, 1.08] 0.00 0.908 2.58E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7293 0.0179 SEADL SEADL_cont 2218 -0.258 0.261 -0.26 [-0.77, 0.25] 22.30 0.252 3.23E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7261 0.0190 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.024 0.029 -0.02 [-0.08, 0.03] 42.50 0.095 4.01E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7244 0.0190 DYSKINESIAS DYSKINESIAS_base 1232 -0.088 0.114 0.92 [0.73, 1.15] 6.90 0.341 4.44E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7260 0.0170 MMSE MMSE_cont 2114 -0.035 0.050 -0.03 [-0.13, 0.06] 0.00 0.676 4.87E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7233 0.0100 SEADL70 SEADL70_surv 1683 0.066 0.105 1.07 [0.87, 1.31] 33.70 0.196 5.27E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7390 0.0113 CONST CONST_base 1472 0.048 0.098 1.05 [0.87, 1.27] 0.00 0.444 6.23E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7330 0.0189 COGi COGi_surv 2244 0.036 0.085 1.04 [0.88, 1.22] 0.00 0.687 6.70E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7289 0.0191 UPDRS_scaled UPDRS_scaled_cont 2994 -0.011 0.026 -0.01 [-0.06, 0.04] 44.10 0.065 6.89E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7236 0.0191 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.013 0.032 -0.01 [-0.08, 0.05] 33.70 0.171 6.91E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7415 0.0186 MOCA MOCA_cont 1074 0.053 0.137 0.05 [-0.22, 0.32] 0.00 0.743 7.02E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7266 0.0066 MOTORFLUX MOTORFLUX_surv 1709 0.020 0.054 1.02 [0.92, 1.13] 0.00 0.890 7.07E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7323 0.0204 DEPR DEPR_base 2138 -0.035 0.102 0.97 [0.79, 1.18] 0.00 0.603 7.31E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7334 0.0174 HY3 HY3_base 1289 -0.041 0.132 0.96 [0.74, 1.24] 0.00 0.647 7.59E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7415 0.0155 SLEEP SLEEP_base 1724 -0.026 0.095 0.97 [0.81, 1.17] 0.00 0.644 7.86E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7232 0.0197 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.008 0.032 -0.01 [-0.07, 0.05] 0.00 0.458 8.03E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7313 0.0206 INS INS_base 2220 0.019 0.080 1.02 [0.87, 1.19] 6.60 0.380 8.17E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7233 0.0196 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.006 0.028 -0.01 [-0.06, 0.05] 0.00 0.854 8.19E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7398 0.0132 HYPOSMIA HYPOSMIA_base 1588 0.014 0.091 1.01 [0.85, 1.21] 0.00 0.552 8.77E-01 0 0 0 0 ITPKB
1:226916078 rs4653767 t c 0.7330 0.0191 HY HY_cont 3627 -0.001 0.010 -0.00 [-0.02, 0.02] 8.20 0.365 9.19E-01 0 0 0 0 ITPKB
17:40741013 rs12951632 t c 0.7403 0.0083 HY3 HY3_base 1289 -0.287 0.131 0.75 [0.58, 0.97] 0.00 0.431 2.78E-02 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7471 0.0196 HY HY_cont 3627 -0.021 0.010 -0.02 [-0.04, -0.00] 41.90 0.062 3.47E-02 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7499 0.0219 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.042 0.029 -0.04 [-0.10, 0.02] 0.00 0.518 1.49E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7561 0.0117 MMSE MMSE_cont 2114 0.059 0.052 0.06 [-0.04, 0.16] 10.00 0.353 2.55E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7523 0.0122 MOCA MOCA_cont 1074 -0.153 0.140 -0.15 [-0.43, 0.12] 43.60 0.150 2.75E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7493 0.0212 HY3 HY3_surv 2582 -0.068 0.071 0.93 [0.81, 1.07] 0.00 0.486 3.42E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7508 0.0176 UPDRS_scaled UPDRS_scaled_cont 2994 -0.026 0.027 -0.03 [-0.08, 0.03] 0.00 0.962 3.42E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7565 0.0158 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.031 0.033 -0.03 [-0.10, 0.03] 0.00 0.483 3.53E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7411 0.0148 CONST CONST_base 1472 0.091 0.099 1.10 [0.90, 1.33] 0.00 0.624 3.54E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7457 0.0182 SLEEP SLEEP_base 1724 0.086 0.096 1.09 [0.90, 1.32] 0.00 0.495 3.70E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7436 0.0092 DYSKINESIAS DYSKINESIAS_base 1232 -0.086 0.117 0.92 [0.73, 1.15] 0.00 0.442 4.63E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7578 0.0175 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.018 0.029 -0.02 [-0.07, 0.04] 0.00 0.800 5.37E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7578 0.0139 SEADL SEADL_cont 2218 -0.160 0.272 -0.16 [-0.69, 0.37] 0.00 0.707 5.57E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7585 0.0163 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.018 0.033 -0.02 [-0.08, 0.05] 0.00 0.914 5.91E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7583 0.0189 DEPR DEPR_base 2138 -0.047 0.104 0.95 [0.78, 1.17] 0.00 0.891 6.50E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7485 0.0178 COGi COGi_surv 2244 0.033 0.085 1.03 [0.88, 1.22] 0.00 0.763 6.96E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7411 0.0129 COGi COGi_base 2859 -0.031 0.098 0.97 [0.80, 1.17] 0.00 0.637 7.49E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7539 0.0200 MOTORFLUX MOTORFLUX_surv 1709 0.013 0.055 1.01 [0.91, 1.13] 0.00 0.489 8.10E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7571 0.0188 DEPR DEPR_surv 1314 -0.020 0.088 0.98 [0.82, 1.17] 0.00 0.949 8.22E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7544 0.0160 SEADL70 SEADL70_surv 1683 -0.020 0.104 0.98 [0.80, 1.20] 30.80 0.216 8.48E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7508 0.0169 MOTORFLUX MOTORFLUX_base 1803 -0.009 0.094 0.99 [0.82, 1.19] 29.50 0.225 9.20E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7566 0.0182 DYSKINESIAS DYSKINESIAS_surv 1856 -0.002 0.066 1.00 [0.88, 1.14] 0.00 0.480 9.75E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7477 0.0160 INS INS_base 2220 0.002 0.081 1.00 [0.86, 1.17] 19.70 0.274 9.79E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7527 0.0171 INS INS_surv 1112 -0.002 0.075 1.00 [0.86, 1.16] 26.20 0.238 9.81E-01 0 0 0 0 RETREG3
17:40741013 rs12951632 t c 0.7436 0.0167 HYPOSMIA HYPOSMIA_base 1588 -0.002 0.091 1.00 [0.84, 1.19] 40.00 0.139 9.86E-01 0 0 0 0 RETREG3
5:134199105 rs11950533 a c 0.0987 0.0110 MOTORFLUX MOTORFLUX_surv 1709 -0.185 0.085 0.83 [0.70, 0.98] 0.00 0.681 2.98E-02 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0955 0.0114 DYSKINESIAS DYSKINESIAS_surv 1856 -0.228 0.105 0.80 [0.65, 0.98] 38.40 0.136 3.00E-02 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0904 0.0110 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.085 0.045 -0.09 [-0.17, 0.00] 0.00 0.940 5.65E-02 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.1050 0.0025 HY3 HY3_base 1289 -0.371 0.211 0.69 [0.46, 1.04] 0.00 0.796 7.87E-02 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0939 0.0133 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.069 0.044 0.07 [-0.02, 0.16] 1.10 0.421 1.20E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0990 0.0136 CONST CONST_base 1472 -0.227 0.149 0.80 [0.59, 1.07] 0.00 0.712 1.28E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.1008 0.0071 HY3 HY3_surv 2582 0.136 0.101 1.15 [0.94, 1.40] 14.80 0.310 1.77E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0988 0.0147 SEADL SEADL_cont 2218 0.500 0.395 0.50 [-0.27, 1.27] 0.00 0.713 2.06E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0951 0.0123 UPDRS_scaled UPDRS_scaled_cont 2994 -0.051 0.041 -0.05 [-0.13, 0.03] 26.50 0.200 2.12E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.1003 0.0126 DEPR DEPR_surv 1314 0.143 0.132 1.15 [0.89, 1.49] 0.00 0.724 2.78E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.1004 0.0127 MOCA MOCA_cont 1074 0.200 0.198 0.20 [-0.19, 0.59] 0.00 0.577 3.14E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0976 0.0104 COGi COGi_surv 2244 0.122 0.125 1.13 [0.88, 1.44] 0.00 0.974 3.27E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0997 0.0077 COGi COGi_base 2859 0.134 0.148 1.14 [0.86, 1.53] 21.40 0.259 3.63E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0947 0.0140 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.044 0.050 0.04 [-0.06, 0.14] 0.00 0.651 3.88E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0972 0.0166 DEPR DEPR_base 2138 0.119 0.154 1.13 [0.83, 1.52] 0.00 0.539 4.40E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0959 0.0136 INS INS_base 2220 0.091 0.126 1.10 [0.86, 1.40] 12.20 0.335 4.68E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0942 0.0142 HY HY_cont 3627 -0.007 0.015 -0.01 [-0.04, 0.02] 21.40 0.234 6.28E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0954 0.0137 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.024 0.050 -0.02 [-0.12, 0.07] 31.90 0.185 6.31E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0958 0.0158 SLEEP SLEEP_base 1724 -0.069 0.148 0.93 [0.70, 1.25] 0.00 0.603 6.42E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.1034 0.0030 DYSKINESIAS DYSKINESIAS_base 1232 0.074 0.176 1.08 [0.76, 1.52] 0.00 0.684 6.73E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0981 0.0134 MMSE MMSE_cont 2114 0.020 0.077 0.02 [-0.13, 0.17] 0.00 0.855 7.93E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0963 0.0148 HYPOSMIA HYPOSMIA_base 1588 -0.032 0.143 0.97 [0.73, 1.28] 0.00 0.476 8.22E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0992 0.0083 SEADL70 SEADL70_surv 1683 0.034 0.156 1.03 [0.76, 1.40] 0.00 0.598 8.25E-01 0 0 0 0 C5orf24
5:134199105 rs11950533 a c 0.0970 0.0118 INS INS_surv 1112 0.012 0.111 1.01 [0.81, 1.26] 0.00 0.544 9.17E-01 0 0 0 0 C5orf24
16:28944396 rs2904880 c g 0.3040 0.0179 HY HY_cont 3627 -0.021 0.010 -0.02 [-0.04, -0.00] 0.00 0.812 3.07E-02 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3070 0.0172 UPDRS_scaled UPDRS_scaled_cont 2994 -0.044 0.026 -0.04 [-0.09, 0.01] 26.30 0.202 8.70E-02 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3029 0.0245 INS INS_surv 1112 -0.087 0.071 0.92 [0.80, 1.05] 32.10 0.195 2.22E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3092 0.0102 MOCA MOCA_cont 1074 0.136 0.129 0.14 [-0.12, 0.39] 12.70 0.329 2.93E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3104 0.0141 MOTORFLUX MOTORFLUX_base 1803 -0.083 0.089 0.92 [0.77, 1.10] 39.10 0.160 3.54E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3070 0.0193 CONST CONST_base 1472 -0.084 0.091 0.92 [0.77, 1.10] 0.00 0.981 3.55E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3040 0.0197 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.028 0.032 -0.03 [-0.09, 0.03] 41.10 0.117 3.81E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3082 0.0195 DEPR DEPR_base 2138 -0.084 0.098 0.92 [0.76, 1.11] 36.50 0.138 3.91E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3062 0.0123 SEADL70 SEADL70_surv 1683 0.080 0.095 1.08 [0.90, 1.30] 0.00 0.501 4.02E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3002 0.0177 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.022 0.028 0.02 [-0.03, 0.08] 2.20 0.402 4.27E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3020 0.0172 DYSKINESIAS DYSKINESIAS_surv 1856 -0.049 0.063 0.95 [0.84, 1.08] 0.00 0.867 4.30E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3095 0.0126 SEADL SEADL_cont 2218 -0.185 0.254 -0.18 [-0.68, 0.31] 0.70 0.424 4.68E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3182 0.0124 DEPR DEPR_surv 1314 0.059 0.086 1.06 [0.90, 1.26] 0.00 0.728 4.92E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3123 0.0105 DYSKINESIAS DYSKINESIAS_base 1232 0.069 0.111 1.07 [0.86, 1.33] 0.00 0.414 5.37E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3104 0.0132 HY3 HY3_surv 2582 0.021 0.066 1.02 [0.90, 1.16] 0.00 0.596 7.51E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3165 0.0088 HY3 HY3_base 1289 -0.037 0.127 0.96 [0.75, 1.24] 0.00 0.990 7.74E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3033 0.0182 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.008 0.032 -0.01 [-0.07, 0.05] 39.50 0.128 8.13E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3140 0.0118 COGi COGi_base 2859 -0.019 0.094 0.98 [0.82, 1.18] 19.10 0.279 8.41E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3055 0.0214 HYPOSMIA HYPOSMIA_base 1588 -0.017 0.087 0.98 [0.83, 1.17] 0.00 0.720 8.46E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3004 0.0185 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.006 0.028 -0.01 [-0.06, 0.05] 26.20 0.220 8.47E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3018 0.0155 MMSE MMSE_cont 2114 0.004 0.048 0.00 [-0.09, 0.10] 31.20 0.179 9.32E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3034 0.0191 INS INS_base 2220 -0.004 0.076 1.00 [0.86, 1.16] 0.00 0.433 9.56E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3060 0.0219 SLEEP SLEEP_base 1724 0.003 0.090 1.00 [0.84, 1.20] 0.00 0.565 9.70E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3071 0.0153 COGi COGi_surv 2244 -0.002 0.079 1.00 [0.85, 1.17] 0.00 0.747 9.79E-01 0 0 0 0 CD19
16:28944396 rs2904880 c g 0.3069 0.0137 MOTORFLUX MOTORFLUX_surv 1709 0.000 0.054 1.00 [0.90, 1.11] 0.00 0.736 9.99E-01 0 0 0 0 CD19
3:161077630 rs1450522 a g 0.6734 0.0256 MOTORFLUX MOTORFLUX_surv 1709 -0.112 0.052 0.89 [0.81, 0.99] 0.00 0.890 3.14E-02 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6732 0.0245 MMSE MMSE_cont 2114 -0.070 0.046 -0.07 [-0.16, 0.02] 16.20 0.303 1.30E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6733 0.0146 HY3 HY3_surv 2582 -0.084 0.065 0.92 [0.81, 1.04] 0.00 0.605 1.96E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6738 0.0118 SEADL SEADL_cont 2218 0.309 0.246 0.31 [-0.17, 0.79] 0.00 0.964 2.09E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6685 0.0124 DYSKINESIAS DYSKINESIAS_base 1232 0.127 0.110 1.14 [0.92, 1.41] 0.00 0.467 2.48E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6771 0.0267 HY HY_cont 3627 -0.009 0.009 -0.01 [-0.03, 0.01] 0.00 0.527 3.31E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6735 0.0306 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.024 0.028 0.02 [-0.03, 0.08] 0.00 0.735 3.91E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6751 0.0205 DEPR DEPR_surv 1314 -0.070 0.083 0.93 [0.79, 1.10] 0.00 0.951 4.00E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6703 0.0318 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.023 0.031 -0.02 [-0.08, 0.04] 0.00 0.669 4.47E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6805 0.0108 CONST CONST_base 1472 -0.063 0.091 0.94 [0.79, 1.12] 0.00 0.957 4.87E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6813 0.0174 DEPR DEPR_base 2138 0.063 0.097 1.06 [0.88, 1.29] 0.00 0.879 5.16E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6806 0.0135 MOCA MOCA_cont 1074 0.079 0.127 0.08 [-0.17, 0.33] 6.80 0.359 5.33E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6681 0.0227 DYSKINESIAS DYSKINESIAS_surv 1856 -0.036 0.061 0.96 [0.86, 1.09] 0.00 0.484 5.57E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6782 0.0182 INS INS_base 2220 0.042 0.075 1.04 [0.90, 1.21] 0.00 0.507 5.72E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6667 0.0334 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.014 0.027 0.01 [-0.04, 0.07] 0.00 0.896 6.10E-01 0 0 0 0 SPTSSB
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3:161077630 rs1450522 a g 0.6677 0.0328 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.015 0.031 -0.02 [-0.08, 0.04] 11.10 0.345 6.17E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6750 0.0121 HY3 HY3_base 1289 0.035 0.124 1.04 [0.81, 1.32] 0.00 0.532 7.76E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6725 0.0195 COGi COGi_surv 2244 0.021 0.078 1.02 [0.88, 1.19] 0.00 0.975 7.85E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6843 0.0152 HYPOSMIA HYPOSMIA_base 1588 -0.023 0.087 0.98 [0.82, 1.16] 0.00 0.753 7.88E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6669 0.0232 INS INS_surv 1112 0.019 0.070 1.02 [0.89, 1.17] 0.00 0.489 7.93E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6711 0.0140 MOTORFLUX MOTORFLUX_base 1803 0.019 0.087 1.02 [0.86, 1.21] 45.00 0.122 8.28E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6707 0.0107 SEADL70 SEADL70_surv 1683 -0.018 0.095 0.98 [0.82, 1.18] 0.00 0.461 8.49E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6859 0.0152 SLEEP SLEEP_base 1724 -0.011 0.091 0.99 [0.83, 1.18] 36.80 0.148 9.05E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6732 0.0282 UPDRS_scaled UPDRS_scaled_cont 2994 -0.002 0.025 -0.00 [-0.05, 0.05] 0.00 0.572 9.36E-01 0 0 0 0 SPTSSB
3:161077630 rs1450522 a g 0.6741 0.0110 COGi COGi_base 2859 -0.006 0.092 0.99 [0.83, 1.19] 0.00 0.730 9.49E-01 0 0 0 0 SPTSSB
3:151108965 rs11707416 a t 0.3743 0.0109 DYSKINESIAS DYSKINESIAS_base 1232 0.228 0.107 1.26 [1.02, 1.55] 0.00 0.611 3.35E-02 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3462 0.0268 SEADL SEADL_cont 2218 0.403 0.250 0.40 [-0.09, 0.89] 0.00 0.687 1.06E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3548 0.0265 SEADL70 SEADL70_surv 1683 -0.118 0.097 0.89 [0.74, 1.07] 0.00 0.485 2.22E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3681 0.0161 MOTORFLUX MOTORFLUX_base 1803 0.085 0.084 1.09 [0.92, 1.28] 0.00 0.417 3.14E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3605 0.0263 INS INS_surv 1112 0.068 0.070 1.07 [0.93, 1.23] 0.00 0.887 3.35E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3721 0.0133 HYPOSMIA HYPOSMIA_base 1588 -0.075 0.083 0.93 [0.79, 1.09] 38.60 0.149 3.68E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3678 0.0203 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.022 0.026 0.02 [-0.03, 0.07] 0.00 0.874 3.90E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3584 0.0273 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.020 0.027 -0.02 [-0.07, 0.03] 0.00 0.516 4.54E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3713 0.0116 INS INS_base 2220 0.051 0.073 1.05 [0.91, 1.21] 0.00 0.758 4.84E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3533 0.0326 DEPR DEPR_surv 1314 -0.051 0.085 0.95 [0.81, 1.12] 29.20 0.216 5.49E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3750 0.0119 CONST CONST_base 1472 -0.049 0.088 0.95 [0.80, 1.13] 0.00 0.442 5.76E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3740 0.0129 SLEEP SLEEP_base 1724 0.046 0.085 1.05 [0.89, 1.24] 2.60 0.405 5.92E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3610 0.0263 COGi COGi_surv 2244 0.039 0.079 1.04 [0.89, 1.21] 0.00 0.664 6.19E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3493 0.0310 MOTORFLUX MOTORFLUX_surv 1709 -0.025 0.052 0.97 [0.88, 1.08] 0.00 0.826 6.27E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3647 0.0194 COGi COGi_base 2859 -0.038 0.091 0.96 [0.81, 1.15] 42.70 0.094 6.75E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3620 0.0276 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.012 0.031 -0.01 [-0.07, 0.05] 37.40 0.144 7.02E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3732 0.0123 HY3 HY3_base 1289 -0.047 0.123 0.95 [0.75, 1.21] 0.00 0.932 7.02E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3589 0.0294 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.011 0.030 0.01 [-0.05, 0.07] 0.00 0.501 7.09E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3574 0.0328 MOCA MOCA_cont 1074 -0.048 0.130 -0.05 [-0.30, 0.21] 42.00 0.160 7.10E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3562 0.0226 HY3 HY3_surv 2582 -0.008 0.064 0.99 [0.87, 1.13] 0.00 0.651 9.04E-01 0 0 0 0 MED12L
3:151108965 rs11707416 a t 0.3517 0.0248 DYSKINESIAS DYSKINESIAS_surv 1856 0.002 0.061 1.00 [0.89, 1.13] 18.20 0.291 9.78E-01 0 0 0 0 MED12L
17:43744203 rs62053943 t c 0.1336 0.0211 HYPOSMIA HYPOSMIA_base 1588 0.249 0.118 1.28 [1.02, 1.62] 0.00 0.992 3.47E-02 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1269 0.0129 MOTORFLUX MOTORFLUX_base 1803 -0.247 0.126 0.78 [0.61, 1.00] 0.00 0.697 5.03E-02 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1259 0.0192 SEADL70 SEADL70_surv 1683 0.268 0.138 1.31 [1.00, 1.71] 19.10 0.293 5.24E-02 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1377 0.0132 HY3 HY3_base 1289 -0.343 0.183 0.71 [0.50, 1.02] 0.00 0.510 6.07E-02 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1327 0.0207 SLEEP SLEEP_base 1724 0.192 0.120 1.21 [0.96, 1.53] 3.10 0.402 1.08E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1347 0.0194 MOTORFLUX MOTORFLUX_surv 1709 -0.105 0.071 0.90 [0.78, 1.04] 0.00 0.437 1.41E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1387 0.0135 CONST CONST_base 1472 -0.148 0.123 0.86 [0.68, 1.10] 24.20 0.260 2.28E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1279 0.0194 COGi COGi_base 2859 -0.151 0.136 0.86 [0.66, 1.12] 0.60 0.424 2.66E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1318 0.0191 DEPR DEPR_surv 1314 -0.128 0.119 0.88 [0.70, 1.11] 44.80 0.107 2.85E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1348 0.0199 HY3 HY3_surv 2582 0.094 0.091 1.10 [0.92, 1.31] 0.00 0.557 3.05E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1134 0.0138 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.040 0.045 0.04 [-0.05, 0.13] 0.00 0.435 3.81E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1298 0.0198 HY HY_cont 3627 -0.011 0.013 -0.01 [-0.04, 0.01] 4.90 0.397 4.17E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1301 0.0112 DYSKINESIAS DYSKINESIAS_base 1232 0.113 0.151 1.12 [0.83, 1.50] 0.00 0.398 4.55E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1300 0.0216 DYSKINESIAS DYSKINESIAS_surv 1856 -0.054 0.086 0.95 [0.80, 1.12] 5.20 0.387 5.30E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1314 0.0194 INS INS_base 2220 0.063 0.104 1.06 [0.87, 1.30] 0.00 0.436 5.45E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1315 0.0268 COGi COGi_surv 2244 -0.066 0.115 0.94 [0.75, 1.17] 31.60 0.165 5.69E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1185 0.0169 UPDRS_scaled UPDRS_scaled_cont 2994 -0.017 0.036 -0.02 [-0.09, 0.05] 38.70 0.100 6.28E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1111 0.0140 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.015 0.040 -0.02 [-0.09, 0.06] 0.00 0.534 7.05E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1356 0.0211 INS INS_surv 1112 -0.027 0.097 0.97 [0.80, 1.18] 0.00 0.741 7.82E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1274 0.0131 DEPR DEPR_base 2138 -0.033 0.138 0.97 [0.74, 1.27] 34.00 0.157 8.12E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1250 0.0214 SEADL SEADL_cont 2218 0.070 0.351 0.07 [-0.62, 0.76] 0.00 0.774 8.41E-01 0 0 0 0 CRHR1
17:43744203 rs62053943 t c 0.1301 0.0245 MOCA MOCA_cont 1074 -0.003 0.175 -0.00 [-0.35, 0.34] 0.00 0.921 9.86E-01 0 0 0 0 CRHR1
1:205723572 rs823118 t c 0.5740 0.0192 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.061 0.029 -0.06 [-0.12, -0.00] 0.00 0.851 3.60E-02 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5688 0.0211 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.051 0.025 0.05 [0.00, 0.10] 11.00 0.345 4.27E-02 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5769 0.0260 HY3 HY3_surv 2582 -0.120 0.062 0.89 [0.79, 1.00] 0.00 0.452 5.30E-02 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5811 0.0135 HYPOSMIA HYPOSMIA_base 1588 -0.095 0.082 0.91 [0.77, 1.07] 0.00 0.688 2.46E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5801 0.0199 COGi COGi_surv 2244 -0.075 0.075 0.93 [0.80, 1.07] 0.00 0.860 3.16E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5760 0.0195 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.026 0.026 -0.03 [-0.08, 0.02] 0.00 0.728 3.18E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5858 0.0196 CONST CONST_base 1472 0.076 0.088 1.08 [0.91, 1.28] 0.00 0.735 3.87E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5693 0.0167 MOTORFLUX MOTORFLUX_base 1803 0.065 0.082 1.07 [0.91, 1.25] 21.30 0.279 4.28E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5731 0.0138 COGi COGi_base 2859 -0.060 0.086 0.94 [0.80, 1.11] 0.00 0.858 4.85E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5661 0.0235 SEADL70 SEADL70_surv 1683 0.058 0.091 1.06 [0.89, 1.27] 0.00 0.524 5.24E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5794 0.0286 SEADL SEADL_cont 2218 0.147 0.231 0.15 [-0.31, 0.60] 0.00 0.742 5.26E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5931 0.0313 MOCA MOCA_cont 1074 -0.062 0.120 -0.06 [-0.30, 0.17] 0.00 0.725 6.05E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5761 0.0052 HY3 HY3_base 1289 0.051 0.120 1.05 [0.83, 1.33] 0.00 0.401 6.73E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5781 0.0248 DEPR DEPR_surv 1314 -0.027 0.079 0.97 [0.83, 1.14] 37.10 0.159 7.31E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5834 0.0199 INS INS_base 2220 -0.023 0.072 0.98 [0.85, 1.13] 25.10 0.229 7.55E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5855 0.0252 DEPR DEPR_base 2138 0.028 0.093 1.03 [0.86, 1.23] 44.50 0.082 7.63E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5746 0.0040 DYSKINESIAS DYSKINESIAS_base 1232 -0.031 0.104 0.97 [0.79, 1.19] 49.20 0.140 7.67E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5755 0.0213 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.008 0.029 0.01 [-0.05, 0.07] 0.00 0.606 7.84E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5850 0.0206 SLEEP SLEEP_base 1724 -0.021 0.087 0.98 [0.83, 1.16] 18.60 0.288 8.13E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5718 0.0242 MOTORFLUX MOTORFLUX_surv 1709 0.009 0.048 1.01 [0.92, 1.11] 26.10 0.230 8.51E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5856 0.0183 HY HY_cont 3627 -0.001 0.009 -0.00 [-0.02, 0.02] 0.00 0.750 8.72E-01 0 0 0 0 NUCKS1
1:205723572 rs823118 t c 0.5780 0.0241 UPDRS_scaled UPDRS_scaled_cont 2994 -0.003 0.024 -0.00 [-0.05, 0.04] 0.00 0.910 8.97E-01 0 0 0 0 NUCKS1
21:38852361 rs2248244 a g 0.2880 0.0085 HY3 HY3_surv 2582 0.151 0.073 1.16 [1.01, 1.34] 0.00 0.666 3.74E-02 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2989 0.0143 INS INS_surv 1112 0.154 0.079 1.17 [1.00, 1.36] 0.00 0.677 5.07E-02 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2914 0.0101 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.056 0.041 0.06 [-0.02, 0.14] 0.00 0.452 1.72E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2904 0.0127 SEADL70 SEADL70_surv 1683 0.154 0.115 1.17 [0.93, 1.46] 0.00 0.825 1.80E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2929 0.0083 CONST CONST_base 1472 0.117 0.092 1.12 [0.94, 1.35] 33.80 0.196 2.05E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2939 0.0079 SLEEP SLEEP_base 1724 0.098 0.090 1.10 [0.92, 1.32] 0.00 0.709 2.78E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2920 0.0088 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.037 0.035 0.04 [-0.03, 0.11] 44.20 0.084 2.82E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2870 0.0033 DYSKINESIAS DYSKINESIAS_base 1232 0.120 0.115 1.13 [0.90, 1.41] 0.00 0.716 2.97E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2914 0.0116 DEPR DEPR_surv 1314 -0.107 0.105 0.90 [0.73, 1.10] 0.00 0.431 3.08E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2870 0.0100 SEADL SEADL_cont 2112 -0.291 0.294 -0.29 [-0.87, 0.28] 36.80 0.148 3.22E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2887 0.0115 COGi COGi_surv 2244 0.086 0.091 1.09 [0.91, 1.30] 0.00 0.744 3.42E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2860 0.0084 COGi COGi_base 2859 0.089 0.095 1.09 [0.91, 1.32] 1.40 0.419 3.50E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2907 0.0082 DEPR DEPR_base 2138 -0.086 0.102 0.92 [0.75, 1.12] 22.50 0.250 4.02E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2956 0.0063 HYPOSMIA HYPOSMIA_base 1588 0.067 0.086 1.07 [0.90, 1.27] 15.20 0.316 4.37E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2887 0.0035 HY3 HY3_base 1289 0.093 0.130 1.10 [0.85, 1.42] 0.00 0.925 4.76E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2799 0.0109 MMSE MMSE_cont 2114 -0.035 0.053 -0.04 [-0.14, 0.07] 0.00 0.608 5.02E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2997 0.0176 MOCA MOCA_cont 1074 -0.102 0.160 -0.10 [-0.42, 0.21] 0.00 0.835 5.24E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2912 0.0108 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.022 0.041 0.02 [-0.06, 0.10] 1.80 0.411 5.91E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2879 0.0045 MOTORFLUX MOTORFLUX_base 1803 0.048 0.091 1.05 [0.88, 1.25] 4.40 0.382 5.98E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2943 0.0114 MOTORFLUX MOTORFLUX_surv 1709 -0.032 0.063 0.97 [0.86, 1.10] 0.00 0.556 6.18E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2862 0.0121 UPDRS_scaled UPDRS_scaled_cont 2994 0.014 0.030 0.01 [-0.05, 0.07] 40.30 0.089 6.57E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2915 0.0106 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.013 0.035 -0.01 [-0.08, 0.06] 0.00 0.483 7.12E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2882 0.0126 HY HY_cont 3627 0.003 0.011 0.00 [-0.02, 0.02] 0.00 0.605 7.61E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2923 0.0087 INS INS_base 2220 0.006 0.077 1.01 [0.87, 1.17] 0.00 0.680 9.38E-01 0 0 0 0 DYRK1A
21:38852361 rs2248244 a g 0.2896 0.0101 DYSKINESIAS DYSKINESIAS_surv 1856 -0.005 0.077 1.00 [0.86, 1.16] 0.00 0.566 9.49E-01 0 0 0 0 DYRK1A
3:18361759 rs73038319 a c 0.9575 0.0119 INS INS_base 2220 -0.355 0.171 0.70 [0.50, 0.98] 0.00 0.607 3.79E-02 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9545 0.0088 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.107 0.070 -0.11 [-0.24, 0.03] 11.80 0.339 1.27E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9508 0.0078 SEADL SEADL_cont 2218 -0.791 0.548 -0.79 [-1.86, 0.28] 0.00 0.692 1.49E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9556 0.0097 MMSE MMSE_cont 2114 -0.147 0.111 -0.15 [-0.36, 0.07] 0.00 0.815 1.85E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9564 0.0057 SEADL70 SEADL70_surv 1683 0.305 0.256 1.36 [0.82, 2.24] 0.00 0.849 2.33E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9535 0.0100 HYPOSMIA HYPOSMIA_base 1588 -0.196 0.194 0.82 [0.56, 1.20] 0.00 0.752 3.13E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9539 0.0105 SLEEP SLEEP_base 1724 0.193 0.207 1.21 [0.81, 1.82] 0.00 0.866 3.52E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9519 0.0101 HY HY_cont 3627 -0.018 0.021 -0.02 [-0.06, 0.02] 42.50 0.059 3.78E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9563 0.0107 DEPR DEPR_base 2138 -0.134 0.230 0.87 [0.56, 1.37] 8.40 0.365 5.59E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9505 0.0052 DYSKINESIAS DYSKINESIAS_surv 1856 -0.065 0.140 0.94 [0.71, 1.23] 0.00 0.520 6.40E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9487 0.0119 MOTORFLUX MOTORFLUX_surv 1709 0.046 0.115 1.05 [0.84, 1.31] 18.00 0.292 6.88E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9565 0.0102 DYSKINESIAS DYSKINESIAS_base 1232 0.089 0.255 1.09 [0.66, 1.80] 31.40 0.233 7.26E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9543 0.0085 CONST CONST_base 1355 -0.063 0.203 0.94 [0.63, 1.40] 0.00 0.853 7.57E-01 0 0 0 0 SATB1
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3:18361759 rs73038319 a c 0.9581 0.0092 MOTORFLUX MOTORFLUX_base 1803 0.051 0.212 1.05 [0.69, 1.60] 41.00 0.148 8.10E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9572 0.0076 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.012 0.062 0.01 [-0.11, 0.13] 0.00 0.939 8.42E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9515 0.0098 COGi COGi_surv 2148 0.032 0.169 1.03 [0.74, 1.44] 0.00 0.939 8.49E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9504 0.0120 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.011 0.061 -0.01 [-0.13, 0.11] 27.60 0.209 8.63E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9493 0.0087 HY3 HY3_surv 2582 0.024 0.147 1.02 [0.77, 1.37] 0.00 0.490 8.69E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9527 0.0099 HY3 HY3_base 1289 -0.038 0.258 0.96 [0.58, 1.60] 0.00 0.824 8.83E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9502 0.0047 MOCA MOCA_cont 1026 -0.039 0.285 -0.04 [-0.60, 0.52] 0.00 0.667 8.92E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9526 0.0084 COGi COGi_base 2859 -0.027 0.197 0.97 [0.66, 1.43] 0.00 0.634 8.92E-01 0 0 0 0 SATB1
3:18361759 rs73038319 a c 0.9444 0.0083 DEPR DEPR_surv 1177 -0.010 0.186 0.99 [0.69, 1.43] 0.00 0.937 9.58E-01 0 0 0 0 SATB1
6:27738801 rs4140646 a g 0.2512 0.0209 DEPR DEPR_surv 1314 -0.186 0.090 0.83 [0.70, 0.99] 0.00 0.845 3.93E-02 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2371 0.0268 COGi COGi_surv 2244 -0.159 0.088 0.85 [0.72, 1.01] 0.00 0.503 7.03E-02 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2465 0.0244 HY3 HY3_surv 2582 -0.104 0.073 0.90 [0.78, 1.04] 14.10 0.317 1.51E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2309 0.0131 SEADL SEADL_cont 2218 -0.342 0.272 -0.34 [-0.88, 0.19] 0.00 0.824 2.09E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2310 0.0168 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.037 0.030 0.04 [-0.02, 0.10] 47.60 0.064 2.16E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2396 0.0200 SLEEP SLEEP_base 1724 0.113 0.096 1.12 [0.93, 1.35] 0.00 0.549 2.40E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2341 0.0294 HY3 HY3_base 1289 0.152 0.140 1.16 [0.89, 1.53] 43.40 0.171 2.76E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2284 0.0187 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.035 0.034 -0.03 [-0.10, 0.03] 9.00 0.360 3.14E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2364 0.0248 UPDRS_scaled UPDRS_scaled_cont 2994 0.026 0.028 0.03 [-0.03, 0.08] 7.70 0.371 3.40E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2401 0.0227 MOTORFLUX MOTORFLUX_surv 1709 -0.053 0.057 0.95 [0.85, 1.06] 0.00 0.633 3.46E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2270 0.0112 SEADL70 SEADL70_surv 1683 0.091 0.102 1.10 [0.90, 1.34] 0.00 0.913 3.72E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2407 0.0208 DEPR DEPR_base 2138 -0.089 0.108 0.91 [0.74, 1.13] 19.60 0.274 4.09E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2300 0.0270 INS INS_base 2220 0.068 0.083 1.07 [0.91, 1.26] 0.00 0.578 4.15E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2270 0.0203 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.022 0.035 0.02 [-0.05, 0.09] 0.00 0.776 5.17E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2248 0.0245 MOTORFLUX MOTORFLUX_base 1803 -0.058 0.098 0.94 [0.78, 1.14] 44.40 0.126 5.53E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2340 0.0285 INS INS_surv 1112 -0.038 0.075 0.96 [0.83, 1.11] 0.00 0.824 6.10E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2256 0.0189 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.015 0.030 0.01 [-0.04, 0.07] 9.00 0.358 6.17E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2337 0.0253 COGi COGi_base 2859 -0.050 0.104 0.95 [0.78, 1.17] 44.10 0.085 6.29E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2329 0.0163 MOCA MOCA_cont 1074 -0.063 0.140 -0.06 [-0.34, 0.21] 0.00 0.997 6.52E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2378 0.0213 CONST CONST_base 1472 0.033 0.098 1.03 [0.85, 1.25] 31.20 0.213 7.34E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2329 0.0151 DYSKINESIAS DYSKINESIAS_surv 1856 -0.022 0.069 0.98 [0.85, 1.12] 45.90 0.086 7.45E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2371 0.0185 HYPOSMIA HYPOSMIA_base 1588 -0.011 0.094 0.99 [0.82, 1.19] 0.00 0.826 9.11E-01 0 0 0 0 LOC100131289
6:27738801 rs4140646 a g 0.2300 0.0279 MMSE MMSE_cont 2114 0.003 0.053 0.00 [-0.10, 0.11] 0.00 0.767 9.49E-01 0 0 0 0 LOC100131289
16:52969426 rs10221156 a g 0.0793 0.0095 HY HY_cont 2077 -0.045 0.022 -0.05 [-0.09, -0.00] 0.00 0.951 3.93E-02 0 0 0 0 CHD9
16:52969426 rs10221156 a g 0.0834 0.0149 INS INS_base 1033 0.156 0.196 1.17 [0.80, 1.71] 38.60 0.164 4.27E-01 0 0 0 0 CHD9
16:52969426 rs10221156 a g 0.0787 0.0144 SLEEP SLEEP_base 1033 -0.175 0.221 0.84 [0.54, 1.29] 14.10 0.325 4.27E-01 0 0 0 0 CHD9
16:52969426 rs10221156 a g 0.0869 0.0118 COGi COGi_surv 1132 -0.122 0.200 0.88 [0.60, 1.31] 25.80 0.249 5.40E-01 0 0 0 0 CHD9
16:52969426 rs10221156 a g 0.0825 0.0067 MMSE MMSE_cont 1066 -0.031 0.102 -0.03 [-0.23, 0.17] 0.00 0.863 7.61E-01 0 0 0 0 CHD9
16:52969426 rs10221156 a g 0.0852 0.0134 HY3 HY3_surv 1299 -0.017 0.137 0.98 [0.75, 1.29] 0.00 0.975 9.03E-01 0 0 0 0 CHD9
16:52969426 rs10221156 a g 0.0784 0.0140 COGi COGi_base 1538 -0.011 0.235 0.99 [0.62, 1.57] 23.50 0.264 9.63E-01 0 0 0 0 CHD9
16:52969426 rs10221156 a g 0.0770 0.0075 UPDRS_scaled UPDRS_scaled_cont 1108 0.000 0.073 -0.00 [-0.14, 0.14] 0.00 0.985 9.99E-01 0 0 0 0 CHD9
16:52636242 rs3104783 a c 0.4252 0.0193 CONST CONST_base 1472 -0.172 0.086 0.84 [0.71, 1.00] 0.00 0.977 4.55E-02 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4280 0.0308 HY3 HY3_base 1289 -0.148 0.119 0.86 [0.68, 1.09] 24.40 0.267 2.17E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4403 0.0238 MOTORFLUX MOTORFLUX_base 1803 0.102 0.083 1.11 [0.94, 1.30] 0.00 0.514 2.18E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4253 0.0251 SLEEP SLEEP_base 1724 0.094 0.084 1.10 [0.93, 1.29] 0.00 0.566 2.64E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4360 0.0204 DEPR DEPR_base 2138 -0.096 0.090 0.91 [0.76, 1.08] 0.00 0.792 2.88E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4394 0.0265 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.021 0.025 0.02 [-0.03, 0.07] 5.50 0.382 4.09E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4380 0.0130 SEADL70 SEADL70_surv 1683 0.066 0.090 1.07 [0.89, 1.27] 16.40 0.310 4.68E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4226 0.0256 HYPOSMIA HYPOSMIA_base 1588 -0.055 0.082 0.95 [0.81, 1.11] 0.00 0.451 4.98E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4346 0.0285 INS INS_base 2220 -0.044 0.071 0.96 [0.83, 1.10] 13.10 0.328 5.32E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4343 0.0217 INS INS_surv 1112 0.034 0.064 1.03 [0.91, 1.17] 0.00 0.747 5.96E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4433 0.0243 UPDRS_scaled UPDRS_scaled_cont 2994 0.012 0.024 0.01 [-0.03, 0.06] 0.00 0.463 6.17E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4330 0.0246 DEPR DEPR_surv 1314 0.025 0.078 1.03 [0.88, 1.19] 0.00 0.767 7.50E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4256 0.0342 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.008 0.026 -0.01 [-0.06, 0.04] 0.00 0.826 7.70E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4216 0.0285 HY3 HY3_surv 2582 -0.018 0.061 0.98 [0.87, 1.11] 33.10 0.153 7.75E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4358 0.0293 HY HY_cont 3627 -0.002 0.009 -0.00 [-0.02, 0.02] 31.60 0.138 8.01E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4394 0.0262 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.006 0.029 0.01 [-0.05, 0.06] 0.00 0.578 8.25E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4325 0.0239 SEADL SEADL_cont 2218 -0.051 0.234 -0.05 [-0.51, 0.41] 0.00 0.975 8.26E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4373 0.0284 COGi COGi_base 2859 0.018 0.088 1.02 [0.86, 1.21] 38.10 0.126 8.40E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4396 0.0249 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.005 0.029 -0.00 [-0.06, 0.05] 0.00 0.779 8.72E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4290 0.0179 MOCA MOCA_cont 1074 -0.016 0.120 -0.02 [-0.25, 0.22] 42.70 0.155 8.95E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4330 0.0202 COGi COGi_surv 2244 0.008 0.074 1.01 [0.87, 1.17] 0.00 0.629 9.15E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4433 0.0269 DYSKINESIAS DYSKINESIAS_base 1232 -0.009 0.104 0.99 [0.81, 1.22] 0.00 0.680 9.34E-01 0 0 0 0 CASC16
16:52636242 rs3104783 a c 0.4277 0.0222 DYSKINESIAS DYSKINESIAS_surv 1856 -0.001 0.058 1.00 [0.89, 1.12] 11.30 0.343 9.88E-01 0 0 0 0 CASC16
11:10558777 rs7938782 a g 0.8939 0.0056 DYSKINESIAS DYSKINESIAS_surv 1856 0.189 0.095 1.21 [1.00, 1.46] 25.50 0.234 4.66E-02 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8935 0.0028 INS INS_surv 1112 0.208 0.111 1.23 [0.99, 1.53] 0.00 0.520 6.07E-02 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8870 0.0049 SEADL70 SEADL70_surv 1683 0.296 0.160 1.34 [0.98, 1.84] 2.90 0.390 6.39E-02 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8861 0.0124 HY3 HY3_base 1289 0.310 0.203 1.36 [0.91, 2.03] 0.00 0.841 1.28E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8905 0.0069 CONST CONST_base 1472 0.211 0.143 1.24 [0.93, 1.64] 0.80 0.402 1.40E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8935 0.0125 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.059 0.043 0.06 [-0.03, 0.14] 0.00 0.894 1.72E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8908 0.0039 DEPR DEPR_surv 1314 0.135 0.131 1.14 [0.89, 1.48] 0.00 0.931 3.02E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8921 0.0083 SLEEP SLEEP_base 1724 0.141 0.139 1.15 [0.88, 1.51] 0.00 0.945 3.11E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8791 0.0111 DYSKINESIAS DYSKINESIAS_base 1232 -0.160 0.163 0.85 [0.62, 1.17] 0.00 0.851 3.25E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8899 0.0081 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.047 0.048 -0.05 [-0.14, 0.05] 0.00 0.853 3.27E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8921 0.0123 UPDRS_scaled UPDRS_scaled_cont 2994 0.033 0.038 0.03 [-0.04, 0.11] 0.00 0.544 3.94E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8870 0.0084 SEADL SEADL_cont 2218 -0.236 0.368 -0.24 [-0.96, 0.48] 0.00 0.912 5.21E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8896 0.0086 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.029 0.048 0.03 [-0.06, 0.12] 0.00 0.861 5.43E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8839 0.0112 MMSE MMSE_cont 2114 0.034 0.068 0.03 [-0.10, 0.17] 15.90 0.305 6.17E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8921 0.0084 HYPOSMIA HYPOSMIA_base 1588 0.060 0.132 1.06 [0.82, 1.38] 0.30 0.414 6.50E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8900 0.0079 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.017 0.041 0.02 [-0.06, 0.10] 0.00 0.522 6.74E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8896 0.0088 DEPR DEPR_base 2138 0.062 0.148 1.06 [0.80, 1.42] 0.00 0.565 6.76E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8903 0.0151 COGi COGi_base 2859 -0.043 0.141 0.96 [0.73, 1.26] 0.00 0.654 7.62E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8866 0.0126 INS INS_base 2220 -0.033 0.114 0.97 [0.77, 1.21] 0.00 0.810 7.71E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8922 0.0092 HY3 HY3_surv 2582 -0.024 0.103 0.98 [0.80, 1.19] 0.00 0.520 8.14E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8911 0.0064 COGi COGi_surv 2244 0.022 0.124 1.02 [0.80, 1.30] 0.00 0.443 8.56E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8904 0.0022 MOTORFLUX MOTORFLUX_surv 1709 -0.009 0.078 0.99 [0.85, 1.15] 43.20 0.103 9.10E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8825 0.0100 MOTORFLUX MOTORFLUX_base 1803 -0.011 0.128 0.99 [0.77, 1.27] 0.00 0.874 9.35E-01 0 0 0 0 RNF141
11:10558777 rs7938782 a g 0.8933 0.0135 HY HY_cont 3627 0.001 0.014 0.00 [-0.03, 0.03] 0.00 0.834 9.52E-01 0 0 0 0 RNF141
14:88464264 rs979812 t g 0.4487 0.0150 HY3 HY3_surv 2582 -0.123 0.062 0.88 [0.78, 1.00] 0.00 0.491 4.73E-02 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4539 0.0178 COGi COGi_surv 2244 -0.120 0.074 0.89 [0.77, 1.03] 0.00 0.509 1.07E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4517 0.0096 MOTORFLUX MOTORFLUX_base 1803 -0.124 0.080 0.88 [0.75, 1.03] 0.00 0.645 1.21E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4433 0.0208 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.032 0.025 -0.03 [-0.08, 0.02] 0.00 0.746 1.96E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4576 0.0165 DYSKINESIAS DYSKINESIAS_surv 1856 0.059 0.058 1.06 [0.95, 1.19] 26.90 0.223 3.11E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4700 0.0205 MMSE MMSE_cont 2114 0.043 0.044 0.04 [-0.04, 0.13] 0.00 0.844 3.21E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4506 0.0053 HY3 HY3_base 1289 0.103 0.113 1.11 [0.89, 1.38] 0.00 0.545 3.59E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4531 0.0064 DYSKINESIAS DYSKINESIAS_base 1232 -0.089 0.101 0.92 [0.75, 1.12] 47.30 0.150 3.81E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4501 0.0103 CONST CONST_base 1472 0.066 0.084 1.07 [0.91, 1.26] 37.30 0.173 4.35E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4479 0.0222 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.020 0.029 0.02 [-0.04, 0.08] 8.40 0.364 4.77E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4571 0.0172 MOTORFLUX MOTORFLUX_surv 1709 -0.033 0.048 0.97 [0.88, 1.06] 0.00 0.819 5.00E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4507 0.0112 COGi COGi_base 2859 0.055 0.086 1.06 [0.89, 1.25] 28.80 0.199 5.20E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4563 0.0192 MOCA MOCA_cont 1074 0.075 0.119 0.08 [-0.16, 0.31] 31.70 0.222 5.28E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4580 0.0188 INS INS_surv 1112 -0.037 0.066 0.96 [0.85, 1.10] 0.00 0.586 5.78E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4594 0.0172 DEPR DEPR_base 2138 0.039 0.087 1.04 [0.88, 1.23] 0.00 0.841 6.51E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4504 0.0234 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.013 0.029 -0.01 [-0.07, 0.04] 0.00 0.664 6.51E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4607 0.0209 SEADL SEADL_cont 2218 -0.088 0.230 -0.09 [-0.54, 0.36] 19.20 0.278 7.01E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4541 0.0165 INS INS_base 2220 0.022 0.069 1.02 [0.89, 1.17] 0.00 0.720 7.56E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4534 0.0219 UPDRS_scaled UPDRS_scaled_cont 2994 0.006 0.023 0.01 [-0.04, 0.05] 28.20 0.185 8.07E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4479 0.0213 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.004 0.025 0.00 [-0.05, 0.05] 41.30 0.103 8.91E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4590 0.0209 HY HY_cont 3627 0.001 0.009 0.00 [-0.02, 0.02] 0.00 0.799 9.09E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4526 0.0183 SEADL70 SEADL70_surv 1683 0.003 0.091 1.00 [0.84, 1.20] 0.00 0.855 9.73E-01 0 0 0 0 GALC
14:88464264 rs979812 t g 0.4537 0.0176 SLEEP SLEEP_base 1724 -0.002 0.081 1.00 [0.85, 1.17] 25.30 0.236 9.77E-01 0 0 0 0 GALC
1:171719769 rs11578699 t c 0.1818 0.0221 HY3 HY3_surv 2582 0.160 0.081 1.17 [1.00, 1.38] 0.00 0.803 4.87E-02 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1830 0.0176 HYPOSMIA HYPOSMIA_base 1588 0.151 0.104 1.16 [0.95, 1.42] 0.00 0.817 1.47E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1820 0.0086 MOCA MOCA_cont 1074 0.200 0.154 0.20 [-0.10, 0.50] 0.00 0.942 1.94E-01 0 0 0 0 VAMP4
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1:171719769 rs11578699 t c 0.1853 0.0182 INS INS_base 2220 0.106 0.091 1.11 [0.93, 1.33] 0.00 0.472 2.42E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1944 0.0211 SEADL70 SEADL70_surv 1683 -0.122 0.121 0.88 [0.70, 1.12] 0.00 0.945 3.11E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1849 0.0191 HY HY_cont 3627 0.010 0.011 0.01 [-0.01, 0.03] 0.00 0.698 3.85E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1868 0.0254 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.024 0.033 -0.02 [-0.09, 0.04] 22.30 0.252 4.61E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1825 0.0168 SLEEP SLEEP_base 1724 0.078 0.108 1.08 [0.88, 1.33] 0.00 0.915 4.70E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1877 0.0237 SEADL SEADL_cont 2218 -0.207 0.297 -0.21 [-0.79, 0.38] 0.00 0.442 4.87E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1803 0.0185 MMSE MMSE_cont 2114 -0.037 0.057 -0.04 [-0.15, 0.08] 35.30 0.146 5.23E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1902 0.0188 DEPR DEPR_base 2138 0.064 0.113 1.07 [0.85, 1.33] 7.70 0.371 5.71E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1887 0.0115 DYSKINESIAS DYSKINESIAS_base 1232 0.062 0.131 1.06 [0.82, 1.38] 0.00 0.845 6.36E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1818 0.0114 CONST CONST_base 1472 -0.044 0.110 0.96 [0.77, 1.19] 0.00 0.775 6.88E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1833 0.0191 COGi COGi_base 2859 0.040 0.113 1.04 [0.83, 1.30] 3.60 0.403 7.23E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1822 0.0128 HY3 HY3_base 1289 0.053 0.150 1.05 [0.79, 1.41] 0.00 0.952 7.24E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1928 0.0220 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.012 0.037 -0.01 [-0.08, 0.06] 0.00 0.693 7.46E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1939 0.0219 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.009 0.037 -0.01 [-0.08, 0.06] 18.10 0.292 8.08E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1828 0.0152 DEPR DEPR_surv 1314 0.019 0.099 1.02 [0.84, 1.24] 0.00 0.683 8.50E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1952 0.0178 MOTORFLUX MOTORFLUX_base 1803 0.017 0.105 1.02 [0.83, 1.25] 42.60 0.137 8.76E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1844 0.0196 COGi COGi_surv 2244 -0.009 0.096 0.99 [0.82, 1.20] 6.70 0.380 9.23E-01 0 0 0 0 VAMP4
1:171719769 rs11578699 t c 0.1848 0.0224 UPDRS_scaled UPDRS_scaled_cont 2994 0.003 0.030 0.00 [-0.06, 0.06] 0.00 0.851 9.28E-01 0 0 0 0 VAMP4
6:30108683 rs9261484 t c 0.2458 0.0127 HY3 HY3_base 1289 0.261 0.133 1.30 [1.00, 1.68] 0.00 0.536 5.01E-02 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2403 0.0286 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.064 0.033 0.06 [-0.00, 0.13] 0.00 0.703 5.25E-02 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2411 0.0202 COGi COGi_surv 2244 0.147 0.083 1.16 [0.98, 1.36] 0.00 0.593 7.84E-02 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2339 0.0083 SEADL70 SEADL70_surv 1683 0.165 0.102 1.18 [0.96, 1.44] 0.00 0.930 1.08E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2386 0.0260 SLEEP SLEEP_base 1724 -0.151 0.097 0.86 [0.71, 1.04] 0.00 0.901 1.18E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2353 0.0104 MOCA MOCA_cont 1074 -0.209 0.137 -0.21 [-0.48, 0.06] 0.00 0.778 1.28E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2392 0.0260 SEADL SEADL_cont 2218 -0.375 0.269 -0.37 [-0.90, 0.15] 0.00 0.541 1.64E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2381 0.0220 DEPR DEPR_surv 1314 0.112 0.091 1.12 [0.94, 1.34] 47.80 0.088 2.17E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2451 0.0270 INS INS_base 2220 -0.076 0.080 0.93 [0.79, 1.09] 0.00 0.527 3.46E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2293 0.0143 MOTORFLUX MOTORFLUX_surv 1709 -0.052 0.058 0.95 [0.85, 1.06] 0.00 0.679 3.67E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2439 0.0151 MOTORFLUX MOTORFLUX_base 1803 0.084 0.094 1.09 [0.90, 1.31] 0.00 0.421 3.73E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2502 0.0346 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.025 0.029 -0.03 [-0.08, 0.03] 0.00 0.621 3.81E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2371 0.0115 DYSKINESIAS DYSKINESIAS_surv 1856 0.051 0.068 1.05 [0.92, 1.20] 0.00 0.836 4.57E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2515 0.0103 DYSKINESIAS DYSKINESIAS_base 1232 -0.064 0.118 0.94 [0.74, 1.18] 0.00 0.915 5.90E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2356 0.0276 HY HY_cont 3627 0.004 0.010 0.00 [-0.02, 0.02] 0.00 0.610 6.72E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2428 0.0285 HYPOSMIA HYPOSMIA_base 1588 0.035 0.092 1.04 [0.87, 1.24] 0.00 0.937 6.99E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2397 0.0133 INS INS_surv 1112 -0.025 0.074 0.98 [0.84, 1.13] 37.90 0.153 7.35E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2344 0.0140 CONST CONST_base 1472 0.024 0.098 1.02 [0.85, 1.24] 0.00 0.649 8.09E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2305 0.0235 MMSE MMSE_cont 2114 -0.011 0.052 -0.01 [-0.11, 0.09] 0.00 0.993 8.30E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2351 0.0167 DEPR DEPR_base 2138 0.020 0.103 1.02 [0.83, 1.25] 2.60 0.410 8.49E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2449 0.0233 COGi COGi_base 2859 -0.018 0.099 0.98 [0.81, 1.19] 0.00 0.964 8.53E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2414 0.0285 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.006 0.033 0.01 [-0.06, 0.07] 37.20 0.145 8.63E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2373 0.0285 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.003 0.029 -0.00 [-0.06, 0.05] 15.90 0.311 9.04E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2431 0.0303 HY3 HY3_surv 2582 0.008 0.072 1.01 [0.87, 1.16] 11.70 0.337 9.13E-01 0 0 0 0 TRIM40
6:30108683 rs9261484 t c 0.2384 0.0264 UPDRS_scaled UPDRS_scaled_cont 2994 -0.001 0.027 -0.00 [-0.05, 0.05] 12.80 0.326 9.62E-01 0 0 0 0 TRIM40
10:15557406 rs896435 t c 0.7000 0.0126 MOTORFLUX MOTORFLUX_base 1803 0.172 0.089 1.19 [1.00, 1.41] 0.00 0.649 5.29E-02 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.6981 0.0292 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.031 0.027 0.03 [-0.02, 0.08] 0.00 0.684 2.43E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.6970 0.0267 COGi COGi_surv 2244 -0.087 0.078 0.92 [0.79, 1.07] 29.10 0.186 2.62E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.6950 0.0229 COGi COGi_base 2859 0.101 0.093 1.11 [0.92, 1.33] 0.00 0.680 2.80E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.6940 0.0253 SLEEP SLEEP_base 1724 -0.071 0.090 0.93 [0.78, 1.11] 0.00 0.444 4.30E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.6971 0.0296 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.023 0.031 -0.02 [-0.08, 0.04] 36.70 0.149 4.65E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.6846 0.0196 SEADL SEADL_cont 2218 0.179 0.248 0.18 [-0.31, 0.67] 0.00 0.936 4.71E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.7088 0.0163 HY3 HY3_base 1289 0.082 0.127 1.09 [0.85, 1.39] 0.00 0.795 5.15E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.6938 0.0258 UPDRS_scaled UPDRS_scaled_cont 2994 -0.016 0.025 -0.02 [-0.06, 0.03] 44.50 0.063 5.29E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.6927 0.0277 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.014 0.028 -0.01 [-0.07, 0.04] 48.60 0.058 6.26E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.6990 0.0169 MOTORFLUX MOTORFLUX_surv 1709 0.022 0.053 1.02 [0.92, 1.13] 0.00 0.610 6.78E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.6904 0.0280 HYPOSMIA HYPOSMIA_base 1588 0.032 0.086 1.03 [0.87, 1.22] 0.00 0.490 7.14E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.7064 0.0203 INS INS_surv 1112 -0.027 0.074 0.97 [0.84, 1.13] 0.00 0.908 7.22E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.6949 0.0142 SEADL70 SEADL70_surv 1683 0.033 0.098 1.03 [0.85, 1.25] 0.00 0.674 7.35E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.7048 0.0201 DYSKINESIAS DYSKINESIAS_surv 1856 0.019 0.062 1.02 [0.90, 1.15] 0.00 0.990 7.65E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.7000 0.0157 CONST CONST_base 1472 -0.026 0.092 0.97 [0.81, 1.17] 0.00 0.895 7.74E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.6948 0.0156 DEPR DEPR_base 2138 -0.026 0.099 0.97 [0.80, 1.18] 0.00 0.605 7.91E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.6914 0.0234 HY HY_cont 3627 0.002 0.010 0.00 [-0.02, 0.02] 0.00 0.650 8.26E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.6921 0.0247 INS INS_base 2220 -0.011 0.076 0.99 [0.85, 1.15] 10.20 0.351 8.87E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.6901 0.0201 MMSE MMSE_cont 2114 -0.005 0.047 -0.01 [-0.10, 0.09] 29.50 0.193 9.09E-01 0 0 0 0 ITGA8
10:15557406 rs896435 t c 0.7070 0.0257 HY3 HY3_surv 2582 0.004 0.066 1.00 [0.88, 1.14] 0.00 0.974 9.55E-01 0 0 0 0 ITGA8
4:114369065 rs13117519 t c 0.1844 0.0160 HY HY_cont 3627 0.021 0.011 0.02 [-0.00, 0.04] 21.50 0.232 5.83E-02 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1860 0.0190 DEPR DEPR_base 2138 -0.192 0.119 0.83 [0.65, 1.04] 0.00 0.448 1.07E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1913 0.0145 SLEEP SLEEP_base 1724 -0.168 0.106 0.85 [0.69, 1.04] 0.00 0.772 1.11E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1843 0.0205 COGi COGi_surv 2244 0.144 0.096 1.16 [0.96, 1.39] 42.20 0.086 1.33E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1852 0.0149 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.053 0.037 -0.05 [-0.12, 0.02] 0.00 0.788 1.46E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1862 0.0150 INS INS_base 2220 0.125 0.089 1.13 [0.95, 1.35] 39.20 0.118 1.60E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1853 0.0087 DYSKINESIAS DYSKINESIAS_base 1232 0.157 0.132 1.17 [0.90, 1.52] 56.50 0.101 2.37E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1897 0.0075 HY3 HY3_base 1289 -0.182 0.156 0.83 [0.61, 1.13] 0.00 0.411 2.45E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1813 0.0157 MOTORFLUX MOTORFLUX_surv 1709 -0.064 0.064 0.94 [0.83, 1.06] 0.00 0.819 3.23E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1860 0.0147 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.034 0.037 -0.03 [-0.11, 0.04] 0.00 0.703 3.56E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1875 0.0150 MMSE MMSE_cont 2114 -0.049 0.055 -0.05 [-0.16, 0.06] 0.00 0.650 3.71E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1834 0.0172 INS INS_surv 1112 0.067 0.083 1.07 [0.91, 1.26] 27.60 0.227 4.20E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1897 0.0150 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.024 0.032 -0.02 [-0.09, 0.04] 2.40 0.411 4.56E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1837 0.0096 COGi COGi_base 2859 -0.081 0.113 0.92 [0.74, 1.15] 7.10 0.375 4.76E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1874 0.0166 CONST CONST_base 1472 -0.075 0.107 0.93 [0.75, 1.14] 0.00 0.767 4.84E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1847 0.0199 DYSKINESIAS DYSKINESIAS_surv 1856 -0.048 0.076 0.95 [0.82, 1.11] 30.70 0.194 5.29E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1852 0.0107 MOTORFLUX MOTORFLUX_base 1803 0.062 0.104 1.06 [0.87, 1.31] 0.00 0.830 5.52E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1833 0.0113 SEADL SEADL_cont 2218 0.173 0.297 0.17 [-0.41, 0.75] 0.00 0.434 5.61E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1877 0.0147 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.013 0.031 -0.01 [-0.07, 0.05] 0.00 0.964 6.77E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1906 0.0198 HY3 HY3_surv 2582 -0.025 0.079 0.98 [0.84, 1.14] 0.00 0.651 7.53E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1863 0.0177 MOCA MOCA_cont 1074 0.022 0.155 0.02 [-0.28, 0.33] 48.50 0.120 8.87E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1913 0.0170 DEPR DEPR_surv 1314 -0.005 0.100 1.00 [0.82, 1.21] 0.00 0.813 9.64E-01 0 0 0 0 CAMK2D
4:114369065 rs13117519 t c 0.1911 0.0103 HYPOSMIA HYPOSMIA_base 1588 0.004 0.099 1.00 [0.83, 1.22] 0.00 0.881 9.68E-01 0 0 0 0 CAMK2D
4:77110365 rs6825004 c g 0.6994 0.0255 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.052 0.028 0.05 [-0.00, 0.11] 0.00 0.913 5.92E-02 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6887 0.0144 DYSKINESIAS DYSKINESIAS_surv 1856 0.101 0.063 1.11 [0.98, 1.25] 8.40 0.364 1.10E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.7005 0.0219 MMSE MMSE_cont 2114 0.073 0.048 0.07 [-0.02, 0.17] 0.00 0.991 1.23E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6898 0.0187 SLEEP SLEEP_base 1724 -0.135 0.091 0.87 [0.73, 1.05] 14.10 0.322 1.40E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6911 0.0253 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.039 0.027 0.04 [-0.01, 0.09] 0.00 0.888 1.46E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6906 0.0199 INS INS_base 2220 -0.107 0.076 0.90 [0.77, 1.04] 0.00 0.578 1.58E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6903 0.0090 MOTORFLUX MOTORFLUX_base 1803 0.119 0.088 1.13 [0.95, 1.34] 0.00 0.692 1.78E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6930 0.0225 HY HY_cont 3627 0.013 0.010 0.01 [-0.01, 0.03] 0.00 0.702 1.82E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6856 0.0207 INS INS_surv 1112 -0.090 0.070 0.91 [0.80, 1.05] 0.00 0.593 2.02E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6979 0.0190 DEPR DEPR_surv 1314 0.094 0.085 1.10 [0.93, 1.30] 0.00 0.612 2.70E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6941 0.0055 DYSKINESIAS DYSKINESIAS_base 1232 0.111 0.111 1.12 [0.90, 1.39] 16.70 0.301 3.18E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6949 0.0238 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.026 0.031 0.03 [-0.03, 0.09] 0.00 0.475 4.05E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6942 0.0244 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.026 0.031 -0.03 [-0.09, 0.03] 0.00 0.711 4.06E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6947 0.0216 MOCA MOCA_cont 1074 0.097 0.127 0.10 [-0.15, 0.35] 0.00 0.954 4.48E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6908 0.0137 DEPR DEPR_base 2138 -0.067 0.097 0.94 [0.77, 1.13] 0.00 0.823 4.86E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6913 0.0228 HYPOSMIA HYPOSMIA_base 1588 0.046 0.087 1.05 [0.88, 1.24] 36.20 0.165 5.95E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6864 0.0135 CONST CONST_base 1472 -0.045 0.093 0.96 [0.80, 1.15] 0.00 0.735 6.27E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6964 0.0162 COGi COGi_base 2859 -0.042 0.092 0.96 [0.80, 1.15] 0.00 0.968 6.47E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6967 0.0069 HY3 HY3_base 1289 0.057 0.128 1.06 [0.82, 1.36] 0.00 0.591 6.58E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6969 0.0231 SEADL SEADL_cont 2218 -0.080 0.247 -0.08 [-0.56, 0.40] 48.80 0.057 7.46E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6947 0.0187 SEADL70 SEADL70_surv 1683 -0.028 0.096 0.97 [0.81, 1.17] 53.70 0.071 7.70E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6853 0.0211 MOTORFLUX MOTORFLUX_surv 1709 0.008 0.053 1.01 [0.91, 1.12] 0.00 0.606 8.84E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6982 0.0231 COGi COGi_surv 2244 0.009 0.079 1.01 [0.86, 1.18] 18.90 0.275 9.15E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.7020 0.0199 HY3 HY3_surv 2582 0.003 0.067 1.00 [0.88, 1.14] 0.00 0.656 9.65E-01 0 0 0 0 SCARB2
4:77110365 rs6825004 c g 0.6962 0.0231 UPDRS_scaled UPDRS_scaled_cont 2994 0.001 0.025 0.00 [-0.05, 0.05] 0.00 0.968 9.69E-01 0 0 0 0 SCARB2
20:6006041 rs77351827 t c 0.1321 0.0025 SEADL70 SEADL70_surv 1683 -0.283 0.151 0.75 [0.56, 1.01] 0.00 0.984 5.99E-02 0 0 0 0 CRLS1
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20:6006041 rs77351827 t c 0.1329 0.0083 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.062 0.043 0.06 [-0.02, 0.15] 0.00 0.449 1.50E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1300 0.0092 HYPOSMIA HYPOSMIA_base 1588 -0.151 0.116 0.86 [0.68, 1.08] 34.90 0.175 1.92E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1315 0.0060 DEPR DEPR_surv 1314 0.139 0.115 1.15 [0.92, 1.44] 38.20 0.152 2.28E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1313 0.0038 INS INS_surv 1112 -0.117 0.100 0.89 [0.73, 1.08] 0.00 0.665 2.41E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1342 0.0085 COGi COGi_base 2712 0.119 0.122 1.13 [0.89, 1.43] 0.00 0.668 3.31E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1335 0.0085 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.034 0.037 -0.03 [-0.11, 0.04] 38.30 0.151 3.59E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1311 0.0056 MOTORFLUX MOTORFLUX_base 1803 -0.104 0.115 0.90 [0.72, 1.13] 0.00 0.439 3.67E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1330 0.0073 HY3 HY3_base 1289 0.139 0.157 1.15 [0.84, 1.56] 0.00 0.943 3.76E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1307 0.0073 MMSE MMSE_cont 2114 -0.058 0.066 -0.06 [-0.19, 0.07] 0.00 0.765 3.81E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1315 0.0069 CONST CONST_base 1472 0.105 0.121 1.11 [0.88, 1.41] 0.00 0.898 3.88E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1325 0.0095 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.035 0.043 0.03 [-0.05, 0.12] 15.50 0.311 4.16E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1303 0.0087 SLEEP SLEEP_base 1724 0.097 0.121 1.10 [0.87, 1.40] 0.00 0.719 4.21E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1367 0.0094 MOTORFLUX MOTORFLUX_surv 1709 0.048 0.071 1.05 [0.91, 1.21] 0.00 0.614 5.01E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1312 0.0071 INS INS_base 2220 0.061 0.101 1.06 [0.87, 1.30] 38.40 0.124 5.48E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1299 0.0090 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.023 0.039 -0.02 [-0.10, 0.05] 0.00 0.736 5.51E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1311 0.0059 DEPR DEPR_base 2138 0.065 0.128 1.07 [0.83, 1.37] 13.30 0.326 6.11E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1317 0.0043 HY3 HY3_surv 2582 -0.028 0.096 0.97 [0.81, 1.17] 0.00 0.633 7.67E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1276 0.0081 SEADL SEADL_cont 2218 0.105 0.356 0.11 [-0.59, 0.80] 5.60 0.387 7.67E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1325 0.0074 DYSKINESIAS DYSKINESIAS_surv 1856 -0.023 0.085 0.98 [0.83, 1.16] 0.00 0.473 7.92E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1341 0.0055 MOCA MOCA_cont 1074 0.040 0.180 0.04 [-0.31, 0.39] 17.90 0.301 8.25E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1318 0.0058 DYSKINESIAS DYSKINESIAS_base 1232 0.025 0.143 1.03 [0.77, 1.36] 60.50 0.080 8.63E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1337 0.0100 UPDRS_scaled UPDRS_scaled_cont 2994 0.005 0.035 0.00 [-0.06, 0.07] 0.00 0.909 8.97E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1334 0.0107 HY HY_cont 3627 0.001 0.013 0.00 [-0.02, 0.03] 0.00 0.946 9.29E-01 0 0 0 0 CRLS1
20:6006041 rs77351827 t c 0.1305 0.0072 COGi COGi_surv 2244 0.005 0.118 1.00 [0.80, 1.27] 0.00 0.632 9.69E-01 0 0 0 0 CRLS1
8:16697593 rs620513 t g 0.2631 0.0109 CONST CONST_base 1472 0.187 0.100 1.21 [0.99, 1.47] 0.00 0.439 6.24E-02 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2637 0.0053 HY3 HY3_base 1289 0.219 0.137 1.24 [0.95, 1.63] 0.00 0.460 1.11E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2524 0.0203 HY3 HY3_surv 2582 -0.093 0.074 0.91 [0.79, 1.05] 17.00 0.291 2.10E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2550 0.0201 COGi COGi_surv 2244 0.101 0.086 1.11 [0.93, 1.31] 0.00 0.576 2.41E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2583 0.0131 DEPR DEPR_base 2138 0.101 0.104 1.11 [0.90, 1.36] 0.00 0.679 3.34E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2393 0.0148 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.030 0.034 0.03 [-0.04, 0.10] 49.30 0.066 3.75E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2609 0.0121 SLEEP SLEEP_base 1724 0.078 0.098 1.08 [0.89, 1.31] 0.00 0.958 4.25E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2482 0.0117 SEADL SEADL_cont 2112 0.174 0.270 0.17 [-0.36, 0.70] 0.00 0.517 5.19E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2376 0.0133 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.019 0.030 -0.02 [-0.08, 0.04] 0.00 0.721 5.22E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2397 0.0143 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.018 0.030 -0.02 [-0.08, 0.04] 2.60 0.410 5.49E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2604 0.0088 HYPOSMIA HYPOSMIA_base 1588 -0.057 0.096 0.94 [0.78, 1.14] 33.90 0.182 5.51E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2463 0.0151 MOTORFLUX MOTORFLUX_surv 1709 0.034 0.059 1.03 [0.92, 1.16] 0.00 0.587 5.62E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2501 0.0217 DYSKINESIAS DYSKINESIAS_surv 1856 0.040 0.070 1.04 [0.91, 1.19] 25.60 0.234 5.70E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2627 0.0111 INS INS_base 2220 0.047 0.083 1.05 [0.89, 1.23] 4.10 0.399 5.73E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2397 0.0139 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.019 0.034 0.02 [-0.05, 0.09] 17.30 0.298 5.77E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2634 0.0374 INS INS_surv 1112 0.014 0.077 1.01 [0.87, 1.18] 0.00 0.733 8.55E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2453 0.0129 DEPR DEPR_surv 1314 0.016 0.089 1.02 [0.85, 1.21] 9.40 0.356 8.55E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2582 0.0087 MOTORFLUX MOTORFLUX_base 1803 0.013 0.096 1.01 [0.84, 1.22] 0.00 0.618 8.90E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2471 0.0223 UPDRS_scaled UPDRS_scaled_cont 2994 0.002 0.027 0.00 [-0.05, 0.05] 0.00 0.494 9.54E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2495 0.0148 SEADL70 SEADL70_surv 1683 0.006 0.110 1.01 [0.81, 1.25] 0.00 0.408 9.56E-01 0 0 0 0 FGF20
8:16697593 rs620513 t g 0.2497 0.0187 HY HY_cont 3627 0.000 0.010 0.00 [-0.02, 0.02] 11.60 0.331 9.79E-01 0 0 0 0 FGF20
17:43798308 rs117615688 a g 0.0484 0.0073 HY3 HY3_base 1289 -0.605 0.330 0.55 [0.29, 1.04] 0.00 0.751 6.69E-02 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0510 0.0062 COGi COGi_base 2450 0.340 0.200 1.40 [0.95, 2.08] 10.10 0.352 8.92E-02 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0540 0.0090 CONST CONST_base 1355 -0.341 0.211 0.71 [0.47, 1.08] 0.00 0.788 1.07E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0497 0.0052 SEADL SEADL_cont 2218 0.891 0.563 0.89 [-0.21, 2.00] 0.00 0.726 1.14E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0557 0.0146 SLEEP SLEEP_base 1724 0.309 0.196 1.36 [0.93, 2.00] 10.70 0.348 1.15E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0503 0.0031 DEPR DEPR_surv 1314 0.276 0.179 1.32 [0.93, 1.87] 21.80 0.270 1.22E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0584 0.0140 HYPOSMIA HYPOSMIA_base 1588 0.247 0.186 1.28 [0.89, 1.84] 54.40 0.052 1.84E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0517 0.0089 MOTORFLUX MOTORFLUX_surv 1709 -0.123 0.122 0.88 [0.70, 1.12] 0.00 0.658 3.13E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0519 0.0049 MOTORFLUX MOTORFLUX_base 1803 0.188 0.199 1.21 [0.82, 1.78] 16.70 0.308 3.43E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0597 0.0128 INS INS_base 2220 0.154 0.173 1.17 [0.83, 1.64] 41.50 0.102 3.74E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0519 0.0126 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.053 0.061 -0.05 [-0.17, 0.07] 2.90 0.398 3.80E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0524 0.0140 HY HY_cont 3627 0.017 0.021 0.02 [-0.02, 0.06] 14.40 0.304 4.23E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0548 0.0079 INS INS_surv 1112 0.107 0.152 1.11 [0.83, 1.50] 0.00 0.672 4.83E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0501 0.0150 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.038 0.066 0.04 [-0.09, 0.17] 0.00 0.772 5.59E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0522 0.0133 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.036 0.070 0.04 [-0.10, 0.17] 0.00 0.637 6.09E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0510 0.0124 UPDRS_scaled UPDRS_scaled_cont 2994 -0.028 0.057 -0.03 [-0.14, 0.08] 0.00 0.928 6.23E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0499 0.0064 DYSKINESIAS DYSKINESIAS_surv 1856 0.057 0.142 1.06 [0.80, 1.40] 0.00 0.632 6.90E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0533 0.0105 COGi COGi_surv 2244 0.071 0.183 1.07 [0.75, 1.54] 0.00 0.587 6.99E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0505 0.0104 HY3 HY3_surv 2582 -0.057 0.161 0.94 [0.69, 1.30] 0.00 0.818 7.23E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0456 0.0042 MOCA MOCA_cont 1074 0.107 0.301 0.11 [-0.48, 0.70] 8.80 0.349 7.23E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0528 0.0128 MMSE MMSE_cont 2114 0.036 0.106 0.04 [-0.17, 0.24] 0.00 0.743 7.34E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0528 0.0056 DYSKINESIAS DYSKINESIAS_base 1232 -0.089 0.270 0.92 [0.54, 1.55] 0.00 0.908 7.43E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0516 0.0137 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.020 0.071 0.02 [-0.12, 0.16] 0.00 0.700 7.78E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0560 0.0152 DEPR DEPR_base 2138 0.052 0.216 1.05 [0.69, 1.61] 28.00 0.205 8.09E-01 0 0 0 0 CRHR1
17:43798308 rs117615688 a g 0.0553 0.0069 SEADL70 SEADL70_surv 1683 0.038 0.225 1.04 [0.67, 1.61] 7.50 0.364 8.67E-01 0 0 0 0 CRHR1
2:102396963 rs11683001 a t 0.3500 0.0201 SLEEP SLEEP_base 1724 0.159 0.087 1.17 [0.99, 1.39] 0.00 0.804 6.90E-02 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3522 0.0216 INS INS_surv 1112 0.121 0.069 1.13 [0.99, 1.29] 38.80 0.148 7.86E-02 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3599 0.0191 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.044 0.027 0.04 [-0.01, 0.10] 0.00 0.645 1.04E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3546 0.0204 DEPR DEPR_base 2138 0.126 0.094 1.13 [0.94, 1.36] 30.50 0.184 1.81E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3551 0.0142 UPDRS_scaled UPDRS_scaled_cont 2994 0.031 0.025 0.03 [-0.02, 0.08] 0.00 0.782 2.20E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3478 0.0204 CONST CONST_base 1472 0.105 0.090 1.11 [0.93, 1.32] 0.00 0.427 2.44E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3545 0.0265 HY3 HY3_surv 2582 -0.060 0.066 0.94 [0.83, 1.07] 0.00 0.547 3.65E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3567 0.0165 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.028 0.031 0.03 [-0.03, 0.09] 7.90 0.368 3.74E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3488 0.0212 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.021 0.028 0.02 [-0.03, 0.07] 0.00 0.680 4.55E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3511 0.0148 HY HY_cont 3627 0.007 0.009 0.01 [-0.01, 0.02] 0.00 0.994 4.78E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3518 0.0217 DEPR DEPR_surv 1314 -0.053 0.083 0.95 [0.81, 1.12] 19.50 0.286 5.21E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3494 0.0197 HYPOSMIA HYPOSMIA_base 1588 -0.052 0.084 0.95 [0.81, 1.12] 0.00 0.932 5.35E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3570 0.0171 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.018 0.031 0.02 [-0.04, 0.08] 3.50 0.399 5.62E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3590 0.0156 SEADL SEADL_cont 2218 0.115 0.251 0.12 [-0.38, 0.61] 17.80 0.289 6.46E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3446 0.0055 MOCA MOCA_cont 1074 0.058 0.128 0.06 [-0.19, 0.31] 21.30 0.283 6.54E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3562 0.0232 HY3 HY3_base 1289 0.043 0.122 1.04 [0.82, 1.33] 38.80 0.195 7.23E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3572 0.0236 MOTORFLUX MOTORFLUX_base 1803 0.030 0.086 1.03 [0.87, 1.22] 0.00 0.839 7.23E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3500 0.0163 INS INS_base 2220 0.026 0.075 1.03 [0.89, 1.19] 24.90 0.230 7.27E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3540 0.0294 DYSKINESIAS DYSKINESIAS_surv 1856 0.018 0.062 1.02 [0.90, 1.15] 0.00 0.949 7.74E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3525 0.0264 SEADL70 SEADL70_surv 1683 0.026 0.098 1.03 [0.85, 1.24] 11.80 0.338 7.92E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3644 0.0129 MMSE MMSE_cont 2114 0.007 0.046 0.01 [-0.08, 0.10] 15.70 0.307 8.86E-01 0 0 0 0 MAP4K4
2:102396963 rs11683001 a t 0.3529 0.0142 COGi COGi_surv 2244 0.005 0.081 1.00 [0.86, 1.18] 0.00 0.858 9.55E-01 0 0 0 0 MAP4K4
18:48683589 rs8087969 t g 0.5631 0.0307 MMSE MMSE_cont 1066 -0.099 0.055 -0.10 [-0.21, 0.01] 5.70 0.374 6.95E-02 0 0 0 0 MEX3C
18:48683589 rs8087969 t g 0.5524 0.0239 UPDRS_scaled UPDRS_scaled_cont 1108 0.034 0.038 0.03 [-0.04, 0.11] 0.00 0.444 3.75E-01 0 0 0 0 MEX3C
18:48683589 rs8087969 t g 0.5311 0.0387 INS INS_base 1033 0.075 0.107 1.08 [0.87, 1.33] 0.00 0.731 4.82E-01 0 0 0 0 MEX3C
18:48683589 rs8087969 t g 0.5486 0.0378 COGi COGi_surv 1132 -0.034 0.104 0.97 [0.79, 1.18] 0.00 0.491 7.46E-01 0 0 0 0 MEX3C
18:48683589 rs8087969 t g 0.5232 0.0358 COGi COGi_base 1538 -0.032 0.121 0.97 [0.76, 1.23] 26.90 0.243 7.91E-01 0 0 0 0 MEX3C
18:48683589 rs8087969 t g 0.5241 0.0318 HY3 HY3_surv 1299 0.010 0.076 1.01 [0.87, 1.17] 45.40 0.120 8.99E-01 0 0 0 0 MEX3C
18:48683589 rs8087969 t g 0.5399 0.0268 HY HY_cont 2077 -0.001 0.012 -0.00 [-0.02, 0.02] 0.00 0.987 9.33E-01 0 0 0 0 MEX3C
10:121415685 rs72840788 a g 0.2210 0.0123 INS INS_surv 1112 -0.148 0.082 0.86 [0.73, 1.01] 0.00 0.874 7.36E-02 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2332 0.0102 MOTORFLUX MOTORFLUX_base 1803 0.162 0.092 1.18 [0.98, 1.41] 0.00 0.522 7.94E-02 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2235 0.0102 MOTORFLUX MOTORFLUX_surv 1709 -0.097 0.057 0.91 [0.81, 1.01] 0.00 0.754 8.87E-02 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2373 0.0155 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.043 0.030 0.04 [-0.02, 0.10] 21.70 0.257 1.54E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2353 0.0081 DEPR DEPR_surv 1314 -0.122 0.093 0.89 [0.74, 1.06] 0.00 0.769 1.92E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2331 0.0102 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.037 0.029 0.04 [-0.02, 0.09] 0.00 0.969 2.08E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2310 0.0119 DEPR DEPR_base 2138 -0.133 0.106 0.88 [0.71, 1.08] 0.00 0.458 2.10E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2254 0.0135 HY HY_cont 3627 0.013 0.011 0.01 [-0.01, 0.03] 0.00 0.722 2.30E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2229 0.0160 COGi COGi_surv 2244 -0.106 0.090 0.90 [0.75, 1.07] 0.00 0.938 2.39E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2314 0.0102 MOCA MOCA_cont 1074 0.165 0.141 0.17 [-0.11, 0.44] 0.00 0.451 2.43E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2325 0.0090 HY3 HY3_base 1289 -0.114 0.136 0.89 [0.68, 1.16] 0.00 0.610 4.01E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2240 0.0144 SEADL70 SEADL70_surv 1683 0.076 0.105 1.08 [0.88, 1.32] 19.20 0.292 4.72E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2321 0.0144 HYPOSMIA HYPOSMIA_base 1588 0.053 0.095 1.05 [0.88, 1.27] 0.00 0.891 5.74E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2304 0.0115 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.017 0.034 0.02 [-0.05, 0.08] 0.00 0.959 6.15E-01 0 0 0 0 BAG3
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10:121415685 rs72840788 a g 0.2287 0.0106 DYSKINESIAS DYSKINESIAS_base 1232 -0.057 0.119 0.94 [0.75, 1.19] 59.70 0.084 6.34E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2307 0.0105 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.016 0.034 -0.02 [-0.08, 0.05] 0.00 0.693 6.44E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2328 0.0135 SLEEP SLEEP_base 1724 -0.032 0.097 0.97 [0.80, 1.17] 0.00 0.920 7.38E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2243 0.0144 SEADL SEADL_cont 2218 -0.084 0.275 -0.08 [-0.62, 0.45] 6.60 0.379 7.59E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2314 0.0120 CONST CONST_base 1472 0.028 0.100 1.03 [0.84, 1.25] 10.80 0.344 7.82E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2292 0.0160 DYSKINESIAS DYSKINESIAS_surv 1856 -0.016 0.068 0.98 [0.86, 1.13] 11.40 0.343 8.15E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2153 0.0140 MMSE MMSE_cont 2114 -0.010 0.053 -0.01 [-0.11, 0.10] 0.00 0.875 8.59E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2346 0.0212 HY3 HY3_surv 2582 -0.012 0.072 0.99 [0.86, 1.14] 31.70 0.165 8.71E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2306 0.0139 COGi COGi_base 2859 0.013 0.102 1.01 [0.83, 1.24] 17.60 0.291 8.96E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2279 0.0133 UPDRS_scaled UPDRS_scaled_cont 2994 -0.002 0.028 -0.00 [-0.06, 0.05] 0.00 0.762 9.36E-01 0 0 0 0 BAG3
10:121415685 rs72840788 a g 0.2285 0.0139 INS INS_base 2220 0.000 0.084 1.00 [0.85, 1.18] 26.30 0.219 9.97E-01 0 0 0 0 BAG3
17:7355621 rs12600861 a c 0.6426 0.0238 SEADL SEADL_cont 2218 -0.429 0.244 -0.43 [-0.91, 0.05] 0.90 0.423 7.91E-02 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6329 0.0298 HY HY_cont 3627 0.013 0.009 0.01 [-0.00, 0.03] 0.00 0.637 1.42E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6479 0.0185 MOCA MOCA_cont 1074 -0.179 0.124 -0.18 [-0.42, 0.06] 23.40 0.271 1.50E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6359 0.0299 UPDRS_scaled UPDRS_scaled_cont 2994 0.034 0.024 0.03 [-0.01, 0.08] 0.00 0.739 1.54E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6452 0.0141 DYSKINESIAS DYSKINESIAS_base 1232 0.108 0.105 1.11 [0.91, 1.37] 46.80 0.153 3.07E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6417 0.0211 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.028 0.030 0.03 [-0.03, 0.09] 38.40 0.136 3.45E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6383 0.0178 HY3 HY3_base 1289 -0.085 0.117 0.92 [0.73, 1.16] 0.00 0.444 4.71E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6409 0.0144 MOTORFLUX MOTORFLUX_base 1803 -0.059 0.084 0.94 [0.80, 1.11] 0.00 0.458 4.81E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6411 0.0185 DYSKINESIAS DYSKINESIAS_surv 1856 0.041 0.059 1.04 [0.93, 1.17] 28.00 0.215 4.87E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6402 0.0220 HY3 HY3_surv 2582 -0.039 0.064 0.96 [0.85, 1.09] 13.80 0.320 5.47E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6420 0.0258 SLEEP SLEEP_base 1724 0.050 0.085 1.05 [0.89, 1.24] 0.00 0.999 5.62E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6380 0.0254 DEPR DEPR_surv 1314 0.045 0.079 1.05 [0.90, 1.22] 0.00 0.800 5.69E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6461 0.0196 CONST CONST_base 1472 -0.049 0.087 0.95 [0.80, 1.13] 0.00 0.485 5.75E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6499 0.0177 MOTORFLUX MOTORFLUX_surv 1709 0.027 0.051 1.03 [0.93, 1.14] 0.00 0.713 5.91E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6531 0.0217 MMSE MMSE_cont 2114 -0.023 0.047 -0.02 [-0.11, 0.07] 0.00 0.524 6.18E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6333 0.0311 COGi COGi_base 2859 -0.036 0.089 0.96 [0.81, 1.15] 41.00 0.105 6.84E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6415 0.0213 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.012 0.030 0.01 [-0.05, 0.07] 0.00 0.540 6.91E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6374 0.0223 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.008 0.027 -0.01 [-0.06, 0.04] 0.00 0.916 7.52E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6518 0.0207 COGi COGi_surv 2244 -0.023 0.076 0.98 [0.84, 1.14] 0.00 0.672 7.67E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6570 0.0167 SEADL70 SEADL70_surv 1683 -0.026 0.096 0.97 [0.81, 1.18] 0.00 0.910 7.88E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6437 0.0183 DEPR DEPR_base 2138 0.022 0.093 1.02 [0.85, 1.23] 16.40 0.301 8.10E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6425 0.0279 HYPOSMIA HYPOSMIA_base 1588 -0.013 0.083 0.99 [0.84, 1.16] 0.00 0.897 8.71E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6443 0.0237 INS INS_base 2220 0.003 0.072 1.00 [0.87, 1.16] 0.00 0.639 9.63E-01 0 0 0 0 CHRNB1
17:7355621 rs12600861 a c 0.6558 0.0200 INS INS_surv 1112 0.001 0.067 1.00 [0.88, 1.14] 0.00 0.780 9.87E-01 0 0 0 0 CHRNB1
16:30977799 rs11150601 a g 0.6731 0.0194 INS INS_surv 1112 -0.123 0.071 0.88 [0.77, 1.01] 46.40 0.097 8.01E-02 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6503 0.0272 HY3 HY3_surv 2582 -0.105 0.064 0.90 [0.79, 1.02] 0.00 0.899 1.02E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6542 0.0186 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.049 0.030 -0.05 [-0.11, 0.01] 0.00 0.750 1.06E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6540 0.0263 INS INS_base 2220 -0.119 0.074 0.89 [0.77, 1.03] 25.10 0.229 1.07E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6536 0.0190 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.046 0.030 -0.05 [-0.11, 0.01] 0.00 0.954 1.29E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6544 0.0231 HY HY_cont 3627 -0.012 0.009 -0.01 [-0.03, 0.01] 15.80 0.289 1.86E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6603 0.0188 HYPOSMIA HYPOSMIA_base 1588 -0.110 0.084 0.90 [0.76, 1.06] 0.00 0.953 1.88E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6439 0.0144 SEADL70 SEADL70_surv 1683 0.118 0.098 1.12 [0.93, 1.36] 0.00 0.925 2.27E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6518 0.0169 COGi COGi_base 2859 0.106 0.092 1.11 [0.93, 1.33] 40.00 0.112 2.49E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6534 0.0203 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.026 0.026 -0.03 [-0.08, 0.03] 0.00 0.828 3.25E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6480 0.0151 MOTORFLUX MOTORFLUX_base 1803 0.083 0.086 1.09 [0.92, 1.29] 0.00 0.836 3.38E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6571 0.0185 DEPR DEPR_surv 1314 -0.069 0.080 0.93 [0.80, 1.09] 4.90 0.385 3.85E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6476 0.0259 UPDRS_scaled UPDRS_scaled_cont 2994 -0.021 0.025 -0.02 [-0.07, 0.03] 0.00 0.935 3.85E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6526 0.0287 SLEEP SLEEP_base 1724 -0.075 0.087 0.93 [0.78, 1.10] 22.70 0.256 3.86E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6451 0.0287 DEPR DEPR_base 2138 -0.057 0.093 0.94 [0.79, 1.13] 0.00 0.565 5.38E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6544 0.0148 HY3 HY3_base 1289 0.063 0.122 1.07 [0.84, 1.35] 0.00 0.840 6.04E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6534 0.0268 MMSE MMSE_cont 2114 0.024 0.046 0.02 [-0.07, 0.11] 0.00 0.964 6.06E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6483 0.0175 MOTORFLUX MOTORFLUX_surv 1709 0.019 0.051 1.02 [0.92, 1.13] 47.20 0.078 7.06E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6521 0.0273 CONST CONST_base 1472 -0.029 0.090 0.97 [0.81, 1.16] 0.00 0.435 7.45E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6556 0.0184 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.009 0.027 -0.01 [-0.06, 0.04] 0.00 0.769 7.54E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6520 0.0154 SEADL SEADL_cont 2218 0.068 0.243 0.07 [-0.41, 0.54] 0.00 0.707 7.79E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6484 0.0101 MOCA MOCA_cont 1074 0.025 0.126 0.03 [-0.22, 0.27] 43.20 0.152 8.41E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6567 0.0255 DYSKINESIAS DYSKINESIAS_surv 1856 -0.010 0.060 0.99 [0.88, 1.11] 47.70 0.075 8.68E-01 0 0 0 0 SETD1A
16:30977799 rs11150601 a g 0.6503 0.0120 DYSKINESIAS DYSKINESIAS_base 1232 -0.011 0.108 0.99 [0.80, 1.22] 66.30 0.052 9.20E-01 0 0 0 0 SETD1A
15:61997385 rs2251086 t c 0.1288 0.0007 DYSKINESIAS DYSKINESIAS_base 1232 -0.276 0.158 0.76 [0.56, 1.03] 0.00 0.661 8.12E-02 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1270 0.0084 COGi COGi_base 2859 0.202 0.128 1.22 [0.95, 1.57] 0.00 0.441 1.16E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1276 0.0101 INS INS_base 2220 0.165 0.106 1.18 [0.96, 1.45] 0.00 0.701 1.20E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1211 0.0153 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.051 0.040 0.05 [-0.03, 0.13] 30.20 0.187 2.01E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1190 0.0125 INS INS_surv 1112 0.128 0.100 1.14 [0.93, 1.38] 36.90 0.161 2.02E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1192 0.0130 MMSE MMSE_cont 2114 0.088 0.069 0.09 [-0.05, 0.22] 31.90 0.173 2.02E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1182 0.0124 UPDRS_scaled UPDRS_scaled_cont 2994 0.032 0.036 0.03 [-0.04, 0.10] 28.50 0.182 3.84E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1199 0.0148 MOTORFLUX MOTORFLUX_surv 1709 0.060 0.075 1.06 [0.92, 1.23] 0.00 0.652 4.30E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1295 0.0101 HYPOSMIA HYPOSMIA_base 1588 0.093 0.120 1.10 [0.87, 1.39] 51.90 0.065 4.38E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1175 0.0130 HY HY_cont 3627 0.010 0.014 0.01 [-0.02, 0.04] 14.20 0.306 4.58E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1268 0.0091 CONST CONST_base 1472 0.090 0.128 1.09 [0.85, 1.41] 0.00 0.450 4.80E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1126 0.0179 DEPR DEPR_surv 1314 0.084 0.125 1.09 [0.85, 1.39] 35.10 0.173 5.03E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1217 0.0137 SEADL70 SEADL70_surv 1683 0.085 0.140 1.09 [0.83, 1.43] 10.80 0.344 5.44E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1223 0.0102 COGi COGi_surv 2244 0.068 0.115 1.07 [0.85, 1.34] 5.00 0.393 5.54E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1188 0.0126 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.017 0.039 -0.02 [-0.09, 0.06] 0.00 0.948 6.71E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1268 0.0126 HY3 HY3_surv 2582 0.038 0.094 1.04 [0.86, 1.25] 0.00 0.746 6.88E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1171 0.0137 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.012 0.045 -0.01 [-0.10, 0.08] 41.20 0.117 7.99E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1265 0.0102 SLEEP SLEEP_base 1724 0.030 0.126 1.03 [0.80, 1.32] 33.60 0.171 8.13E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1287 0.0007 HY3 HY3_base 1289 -0.039 0.172 0.96 [0.69, 1.35] 0.00 0.534 8.21E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1254 0.0126 DYSKINESIAS DYSKINESIAS_surv 1856 -0.017 0.088 0.98 [0.83, 1.17] 0.00 0.718 8.50E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1210 0.0124 MOCA MOCA_cont 1074 -0.028 0.184 -0.03 [-0.39, 0.33] 0.00 0.922 8.79E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1170 0.0126 DEPR DEPR_base 2138 -0.007 0.145 0.99 [0.75, 1.32] 0.00 0.713 9.64E-01 0 0 0 0 VPS13C
15:61997385 rs2251086 t c 0.1250 0.0080 MOTORFLUX MOTORFLUX_base 1803 -0.005 0.125 0.99 [0.78, 1.27] 0.00 0.653 9.67E-01 0 0 0 0 VPS13C
8:130901909 rs2086641 t c 0.7075 0.0247 INS INS_base 2220 -0.132 0.076 0.88 [0.76, 1.02] 0.00 0.482 8.17E-02 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7160 0.0256 HYPOSMIA HYPOSMIA_base 1588 0.136 0.088 1.15 [0.96, 1.36] 30.80 0.204 1.24E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7224 0.0151 MOTORFLUX MOTORFLUX_surv 1709 0.093 0.062 1.10 [0.97, 1.24] 0.00 0.561 1.33E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7195 0.0163 COGi COGi_base 2859 -0.141 0.096 0.87 [0.72, 1.05] 0.00 0.769 1.42E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7083 0.0301 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.055 0.039 0.06 [-0.02, 0.13] 0.00 0.577 1.57E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7153 0.0177 CONST CONST_base 1472 0.132 0.094 1.14 [0.95, 1.37] 7.00 0.367 1.61E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7072 0.0302 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.050 0.039 0.05 [-0.03, 0.13] 0.00 0.689 2.04E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7159 0.0151 HY3 HY3_surv 2582 0.089 0.075 1.09 [0.94, 1.27] 9.90 0.353 2.37E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7063 0.0136 DYSKINESIAS DYSKINESIAS_base 1232 0.126 0.114 1.13 [0.91, 1.42] 0.00 0.757 2.69E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7147 0.0304 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.034 0.034 0.03 [-0.03, 0.10] 28.10 0.204 3.19E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7218 0.0112 SEADL70 SEADL70_surv 1683 0.107 0.120 1.11 [0.88, 1.41] 0.00 0.603 3.70E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7266 0.0138 SEADL SEADL_cont 2218 -0.243 0.291 -0.24 [-0.81, 0.33] 0.00 0.866 4.04E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7102 0.0227 MMSE MMSE_cont 2114 -0.044 0.053 -0.04 [-0.15, 0.06] 0.00 0.979 4.07E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7094 0.0155 MOTORFLUX MOTORFLUX_base 1803 -0.072 0.090 0.93 [0.78, 1.11] 44.80 0.123 4.22E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7092 0.0252 DEPR DEPR_base 2138 -0.076 0.099 0.93 [0.76, 1.12] 33.70 0.159 4.39E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7049 0.0276 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.024 0.034 0.02 [-0.04, 0.09] 0.00 0.948 4.77E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7152 0.0265 UPDRS_scaled UPDRS_scaled_cont 2994 0.021 0.030 0.02 [-0.04, 0.08] 21.60 0.244 4.85E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7211 0.0205 COGi COGi_surv 2244 0.049 0.093 1.05 [0.88, 1.26] 0.00 0.849 5.97E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7195 0.0188 DYSKINESIAS DYSKINESIAS_surv 1856 0.040 0.076 1.04 [0.90, 1.21] 0.00 0.894 5.99E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7185 0.0268 HY HY_cont 3627 -0.005 0.011 -0.00 [-0.03, 0.02] 0.00 0.829 6.56E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7237 0.0151 DEPR DEPR_surv 1314 -0.045 0.103 0.96 [0.78, 1.17] 0.00 0.502 6.61E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7278 0.0173 MOCA MOCA_cont 1074 0.056 0.155 0.06 [-0.25, 0.36] 0.00 0.808 7.18E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7129 0.0144 HY3 HY3_base 1289 0.038 0.130 1.04 [0.80, 1.34] 0.00 0.459 7.72E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7308 0.0239 INS INS_surv 1112 0.009 0.079 1.01 [0.86, 1.18] 31.60 0.199 9.11E-01 0 0 0 0 FAM49B
8:130901909 rs2086641 t c 0.7105 0.0258 SLEEP SLEEP_base 1724 0.004 0.093 1.00 [0.84, 1.21] 19.10 0.284 9.64E-01 0 0 0 0 FAM49B
9:34046391 rs6476434 t c 0.7222 0.0116 COGi COGi_base 2859 -0.164 0.094 0.85 [0.71, 1.02] 3.80 0.401 8.20E-02 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7237 0.0192 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.047 0.029 -0.05 [-0.10, 0.01] 0.00 0.558 1.07E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7283 0.0073 DYSKINESIAS DYSKINESIAS_base 1232 -0.166 0.111 0.85 [0.68, 1.05] 0.00 0.697 1.35E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7240 0.0197 DYSKINESIAS DYSKINESIAS_surv 1856 -0.088 0.065 0.92 [0.81, 1.04] 51.80 0.053 1.74E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7205 0.0179 DEPR DEPR_base 2138 -0.131 0.101 0.88 [0.72, 1.07] 0.00 0.607 1.96E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7182 0.0219 MOTORFLUX MOTORFLUX_surv 1709 0.069 0.055 1.07 [0.96, 1.19] 0.00 0.992 2.08E-01 0 0 0 0 UBAP2
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9:34046391 rs6476434 t c 0.7220 0.0156 INS INS_surv 1112 -0.084 0.072 0.92 [0.80, 1.06] 0.00 0.809 2.45E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7275 0.0110 CONST CONST_base 1472 0.105 0.095 1.11 [0.92, 1.34] 0.00 0.467 2.67E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7321 0.0081 HY3 HY3_base 1289 -0.119 0.129 0.89 [0.69, 1.14] 0.00 0.415 3.55E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7080 0.0143 MOCA MOCA_cont 1074 0.119 0.134 0.12 [-0.14, 0.38] 0.00 0.805 3.77E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7234 0.0183 HY3 HY3_surv 2582 -0.059 0.071 0.94 [0.82, 1.08] 0.00 0.905 4.02E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7166 0.0152 HY HY_cont 3627 0.007 0.010 0.01 [-0.01, 0.03] 25.10 0.197 4.58E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7270 0.0101 HYPOSMIA HYPOSMIA_base 1588 0.062 0.091 1.06 [0.89, 1.27] 2.10 0.403 4.95E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7252 0.0094 INS INS_base 2220 0.050 0.078 1.05 [0.90, 1.23] 0.00 0.501 5.20E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7097 0.0121 SEADL70 SEADL70_surv 1683 0.053 0.106 1.05 [0.86, 1.30] 0.00 0.510 6.14E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7101 0.0152 MMSE MMSE_cont 2114 0.020 0.048 0.02 [-0.07, 0.11] 15.60 0.307 6.77E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7285 0.0100 SLEEP SLEEP_base 1724 0.036 0.094 1.04 [0.86, 1.25] 27.40 0.220 6.99E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7132 0.0145 COGi COGi_surv 2244 0.032 0.084 1.03 [0.88, 1.22] 2.90 0.410 7.08E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7277 0.0076 MOTORFLUX MOTORFLUX_base 1803 -0.031 0.092 0.97 [0.81, 1.16] 0.00 0.417 7.32E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7070 0.0110 SEADL SEADL_cont 2218 0.050 0.258 0.05 [-0.46, 0.56] 20.00 0.271 8.47E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7219 0.0175 DEPR DEPR_surv 1314 0.014 0.090 1.01 [0.85, 1.21] 0.00 0.741 8.76E-01 0 0 0 0 UBAP2
9:34046391 rs6476434 t c 0.7223 0.0060 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.003 0.028 0.00 [-0.05, 0.06] 43.30 0.116 9.09E-01 0 0 0 0 UBAP2
6:32578772 rs112485576 a c 0.1439 0.0185 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.070 0.040 0.07 [-0.01, 0.15] 8.10 0.367 8.23E-02 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1450 0.0185 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.062 0.040 0.06 [-0.02, 0.14] 0.00 0.743 1.23E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1436 0.0185 UPDRS_scaled UPDRS_scaled_cont 2994 0.049 0.033 0.05 [-0.02, 0.11] 0.00 0.889 1.33E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1484 0.0183 INS INS_base 2220 -0.136 0.099 0.87 [0.72, 1.06] 0.00 0.548 1.72E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1455 0.0182 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.045 0.035 0.04 [-0.02, 0.11] 0.00 0.851 2.00E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1444 0.0161 DEPR DEPR_base 2138 0.135 0.125 1.14 [0.90, 1.46] 0.00 0.878 2.80E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1432 0.0174 COGi COGi_surv 2244 0.106 0.104 1.11 [0.91, 1.36] 37.50 0.119 3.09E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1514 0.0100 MOTORFLUX MOTORFLUX_base 1803 -0.104 0.113 0.90 [0.72, 1.12] 0.00 0.687 3.57E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1495 0.0141 COGi COGi_base 2859 -0.106 0.124 0.90 [0.71, 1.15] 0.00 0.736 3.92E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1421 0.0080 MOTORFLUX MOTORFLUX_surv 1709 0.049 0.071 1.05 [0.91, 1.21] 0.00 0.575 4.86E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1380 0.0207 HY HY_cont 3627 -0.007 0.013 -0.01 [-0.03, 0.02] 0.00 0.901 5.78E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1487 0.0108 HY3 HY3_base 1289 0.080 0.159 1.08 [0.79, 1.48] 28.00 0.249 6.17E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1405 0.0099 DYSKINESIAS DYSKINESIAS_surv 1856 -0.039 0.084 0.96 [0.82, 1.13] 0.00 0.603 6.47E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1453 0.0209 HYPOSMIA HYPOSMIA_base 1588 0.052 0.115 1.05 [0.84, 1.32] 0.00 0.768 6.51E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1454 0.0201 SLEEP SLEEP_base 1724 0.044 0.120 1.04 [0.83, 1.32] 19.50 0.281 7.16E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1412 0.0244 SEADL SEADL_cont 2218 0.119 0.337 0.12 [-0.54, 0.78] 0.00 0.970 7.23E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1408 0.0151 MMSE MMSE_cont 2114 -0.020 0.063 -0.02 [-0.14, 0.10] 0.00 0.768 7.55E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1417 0.0070 SEADL70 SEADL70_surv 1683 0.031 0.128 1.03 [0.80, 1.33] 33.90 0.195 8.07E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1406 0.0131 INS INS_surv 1112 0.022 0.095 1.02 [0.85, 1.23] 0.00 0.912 8.18E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1488 0.0160 HY3 HY3_surv 2582 0.019 0.086 1.02 [0.86, 1.21] 0.00 0.647 8.23E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1338 0.0269 MOCA MOCA_cont 1074 0.029 0.174 0.03 [-0.31, 0.37] 3.20 0.377 8.68E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1489 0.0197 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.005 0.036 0.00 [-0.06, 0.07] 20.00 0.271 8.90E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1443 0.0143 CONST CONST_base 1472 0.015 0.121 1.02 [0.80, 1.29] 0.00 0.781 9.02E-01 0 0 0 0 HLA-DRB5
6:32578772 rs112485576 a c 0.1372 0.0082 DEPR DEPR_surv 1314 0.000 0.113 1.00 [0.80, 1.25] 0.00 0.904 9.98E-01 0 0 0 0 HLA-DRB5
10:104015279 rs10748818 a g 0.8586 0.0126 DEPR DEPR_base 2138 0.232 0.134 1.26 [0.97, 1.64] 0.00 0.987 8.39E-02 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8543 0.0115 HY3 HY3_surv 2582 -0.145 0.085 0.87 [0.73, 1.02] 0.00 0.511 8.88E-02 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8454 0.0163 DYSKINESIAS DYSKINESIAS_base 1232 0.223 0.143 1.25 [0.94, 1.66] 0.00 0.732 1.19E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8517 0.0197 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.053 0.041 0.05 [-0.03, 0.13] 0.00 0.826 1.87E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8500 0.0173 DYSKINESIAS DYSKINESIAS_surv 1856 0.108 0.083 1.11 [0.95, 1.31] 43.10 0.103 1.93E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8530 0.0158 HY HY_cont 3627 0.016 0.012 0.02 [-0.01, 0.04] 0.00 0.555 1.94E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8623 0.0102 SLEEP SLEEP_base 1724 0.157 0.123 1.17 [0.92, 1.49] 26.20 0.228 2.01E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8488 0.0213 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.037 0.036 0.04 [-0.03, 0.11] 13.60 0.324 2.98E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8468 0.0235 MOCA MOCA_cont 1074 0.161 0.166 0.16 [-0.16, 0.49] 23.20 0.272 3.31E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8550 0.0068 SEADL70 SEADL70_surv 1683 -0.117 0.123 0.89 [0.70, 1.13] 23.50 0.264 3.41E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8500 0.0191 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.032 0.035 0.03 [-0.04, 0.10] 8.10 0.365 3.67E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8531 0.0185 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.035 0.041 0.04 [-0.04, 0.11] 7.40 0.372 3.87E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8515 0.0147 COGi COGi_surv 2244 -0.085 0.104 0.92 [0.75, 1.13] 0.00 0.873 4.18E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8485 0.0155 MOTORFLUX MOTORFLUX_base 1803 0.088 0.114 1.09 [0.87, 1.37] 23.50 0.265 4.42E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8523 0.0140 COGi COGi_base 2859 -0.087 0.120 0.92 [0.72, 1.16] 25.30 0.227 4.71E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8525 0.0187 SEADL SEADL_cont 2218 0.233 0.325 0.23 [-0.40, 0.87] 4.10 0.399 4.73E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8525 0.0157 INS INS_surv 1112 -0.057 0.092 0.94 [0.79, 1.13] 11.90 0.339 5.35E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8589 0.0086 CONST CONST_base 1472 0.074 0.122 1.08 [0.85, 1.37] 0.00 0.434 5.45E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8614 0.0107 HYPOSMIA HYPOSMIA_base 1588 0.065 0.115 1.07 [0.85, 1.34] 0.00 0.894 5.71E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8523 0.0151 HY3 HY3_base 1289 0.092 0.168 1.10 [0.79, 1.52] 0.00 0.682 5.82E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8536 0.0140 MMSE MMSE_cont 2114 0.034 0.062 0.03 [-0.09, 0.15] 31.60 0.175 5.85E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8516 0.0172 INS INS_base 2220 0.053 0.098 1.05 [0.87, 1.28] 0.00 0.454 5.94E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8541 0.0103 MOTORFLUX MOTORFLUX_surv 1709 -0.032 0.067 0.97 [0.85, 1.10] 0.00 0.931 6.31E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8524 0.0164 UPDRS_scaled UPDRS_scaled_cont 2994 0.012 0.033 0.01 [-0.05, 0.08] 31.70 0.154 7.09E-01 0 0 0 0 GBF1
10:104015279 rs10748818 a g 0.8548 0.0087 DEPR DEPR_surv 1314 -0.024 0.112 0.98 [0.78, 1.22] 0.00 0.549 8.33E-01 0 0 0 0 GBF1
4:925376 rs873786 t c 0.0955 0.0040 SEADL70 SEADL70_surv 1683 0.255 0.148 1.29 [0.97, 1.73] 28.30 0.233 8.53E-02 0 0 0 0 GAK
4:925376 rs873786 t c 0.0974 0.0110 MOCA MOCA_cont 1074 0.310 0.200 0.31 [-0.08, 0.70] 42.80 0.155 1.22E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0933 0.0071 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.068 0.050 -0.07 [-0.17, 0.03] 38.10 0.138 1.68E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0930 0.0044 COGi COGi_base 2859 -0.166 0.154 0.85 [0.63, 1.15] 38.80 0.120 2.82E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0933 0.0036 HYPOSMIA HYPOSMIA_base 1588 -0.150 0.140 0.86 [0.65, 1.13] 14.50 0.322 2.83E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0970 0.0093 SEADL SEADL_cont 2218 -0.388 0.395 -0.39 [-1.16, 0.39] 0.00 0.857 3.26E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0964 0.0085 MMSE MMSE_cont 2114 0.074 0.077 0.07 [-0.08, 0.22] 0.00 0.866 3.36E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0926 0.0035 INS INS_base 2220 -0.116 0.122 0.89 [0.70, 1.13] 0.00 0.806 3.46E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0936 0.0037 SLEEP SLEEP_base 1724 -0.117 0.143 0.89 [0.67, 1.18] 0.00 0.764 4.14E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0950 0.0077 DEPR DEPR_surv 1314 0.101 0.125 1.11 [0.87, 1.41] 0.00 0.505 4.17E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0940 0.0056 DYSKINESIAS DYSKINESIAS_surv 1856 -0.084 0.105 0.92 [0.75, 1.13] 0.00 0.973 4.25E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0929 0.0061 MOTORFLUX MOTORFLUX_surv 1709 -0.065 0.084 0.94 [0.80, 1.10] 0.00 0.650 4.40E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0930 0.0020 CONST CONST_base 1472 -0.096 0.153 0.91 [0.67, 1.23] 26.00 0.248 5.31E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0932 0.0076 UPDRS_scaled UPDRS_scaled_cont 2994 -0.019 0.040 -0.02 [-0.10, 0.06] 0.00 0.736 6.37E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0930 0.0032 MOTORFLUX MOTORFLUX_base 1803 0.064 0.140 1.07 [0.81, 1.40] 0.00 0.524 6.45E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0913 0.0006 HY3 HY3_base 1289 0.084 0.197 1.09 [0.74, 1.60] 0.00 0.467 6.68E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0928 0.0076 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.018 0.050 0.02 [-0.08, 0.12] 1.50 0.413 7.13E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0911 0.0090 HY3 HY3_surv 2582 -0.032 0.109 0.97 [0.78, 1.20] 0.00 0.699 7.67E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0968 0.0074 INS INS_surv 1112 0.029 0.109 1.03 [0.83, 1.27] 0.00 0.837 7.88E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0943 0.0068 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.010 0.043 0.01 [-0.07, 0.09] 29.90 0.211 8.21E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0948 0.0079 COGi COGi_surv 2244 0.027 0.127 1.03 [0.80, 1.32] 0.00 0.487 8.35E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0924 0.0075 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.008 0.045 -0.01 [-0.10, 0.08] 0.00 0.496 8.65E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0934 0.0043 DEPR DEPR_base 2138 -0.011 0.159 0.99 [0.72, 1.35] 0.00 0.593 9.47E-01 0 0 0 0 GAK
4:925376 rs873786 t c 0.0911 0.0007 DYSKINESIAS DYSKINESIAS_base 1232 -0.002 0.179 1.00 [0.70, 1.42] 0.00 0.882 9.93E-01 0 0 0 0 GAK
4:170583157 rs62333164 a g 0.3335 0.0150 DEPR DEPR_surv 1314 -0.151 0.088 0.86 [0.72, 1.02] 46.80 0.094 8.56E-02 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3262 0.0087 DYSKINESIAS DYSKINESIAS_base 1232 0.189 0.111 1.21 [0.97, 1.50] 48.10 0.146 8.79E-02 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3330 0.0117 MMSE MMSE_cont 2114 -0.082 0.049 -0.08 [-0.18, 0.01] 11.20 0.343 9.34E-02 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3177 0.0164 INS INS_surv 1112 -0.115 0.074 0.89 [0.77, 1.03] 0.00 0.874 1.20E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3253 0.0207 MOTORFLUX MOTORFLUX_surv 1709 -0.084 0.054 0.92 [0.83, 1.02] 0.00 0.811 1.21E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3283 0.0089 CONST CONST_base 1472 -0.135 0.091 0.87 [0.73, 1.04] 0.00 0.605 1.39E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3212 0.0155 MOTORFLUX MOTORFLUX_base 1803 0.111 0.089 1.12 [0.94, 1.33] 46.60 0.112 2.11E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3339 0.0180 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.026 0.028 0.03 [-0.03, 0.08] 0.00 0.894 3.57E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3314 0.0201 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.029 0.032 -0.03 [-0.09, 0.03] 0.00 0.955 3.62E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3224 0.0183 SEADL70 SEADL70_surv 1683 0.070 0.101 1.07 [0.88, 1.31] 0.00 0.492 4.85E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3274 0.0222 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.017 0.028 -0.02 [-0.07, 0.04] 2.20 0.402 5.29E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3278 0.0149 INS INS_base 2220 -0.033 0.076 0.97 [0.83, 1.12] 0.00 0.933 6.64E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3267 0.0142 HY3 HY3_surv 2582 0.025 0.069 1.03 [0.90, 1.17] 39.00 0.108 7.18E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3308 0.0082 HY3 HY3_base 1289 -0.045 0.128 0.96 [0.74, 1.23] 21.50 0.280 7.28E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3341 0.0176 UPDRS_scaled UPDRS_scaled_cont 2994 -0.009 0.026 -0.01 [-0.06, 0.04] 0.00 0.677 7.39E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3325 0.0145 HYPOSMIA HYPOSMIA_base 1588 0.028 0.085 1.03 [0.87, 1.21] 0.00 0.898 7.43E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3293 0.0234 MOCA MOCA_cont 1074 -0.040 0.133 -0.04 [-0.30, 0.22] 2.30 0.381 7.66E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3252 0.0173 DYSKINESIAS DYSKINESIAS_surv 1856 0.015 0.063 1.02 [0.90, 1.15] 24.50 0.242 8.09E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3342 0.0153 HY HY_cont 3627 0.002 0.010 0.00 [-0.02, 0.02] 0.00 0.851 8.44E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3286 0.0177 COGi COGi_surv 2244 -0.012 0.083 0.99 [0.84, 1.16] 0.00 0.891 8.87E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3313 0.0234 SEADL SEADL_cont 2218 -0.029 0.258 -0.03 [-0.54, 0.48] 0.00 0.817 9.11E-01 0 0 0 0 CLCN3
4:170583157 rs62333164 a g 0.3326 0.0195 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.000 0.032 0.00 [-0.06, 0.06] 36.60 0.149 9.98E-01 0 0 0 0 CLCN3
18:40673380 rs12456492 a g 0.6325 0.0137 MMSE MMSE_cont 2114 -0.078 0.046 -0.08 [-0.17, 0.01] 0.00 0.895 8.71E-02 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6422 0.0255 MOTORFLUX MOTORFLUX_surv 1709 -0.082 0.052 0.92 [0.83, 1.02] 5.60 0.385 1.12E-01 0 0 0 0 RIT2
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18:40673380 rs12456492 a g 0.6428 0.0173 DEPR DEPR_base 2138 -0.111 0.093 0.89 [0.75, 1.07] 13.40 0.325 2.30E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6338 0.0123 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.032 0.030 -0.03 [-0.09, 0.03] 0.00 0.486 2.90E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6498 0.0196 COGi COGi_base 2859 0.086 0.091 1.09 [0.91, 1.30] 0.00 0.903 3.44E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6530 0.0176 SLEEP SLEEP_base 1724 -0.081 0.086 0.92 [0.78, 1.09] 7.90 0.368 3.48E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6577 0.0185 CONST CONST_base 1472 0.082 0.089 1.09 [0.91, 1.29] 34.00 0.195 3.57E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6551 0.0202 HYPOSMIA HYPOSMIA_base 1588 -0.074 0.084 0.93 [0.79, 1.09] 51.10 0.069 3.81E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6343 0.0127 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.024 0.030 -0.02 [-0.08, 0.04] 21.30 0.267 4.31E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6538 0.0108 DYSKINESIAS DYSKINESIAS_base 1232 0.078 0.108 1.08 [0.87, 1.34] 0.00 0.628 4.73E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6441 0.0321 MOCA MOCA_cont 1074 -0.090 0.127 -0.09 [-0.34, 0.16] 0.00 0.426 4.76E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6452 0.0258 COGi COGi_surv 2244 0.054 0.079 1.06 [0.90, 1.23] 0.00 0.570 4.99E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6387 0.0170 UPDRS_scaled UPDRS_scaled_cont 2994 -0.015 0.024 -0.02 [-0.06, 0.03] 0.00 0.657 5.33E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6469 0.0228 HY HY_cont 3627 -0.005 0.009 -0.00 [-0.02, 0.01] 0.00 0.662 6.13E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6574 0.0172 INS INS_base 2220 -0.036 0.073 0.96 [0.84, 1.11] 0.00 0.511 6.25E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6477 0.0113 HY3 HY3_base 1289 0.059 0.121 1.06 [0.84, 1.34] 0.00 0.957 6.28E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6352 0.0136 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.011 0.026 -0.01 [-0.06, 0.04] 32.60 0.191 6.84E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6355 0.0240 DEPR DEPR_surv 1314 -0.028 0.084 0.97 [0.83, 1.15] 26.80 0.233 7.38E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6387 0.0281 SEADL70 SEADL70_surv 1683 -0.017 0.094 0.98 [0.82, 1.18] 55.60 0.061 8.55E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6335 0.0260 SEADL SEADL_cont 2218 -0.042 0.243 -0.04 [-0.52, 0.43] 0.00 0.854 8.63E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6402 0.0219 HY3 HY3_surv 2582 -0.011 0.066 0.99 [0.87, 1.13] 36.10 0.130 8.67E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6425 0.0216 DYSKINESIAS DYSKINESIAS_surv 1856 -0.009 0.059 0.99 [0.88, 1.11] 0.00 0.992 8.82E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6326 0.0128 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.003 0.027 -0.00 [-0.06, 0.05] 10.80 0.346 9.04E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6580 0.0221 INS INS_surv 1112 -0.005 0.070 0.99 [0.87, 1.14] 0.00 0.938 9.38E-01 0 0 0 0 RIT2
18:40673380 rs12456492 a g 0.6456 0.0186 MOTORFLUX MOTORFLUX_base 1803 -0.005 0.084 1.00 [0.84, 1.17] 0.00 0.774 9.55E-01 0 0 0 0 RIT2
8:22525980 rs2280104 t c 0.3768 0.0166 MOCA MOCA_cont 1074 -0.205 0.123 -0.20 [-0.45, 0.04] 0.00 0.448 9.58E-02 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3801 0.0057 CONST CONST_base 1472 -0.137 0.087 0.87 [0.74, 1.03] 0.00 0.967 1.17E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3745 0.0236 DYSKINESIAS DYSKINESIAS_surv 1856 0.080 0.060 1.08 [0.96, 1.22] 0.00 0.696 1.79E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3603 0.0184 SEADL SEADL_cont 2218 -0.320 0.240 -0.32 [-0.79, 0.15] 15.70 0.307 1.83E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3772 0.0235 COGi COGi_base 2859 0.118 0.089 1.13 [0.95, 1.34] 0.00 0.813 1.83E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3745 0.0062 DYSKINESIAS DYSKINESIAS_base 1232 0.122 0.102 1.13 [0.92, 1.38] 0.00 0.713 2.33E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3752 0.0181 COGi COGi_surv 2244 0.086 0.073 1.09 [0.94, 1.26] 22.00 0.248 2.42E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3638 0.0229 SEADL70 SEADL70_surv 1683 0.109 0.095 1.12 [0.93, 1.34] 40.10 0.154 2.52E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3771 0.0254 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.023 0.029 0.02 [-0.03, 0.08] 0.00 0.709 4.42E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3679 0.0155 MOTORFLUX MOTORFLUX_base 1803 -0.064 0.083 0.94 [0.80, 1.10] 0.00 0.429 4.44E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3752 0.0275 UPDRS4_scaled UPDRS4_scaled_cont 1798 -0.017 0.025 -0.02 [-0.07, 0.03] 0.00 0.705 5.12E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3696 0.0184 DEPR DEPR_surv 1314 0.044 0.080 1.05 [0.89, 1.22] 12.70 0.334 5.80E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3858 0.0325 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.013 0.026 -0.01 [-0.06, 0.04] 0.00 0.880 6.20E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3816 0.0206 HYPOSMIA HYPOSMIA_base 1588 -0.039 0.082 0.96 [0.82, 1.13] 53.50 0.056 6.38E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3807 0.0299 UPDRS_scaled UPDRS_scaled_cont 2994 -0.010 0.024 -0.01 [-0.06, 0.04] 0.00 0.482 6.96E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3829 0.0210 SLEEP SLEEP_base 1724 0.024 0.085 1.02 [0.87, 1.21] 37.10 0.145 7.81E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3779 0.0070 HY3 HY3_base 1289 0.027 0.116 1.03 [0.82, 1.29] 0.00 0.798 8.17E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3727 0.0250 DEPR DEPR_base 2138 0.017 0.091 1.02 [0.85, 1.22] 0.00 0.875 8.52E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3781 0.0184 INS INS_base 2220 -0.012 0.071 0.99 [0.86, 1.14] 0.00 0.969 8.62E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3841 0.0071 INS INS_surv 1112 -0.007 0.067 0.99 [0.87, 1.13] 0.00 0.806 9.12E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3896 0.0274 HY HY_cont 3627 0.000 0.009 -0.00 [-0.02, 0.02] 25.90 0.190 9.84E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3728 0.0198 MOTORFLUX MOTORFLUX_surv 1709 -0.001 0.050 1.00 [0.91, 1.10] 0.00 0.777 9.85E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3737 0.0265 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.000 0.029 -0.00 [-0.06, 0.06] 0.00 0.806 9.93E-01 0 0 0 0 BIN3
8:22525980 rs2280104 t c 0.3712 0.0211 MMSE MMSE_cont 2114 0.000 0.046 -0.00 [-0.09, 0.09] 0.00 0.475 9.95E-01 0 0 0 0 BIN3
11:133787001 rs3802920 t g 0.2152 0.0183 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.048 0.030 0.05 [-0.01, 0.11] 47.20 0.092 1.06E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2189 0.0163 COGi COGi_base 2859 0.155 0.101 1.17 [0.96, 1.42] 0.00 0.586 1.26E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2157 0.0143 DYSKINESIAS DYSKINESIAS_surv 1856 0.087 0.067 1.09 [0.96, 1.24] 0.00 0.802 1.91E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2153 0.0119 MOTORFLUX MOTORFLUX_surv 1709 -0.059 0.058 0.94 [0.84, 1.06] 0.00 0.568 3.10E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2053 0.0157 SEADL SEADL_cont 2218 -0.283 0.281 -0.28 [-0.83, 0.27] 0.00 0.729 3.15E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2199 0.0205 HYPOSMIA HYPOSMIA_base 1588 -0.094 0.094 0.91 [0.76, 1.09] 0.00 0.861 3.17E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2213 0.0194 INS INS_base 2220 0.077 0.084 1.08 [0.92, 1.27] 28.20 0.203 3.60E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2136 0.0145 MMSE MMSE_cont 2114 0.047 0.053 0.05 [-0.06, 0.15] 0.00 0.863 3.80E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2127 0.0128 INS INS_surv 1112 -0.061 0.076 0.94 [0.81, 1.09] 0.00 0.777 4.19E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2106 0.0165 UPDRS_scaled UPDRS_scaled_cont 2994 0.019 0.028 0.02 [-0.04, 0.07] 17.50 0.282 4.96E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2268 0.0009 DYSKINESIAS DYSKINESIAS_base 1232 0.075 0.120 1.08 [0.85, 1.36] 0.00 0.758 5.31E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2108 0.0197 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.018 0.031 0.02 [-0.04, 0.08] 0.00 0.786 5.54E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2210 0.0155 DEPR DEPR_surv 1314 0.052 0.093 1.05 [0.88, 1.26] 47.60 0.090 5.81E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2089 0.0122 MOCA MOCA_cont 1074 -0.074 0.143 -0.07 [-0.35, 0.21] 0.00 0.896 6.03E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2129 0.0091 SEADL70 SEADL70_surv 1683 -0.053 0.114 0.95 [0.76, 1.19] 2.50 0.392 6.42E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2122 0.0171 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.016 0.034 -0.02 [-0.08, 0.05] 0.00 0.923 6.49E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2240 0.0167 SLEEP SLEEP_base 1724 -0.043 0.099 0.96 [0.79, 1.16] 0.00 0.617 6.63E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2106 0.0170 HY HY_cont 3627 0.004 0.011 0.00 [-0.02, 0.02] 0.00 0.796 7.17E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2101 0.0123 COGi COGi_surv 2244 0.030 0.089 1.03 [0.86, 1.23] 0.00 0.705 7.37E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2274 0.0010 HY3 HY3_base 1289 0.037 0.135 1.04 [0.80, 1.35] 0.00 0.812 7.85E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2245 0.0147 DEPR DEPR_base 2138 -0.028 0.107 0.97 [0.79, 1.20] 17.70 0.291 7.92E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2137 0.0175 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.009 0.034 0.01 [-0.06, 0.08] 0.00 0.794 8.05E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2083 0.0184 HY3 HY3_surv 2582 0.015 0.076 1.02 [0.87, 1.18] 0.00 0.886 8.40E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2223 0.0136 CONST CONST_base 1472 -0.010 0.099 0.99 [0.82, 1.20] 0.00 0.703 9.21E-01 0 0 0 0 IGSF9B
11:133787001 rs3802920 t g 0.2292 0.0045 MOTORFLUX MOTORFLUX_base 1803 -0.002 0.095 1.00 [0.83, 1.20] 26.40 0.246 9.87E-01 0 0 0 0 IGSF9B
6:133210361 rs75859381 t c 0.9701 0.0080 COGi COGi_surv 1704 -0.401 0.257 0.67 [0.40, 1.11] 8.00 0.367 1.19E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9638 0.0100 SLEEP SLEEP_base 1489 0.441 0.308 1.55 [0.85, 2.84] 0.00 0.858 1.52E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9636 0.0089 MOTORFLUX MOTORFLUX_surv 1033 0.271 0.217 1.31 [0.86, 2.00] 0.00 0.870 2.11E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9634 0.0058 MMSE MMSE_cont 1384 0.178 0.156 0.18 [-0.13, 0.48] 44.40 0.109 2.55E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9559 0.0088 COGi COGi_base 1652 -0.269 0.278 0.76 [0.44, 1.32] 42.60 0.137 3.32E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9644 0.0051 UPDRS2_scaled UPDRS2_scaled_cont 1034 0.135 0.170 0.14 [-0.20, 0.47] 0.00 0.403 4.26E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9650 0.0064 DYSKINESIAS DYSKINESIAS_surv 1049 -0.209 0.270 0.81 [0.48, 1.38] 16.00 0.312 4.39E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9618 0.0042 DEPR DEPR_base 1301 0.363 0.476 1.44 [0.57, 3.65] 0.00 0.479 4.45E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9599 0.0064 UPDRS3_scaled UPDRS3_scaled_cont 1378 0.080 0.120 0.08 [-0.16, 0.32] 0.00 0.576 5.09E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9691 0.0066 SEADL70 SEADL70_surv 1352 0.275 0.444 1.32 [0.55, 3.14] 4.80 0.369 5.36E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9638 0.0106 CONST CONST_base 1240 -0.170 0.310 0.84 [0.46, 1.55] 41.70 0.162 5.84E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9644 0.0101 HYPOSMIA HYPOSMIA_base 1212 -0.151 0.294 0.86 [0.48, 1.53] 0.00 0.939 6.09E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9564 0.0132 HY HY_cont 2898 0.013 0.031 0.01 [-0.05, 0.07] 0.00 0.532 6.82E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9590 0.0071 HY3 HY3_surv 1796 0.074 0.205 1.08 [0.72, 1.61] 0.00 0.596 7.18E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9648 0.0108 INS INS_base 1387 -0.075 0.293 0.93 [0.52, 1.65] 0.00 0.784 7.97E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9671 0.0059 SEADL SEADL_cont 1643 -0.217 0.920 -0.22 [-2.02, 1.59] 19.30 0.288 8.13E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9566 0.0124 UPDRS_scaled UPDRS_scaled_cont 1929 -0.019 0.093 -0.02 [-0.20, 0.16] 0.00 0.635 8.38E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9697 0.0067 MOCA MOCA_cont 1074 0.037 0.495 0.04 [-0.93, 1.01] 0.00 0.457 9.40E-01 0 0 0 0 RPS12
6:133210361 rs75859381 t c 0.9645 0.0048 UPDRS1_scaled UPDRS1_scaled_cont 1039 -0.005 0.171 -0.00 [-0.34, 0.33] 0.00 0.941 9.79E-01 0 0 0 0 RPS12
7:66009851 rs76949143 a t 0.0460 0.0045 COGi COGi_base 1538 0.439 0.284 1.55 [0.89, 2.70] 45.60 0.118 1.22E-01 0 0 0 0 GS1-124K5.11
7:66009851 rs76949143 a t 0.0443 0.0049 MMSE MMSE_cont 1066 0.144 0.138 0.14 [-0.13, 0.41] 0.00 0.861 2.96E-01 0 0 0 0 GS1-124K5.11
7:66009851 rs76949143 a t 0.0440 0.0064 HY HY_cont 2077 0.027 0.030 0.03 [-0.03, 0.09] 0.00 0.985 3.65E-01 0 0 0 0 GS1-124K5.11
7:66009851 rs76949143 a t 0.0477 0.0061 HY3 HY3_surv 1299 0.137 0.184 1.15 [0.80, 1.64] 0.00 0.986 4.55E-01 0 0 0 0 GS1-124K5.11
7:66009851 rs76949143 a t 0.0439 0.0065 UPDRS_scaled UPDRS_scaled_cont 1108 0.067 0.095 0.07 [-0.12, 0.25] 22.30 0.272 4.76E-01 0 0 0 0 GS1-124K5.11
7:66009851 rs76949143 a t 0.0425 0.0058 COGi COGi_surv 1132 0.096 0.250 1.10 [0.68, 1.80] 0.00 0.418 7.00E-01 0 0 0 0 GS1-124K5.11
7:66009851 rs76949143 a t 0.0432 0.0050 INS INS_base 1033 0.057 0.280 1.06 [0.61, 1.83] 0.00 0.545 8.39E-01 0 0 0 0 GS1-124K5.11
14:75373034 rs3742785 a c 0.7856 0.0121 MOTORFLUX MOTORFLUX_base 1803 -0.161 0.105 0.85 [0.69, 1.04] 15.40 0.317 1.23E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7806 0.0154 SEADL SEADL_cont 2218 -0.471 0.310 -0.47 [-1.08, 0.14] 0.00 0.826 1.29E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7809 0.0156 HY3 HY3_base 1289 -0.190 0.142 0.83 [0.63, 1.09] 0.00 0.895 1.83E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7830 0.0130 DEPR DEPR_base 2138 0.139 0.115 1.15 [0.92, 1.44] 0.00 0.853 2.28E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7874 0.0141 COGi COGi_surv 2244 -0.115 0.098 0.89 [0.74, 1.08] 0.00 0.935 2.43E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7833 0.0136 HY3 HY3_surv 2582 -0.079 0.078 0.92 [0.79, 1.08] 0.00 0.477 3.10E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7876 0.0125 DYSKINESIAS DYSKINESIAS_base 1232 -0.116 0.134 0.89 [0.69, 1.16] 0.00 0.486 3.87E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7835 0.0226 DYSKINESIAS DYSKINESIAS_surv 1856 0.062 0.080 1.06 [0.91, 1.25] 0.00 0.547 4.35E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7912 0.0130 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.030 0.043 -0.03 [-0.12, 0.06] 4.10 0.395 4.89E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7846 0.0157 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.024 0.037 -0.02 [-0.10, 0.05] 0.00 1.000 5.11E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7880 0.0133 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.024 0.037 0.02 [-0.05, 0.10] 0.00 0.661 5.21E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7830 0.0127 HY HY_cont 3627 -0.007 0.012 -0.01 [-0.03, 0.02] 8.50 0.362 5.36E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7862 0.0161 MOTORFLUX MOTORFLUX_surv 1709 0.041 0.067 1.04 [0.91, 1.19] 0.00 0.696 5.42E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7898 0.0129 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.022 0.043 -0.02 [-0.11, 0.06] 32.10 0.183 6.13E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7874 0.0113 UPDRS_scaled UPDRS_scaled_cont 2994 -0.014 0.033 -0.01 [-0.08, 0.05] 1.40 0.426 6.65E-01 0 0 0 0 RPS6KL1
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14:75373034 rs3742785 a c 0.7821 0.0134 HYPOSMIA HYPOSMIA_base 1588 -0.038 0.096 0.96 [0.80, 1.16] 2.80 0.399 6.97E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7791 0.0201 DEPR DEPR_surv 1314 -0.037 0.107 0.96 [0.78, 1.19] 0.00 0.917 7.34E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7877 0.0125 INS INS_surv 1112 -0.029 0.087 0.97 [0.82, 1.15] 0.00 0.818 7.45E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7806 0.0196 MOCA MOCA_cont 1074 -0.049 0.166 -0.05 [-0.37, 0.28] 43.50 0.150 7.70E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7837 0.0118 COGi COGi_base 2859 -0.024 0.107 0.98 [0.79, 1.20] 0.00 0.870 8.21E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7810 0.0135 SLEEP SLEEP_base 1724 -0.018 0.102 0.98 [0.80, 1.20] 0.00 0.907 8.61E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7838 0.0126 MMSE MMSE_cont 2114 -0.007 0.057 -0.01 [-0.12, 0.10] 0.00 0.878 8.98E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7916 0.0037 SEADL70 SEADL70_surv 1683 -0.014 0.121 0.99 [0.78, 1.25] 0.00 0.998 9.07E-01 0 0 0 0 RPS6KL1
14:75373034 rs3742785 a c 0.7834 0.0140 CONST CONST_base 1472 -0.012 0.104 0.99 [0.81, 1.21] 0.00 0.412 9.09E-01 0 0 0 0 RPS6KL1
1:154898185 rs114138760 c g 0.0194 0.0036 DEPR DEPR_surv 1177 0.407 0.270 1.50 [0.89, 2.55] 0.00 0.998 1.31E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0164 0.0037 MOTORFLUX MOTORFLUX_surv 1709 0.271 0.186 1.31 [0.91, 1.89] 0.00 0.543 1.45E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0156 0.0033 CONST CONST_base 1355 0.501 0.355 1.65 [0.82, 3.31] 44.60 0.144 1.58E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0153 0.0034 DEPR DEPR_base 1683 0.579 0.422 1.78 [0.78, 4.08] 17.50 0.300 1.70E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0142 0.0035 UPDRS2_scaled UPDRS2_scaled_cont 1956 -0.137 0.133 -0.14 [-0.40, 0.12] 0.00 0.689 3.04E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0178 0.0051 HY3 HY3_surv 1498 0.235 0.279 1.26 [0.73, 2.19] 41.90 0.142 4.00E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0137 0.0041 DYSKINESIAS DYSKINESIAS_base 1232 0.375 0.482 1.45 [0.57, 3.74] 0.00 0.846 4.37E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0148 0.0035 MOTORFLUX MOTORFLUX_base 1803 0.259 0.352 1.30 [0.65, 2.58] 0.00 0.928 4.61E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0149 0.0029 DYSKINESIAS DYSKINESIAS_surv 1656 0.165 0.233 1.18 [0.75, 1.86] 0.00 0.756 4.81E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0154 0.0029 SEADL SEADL_cont 1836 -0.694 1.020 -0.69 [-2.69, 1.31] 0.00 0.765 4.96E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0164 0.0046 HY3 HY3_base 1289 -0.374 0.557 0.69 [0.23, 2.05] 0.00 0.870 5.02E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0163 0.0034 SLEEP SLEEP_base 1460 -0.240 0.374 0.79 [0.38, 1.64] 0.00 0.706 5.22E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0143 0.0035 HY HY_cont 3060 -0.026 0.040 -0.03 [-0.10, 0.05] 0.00 0.745 5.24E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0141 0.0031 INS INS_base 1854 0.181 0.320 1.20 [0.64, 2.24] 23.70 0.263 5.72E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0160 0.0039 COGi COGi_surv 2030 0.103 0.313 1.11 [0.60, 2.05] 0.00 0.975 7.41E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0150 0.0034 UPDRS1_scaled UPDRS1_scaled_cont 1964 -0.039 0.128 -0.04 [-0.29, 0.21] 34.10 0.180 7.62E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0148 0.0036 UPDRS3_scaled UPDRS3_scaled_cont 1997 -0.036 0.125 -0.04 [-0.28, 0.21] 0.00 0.465 7.74E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0150 0.0033 COGi COGi_base 2219 0.112 0.435 1.12 [0.48, 2.62] 0.00 0.890 7.97E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0140 0.0033 UPDRS4_scaled UPDRS4_scaled_cont 1651 0.027 0.114 0.03 [-0.20, 0.25] 0.00 0.671 8.10E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0137 0.0035 UPDRS_scaled UPDRS_scaled_cont 2730 0.025 0.110 0.03 [-0.19, 0.24] 16.40 0.301 8.20E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0154 0.0028 MOCA MOCA_cont 1026 -0.103 0.519 -0.10 [-1.12, 0.91] 14.60 0.310 8.42E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0141 0.0040 MMSE MMSE_cont 1850 -0.040 0.203 -0.04 [-0.44, 0.36] 42.00 0.125 8.44E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0158 0.0034 HYPOSMIA HYPOSMIA_base 1334 -0.034 0.386 0.97 [0.45, 2.06] 0.00 0.522 9.29E-01 0 0 0 0 PMVK
1:154898185 rs114138760 c g 0.0142 0.0020 SEADL70 SEADL70_surv 1683 -0.014 0.375 0.99 [0.47, 2.06] 0.00 0.959 9.70E-01 0 0 0 0 PMVK
12:123326598 rs10847864 t g 0.3732 0.0205 INS INS_surv 1112 0.097 0.067 1.10 [0.97, 1.26] 0.00 0.618 1.48E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3696 0.0237 SLEEP SLEEP_base 1724 0.118 0.087 1.13 [0.95, 1.33] 0.00 0.425 1.72E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3770 0.0204 SEADL70 SEADL70_surv 1683 -0.124 0.094 0.88 [0.73, 1.06] 0.00 0.872 1.90E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3878 0.0222 SEADL SEADL_cont 2112 0.308 0.240 0.31 [-0.16, 0.78] 37.80 0.141 1.99E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3810 0.0263 HY HY_cont 3627 -0.011 0.009 -0.01 [-0.03, 0.01] 0.00 0.959 2.06E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3738 0.0226 INS INS_base 2220 0.089 0.073 1.09 [0.95, 1.26] 8.30 0.366 2.25E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3780 0.0266 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.030 0.027 -0.03 [-0.08, 0.02] 0.00 0.506 2.65E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3784 0.0267 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.025 0.026 0.02 [-0.03, 0.08] 43.30 0.117 3.39E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3795 0.0291 COGi COGi_surv 2244 -0.071 0.079 0.93 [0.80, 1.09] 34.90 0.139 3.67E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3662 0.0206 HYPOSMIA HYPOSMIA_base 1588 -0.072 0.083 0.93 [0.79, 1.10] 0.00 0.615 3.91E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3619 0.0116 HY3 HY3_base 1289 -0.101 0.123 0.90 [0.71, 1.15] 0.00 0.466 4.11E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3855 0.0286 MOCA MOCA_cont 1074 0.079 0.123 0.08 [-0.16, 0.32] 7.90 0.354 5.22E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3638 0.0165 COGi COGi_base 2859 0.046 0.089 1.05 [0.88, 1.25] 0.00 0.972 6.09E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3845 0.0228 DEPR DEPR_base 2138 -0.047 0.094 0.95 [0.79, 1.15] 14.00 0.321 6.21E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3698 0.0208 CONST CONST_base 1472 -0.037 0.088 0.96 [0.81, 1.15] 0.00 0.831 6.74E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3834 0.0275 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.007 0.030 0.01 [-0.05, 0.07] 49.10 0.067 8.09E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3877 0.0319 DEPR DEPR_surv 1314 0.018 0.080 1.02 [0.87, 1.19] 20.20 0.281 8.23E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3687 0.0127 DYSKINESIAS DYSKINESIAS_base 1232 0.016 0.107 1.02 [0.82, 1.25] 59.30 0.086 8.79E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3733 0.0259 HY3 HY3_surv 2582 0.010 0.066 1.01 [0.89, 1.15] 44.10 0.074 8.79E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3816 0.0227 MOTORFLUX MOTORFLUX_surv 1709 0.006 0.050 1.01 [0.91, 1.11] 0.00 0.940 9.07E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3738 0.0162 MOTORFLUX MOTORFLUX_base 1803 0.009 0.086 1.01 [0.85, 1.19] 0.00 0.568 9.21E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3944 0.0218 MMSE MMSE_cont 2114 0.001 0.045 0.00 [-0.09, 0.09] 21.50 0.259 9.90E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3816 0.0285 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.000 0.030 -0.00 [-0.06, 0.06] 15.90 0.309 9.93E-01 0 0 0 0 HIP1R
12:123326598 rs10847864 t g 0.3806 0.0285 UPDRS_scaled UPDRS_scaled_cont 2994 0.000 0.024 -0.00 [-0.05, 0.05] 0.00 0.442 9.96E-01 0 0 0 0 HIP1R
1:205737739 rs11557080 a g 0.1349 0.0111 COGi COGi_surv 2244 -0.164 0.115 0.85 [0.68, 1.06] 0.00 0.945 1.54E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1443 0.0245 DEPR DEPR_base 2138 -0.175 0.134 0.84 [0.65, 1.09] 0.00 0.556 1.94E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1436 0.0218 UPDRS2_scaled UPDRS2_scaled_cont 2103 -0.054 0.043 -0.05 [-0.14, 0.03] 16.40 0.305 2.05E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1303 0.0089 HY3 HY3_base 1289 -0.228 0.185 0.80 [0.55, 1.14] 35.50 0.212 2.18E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1432 0.0144 SEADL SEADL_cont 2112 0.400 0.331 0.40 [-0.25, 1.05] 0.00 0.569 2.27E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1426 0.0163 MOTORFLUX MOTORFLUX_surv 1709 0.079 0.069 1.08 [0.95, 1.24] 0.00 0.761 2.55E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1418 0.0263 SLEEP SLEEP_base 1724 -0.141 0.125 0.87 [0.68, 1.11] 0.00 0.535 2.57E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1412 0.0138 MOCA MOCA_cont 1074 0.191 0.171 0.19 [-0.14, 0.52] 0.00 0.859 2.64E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1424 0.0200 UPDRS_scaled UPDRS_scaled_cont 2994 -0.032 0.034 -0.03 [-0.10, 0.03] 0.00 0.578 3.53E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1410 0.0226 MMSE MMSE_cont 2114 0.055 0.064 0.06 [-0.07, 0.18] 0.00 0.490 3.90E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1402 0.0216 CONST CONST_base 1472 0.092 0.123 1.10 [0.86, 1.40] 0.00 0.888 4.56E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1357 0.0087 COGi COGi_base 2859 -0.091 0.132 0.91 [0.71, 1.18] 12.90 0.329 4.93E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1433 0.0217 UPDRS3_scaled UPDRS3_scaled_cont 2446 -0.023 0.038 -0.02 [-0.10, 0.05] 0.00 0.974 5.39E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1467 0.0230 UPDRS1_scaled UPDRS1_scaled_cont 2111 -0.021 0.042 -0.02 [-0.10, 0.06] 0.00 0.672 6.13E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1455 0.0301 DEPR DEPR_surv 1314 0.054 0.111 1.06 [0.85, 1.31] 47.10 0.092 6.26E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1401 0.0171 MOTORFLUX MOTORFLUX_base 1803 0.049 0.121 1.05 [0.83, 1.33] 0.00 0.686 6.85E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1348 0.0086 DYSKINESIAS DYSKINESIAS_base 1232 0.054 0.156 1.06 [0.78, 1.43] 24.00 0.268 7.28E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1433 0.0224 INS INS_base 2220 0.034 0.101 1.03 [0.85, 1.26] 0.00 0.708 7.41E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1453 0.0248 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.009 0.037 0.01 [-0.06, 0.08] 0.00 0.646 8.15E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1420 0.0242 HYPOSMIA HYPOSMIA_base 1588 -0.021 0.117 0.98 [0.78, 1.23] 0.00 0.794 8.59E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1365 0.0124 HY3 HY3_surv 2582 0.014 0.092 1.01 [0.85, 1.21] 33.80 0.148 8.77E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1402 0.0160 DYSKINESIAS DYSKINESIAS_surv 1856 0.013 0.084 1.01 [0.86, 1.19] 0.00 0.518 8.82E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1434 0.0207 INS INS_surv 1112 -0.005 0.093 1.00 [0.83, 1.20] 0.00 0.562 9.62E-01 0 0 0 0 RAB29
1:205737739 rs11557080 a g 0.1369 0.0103 SEADL70 SEADL70_surv 1683 0.006 0.134 1.01 [0.77, 1.31] 0.00 0.529 9.67E-01 0 0 0 0 RAB29
2:169110394 rs1474055 t c 0.1414 0.0081 DYSKINESIAS DYSKINESIAS_surv 1856 -0.110 0.084 0.90 [0.76, 1.06] 0.00 0.658 1.90E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1346 0.0049 DYSKINESIAS DYSKINESIAS_base 1232 0.181 0.146 1.20 [0.90, 1.59] 0.00 0.715 2.17E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1383 0.0093 UPDRS4_scaled UPDRS4_scaled_cont 1798 0.039 0.037 0.04 [-0.03, 0.11] 49.70 0.077 2.90E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1471 0.0119 MOCA MOCA_cont 1074 0.169 0.168 0.17 [-0.16, 0.50] 0.00 0.855 3.13E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1439 0.0089 HY3 HY3_surv 2582 -0.085 0.091 0.92 [0.77, 1.10] 0.00 0.902 3.48E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1386 0.0092 UPDRS2_scaled UPDRS2_scaled_cont 2103 0.039 0.042 0.04 [-0.04, 0.12] 0.00 0.942 3.63E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1464 0.0094 MOTORFLUX MOTORFLUX_surv 1709 0.055 0.067 1.06 [0.93, 1.21] 0.00 0.775 4.14E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1362 0.0105 DEPR DEPR_base 2138 -0.093 0.139 0.91 [0.69, 1.20] 1.90 0.415 5.03E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1421 0.0120 COGi COGi_surv 2244 -0.070 0.106 0.93 [0.76, 1.15] 0.00 0.919 5.07E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1382 0.0100 HYPOSMIA HYPOSMIA_base 1588 -0.075 0.114 0.93 [0.74, 1.16] 49.40 0.079 5.09E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1363 0.0062 HY3 HY3_base 1289 0.109 0.166 1.12 [0.81, 1.54] 58.60 0.089 5.12E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1501 0.0175 INS INS_surv 1112 0.057 0.091 1.06 [0.89, 1.27] 0.00 0.842 5.27E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1452 0.0092 DEPR DEPR_surv 1314 0.068 0.113 1.07 [0.86, 1.34] 12.80 0.333 5.49E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1382 0.0122 HY HY_cont 3627 0.008 0.013 0.01 [-0.02, 0.03] 28.60 0.165 5.59E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1359 0.0095 INS INS_base 2220 0.059 0.103 1.06 [0.87, 1.30] 0.00 0.929 5.64E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1366 0.0076 COGi COGi_base 2859 -0.070 0.126 0.93 [0.73, 1.19] 22.40 0.252 5.77E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1378 0.0115 CONST CONST_base 1472 0.053 0.121 1.05 [0.83, 1.34] 18.40 0.298 6.63E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1391 0.0095 UPDRS1_scaled UPDRS1_scaled_cont 2111 0.017 0.042 0.02 [-0.07, 0.10] 0.00 0.973 6.87E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1363 0.0110 UPDRS_scaled UPDRS_scaled_cont 2994 0.013 0.035 0.01 [-0.05, 0.08] 0.00 0.954 7.13E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1363 0.0103 SLEEP SLEEP_base 1724 0.027 0.121 1.03 [0.81, 1.30] 0.00 0.782 8.23E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1447 0.0091 SEADL SEADL_cont 2218 -0.073 0.333 -0.07 [-0.73, 0.58] 0.00 0.695 8.27E-01 0 0 0 0 STK39
2:169110394 rs1474055 t c 0.1380 0.0081 UPDRS3_scaled UPDRS3_scaled_cont 2446 0.003 0.038 0.00 [-0.07, 0.08] 37.30 0.132 9.46E-01 0 0 0 0 STK39
base, logistic regression model at the baseline; surv, Cox survival model; cont, linear mixed effect model
CONST, constipation; COGi, cognitive impairment; INS, insomnia; SLEEP, daytime sleepiness; MOTORFLUX, motor fluctuations; HY3, Hoehn Yahr scale 3 or greater; RBD, REM sleep behavior disorder; DEPR, depression; MMSE, Mini Mental State Exami-tion; Montreal Cognitive 
Assessment, SEADL, Schwab and England Activities of Daily Living Scale; UPDRS, Unified Parkinson Disease Rating Scale; MDS-UPDRS, Movment Disorder Society revised version of UPDRS.
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Supplemental Table 5 The Estimated Study Size to Detect at Least One Variant with Genome-wide Significance
Phenotype Top_SNP A1 A2 MAF BETA SE P N N_Multiplier N_required Sig_in_1.3_larger_N
base_HYPOSMIA 1:56034603 C A 0.119 0.570 0.118 1.49E-06 1588 1.30 2064 TRUE
base_MOTORFLUX 2:170778662 C G 0.143 0.734 0.162 6.08E-06 1568 1.48 2325 FALSE
base_SLEEP 17:27353069 A G 0.188 0.592 0.118 5.56E-07 1724 1.20 2062 TRUE
base_HY3 2:232324780 A G 0.349 0.610 0.122 5.71E-07 1289 1.20 1545 TRUE
base_CONST 2:18336194 A G 0.269 0.479 0.097 8.59E-07 1472 1.24 1825 TRUE
base_INS 10:112956055 A G 0.318 -0.455 0.083 4.74E-08 2220 1.00 2212 TRUE
base_DYSKINESIAS 1:182045339 C G 0.066 0.898 0.212 2.25E-05 1232 1.70 2100 FALSE
base_DEPR 17:33680811 A C 0.164 0.554 0.114 1.22E-06 2138 1.28 2730 TRUE
base_COGi 8:116961224 A G 0.080 1.013 0.190 9.77E-08 1538 1.05 1612 TRUE
cont_HY 10:27370747 G A 0.063 0.098 0.020 8.68E-07 3627 1.24 4501 TRUE
cont_SEADL 11:88031232 C T 0.299 1.469 0.281 1.74E-07 2218 1.09 2424 TRUE
cont_UPDRS 6:25370200 T G 0.050 0.486 0.101 1.41E-06 1792 1.29 2318 TRUE
cont_UPDRS4_scaled 10:90420315 T G 0.240 0.201 0.041 1.14E-06 1798 1.27 2283 TRUE
cont_UPDRS2_scaled 19:17340155 A G 0.074 0.294 0.060 9.66E-07 2301 1.25 2881 TRUE
cont_MMSE 6:2977327 A G 0.056 -0.709 0.135 1.51E-07 1066 1.08 1153 TRUE
cont_UPDRS3_scaled 5:60307904 G A 0.409 0.149 0.031 1.09E-06 2822 1.27 3570 TRUE
cont_UPDRS_scaled 12:129483261 T C 0.139 -0.298 0.058 2.96E-07 1108 1.14 1261 TRUE
cont_MOCA 14:54619316 C T 0.188 -0.937 0.199 2.61E-06 1074 1.37 1468 FALSE
surv_SEADL70 22:50944128 A G 0.288 0.488 0.103 2.03E-06 1683 1.34 2249 FALSE
surv_MOTORFLUX 8:142310903 T G 0.134 0.431 0.087 6.21E-07 1709 1.21 2062 TRUE
surv_HY3 9:108058562 A T 0.075 0.711 0.129 3.46E-08 1890 0.98 1844 TRUE
surv_INS 2:241442030 T C 0.060 0.703 0.144 9.75E-07 1112 1.25 1393 TRUE
surv_DYSKINESIAS 12:121627464 A T 0.068 0.509 0.100 3.76E-07 1856 1.16 2151 TRUE
surv_DEPR 14:52568619 C T 0.095 0.640 0.127 4.66E-07 1395 1.18 1645 TRUE
surv_COGi 21:17309623 G C 0.083 0.912 0.170 7.76E-08 1132 1.03 1167 TRUE
Top_SNP, the SNP with the smallest p-value;
Multiplier, Multiplier of the N to have enough power to detect the Top_SNP at the significance level of 5E-8;
N_required, The total number required to detect the Top_SNP at the significance level of 5E-8;
Sig_in_1.3_larger_N, Whether or not obtaining at least one genome-wide significant variant for that phenotype if the N was 1.3 times larger;
base, logistic regression model at the baseline; surv, Cox survival model; cont, linear mixed effect model
CONST, constipation; COGi, cognitive impairment; INS, insomnia; SLEEP, daytime sleepiness; MOTORFLUX, motor fluctuations; HY3, Hoehn Yahr scale 3 or greater; RBD, REM sleep behavior 
disorder; DEPR, depression; MMSE, Mini Mental State Exami-tion; Montreal Cognitive Assessment, SEADL, Schwab and England Activities of Daily Living Scale; UPDRS, Unified Parkinson 
Disease Rating Scale; MDS-UPDRS, Movment Disorder Society revised version of UPDRS."   
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Appendix A: The description of study cohorts
Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) was a 
randomized clinical trial conducted between September 1987 and November 1989 at 28 sites 
across US and Canada. The primary objective was to test the efficacy of deprenyl and/or 
tocopherol. 800 patients with Parkinson’s disease diagnosed within 5 years and not requiring 
symptomatic treatment were observed for up to 2 years.1 The study was supported by a Public 
Health Service grant (NS24778) from the National Institute of Neurological Disorders and 
Stroke; by grants from the General Clinical Research Centers Program of the National Institutes 
of Health at Columbia University (RR00645), the University of Virginia (RR00847), the 
University of Pennsylvania (RR00040), the University of Iowa (RR00059), Ohio State 
University (RR00034), Massachusetts General Hospital (RR01066), the University of Rochester 
(RR00044), Brown University (RR02038), Oregon Health Sciences University (RR00334), 
Baylor College of Medicine (RR00350), the University of California, San Diego (RR00827), 
Johns Hopkins University (RR00035), the University of Michigan (RR00042), and Washington 
University (RR00036); the Parkinson's Disease Foundation at Columbia-Presbyterian Medical 
Center, New York; the National Parkinson Foundation, Miami; the Parkinson Foundation of 
Canada, Toronto; the United Parkinson Foundation, Chicago; the American Parkinson's Disease 
Association, New York; and the University of Rochester, Rochester, N.Y.
Drug Interaction with Genes in Parkinson's Disease (DIGPD) is a cohort with 413 patients with 
Parkinson’s disease diagnosed by UK Parkinson’s disease society brain bank clinical diagnostic 
(UKPDSBB) criteria with disease duration less than 5 years at the entry.2 It is an ongoing study 
since 2009, and the participants are followed for up to 7 years at eight sites in France. (Corvol et 
al., in press in Neurology). DNA samples were collected from all of them. DIGPD is sponsored 
by Assistance Publique Hôpitaux de Paris, funded by a grant from the French Ministry of Health 
(PHRC 2008, AOM08010) and a grant from the Agence Nationale pour la Sécurité des 
Médicaments (ANSM 2013).
Harvard Biomarkers Study (HBS) is a longitudinal case-control study. More than 2,700 
individuals with early-stage PD, patients with memory impairment, and controls without 
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neurological disease were enrolled and longitudinally phenotyped since 2008.3 HBS was 
supported by the Harvard NeuroDiscovery Center, MJFF, NINDS U01NS082157, 
U01NS100603, and the Massachusetts Alzheimer’s Disease Research Center NIA 
P50AG005134.
NIH Exploratory Trials in Parkinson's Disease Large Simple Study 1 (NET-PD LS1) was a 
randomized study conducted between March 2007 and September 2013 to determine if the 
nutritional supplement creatine slows the clinical progression of Parkinson’s disease over time. 
1741 patients from 50 sites in the US and Canada participated.4 They were within 5 years from 
diagnosis. The plan was for them to be followed for at least 5 years, but the study ended early for 
futility based on an interim analysis at which point the median follow-up time was 4 years.  
Financial support for the LS-1 study was provided by National Institute of Neurological 
Disorders and Stroke (NINDS) grant U01NS43128.
Oslo PD study[Citation error] (Oslo) is an ongoing study since 2007, with 317 patients 
diagnosed with ULPDSBB criteria with modification of allowing family history. The participants 
are being followed up to 6 years in prospective (30 years in retrospective) at Oslo University 
Hospital in Norway.5 Oslo PD is supported by the Research Council of Norway and South-
Eastern Norway Regional Health Authority.
ParkFit cohort was originally a randomized trial evaluating a multifaceted behavioural change 
programme to increase physical activities in patients with Parkinson’s disease.6 The study 
conducted from September 2008 to February 2012 at a single center in the Netherlands, with 586 
patients with Parkinson’s disease diagnosed by UKPDSBB, with Hoehn Yahr stage 3 or lower, 
and with sedentary lifestyle at the entry. They were followed up for 2 years. The primary 
objective was concluded as not significant6.  ParkFit is supported by ZonMw (the Netherlands 
Organization for Health Research and Development (75020012)) and the Michael J Fox 
Foundation for Parkinson’s research, VGZ (health insurance company), GlaxoSmithKline, and 
the National Parkinson Foundation.
The Norwegian ParkWest study (ParkWest) is an ongoing prospective longitudinal multicenter 
cohort study of patients with incident Parkinson’s disease from Western and Southern Norway, 
designed to study the incidence, neurobiology and prognosis of PD.7 Between November 1st 
2004 and 31st of August 2006, all new cases of Parkinson Disease within the study area (Sogn 
and Fjordane, Hordaland, Rogaland and Aust-Agder) were recruited, and since the start of the 
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study 212 of these patients and their age-/sex-matched control group were followed. The 
Norwegian ParkWest study is supported by the Research Council of Norway, the Western 
Norway Regional Health Authority, Stavanger University Hospital Research Funds, and the 
Norwegian Parkinson’s Disease Association.
The National Institute of Neurological Disorders and Stroke (NINDS) Parkinson’s Disease 
Biomarker Program (PDBP) is aiming to discover new diagnostic and progression biomarkers 
for Parkinson’s disease.8 It is a combined cohort of 9 PDBP-funded research studies. The 
members have various stages of Parkinson’s disease and recruited throughout the United States. 
Parkinsonism: Incidence and Cognitive and Non-motor heterogeneity In Cambridgeshire 
(PICNICS) is a population-based longitudinal study of 282 incident PD cases recruited between 
2008 and 2013 with ongoing follow-up at 18 month intervals.9,10 PD cases were diagnosed based 
on the UKPDSBB criteria, and followed up at a single center in the UK. PICNICS has received 
funding from the Cure Parkinson’s Trust, the Van Geest Foundation and is supported by the the 
National Institute of Health Research Cambridge Biomedical Research Centre.
Parkinson’s progression markers initiative (PPMI) is an ongoing study started on July 2010, 
enrolling 424 patients with Parkinson’s disease diagnosed within 2 years from the study entry 
date.11 The study sites are located in 33 sites across the US, Europe, Israel and Australia11. PPMI 
is supported by  the Michael J Fox Foundation for Parkinson’s Research.
Parkinson Research Examination of CEP1348 Trial (PreCEPT) is a clinical trial of the mixed 
lineage kinase inhibitor CEP‐1357,4 sponsored by Cephalon, Inc. (West Chester, PA) and H. 
Lundbeck A/S (Valby-Copenhagen, Denmark). The study was conducted at 65 sites in North 
America. The trial enrolled 806 early, untreated PD patients within one year from the onset. The 
original trial was started in April 2002 and terminated in August 2005 due to the futility, but the 
participants were continuously followed-up in the prospective observational study (PostCEPT).12
The studies were funded by NINDS 5U01NS050095‐05, Department of Defense Neurotoxin 
Exposure Treatment Parkinson's Research Program. Grant Number: W23RRYX7022N606, the 
Michael J Fox Foundation for Parkinson’s research, Parkinson's Disease Foundation, Lundbeck 
Pharmaceuticals. Cephalon Inc, Lundbeck Inc, John Blume Foundation, Smart Family 
Foundation,  RJG Foundation,  Kinetics Foundation, National Parkinson Foundation, Amarin 
Neuroscience LTD, CHDI Foundation Inc, National Institutes of Health (NHGRI, NINDS), 
Columbia Parkinson's Disease Research Center.
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Profiling Parkinson’s disease study (ProPark) is an ongoing study started from May 2003. 
Initially, 420 patients recruited in several sites in the Netherlands by March 2006.13 Patients were 
diagnosed with UKPDSBB criteria and in various disease durations at the enrollment. They are 
evaluated annually with the SCOPA scale. This study is funded by the Alkemade-Keuls 
Foundation, Stichting Parkinson Fonds, Parkinson Vereniging, The Netherlands Organisation for 




Harvard Biomarkers Study. Co-Directors: Harvard NeuroDiscovery Center: Clemens R. 
Scherzer, Bradley T. Hyman, Charles G. Jennings; Investigators and Study Coordinators: 
Harvard NeuroDiscovery Center: Yuliya Kuras, Daly Franco, Frank Zhu; Brigham and Women’s 
Hospital: Lewis R. Sudarsky, Michael T. Hayes, Chizoba C. Umeh, Reisa Sperling; 
Massachusetts General Hospital: John H. Growdon, Michael A. Schwarzschild, Albert Y. Hung, 
Alice W. Flaherty, Deborah Blacker, Anne-Marie Wills, U. Shivraj Sohur, Vivek K. Unni, Nicte 
I. Mejia, Anand Viswanathan, Stephen N. Gomperts, Vikram Khurana, Mark W. Albers, Maria 
Allora-Palli, Alireza Atri, David Hsu, Alexandra Kimball, Scott McGinnis, Nutan Sharma, John 
Becker, Randy Buckner, Thomas Byrne, Maura Copeland, Bradford Dickerson, Matthew Frosch, 
Theresa Gomez-Isla, Steven Greenberg, James Gusella, Julius Hedden, Elizabeth Hedley-Whyte, 
Keith Johnson, Raymond Kelleher, Aaron Koenig, Maria Marquis-Sayagues, Gad Marshall, 
Sergi Martinez-Ramirez, Donald McLaren, Olivia Okereke, Elena Ratti, Christopher William, 
Koene Van Dij, Shuko Takeda, Anat Stemmer-Rachaminov, Jessica Kloppenburg, Catherine 
Munro, Rachel Schmid, Sarah Wigman, Sara Wlodarcsyk; University of Ottawa: Michael G. 
Schlossmacher; Scientific Advisory Board: Massachusetts General Hospital: John H. Growdon; 
Brigham and Women’s Hospital: Dennis J. Selkoe, Reisa Sperling; Harvard School of Public 
Health: Alberto Ascherio; Data Coordination: Harvard NeuroDiscovery Center: Thomas Yi, 
Massachusetts General Hospital: Joseph J. Locascio, Haining Li; Biobank Management Staff: 
Harvard NeuroDiscovery Center: Gabriel Stalberg, Zhixiang Liao.
Parkinson Study Group DATATOP investigators: Steering Committee — Ira Shoulson, M.D. 
(principal investigator), University of Rochester, Rochester, N.Y.; Stanley Fahn, M.D. (co-
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principal investigator), Columbia–Presbyterian Medical Center, New York; David Oakes, Ph.D. 
(chief biostatistician, 1987 to present), University of Rochester; Charles Odoroff Ph.D. 
(deceased) (chief biostatistician, 1985–1987), University of Rochester; Anthony Lang, M.D., 
Toronto Western Hospital, Toronto; J. William Langston, M.D., California Parkinson's 
Foundation, San Jose, Calif.; Peter LeWitt, M.D., Sinai Hospital, Detroit; Warren Olanow, M.D., 
University of South Florida, Tampa; John B. Penney, M.D. (deceased), University of Michigan, 
Ann Arbor; and Caroline Tanner, M.D., Rush–Presbyterian–St. Luke's Medical Center, Chicago. 
Participating Investigators — William Koller, M.D. (deceased), University of Kansas, Kansas 
City; Warren Olanow, M.D., University of South Florida; Robert Rodnitzky, M.D., University of 
Iowa, Iowa City; J. Stephen Fink, M.D., Ph.D. (deceased), and John H. Growdon, M.D., 
Massachusetts General Hospital, Boston; George Paulson, M.D., Ohio State University, 
Columbus; Roger Kurlan, M.D., University of Rochester; Joseph H. Friedman, M.D., Roger 
Williams General Hospital, Providence; Stephen Gancher, M.D., and John Nutt, M.D., Oregon 
Health Sciences University, Portland; Ali H. Rajput, M.D., University of Saskatchewan, 
Saskatoon; James Bennett, M.D., Ph.D., and George F. Wooten, M.D., University of Virginia, 
Charlottesville; Peter LeWitt, M.D., Sinai Hospital, Detroit; Christopher Goetz, M.D., Caroline 
Tanner, M.D., Kathleen Shannon, M.D., and Harold Klawans, M.D. (deceased), Rush–
Presbyterian–St. Luke's Medical Center, Chicago; Oksana Suchowersky, M.D., University of 
Calgary, Calgary, Alta.; Mitchell Brin, M.D., and Susan Bressman, M.D., Columbia–
Presbyterian Medical Center, New York; William J. Weiner, M.D. (deceased), and Juan 
Sanchez-Ramos, M.D., Ph.D., University of Miami, Miami; Joseph Jankovic, M.D., Baylor 
College of Medicine, Houston; John B. Penney, M.D. (deceased), University of Michigan, Ann 
Arbor; Anthony Lang, M.D., Toronto Western Hospital, Toronto; Margaret Hoehn, M.D. 
(deceased), St. Luke's Hospital, Denver; James Tetrud, M.D., California Parkinson's Foundation, 
San Jose; J. David Grimes, M.D. (deceased), Ottawa Civic Hospital, Ottawa, Ont.; Ronald 
Pfeiffer, M.D., University of Nebraska and Creighton University, Omaha; Cliff Shults, M.D. 
(deceased), and Leon Thal, M.D. (deceased), University of California, San Diego; Serge 
Gauthier, M.D., Montreal General Hospital and McGill University, Montreal; Lawrence I. 
Golbe, M.D., University of Medicine and Dentistry of New Jersey, New Brunswick; Joel S. 
Perlmutter, M.D., Washington University, St. Louis; Hamilton Moses III, M.D., Johns Hopkins 
Page 87 of 106































































University, Baltimore; and Howard I. Hurtig, M.D., and Matthew Stern, M.D., The Graduate 
Hospital, Philadelphia.
Site Coordinators — Ruth Barter, R.N., and Bridget Vetere-Over-field, R.N., Kansas City, 
Kans.; Lisa Gauger, B.A., and Terresita Malapira, R.N., Tampa, Fla.; Judith Dobson, R.N., Iowa 
City, Iowa; Susan Atamian, R.N., Marsh Tennis, R.N., Jennifer B. Cohen, B.A., and Gena 
Desclos, B.A., Boston; Lena Denio, M.T., Steven Huber, Ph.D., and Teresa Woike, R.N., 
Columbus, Ohio; Jill Behr, R.N., M.S., and Irenita Gardiner, R.N., Rochester, N.Y.; Margaret 
Lannon, R.N., M.S., Providence, R.I.; Julie Carter, R.N., and Susanne Northrup, Portland, Ore.; 
Bernice Kanigan, R.N., Saskatoon, Sask.; Margaret Turk, R.N., M.S., and Elke Landow, R.N., 
Charlottesville, Va.; Patricia Schlick, R.N., and Kathie Mistura, R.N., Detroit; V. Susan Carrol, 
R.N., M.S., Jeana Thelen, R.N., and Joan Lechner, Chicago; Carol Demong, R.N., Calgary, 
Alta.; Linda Winfield, R.N., and Carol Moskowitz, R.N., New York; Angela Ingenito, R.N., 
Carol Sheldon, R.N., and Lisa Cornelius, B.A., Miami; Dorothy Heiberg, R.N., Houston; Jan 
Brady, R.N., M.S., Ann Arbor, Mich.; Catherine Kierans, R.N., M.A., and Loretta Bell-
Scantlebury, R.N., Toronto; Helena Weber, M.T., M.A., Denver; Deborah Savoini, R.N., Paula 
Lewis, R.N., and S. Jerome Kutner, Ph.D., San Jose, Calif.; Peggy Gray, R.N., Ottawa, Ont.; 
Ruth Hofman, R.N., and Carolyn Glaeske, R.N., Omaha; Mary Margaret Pay, R.N., and David 
Salmon, Ph.D., San Diego; Frances McFaul, R.N., and Donna Amyot, R.N., Montreal; Mary 
Bergen, R.N., New Brunswick, N.J.; Lori McGee-Minnich, R.N., St. Louis; Patricia O'Donnell, 
R.N., M.S., Baltimore; and Susie Ferrise, R.N., and Kathy Shallow, B.A., Philadelphia.
Coordination and Data Center (University of Rochester Medical Center, Suite 160, 1325 Mt. 
Hope Ave., Rochester, NY 14620) — Rita M. Pelusio, M.S.Ed. (program manager); Alice 
Rudolph, Ph.D. (chief study coordinator); Peter Como, Ph.D. (neuropsychology consultant); 
Charlyne Miller, R.N., M.S. (nurse clinician); Michael Linsner, B.S., Joseph Connorton, B.A., 
and Judith Nusbaum, B.A. (analyst programmers); Carrie Irvine, B.S., and Constance Orme, 
B.A. (information analysts); Ruth Nobel, Deborah Baker, Donna LaDonna, Mary Ellen Rothfuss, 
and Lynn Doerr (deceased) (secretarial staff); Jacqueline Wendel, B.T. (CLINFO manager); and 
Belinda Rodriguez, Virginia Collins, Scott Dalston, and Paul Bivrell (student clerks).
Biostatistics Center (Division of Biostatistics, University of Rochester Medical Center, 
Rochester, NY 14642) — Charles Odoroff, Ph.D. (deceased), and David Oakes, Ph.D. (chief 
biostatisticians); Michael McDermott, Ph.D., and Shirley Eberly, M.S. (biostatisticians); Sandra 
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Plumb, B.S. (lead programmer); Arthur Watts, B.S., Lori Yorkey, B.A., Anna Choi, B.A., and 
Karen Gerwitz, B.S. (analyst programmers).
Pharmacy Center (Strong Memorial Hospital, Rochester, NY 14642) — Paul Evans, R.Ph. (chief 
pharmacist); Lori Dellapena and Verna Singletary (pharmacy technicians).
Safety Monitoring Committee (Rochester, N.Y.) — Robert Herndon, M.D. (chair, January 1, 
1987–June 30, 1988), Pierre Tariot, M.D. (chair, July 1, 1988 to present), Edward Bell, 
Pharm.D., Robert C. Griggs, M.D., W. Jackson Hall, Ph.D., Sandra Plumb, B.S. (lead 
programmer), and Arthur Watts, B.S. (analyst programmer).
Scientific Advisory Committee — C. David Marsden, D.Sc. (deceased) (chair), London; Gerald 
Cohen, Ph.D. (deceased), Joseph Fleiss, Ph.D. (deceased), and Richard Mayeux, M.D., New 
York; and Laurence Jacobs, M.D., and Arthur J. Moss, M.D., Rochester, N.Y.
Clinical Trials Monitoring Committee (National Institute of Neurological Diseases and Stroke) 
— Emanuel M. Stadlan, M.D. (chair), Bethesda, Md.; Milton Alter, M.D. (deceased), 
Philadelphia; Jesse Cedarbaum, M.D., White Plains, N.Y.; Jonas Ellenberg, Ph.D., Bethesda, 
Md.; and Robert Kibler, M.D., Atlanta.
Assay Standards Committee — Robert Roth, Ph.D. (chair), New Haven, Conn.; Harvey Cohen, 
M.D., Ph.D., Rochester, N.Y.; Matthew Galloway, Ph.D., Detroit; Ian Irwin, Ph.D., San Jose, 
Calif.; Peter LeWitt, M.D., Detroit; Govind Vatassery, Ph.D., Minneapolis.
Neuropsychological Testing Committee — Richard Mayeux, M.D. (chair), New York; Peter 
Como, Ph.D., Rochester, N.Y.; Jean St. Cyr, Ph.D., Toronto; Yaakov Stern, Ph.D., and Janet 
Williams, D.S.W., New York; and Robert Wilson, Ph.D., Chicago.
Cerebrospinal Fluid Assay Center (Wayne State University, Detroit, MI 48207) — Matthew P. 
Galloway, Ph.D. (director); Mike Kaplan (deceased) and Rashid Lodhi.
Deprenyl Metabolities Assay Center (Institute for Medical Research, San Jose, CA 95128) — Ian 
Irwin, Ph.D. (director).
Blood Tocopherol Assay Center (Our Lady of Mercy Medical Center, Bronx, NY 10466) — 
Edward Norkus, Ph.D. (director).
Specimen Repository (Department of Neurology, University of Rochester, Rochester, NY 14642) 
— Dorothy Flood, Ph.D. (director), Thomas McNeill, Ph.D., Norma Harary, Ph.D., and Laurie 
Koek, B.S.
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Laboratory Surveillance Testing (SciCor Laboratories, Indianapolis, IN 46241) — Robert L. 
Creveling, M.D. (director).
 
Parkinson Study Group PRECEPT investigators: Steering committee: University of Rochester, 
Rochester, NY: Ira Shoulson, MD (principal investigator), Steven Schwid, MD (medical 
monitor), Christopher Hyson, MD (medical monitor), David Oakes, PhD (chief biostatistician), 
Emily Gorbold, BA, (project coordinator), Alice Rudolph, PhD (project coordinator), Aileen 
Shinaman, JD (Parkinson Study Group executive director), Cornelia Kamp, MBA (director, 
Clinical Research Operations), Karl Kieburtz, MD, MPH (director, Clinical Trials Coordination 
Center); Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada: 
Anthony Lang, MD (coprincipal investigator); Columbia University Medical Center, New York, 
NY: Stanley Fahn, MD; Duke University Medical Center, Durham, NC: Lisa Gauger, BA; Rush 
University Medical Center, Chicago, IL: Christopher Goetz, MD; Institute for 
Neurodegenerative Disorders, New Haven, CT: Kenneth Marek, MD, John Seibyl, MD.
Participating investigators and coordinators: Colorado Neurological Institute, Englewood, CO: 
Lauren Seeberger, MD, Rajeev Kumar, MD; London Health Sciences Center, London, Canada: 
Mandar Jog, MD, Cheryl Horn, RN; Rush–Presbyterian–St. Luke’s Medical Center, Chicago, IL: 
Kathleen Shannon, MD, Lucia Blasucci, RN, CCRC; University of Colorado Health Sciences 
Center, Denver, CO: Maureen Leehey, MD, Teresa Derian, RN; Ottawa Hospital Civic Site, 
Ottawa, Ontario, Canada: David Grimes, MD, Melodie Mortensen, BSCN, Keely Haas, RN; 
University of Minnesota/ Minnesota VA Medical Center, Minneapolis, MN: Paul Tuite, MD, 
Susan Rolandelli, RN; University of California Irvine, Irvine, CA: Neal Hermanowicz, MD, 
Shari Niswonger, RN; University of Rochester, Rochester, NY: Roger Kurlan, MD, Irenita 
Gardiner, RN, CCRC; Toronto Western Hospital, University Health Network, Toronto, Ontario, 
Canada: Janis Miyasaki, MD, FRCPC, Lisa Johnston, RN, BSCN, CNN; The Parkinson’s 
Institute, Sunnyvale, CA: James Tetrud, MD, Tracy Stewart, RN; NeuroHealth PD Movement 
Disorders Center, Warwick, RI: Joseph Friedman, MD, Hubert Fernandez, MD, Margaret 
Lannon, RN, MS; University of Iowa, Iowa City, IA: Robert Rodnitzky, MD, Judith Dobson, RN, 
CCRC; Mayo Clinic Arizona, Scottsdale, AZ: Virgilio Evidente, MD, Marlene Lind, RN; Oregon 
Health & Science University, Portland, OR: Julie Carter, RN, MN, ANP, Pamela Andrews, BS; 
Chum-Hotel Dieu/McGill Center for Studies in Aging, Montreal, Quebec, Canada: Michel 
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Panisset, MD; Washington University School of Medicine, St. Louis, MO: Brad Racette, MD, 
Patricia Deppen, RN; Baylor College of Medicine, Houston, TX: Joseph Jankovic, MD, Christine 
Hunter, RN, CCRC; Institute for Neurodegenerative Disorders, New Haven, CT: Danna 
Jennings, MD, Barbara Fussell, RN; Albany Medical College, Albany, NY: Eric Molho, MD, 
Stewart Factor, MD; Indiana University School of Medicine, Indianapolis, IN: Joanne 
Wojcieszek, MD; University of California–Davis, Sacramento, CA: Lin Zhang, MD, PhD, Lisa 
Wilson, MS, CCRP, Teresa Tempkin, RNC, MSN; Duke University Medical Center, Durham, 
NC: Burton Scott, MD, Joanne Field, BSN, RN; Cleveland Clinic, Cleveland, OH: Thyagarajan 
Subramanian, MD, Ruth Kolb, CCRP; University of Pennsylvania, Philadelphia, PA: Andrew 
Siderowf, MD, Amy Colcher, MD, Heather Maccarone, RN, BSN; University of South Florida, 
Tampa, FL: Robert Hauser, MD, Joanne Nemeth, RN; Johns Hopkins University, Baltimore, 
MD: Joseph Savitt, MD, PhD, Kevin Biglan, MD, MPH, Melissa Gerstenhaber, RNC, MSN; 
University of Cincinnati/Cincinnati Children’s Hospital, Cincinnati, OH: Alok Sahay, MD, Arif 
Dalvi, MD, Maureen Gartner, RN, Donna Schwieterman, MA, CCRC; Mayo Clinic Jacksonville, 
Jacksonville, FL: Ryan Uitti, MD, Margaret Turk, RN; University of Sherbrooke, Sherbrooke, 
Quebec, Canada: Jean Rivest, MD, Daniel Soucy, RN; University of Virginia, Charlottesville, 
VA: Frederick Wooten, MD, Elke Rost-Ruffner, RN, BSN; Massachusetts General Hospital, 
Boston, MA: Michael Schwarzschild, MD, PhD, Marsha Tennis, RN; Medical College of 
Georgia, Augusta, GA: Kapil Sethi, MD, Lisa Hatch, RN, BSN; University of Tennessee–
Memphis, Memphis, TN: Ronald Pfeiffer, MD, Brenda Pfeiffer, RN, BSN; North Shore–LIJ 
Health System, Manhasset, NY: Andrew Feigin, MD, Jean Ayan, RN, Barbara Shannon, RN; 
Northwestern University, Chicago, IL: Tanya Simuni, MD, Karen Williams, BA, Michele Wolff, 
BA; Medical University of Ohio, Toledo, OH: Lawrence Elmer, MD, PhD, Kathy Davis, RN; 
University of Connecticut, Glastonbury, CT: Antonelle de Marcaida, MD, Sheila Thurlow, RN; 
Hotel-Dieu Hospital–CHUM, Montreal, Quebec, Canada: Sylvain Chouinard, MD, Hubert 
Poiffaut, RN; Barrow Neurological Institute, Phoenix, AZ: Holly Shill, MD, Mark Stacy, MD, 
Lynn Marlor, BSN, MSHS, Jill Danielson, RN; The Parkinson’s & Movement Disorder Institute, 
Fountain Valley, CA: Daniel Truong, MD, Jacky Vo, MS; LSU Health Science Center 
Shreveport, Shreveport, LA: Richard Zweig, MD, Rhonda Feldt, RN; Columbia University 
Medical Center, NY, NY: Cheryl Waters, MD, Angel Figueroa, BBA, Anne Tam, BS, CCRC; 
University of Kansas Medical Center, Kansas City, KS: Rajesh Pahwa, MD, Amy Parsons, RN, 
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BSN; University of Southern California, Los Angeles, CA: Jennifer Hui, MD, Allan Wu, MD, 
Connie Kawai, RN, BSN, CCRC; University of Alberta, Edmonton, AB, Canada: Richard 
Camicioli, MD, Pamela King, BScN, RN; University of Chicago, Chicago, IL: Arif Dalvi, MD, 
Un Jung Kang, MD, Elizabeth Shaviers, Barbara Harding-Clay, CMA, CCRC; University of 
Maryland School of Medicine, Baltimore, MD: Stephen Reich, MD, Lisa Shulman, MD, Carol 
Dignon, RN, MSN, Kelly Dustin, RN: UMDNJ Robert Wood Johnson Medical School, New 
Brunswick, NJ: Margery Mark, MD, Deborah Caputo, RN, MSN; Saskatoon Dist Health Board 
Royal University Hospital, Saskatoon SK, Canada: Ali Rajput, MD; Boston University, Boston, 
MA: Peter Novak, MD, Cathi-Ann Thomas, RN, MS; Pacific Neuroscience Medical Group, 
Oxnard, CA: James Sutton, MD, Juanita Young, CCRC; University of California–San Diego, La 
Jolla, CA: David Song, MD, Deborah Fontaine, RNCS, MS; Creighton University, Omaha, NE: 
John M. Bertoni, MD, PhD, Carolyn Peterson, RN; Medical College of Wisconsin, Milwaukee, 
WI: Karen Blindauer, MD, Jeannine Petit, ANP; Scott & White Hospital/Texas A&M University, 
Temple, TX: Bala Manyam, MD, Dani lle McNeil-Keller, LMSW, Jacqueline Whetteckey, MD; 
Clinical Neuroscience Center, Southfield, MI: Peter LeWitt, MD, Maryan DeAngelis, RN, 
CCRC; University of Calgary, Calgary, AB, Canada: Ranjit Ranawaya, MD, Oksana 
Suchowersky, MD, Carol Pantella, RN; Brigham&Women’s Hospital, Boston, MA: Lewis 
Sudarsky, MD; Beth Israel Deaconess Medical Center, Boston, MA: Daniel Tarsy, MD, Linda 
Paul, NP, Lisa Scollins, NP; Long Island Jewish Medical Center, New Hyde Park, NY: Mark 
Forrest Gordon, MD; Beth Israel Medical Center, NY, NY: Susan Bressman, MD, Alessandro 
DiRocco, MD, Karyn Boyar, RN, CNS, FNP; Stanford University Medical Center, Stanford, CA: 
Helen Bronte-Stewart, MD, Amy Andrzejewski, BS; UMDNJ School of Osteopathic Medicine, 
Stratford, NJ: Gerald Podskalny, DO; Cleveland Clinic Florida–Weston, Weston, FL: Nestor 
Galvez- Jimenez, MD, Jose Alvarez, CCRC; University of Arkansas for Medical Sciences, Little 
Rock, AR: Sami Harik, MD, Samer Tabbal, MD, Jana Patterson, RN
Biostatistics and coordination center staff: University of Rochester, Rochester, NY: Arthur Watts, 
BS, Rory Doolan, BA, Michele Goldstein, BS, Connie Orme, BA, Larry Preston, BPS, Tina 
Winebrenner.
Data monitoring committee: The Parkinson’s Institute, Sunnyvale, CA: Caroline Tanner, MD, 
PhD (chair); Johns Hopkins University, Baltimore, MD: Steven Piantadosi, MD, PhD; University 
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of British Columbia, Vancouver, BC, Canada: Jon Stoessl, MD, Paul Keown, MD; University of 
Pennsylvania, Philadelphia, PA: Lynn Schuchter, MD.
The following employees of Cephalon, Inc. and H. Lundbeck A/S were substantively involved in 
the design, conduct, and analysis of PRECEPT: Lundbeck A/S, Copenhagen, Denmark: Misser 
Forrest, MD, Thomas Bisgaard, MPolSc, Erik Bardrum Nielsen, PhD, Sissel Vorstrup, MD. 
Cephalon, Inc., Fraser, PA: Heather Snyder, PhD, John Ondrasik, PhD, Lilliam Kingsbury, PhD, 
Steve Mulcahy, MS, Coleen Myers, BSN, Lesley Russell, MD.
 
Parkinson Study Group PostCEPT investigators:
Steering Committee: University of Rochester, Rochester, NY: Ira Shoulson, MD (principal 
investigator), Karl Kieburtz, MD, MPH, Bernard Ravina, MD, MCSE, David Oakes, PhD (chief 
biostatistician), Emily Flagg, BA (project coordinator), Roger Kurlan, MD; Toronto Western 
Hospital, University Health Network, Toronto, Ontario, Canada: Anthony Lang, MD; Rush 
University Medical Center, Chicago, IL: Christopher Goetz, MD; Institute for 
Neurodegenerative Disorders, New Haven, CT: Kenneth Marek, MD; The Parkinson’s Institute, 
Sunnyvale, CA: Caroline Tanner, PhD, Robin Elliot, MA; Columbia University, New York, NY: 
Stanley Fahn, MD.
Oversight Committee: Cephalon, Inc., Fraser, PA: Gilbert Block; Lundbeck A/S, Copenhagen, 
Denmark: Misser Forrest, MD; Department of Defense, Washington D.C.: Stephen Grate, DVM; 
The Parkinson’s Disease Foundation, New York, NY: Robin Elliot, MA; NIH/NINDS, Bethesda, 
MD: Diane DiEuliis, PhD, Wendy R. Galpern, MD, PhD.
PostCEPT Participating Investigators and Coordinators: Chum-Hotel Dieu/McGill Center for 
Studies in Aging, Montreal, Quebec, Canada: Michel Panisset, MD, Sylvain Chouinard, MD, 
Johanne Blais; London Health Sciences, London, Ontario, Canada: Mandar Jog, MD; Colorado 
Neurological Institute, Englewood CO: Dawn Miracle, BS, MS; Rush University Medical 
Center, Chicago, IL: Kathleen M. Shannon, MD; University of Colorado Health Sciences Center, 
Denver, CO: Maureen Leehey, MD, Teresa Derian, RN; University of California, Irvine, Irvine, 
CA and The Phillip & Carol Traub Center for Parkinson’s Disease, Eisenhower Medical Center, 
Rancho Mirage, CA: Neal Hermanowicz, MD, Shari Niswonger, RN; Ottawa Hospital Civic 
Site, Ottawa, Ontario, Canada: David Grimes, MD, RN; University of Rochester, Rochester, NY: 
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Roger Kurlan, MD, Nancy Pearson, RN, MS; NeuroHealth Parkinson’s Disease Movement 
Disorders Center, Warwick, RI: Joseph Friedman, MD, Margaret Lannon, RN, MS; The 
Parkinson’s Institute, Sunnyvale, CA; Toronto Western Hospital, University Health Network, 
Toronto, Ontario, Canada; University of Minnesota/ Minnesota VA Medical Center, 
Minneapolis, MN: Paul Tuite, MD, Susan Rolandelli, RN; University of Iowa, Iowa City, IA: 
Robert Rodnitzky, MD, Judith Dobson, RN; Duke University Medical Center, Durham, NC: 
Burton Scott, MD, Joanne Field, BSN, RN; Oregon Health & Science University, Portland, OR: 
Julie Carter, RN, MN, ANP, Pamela Andrews; University of Pennsylvania, Philadelphia, PA: 
Andrew Siderowf, MD, Lisa Altin, BS; University of Sherbrooke, Sherbrooke, Quebec, Canada: 
Daniel Soucy, RN; Johns Hopkins University, Baltimore, MD: Joseph Savitt, MD, PhD, Melissa 
Gerstenhaber, RNC, MSN; LSU Health Science Center Shreveport, Shreveport, LA: Richard 
Zweig, MD, Collette Hilliard, MS; Baylor College of Medicine, Houston, TX: Joseph Jankovic, 
MD, Christine Hunter, RN, CCRC; Columbia University Medical Center, New York, NY: 
Cheryl Waters, MD, Angel Figueroa, CCRC; Northwestern University, Chicago, IL: Tanya 
Simuni, MD, Karen Williams; Saskatoon Dist Health Board Royal University Hospital, 
Saskatoon SK, Canada: Ali Rajput, MD, Marilyn Martin, BSc, ADV; University of 
Cincinnati/Cincinnati Children’s Hospital, Cincinnati, OH: Alberto Espay, MD, MSC; Sun 
Health Research Institute, Sun City, AZ: Holly Shill, MD; University of South Florida, Tampa, 
FL; University of Tennessee-Memphis, Memphis, TN: Ronald Pfeiffer, MD, Brenda Pfeiffer, 
RN, BSN; University of Virginia, Charlottesville, VA: Frederick Wooten, MD, Margaret F. 
Keller, RN, MS, CCRC; Albany Medical College, Albany, NY: Eric Molho, MD, Katy Regan; 
Boston University, Boston, MA: Marie H. Saint-Hilaire, MD, Cathi-Ann Thomas, RN, MS; 
Mayo Clinic Jacksonville, Jacksonville, FL: Margaret Turk, RN; Medical College of Georgia, 
Augusta, GA: Buff Dill, BS, ED; Milton S. Hershey Medical Center, Hershey, PA: Thyagarajan 
Subramanian, MD, Donna Stuppy, LPN; Institute for Neurodegenerative Disorders, New Haven, 
CT; UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ: Margery H. Mark, 
MD, Debbie Caputo, MSN, FNP-BC; University of Maryland School of Medicine, Baltimore, 
MD; Massachusetts General Hospital, Charleston, MA: Michael Schwarzschild, MD, PhD; 
University of Toledo Health Science Center, Toledo, OH: Lawrence Elmer, MD, PhD, Kathy 
Davis, RN Stephanie Wilson, RN, MSN, CCRC; University of Alberta, Edmonton, AB, Canada: 
Richard Camicioli, MD, Pamela King, BScN, RN; University of California Davis, Sacramento, 
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CA: Lin Zhang, MD, PhD, John Bautista; University of Southern California, Los Angeles, CA; 
Creighton University, Omaha, NE; Pacific Neuroscience Medical Group, Oxnard, CA; 
University of Calgary, Calgary, AB, Canada: Ranjit Ranawaya, MD; University of California 
San Diego, La Jolla, CA: David Song, MD, Deborah Fontaine, RNCS, MS; University of Kansas 
Medical Center, Kansas City, KS: Kelly Lyons, PhD, Carey Mack, RN; Beth Israel Deaconess 
Medical Center, Boston, MA: Daniel Tarsy, MD, Peggy Rose, RN; Brigham & Women’s 
Hospital, Boston, MA: Lewis Sudarsky, MD, Georgette Hage, MD; Cleveland Clinic Florida-
Weston, Weston, FL: Nestor Galvez- Jimenez, MD; The Parkinson’s & Movement Disorder 
Institute, Fountain Valley, CA: Daniel Truong, MD; University of Chicago, Chicago, IL: Un 
Jung Kang, MD, Joan Young, CCRC; North Shore-LIJ Health System, Manhasset, NY: Andrew 
Feigin, MD, Jean Ayan, RN; Stanford University Medical Center, Stanford, CA: Helen Bronte-
Stewart, MD; Beth Israel Medical Center, New York, NY: Karyn Boyar, RN, CNS, FNP; 
University of Arkansas for Medical Sciences, Little Rock, AR: Jana Patterson, RN.
Biostatistics and Coordination Center Staff: University of Rochester, Rochester, NY: Earl 
Westerlund, Lisa Lang, Tina Winebrenner, Nicole McMullen, Sandra Plumb, Cindy Casaceli, 
MBA.
 
DIGPD Study group. Steering committee: Jean-Christophe Corvol, MD, PhD (Pitié-Salpêtrière 
Hospital, Paris, principal investigator of DIGPD), Alexis Elbaz, MD, PhD (CESP, Villejuif, 
member of the steering committee), Marie Vidailhet, MD (Pitié-Salpêtrière Hospital, Paris, 
member of the steering committee), Alexis Brice, MD (Pitié-Salpêtrière Hospital, Paris, member 
of the steering committee and PI for genetic analysis) ; Statistical analyses: Alexis Elbaz, MD, 
PhD (CESP, Villejuif, PI for statistical analyses), Fanny Artaud, PhD (CESP, Villejuif, 
statistician); Principal investigators for sites (alphabetical order): Frédéric Bourdain, MD (CH 
Foch, Suresnes, PI for site), Jean-Philippe Brandel, MD (Fondation Rothschild, Paris, PI for 
site), Jean-Christophe Corvol, MD, PhD (Pitié-Salpêtrière Hospital, Paris, PI for site), Pascal 
Derkinderen, MD, PhD (CHU Nantes, PI for site), Franck Durif, MD (CHU Clermont-Ferrand, 
PI for site), Richard Levy, MD, PhD (CHU Saint-Antoine, Paris, PI for site), Fernando Pico, MD 
(CH Versailles, PI for site), Olivier Rascol, MD (CHU Toulouse, PI for site); Co-investigators 
(alphabtical order): Anne-Marie Bonnet, MD (Pitié-Salpêtrière Hospital, Paris, site investigator), 
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Cecilia Bonnet, MD, PhD (Pitié-Salpêtrière Hospital, Paris, site investigator), Christine Brefel-
Courbon, MD (CHU Toulouse, site investigator), Florence Cormier-Dequaire, MD (Pitié-
Salpêtrière Hospital, Paris, site investigator), Bertrand Degos, MD, PhD (Pitié-Salpêtrière 
Hospital, site investigator), Bérangère Debilly, MD (CHU Clermont-Ferrand, site investigator), 
Alexis Elbaz, MD, PhD (Pitié-Salpêtrière Hospital, Paris, site investigator), Monique Galitsky 
(CHU de Toulouse, site investigator), David Grabli, MD, PhD (Pitié-Salpêtrière Hospital, Paris, 
site investigator), Andreas Hartmann, MD, PhD (Pitié-Salpêtrière Hospital, Paris, site 
investigator), Stephan Klebe, MD (Pitié-Salpêtrière Hospital, Paris, site investigator), Julia 
Kraemmer, MD (Pitié-Salpêtrière Hospital, site investigator), Lucette Lacomblez, MD (Pitié-
Salpêtrière Hospital, Paris, site investigator), Sara Leder, MD (Pitié-Salpêtrière Hospital, Paris, 
site investigator), Graziella Mangone, MD, PhD (Pitié-Salpêtrière Hospital, Paris, site 
investigator), Louise-Laure Mariani, MD (Pitié-Salpêtrière Hospital, Paris, site investigator), 
Ana-Raquel Marques, MD (CHU Clermont Ferrand, site investigator), Valérie Mesnage, MD 
(CHU Saint Antoine, Paris, site investigator), Julia Muellner, MD (Pitié-Salpêtrière Hospital, 
Paris, site investigator), Fabienne Ory-Magne, MD (CHU Toulouse, site investigator), Violaine 
Planté-Bordeneuve, MD (Henri Mondor Hospital, Créteil, site investigator), Emmanuel Roze, 
MD, PhD (Pitié-Salpêtrière Hospital, Paris, site investigator), Melissa Tir, MD (CH Versailles, 
site investigator), Marie Vidailhet, MD (Pitié-Salpêtrière Hospital, Paris, site investigator), Hana 
You, MD (Pitié-Salpêtrière Hospital, Paris, site investigator); Neuropsychologists: Eve 
Benchetrit, MS (Pitié-Salpêtrière Hospital, Paris, neuropsychologist), Julie Socha, MS (Pitié-
Salpêtrière Hospital, Paris, neuropsychologist), Fanny Pineau, MS (Pitié-Salpêtrière Hospital, 
Paris, neuropsychologist), Tiphaine Vidal, MS  (CHU Clermont-Ferrand, neuropsychologist), 
Elsa Pomies (CHU de Toulouse, neuropsychologist), Virginie Bayet (CHU de Toulouse, 
neuropsychologist); Genetic core: Alexis Brice (Pitié-Salpêtrière Hospital, Paris, PI for genetic 
studies), Suzanne Lesage, PhD (INSERM, ICM, Paris, genetic analyses), Khadija Tahiri, PhD 
(INSERM, ICM, Paris, lab technician) Hélène Bertrand, MS (INSERM, ICM, Paris, lab 
technician), Graziella Mangone, MD, PhD (Pitié-Salpêtrière Hospital, Paris, genetic analyses);
Sponsor activities and clinical research assistants: Alain Mallet, PhD (Pitié-Salpêtrière Hospital, 
Paris, sponsor representative), Coralie Villeret (Hôpital Saint Louis, Paris, Project manager), 
Merry Mazmanian (Pitié-Salpêtrière Hospital, Paris, project manager), Hakima Manseur (Pitié-
Salpêtrière Hospital, Paris, clinical research assistant), Mostafa Hajji (Pitié-Salpêtrière Hospital, 
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Paris, data manager), Benjamin Le Toullec, MS (Pitié-Salpêtrière Hospital, Paris, clinical 
research assistant), Vanessa Brochard, PhD (Pitié-Salpêtrière Hospital, Paris, project manager), 
Monica Roy, MS (CHU de Nantes, clinical researh assistant), Isabelle Rieu, PhD (CHU 
Clermont-Ferrand, clinical research assistant), Stéphane Bernard (CHU Clermont-Ferrand, 
clinical research assistant), Antoine Faurie-Grepon (CHU de Toulouse, clnical research 
assistant).
ParkWest: Principal investigators: Guido Alves (Norwegian Centre for Movement Disorders, 
Stavanger University Hospital), Ole-Bjørn Tysnes (Haukeland University Hospital). 
Investigators and study coordinators: Karen Herlofson, Solgunn Ongre, Siri Bruun (Sørlandet 
Hospital Arendal); Ineke HogenEsch, Marianne Kjerandsen, Liv Kari Håland (Haugesund 
Hospital); Wenche Telstad, Aliaksei Labusau, Jane Kastet (Førde Hospital); Bernd Müller, Geir 
Olve Skeie, Charalampos Tzoulis (Haukeland University Hospital); Kenn Freddy Pedersen, 
Michaela Dreetz Gjerstad, Elin Bjelland Forsaa, Jodi Maple-Grødem, Johannes Lange, 
Veslemøy Hamre Frantzen, Anita Laugaland, Karen Simonsen, Ingvild Dalen (Stavanger 
University Hospital).
 
PICNICS: Principal investigator -Roger Barker; study team - Caroline H Williams-Gray, 
Jonathan R Evans, David P Breen, Gemma Cummins, Marta Camacho, Ruwani Wijeyekoon, 
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United Kingdom: Alastair J Noyce (Preventive Neurology Unit, Wolfson Institute of Preventive 
Medicine, QMUL, London, UK and Department of Molecular Neuroscience, UCL, London, 
UK), Rauan Kaiyrzhanov (Department of Molecular Neuroscience, UCL Institute of Neurology, 
London, UK), Ben Middlehurst (Institute of Translational Medicine, University of Liverpool, 
Liverpool, UK), Demis A Kia (UCL Genetics Institute; and Department of Molecular 
Neuroscience, UCL Institute of Neurology, London, UK), Manuela Tan (Department of Clinical 
Neuroscience, University College London, London, UK), Henry Houlden (Department of 
Molecular Neuroscience, UCL Institute of Neurology, London, UK),  Huw R Morris 
(Department of Clinical Neuroscience, University College London, London, UK), Helene Plun-
Favreau (Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK), 
Peter Holmans (Biostatistics & Bioinformatics Unit, Institute of Psychological Medicine and 
Clinical Neuroscience, MRC Centre for Neuropsychiatric Genetics & Genomics, Cardiff, UK), 
John Hardy (Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK), 
Daniah Trabzuni (Department of Molecular Neuroscience, UCL Institute of Neurology, London, 
UK; Department of Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, 
11211 Saudi Arabia), John Quinn (Institute of Translational Medicine, University of Liverpool, 
Liverpool, UK), Vivien Bubb (Institute of Translational Medicine, University of Liverpool, 
Liverpool, UK), Kin Y Mok (Department of Molecular Neuroscience, UCL Institute of 
Neurology, London, UK), Kerri J. Kinghorn (Institute of Healthy Ageing, University College 
London, London, UK), Nicholas W Wood (UCL Genetics Institute; and Department of 
Molecular Neuroscience, UCL Institute of Neurology, London, UK), Patrick Lewis (University 
of Reading, Reading, UK), Sebastian Schreglmann (Department of Molecular Neuroscience, 
UCL Institute of Neurology, London, UK), Ruth Lovering (University College London, London, 
UK), Lea R’Bibo (Department of Molecular Neuroscience, UCL Institute of Neurology, London, 
UK), Claudia Manzoni (University of Reading, Reading, UK), Mie Rizig (Department of 
Molecular Neuroscience, UCL Institute of Neurology, London, UK), Mina Ryten (Department of 
Molecular Neuroscience, UCL Institute of Neurology, London, UK), Sebastian Guelfi 
(Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK), Valentina 
Escott-Price (MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University 
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School of Medicine, Cardiff, UK), Viorica Chelban (Department of Molecular Neuroscience, 
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London, UK), Nigel Williams (MRC Centre for Neuropsychiatric Genetics and Genomics, 
Cardiff, UK), Karen E. Morrison (Faculty of Medicine, University of Southampton, UK), Carl 
Clarke (University of Birmingham, Birmingham, UK and Sandwell and West Birmingham 
Hospitals NHS Trust, Birmingham, UK).
 
France: Alexis Brice (Institut du Cerveau et de la Moelle épinière, ICM, Inserm U 1127, CNRS, 
UMR 7225, Sorbonne Universités, UPMC University Paris 06, UMR S 1127, AP-HP, Pitié-
Salpêtrière Hospital, Paris, France), Fabrice Danjou (Institut du Cerveau et de la Moelle épinière, 
ICM, Inserm U 1127, CNRS, UMR 7225, Sorbonne Universités, UPMC University Paris 06, 
UMR S 1127, AP-HP, Pitié-Salpêtrière Hospital, Paris, France), Suzanne Lesage (Institut du 
Cerveau et de la Moelle épinière, ICM, Inserm U 1127, CNRS, UMR 7225, Sorbonne 
Universités, UPMC University Paris 06, UMR S 1127, AP-HP, Pitié-Salpêtrière Hospital, Paris, 
France), Jean-Christophe Corvol (Institut du Cerveau et de la Moelle épinière, ICM, Inserm U 
1127, CNRS, UMR 7225, Sorbonne Universités, UPMC University Paris 06, UMR S 1127, 
Centre d’Investigation Clinique Pitié Neurosciences CIC-1422, AP-HP, Pitié-Salpêtrière 
Hospital, Paris, France), Maria Martinez (INSERM UMR 1220; and Paul Sabatier University, 
Toulouse, France), 
Germany: Claudia Schulte (Department for Neurodegenerative Diseases, Hertie Institute for 
Clinical Brain Research, University of Tübingen, and DZNE, German Center for 
Neurodegenerative Diseases, Tübingen, Germany), Kathrin Brockmann (Department for 
Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of 
Tübingen, and DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany), 
Javier Simón-Sánchez (Department for Neurodegenerative Diseases, Hertie Institute for Clinical 
Brain Research, University of Tübingen, and DZNE, German Center for Neurodegenerative 
Diseases, Tübingen, Germany), Peter Heutink (DZNE, German Center for Neurodegenerative 
Diseases and Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain 
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Research, University of Tübingen, Tübingen, Germany), Patrizia Rizzu  (DZNE, German Center 
for Neurodegenerative Diseases), Manu Sharma (Centre for Genetic Epidemiology, Institute for 
Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany), Thomas 
Gasser (Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain 
Research, and DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany), 
United States of America: Mark R Cookson (Laboratory of Neurogenetics, National Institute 
on Aging, Bethesda, USA), Sara Bandres-Ciga (Laboratory of Neurogenetics, National Institute 
on Aging, Bethesda, MD, USA), Cornelis Blauwendraat (Laboratory of Neurogenetics, National 
Institute on Aging, Bethesda, MD, USA), David W. Craig (Department of Translational 
Genomics, Keck School of Medicine, University of Southern California, Los Angeles, USA), 
Kimberley Billingsley (Laboratory of Neurogenetics, National Institute on Aging, Bethesda, 
MD, USA), Derek Narendra (Inherited Movement Disorders Unit, National Institute of 
Neurological Disorders and Stroke, Bethesda, MD, USA), Faraz Faghri (Laboratory of 
Neurogenetics, National Institute on Aging, Bethesda, USA; Department of Computer Science, 
University of Illinois at Urbana-Champaign, Urbana, IL, USA), J Raphael Gibbs (Laboratory of 
Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA), 
Dena G. Hernandez (Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, 
USA), Kendall Van Keuren-Jensen (Neurogenomics Division, TGen, Phoenix, AZ USA), Joshua 
M. Shulman (Departments of Neurology, Neuroscience, and Molecular & Human Genetics, 
Baylor College of Medicine, Houston, Texas, USA; Jan and Dan Duncan Neurological Research 
Institute, Texas Children’s Hospital, Houston, Texas, USA), Hirotaka Iwaki (Laboratory of 
Neurogenetics, National Institute on Aging, Bethesda, MD, USA), Hampton L. Leonard 
(Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA),  Mike A. Nalls 
(Laboratory of Neurogenetics, National Institute on Aging, Bethesda, USA; CEO/Consultant 
Data Tecnica International, Glen Echo, MD, USA), Laurie Robak (Baylor College of Medicine, 
Houston, Texas, USA), Jose Bras (Center for Neurodegenerative Science, Van Andel Research 
Institute, Grand Rapids, Michigan, USA), Rita Guerreiro (Center for Neurodegenerative Science, 
Van Andel Research Institute, Grand Rapids, Michigan, USA), Steven Lubbe (Ken and Ruth 
Davee Department of Neurology, Northwestern University Feinberg School of Medicine, 
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Chicago, IL, USA), Steven Finkbeiner (Departments of Neurology and Physiology, University of 
California, San Francisco; Gladstone Institute of Neurological Disease; Taube/Koret Center for 
Neurodegenerative Disease Research, San Francisco, CA, USA),  Niccolo E. Mencacci 
(Northwestern University Feinberg School of Medicine, Chicago, IL, USA), Codrin Lungu 
(National Institutes of Health Division of Clinical Research, NINDS, National Institutes of 
Health, Bethesda, MD, USA), Andrew B Singleton (Laboratory of Neurogenetics, National 
Institute on Aging, Bethesda, MD, USA), Sonja W. Scholz (Neurodegenerative Diseases 
Research Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA), 
Xylena Reed (Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA). 
Roy N. Alcalay (Department of Neurology, College of Physicians and Surgeons, Columbia 
University Medical Center, New York, NY, USA, Taub Institute for Research on Alzheimer's 
Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University Medical 
Center, New York, NY, USA)
Canada: Ziv Gan-Or (Montreal Neurological Institute and Hospital, Department of Neurology 
& Neurosurgery, Department of Human Genetics, McGill University, Montréal, QC, H3A 0G4, 
Canada), Guy A. Rouleau (Montreal Neurological Institute and Hospital, Department of 
Neurology & Neurosurgery, Department of Human Genetics, McGill University, Montréal, QC, 
H3A 0G4, Canada), Lynne Krohn (Montreal Neurological Institute and Hospital, Department of 
Neurology & Neurosurgery, Department of Human Genetics, McGill University, Montréal, QC, 
H3A 0G4, Canada),
The Netherlands: Jacobus J van Hilten (Department of Neurology, Leiden University Medical 
Center, Leiden, Netherlands), Johan Marinus (Department of Neurology, Leiden University 
Medical Center, Leiden, Netherlands)
Spain: Astrid D. Adarmes-Gómez (Instituto de Biomedicina de Sevilla (IBiS), Hospital 
Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville), Miquel Aguilar (Fundació 
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Docència i Recerca Mútua de Terrassa and Movement Disorders Unit, Department of Neurology, 
University Hospital Mutua de Terrassa, Terrassa, Barcelona.), Ignacio Alvarez (Fundació 
Docència i Recerca Mútua de Terrassa and Movement Disorders Unit, Department of Neurology, 
University Hospital Mutua de Terrassa, Terrassa, Barcelona.),Victoria Alvarez (Hospital 
Universitario Central de Asturias, Oviedo), Francisco Javier Barrero (Hospital Universitario San 
Cecilio de Granada, Universidad de Granada), Jesús Alberto Bergareche Yarza (Instituto de 
Investigación Sanitaria Biodonostia, San Sebastián), Inmaculada Bernal-Bernal (Instituto de 
Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de 
Sevilla, Seville), Marta Blazquez (Hospital Universitario Central de Asturias, Oviedo), Marta 
Bonilla-Toribio (Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del 
Rocío/CSIC/Universidad de Sevilla, Seville), Juan A. Botía (Universidad de Murcia, Murcia), 
María Teresa Boungiorno (Fundació Docència i Recerca Mútua de Terrassa and Movement 
Disorders Unit, Department of Neurology, University Hospital Mutua de Terrassa, Terrassa, 
Barcelona.) Dolores Buiza-Rueda (Instituto de Biomedicina de Sevilla (IBiS), Hospital 
Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville), Ana Cámara (Hospital 
Clinic de Barcelona), Fátima Carrillo (Instituto de Biomedicina de Sevilla (IBiS), Hospital 
Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville), Mario Carrión-Claro 
(Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del 
Rocío/CSIC/Universidad de Sevilla, Seville), Debora Cerdan (Hospital General de Segovia, 
Segovia), Jordi Clarimón (Memory Unit, Department of Neurology, IIB Sant Pau, Hospital de la 
Santa Creu i Sant Pau, Universitat Autònoma de Barcelona and Centro de Investigación 
Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid),Yaroslau 
Compta (Hospital Clinic de Barcelona), Monica Diez-Fairen (Fundació Docència i Recerca 
Mútua de Terrassa and Movement Disorders Unit, Department of Neurology, University 
Hospital Mutua de Terrassa, Terrassa, Barcelona.), Oriol Dols-Icardo (Memory Unit, 
Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat 
Autònoma de Barcelona, Barcelona, and Centro de Investigación Biomédica en Red en 
Enfermedades Neurodegenerativas (CIBERNED), Madrid), Jacinto Duarte (Hospital General de 
Segovia, Segovia), Raquel Duran (Centro de Investigacion Biomedica, Universidad de Granada, 
Granada), Francisco Escamilla-Sevilla (Hospital Universitario Virgen de las Nieves, Instituto de 
Investigación Biosanitaria de Granada, Granada), Mario Ezquerra (Hospital Clinic de 
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Barcelona), Cici Feliz (Departmento de Neurologia, Instituto de Investigación Sanitaria 
Fundación Jiménez Díaz, Madrid, Spain), Manel Fernández (Hospital Clinic de Barcelona), 
Rubén Fernández-Santiago (Hospital Clinic de Barcelona), Ciara Garcia (Hospital Universitario 
Central de Asturias, Oviedo), Pedro García-Ruiz (Instituto de Investigación Sanitaria Fundación 
Jiménez Díaz, Madrid), Pilar Gómez-Garre (Instituto de Biomedicina de Sevilla (IBiS), Hospital 
Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville), Maria Jose Gomez 
Heredia (Hospital Universitario Virgen de la Victoria, Malaga), Isabel Gonzalez-Aramburu 
(Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander) ,Ana Gorostidi Pagola 
(Instituto de Investigación Sanitaria Biodonostia, San Sebastián), Janet Hoenicka (Institut de 
Recerca Sant Joan de Déu, Barcelona), Jon Infante (Hospital Universitario Marqués de 
Valdecilla-IDIVAL and University of Cantabria, Santander, and Centro de Investigación 
Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Silvia Jesús (Instituto 
de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de 
Sevilla, Seville), Adriano Jimenez-Escrig (Hospital Universitario Ramón y Cajal, Madrid), Jaime 
Kulisevsky (Movement Disorders Unit, Department of Neurology, IIB Sant Pau, Hospital de la 
Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, and Centro de 
Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED)), Miguel 
A. Labrador-Espinosa (Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen 
del Rocío/CSIC/Universidad de Sevilla, Seville),  Jose Luis Lopez-Sendon (Hospital 
Universitario Ramón y Cajal, Madrid), Adolfo López de Munain Arregui (Instituto de 
Investigación Sanitaria Biodonostia, San Sebastián), Daniel Macias (Instituto de Biomedicina de 
Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville), 
Irene Martínez Torres (Department of Neurology, Instituto de Investigación Sanitaria La Fe, 
Hospital Universitario y Politécnico La Fe, Valencia), Juan Marín (Movement Disorders Unit, 
Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat 
Autònoma de Barcelona, Barcelona, and Centro de Investigación Biomédica en Red en 
Enfermedades Neurodegenerativas (CIBERNED)), Maria Jose Marti (Hospital Clinic 
Barcelona), Juan Carlos Martínez-Castrillo (Instituto Ramón y Cajal de Investigación Sanitaria, 
Hospital Universitario Ramón y Cajal, Madrid), Carlota Méndez-del-Barrio (Instituto de 
Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de 
Sevilla, Seville), Manuel Menéndez González (Hospital Universitario Central de Asturias, 
Page 104 of 106































































Oviedo), Marina Mata (Department of Neurology, Hospital Universitario Infanta Sofía, Madrid, 
Spain) Adolfo Mínguez (Hospital Universitario Virgen de las Nieves, Granada, Instituto de 
Investigación Biosanitaria de Granada), Pablo Mir (Instituto de Biomedicina de Sevilla (IBiS), 
Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville), Elisabet 
Mondragon Rezola (Instituto de Investigación Sanitaria Biodonostia, San Sebastián), Esteban 
Muñoz (Hospital Clinic Barcelona), Javier Pagonabarraga (Movement Disorders Unit, 
Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat 
Autònoma de Barcelona, Barcelona, and Centro de Investigación Biomédica en Red en 
Enfermedades Neurodegenerativas (CIBERNED)), Pau Pastor (Fundació Docència i Recerca 
Mútua de Terrassa and Movement Disorders Unit, Department of Neurology, University 
Hospital Mutua de Terrassa, Terrassa, Barcelona.), Francisco Perez Errazquin (Hospital 
Universitario Virgen de la Victoria, Malaga), Teresa Periñán-Tocino (Instituto de Biomedicina 
de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 
Seville), Javier Ruiz-Martínez (Hospital Universitario Donostia, Instituto de Investigación 
Sanitaria Biodonostia, San Sebastián), Clara Ruz (Centro de Investigacion Biomedica, 
Universidad de Granada, Granada), Antonio Sanchez Rodriguez (Hospital Universitario Marqués 
de Valdecilla-IDIVAL, Santander), María Sierra (Hospital Universitario Marqués de Valdecilla-
IDIVAL, Santander), Esther Suarez-Sanmartin (Hospital Universitario Central de Asturias, 
Oviedo), Cesar Tabernero (Hospital General de Segovia, Segovia), Juan Pablo Tartari (Fundació 
Docència i Recerca Mútua de Terrassa and Movement Disorders Unit, Department of Neurology, 
University Hospital Mutua de Terrassa, Terrassa, Barcelona), Cristina Tejera-Parrado (Instituto 
de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de 
Sevilla, Seville), Eduard Tolosa  (Hospital Clinic Barcelona), Francesc Valldeoriola (Hospital 
Clinic Barcelona), Laura Vargas-González (Instituto de Biomedicina de Sevilla (IBiS), Hospital 
Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville), Lydia Vela (Department 
of Neurology, Hospital Universitario Fundación Alcorcón, Madrid), Francisco Vives (Centro de 
Investigacion Biomedica, Universidad de Granada, Granada).
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Norway: Lasse Pihlstrom (Department of Neurology, Oslo University Hospital, Oslo, Norway), 
Mathias Toft (Department of Neurology and Institute of Clinical Medicine, Oslo University 
Hospital, Oslo, Norway)
Estonia: Sulev Koks (Department of Pathophysiology, University of Tartu, Tartu, Estonia; 
Department of Reproductive Biology, Estonian University of Life Sciences, Tartu, Estonia), Pille 
Taba (Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia)
Israel: Sharon Hassin-Baer (The Movement Disorders Institute, Department of Neurology and 
Sagol Neuroscience Center, Chaim Sheba Medical Center, Tel-Hashomer, 5262101, Ramat Gan, 
Israel, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel)
Finland: Kari Majamaa (Institute of Clinical Medicine, Department of Neurology, University of 
Oulu, Oulu, Finland; Department of Neurology and Medical Research Center, Oulu University 
Hospital, Oulu, Finland), Ari Siitonen (Institute of Clinical Medicine, Department of Neurology, 
University of Oulu, Oulu, Finland; Department of Neurology and Medical Research Center, 
Oulu University Hospital, Oulu, Finland), Pentti Tienari (Clinical Neurosciences, Neurology, 
University of Helsinki, Helsinki, Finland, Helsinki University Hospital, Helsinki, Finland)
Nigeria: Njideka U. Okubadejo (University of Lagos, Lagos State, Nigeria), Oluwadamilola O. 
Ojo (University of Lagos, Lagos State, Nigeria), 
Kazakhstan: Coordinator - Rauan Kaiyrzhanov (Department of Molecular Neuroscience, UCL 
Institute of Neurology, London, UK), Chingiz Shashkin (Kazakh National Medical University 
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named after Asfendiyarov, Almaty, Kazakhstan), Nazira Zharkinbekova (South Kazakhstan 
Medical Academy, Shymkent, Kazakhstan), Vadim Akhmetzhanov (Astana Medical University, 
Astana Kazakhstan), Akbota Aitkulova (National Center for Biotechnology, Astana, Kazakhstan; 
Al-Farabi Kazakh national university. Almaty Kazakhstan), Elena Zholdybayeva (National 
Center for Biotechnology, Astana, Kazakhstan), Zharkyn Zharmukhanov (National Center for 
Biotechnology, Astana, Kazakhstan), Gulnaz Kaishybayeva (Scientific and practical center 
“Institute of neurology named after Smagul Kaishibayev”, Almaty, Kazakhstan), Altynay 
Karimova (Scientific and practical center “Institute of neurology named after Smagul 
Kaishibayev”, Almaty, Kazakhstan), Dinara Sadykova (Astana Medical University, Astana, 
Kazakhstan).
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